<SEC-DOCUMENT>0001785530-23-000025.txt : 20230810
<SEC-HEADER>0001785530-23-000025.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810070051
ACCESSION NUMBER: 0001785530-23-000025
CONFORMED SUBMISSION TYPE: 10-Q
PUBLIC DOCUMENT COUNT: 63
CONFORMED PERIOD OF REPORT: 20230630
FILED AS OF DATE: 20230810
DATE AS OF CHANGE: 20230810
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc.
CENTRAL INDEX KEY: 0001785530
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 823523180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 10-Q
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 231157127
BUSINESS ADDRESS:
STREET 1: 200 TALCOTT AVENUE
STREET 2: 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-952-0555
MAIL ADDRESS:
STREET 1: 200 TALCOTT AVENUE
STREET 2: 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>howl-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:553e33e0-2e01-4068-99ee-43b139347fc6,g:d188e74b-5927-4b57-8b22-a41aa0482b0b,d:4cadfe64e5d042d7864e5d59b36d7f40--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:howl="http://werewolftx.com/20230630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>
<title>howl-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001785530</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-28">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="howl-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">howl:JazzCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TrancheILoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TrancheIILoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001785530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________________________________________________________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">☒</ix:nonNumeric></span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">☐</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from____________to_____________.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40366</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">WEREWOLF THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">82-3523180</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">200 Talcott Ave</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">2nd Floor</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Watertown</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Massachusetts</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">02472</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Registrant’s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">952‑0555</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">HOWL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> ☒ No ☐</span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> ☒ No ☐</span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company, or an emerging growth company.</span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.</span></div><div style="margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">☐</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non‑accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">☒</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">☒</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">☒</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="f-24">☒</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">☐</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">☒</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of August 4, 2023, there were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">35,658,050</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> shares of comm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">on stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:100%">Table of Contents</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.85pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_19">Condensed Consolidated Balance Sheets as of </a>June 30, 2023<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_19"> and </a>December 31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_22">Condensed Consolidated Statements of Operations for the </a>Three and Six Months Ended June 30, 2023 <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_22">and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_25">Condensed Consolidated Statements of Stockholders’ Equity for the </a>Three and Six Months Ended June 30, 2023<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_25"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_28">Condensed Consolidated Statements of Cash Flows for the </a>Six Months Ended June 30, 2023<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_28"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_31">Notes to </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_31">Condensed </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_31">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_70">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_70">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_91">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_91">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_94">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_94">24</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_100">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_100">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_124">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_127">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_127">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_130">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_130">70</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_133">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">References to Werewolf</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form 10-Q, or Quarterly Report, the “Company,” “Werewolf,” “Werewolf Therapeutics,” “we,” “us,” “our,” and similar references, except where the context requires otherwise, refer to Werewolf Therapeutics, Inc. and its consolidated subsidiary, and “board of directors” refers to the board of directors of Werewolf Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements and Industry Data</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act, that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the initiation, timing, progress and results of our research and development programs, preclinical studies and ongoing and planned clinical trials, including the anticipated timing of data announcements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our estimates regarding expenses, capital requirements, need for additional financing and the period over which we believe our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our plans to develop and, if approved, subsequently commercialize product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the timing of and our ability to submit applications and obtain and maintain regulatory approvals for product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the potential advantages of our PREDATOR platform and our ability to use our platform to identify and develop future product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our estimates regarding the potential market opportunities for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our intellectual property position and our expectations regarding our ability to obtain and maintain intellectual property protection;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the impact of government laws and regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">developments and expectations regarding developments and projections relating to our competitors and our industry.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report, particularly in Part II, Item 1A. “Risk Factors”, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">You should read this Quarterly Report and the documents that we have filed or incorporated by reference as exhibits to this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely on these statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trademarks and Trade names</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. The service marks and trademarks that we own include the marks PREDATOR™ and INDUKINE™. Other trademarks, service marks and trade names appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Quarterly Report are listed without the ® and ™ symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business is subject to numerous risks that, if realized, could materially and adversely affect our business, financial condition, results of operations and future growth prospects. These risks are discussed more fully in Part II, Item 1A. “Risk Factors” in this Quarterly Report. These risks include, but are not limited to, the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue from product sales or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We will need to obtain substantial additional funding to finance our operations and complete the development and any commercialization of WTX-124, WTX-330 and any future product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We are early in our development efforts and our current product candidates will require successful completion of preclinical and clinical development before we can seek regulatory approval for any product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">Our business is highly dependent on the success of our initial INDUKINE molecules, which are in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and launch a product commercially.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">Our approach to the discovery and development of product candidates based on our PREDATOR platform is unproven, and we do not know whether we will be able to develop any products of commercial value.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">Manufacturing INDUKINE molecules is subject to risk since they are a novel class of multi-domain biologics that include protease cleavable linkers, and they have never been produced on a commercial scale. We may be unable to manufacture INDUKINE molecules at the scale needed for clinical development and commercial production on a timely basis or at all.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">Preclinical studies and clinical trials are expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We are developing WTX-124, and could develop WTX-330 and potentially future product candidates, in combination with third-party drugs, some of which may still be in development, and we will have limited or no control over the safety, supply, regulatory status or regulatory approval of such drugs.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">The manufacturing of biologics is complex, and we do not have our own clinical manufacturing capabilities. We will rely on third parties to produce preclinical, clinical and commercial supplies of all current and any future product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">We rely on our license agreement with Harpoon Therapeutics, Inc. for patent rights with respect to our product candidates and may in the future acquire additional third-party intellectual property rights on which we may similarly rely. We face risks with respect to such reliance, including the risk that we could lose these rights that are important to our business if we fail to comply with our obligations under these licenses.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.9pt;font-weight:400;line-height:120%;padding-left:32.89pt">Our proprietary position in part depends upon patents that are manufacturing, formulation or method-of-use patents, which may not prevent a competitor or other third party from using the same product candidate for another use.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:32.85pt">We have identified a material weakness in our internal control over financial reporting, and that weakness has led to a conclusion that our internal control over financial reporting and disclosure controls and procedures were not effective as of June 30, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our inability to remediate the material weakness, our discovery of additional weaknesses, and our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_16"></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_19"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Werewolf Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(amounts in thousands, except par value amounts)</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">137,452</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">129,315</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">3,020</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">3,957</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">6,927</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">6,928</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">147,399</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">140,200</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">8,381</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">8,988</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">21,015</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">1,214</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease right of use asset</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-44">7,788</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">8,463</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-46">652</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,380</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-48">185,235</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-49">160,245</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities and Stockholders’ Equity:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">1,490</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">1,221</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">9,940</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">14,152</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liability, current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">1,970</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">2,084</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue, current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,606</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">6,532</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">15,006</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">23,989</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liability, net of current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">11,705</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">12,600</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue, net of current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="f-62">783</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">1,128</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes payable, net of discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-64">39,142</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="f-65">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-66">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-67">191</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-68">66,636</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-69">37,908</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.7pt;text-align:justify;text-indent:-18.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-70"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-71"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stockholders’ equity:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-72"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-73">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-74"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-75">5,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2023 and December 31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-76"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-79">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of June 30, 2023 and December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-80">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-81">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-82"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-83">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-85">200,000</ix:nonFraction></ix:nonFraction> shares authorized as of June 30, 2023 and December 31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-86">35,642</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-87">31,515</ix:nonFraction> shares issued as of June 30, 2023 and December 31, 2022, respectively; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-88">35,642</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-89">31,434</ix:nonFraction> shares outstanding as of June 30, 2023 and December 31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-90">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-91">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-92">442,381</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-93">429,039</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-94">323,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-95">306,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stockholders’ equity</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">118,599</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">122,337</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities and stockholders’ equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">185,235</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">160,245</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Werewolf Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(amounts in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 5.5pt 2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-100">8,081</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-101">4,148</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-102">12,545</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-103">4,148</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">9,583</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">13,887</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">21,289</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">24,832</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">4,565</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">5,233</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">9,546</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">9,654</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-112">14,148</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-113">19,120</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">30,835</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">34,486</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">6,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">14,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">18,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-119">30,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-120">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-121">281</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">1,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-123">265</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-124">994</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-125">97</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-126">2,341</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-127">136</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-128">969</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-129">378</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">1,210</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-131">401</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">5,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">14,594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">17,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">29,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-136"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-137">0.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-138"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-139">0.53</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-140"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-141">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-143">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-144"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-145">35,558</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-146"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-147">27,517</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-148"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-149">35,173</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-150"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-151">27,455</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Werewolf Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders’ Equity (unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(amounts in thousands)</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:23.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.066%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders’ Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-152">31,515</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-153">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">429,039</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">306,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">122,337</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from at the market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-157">103</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-158">3,824</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-159">8,610</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-160">8,610</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">2,108</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-162">2,108</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">11,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">11,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-165">35,339</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-166">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">439,757</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">318,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">121,073</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from at the market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-170">31</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-171">272</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-172">644</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-173">644</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-174">29</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-175">45</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-176">45</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-177">1,930</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-178">1,930</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-179">2</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-180">5</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-181">5</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">5,098</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">5,098</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-184">35,642</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-185">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">442,381</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">323,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">118,599</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders’ Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-189">27,608</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-190">2</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">405,680</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">252,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">152,787</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-194">1,745</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-195">1,745</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-196">46</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-197">129</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-198">129</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">15,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">15,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-201">27,654</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-202">2</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">407,554</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">268,238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">139,318</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from at the market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-206">314</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-207">801</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-208">3,339</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-209">3,339</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">1,777</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-211">1,777</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-212">1</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-213">1</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-214">1</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">14,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">14,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-217">28,456</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-218">2</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">412,671</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">282,832</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-221">129,841</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Werewolf Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(amounts in thousands)</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">17,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-223">29,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-224">4,038</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-225">3,522</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-226">859</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-227">283</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:NonCashInterestExpense" scale="3" id="f-228">92</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="howl:NonCashInterestExpense" format="ixt:fixed-zero" scale="3" id="f-229">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-230">675</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-231">961</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of success payment liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-232">1,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="f-233">262</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-234">60</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-235">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets    </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-236">863</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-237">2,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="f-238">1</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-239">2,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-240">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-241">1,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="f-242">345</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="f-243">132</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-244">3,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-245">3,528</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-246">5,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-247">13,071</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="howl:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-248">1,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="howl:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" scale="3" id="f-249">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-250">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-251">191</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-252">20,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-253">14,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-254">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-255">1,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-256">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-257">1,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from at the market offering of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-258">9,388</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-259">3,653</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from drawdown of term loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-260">40,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="f-261">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of equity issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-262">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-263">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuances under Employee Stock Purchase Plan </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-264">45</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="f-265">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-266">5</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-267">160</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-268">49,315</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-269">3,574</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-270">28,146</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-271">11,819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents—beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-272">130,529</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-273">158,830</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents—end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-274">158,675</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-275">147,011</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-276">13</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-277">1,881</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs in accounts payable and accrued expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-278">15</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="howl:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-279">75</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-280">742</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-281">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercise receivables in prepaid expenses and other current assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" format="ixt:fixed-zero" scale="3" id="f-282">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="howl:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="f-283">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Werewolf Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_34"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-284" continuedAt="f-284-1" escape="true">Nature of Business </ix:nonNumeric></span></div><ix:continuation id="f-284-1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Werewolf Therapeutics, Inc. (“Werewolf” or the “Company”) was incorporated in the state of Delaware in October 2017. The Company is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The Company’s headquarters are located in Watertown, Massachusetts. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, raising capital and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-285">137.5</ix:nonFraction> million at June 30, 2023. The Company expects that its cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements for at least twelve months from the filing date of this Quarterly Report. However, additional funding will be necessary beyond this point to fund future preclinical and clinical activities. The Company expects to finance its future cash needs through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements.</span></div></ix:continuation><div id="i4cadfe64e5d042d7864e5d59b36d7f40_37"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-286" continuedAt="f-286-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-286-1" continuedAt="f-286-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-287" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of June 30, 2023 and December 31, 2022, and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States of America (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments which are necessary for a fair presentation of the Company’s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC (the “Annual Report”).</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information presented in the condensed consolidated financial statements and related notes as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022, is unaudited. The December 31, 2022 condensed consolidated balance sheet included herein was derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interim results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Werewolf Therapeutics, Inc. and its wholly owned subsidiary, Werewolf Therapeutics Mass Securities, Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant accounting policies and estimates used in the preparation of the condensed consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-288" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and the fair value of the success payment liability. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-289" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><ix:continuation id="f-286-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="f-290" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events and transactions that occurred in the period from the balance sheet date to the date that the financial statements were issued. Other than as described in these condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i4cadfe64e5d042d7864e5d59b36d7f40_40"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-291" continuedAt="f-291-1" escape="true">Jazz Collaboration and License Agreement</ix:nonNumeric></span></div><ix:continuation id="f-291-1" continuedAt="f-291-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company entered into an exclusive global collaboration and license agreement (the “Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited (“Jazz”) pursuant to which the Company granted Jazz certain licenses to develop and commercialize products containing the Company’s Interferon alpha (“IFNα”) INDUKINE™ molecule, JZP898 (formerly WTX-613), as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria (each such product, a “Licensed Product”). Under the Collaboration Agreement, the Company is responsible for certain pre-clinical development activities with respect to JZP898 and other development activities specified in mutually agreed upon development plans. Jazz will generally reimburse the Company for the cost of such activities. Jazz will be responsible for all other development and commercialization activities conducted to exploit the Licensed Products, including submission of an investigational new drug application (“IND”) to the U.S. Food and Drug Administration (the “FDA”). Jazz received IND application clearance for JZP898 in July 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Collaboration Agreement, the Company received a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:NonRefundableUpfrontCashPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-292">15.0</ix:nonFraction> million in April 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Milestones and Royalties</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:DevelopmentAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="f-293">520.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:SalesBasedMilestonesUpTo" format="ixt:num-dot-decimal" scale="6" id="f-294">740.0</ix:nonFraction> million in sales-based milestones for all Licensed Products. In addition, the Company is eligible to receive tiered mid-single digit royalties based on Jazz’s, and any of its affiliates’ and sublicensees’ annual net sales of Licensed Products, subject to reduction in specified circumstances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis under ASC 606</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Identification of the Contract(s)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assessed the Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Identification of Promises and Performance Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has concluded that the exclusive license to its intellectual property, JZP898, and the non-exclusive corresponding “know-how” are not capable of being distinct from the other promises within the contract, and as such, the Company has determined that the license and “know-how” combined with the other research and development services and supply represent a single combined performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Determination of Transaction Price</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The overall transaction price as of the inception of the contract was determined to be $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:CollaborativeAgreementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-295">32.3</ix:nonFraction> million, which is comprised of the nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:NonRefundableUpfrontCashPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-296">15.0</ix:nonFraction> million and the estimated costs for research services of $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:CollaborationAgreementEstimatedFutureReimbursableCosts" format="ixt:num-dot-decimal" scale="6" id="f-297">17.3</ix:nonFraction> million. Outside of the estimated costs for research services, there is no other variable consideration included in the transaction price at inception. The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential development and regulatory milestone payment under this agreement is zero, as achievement of those milestones is uncertain and highly susceptible to factors outside the Company’s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based royalties, including milestones based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="howl:NonRefundableUpfrontCashPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-298">15.0</ix:nonFraction> million was recorded as deferred revenue and, along with payments related to the Company’s conduct of research services under the Collaboration Agreement, will be recognized as revenue over approximately <ix:nonNumeric contextRef="c-44" name="howl:CollaborationAgreementTerm" format="ixt-sec:duryear" id="f-299">3.7</ix:nonNumeric> years using an input-based measurement of actual costs incurred as a percentage of the estimated total costs expected to be incurred over the expected term of conduct of the research services. Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">e Company believes this input-based method to recognize revenue best reflects the transfer of value to Jazz.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recognition of Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, using the cost-to-cost input method, which best depicts the research services performed for the customer, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-300">12.5</ix:nonFraction> million of revenue related to the Collaboration Agreement. As of June 30, 2023, there is $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-301">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-302">0.8</ix:nonFraction> million of current and long-term deferred revenue, respectively, related to the Collaboration Agreement. All costs associated with the Collaboration Agreement are recorded in research and development expense in the condensed consolidated statements of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><ix:continuation id="f-291-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">“Unbilled receivables” of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:UnbilledReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-303">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnbilledReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-304">4.1</ix:nonFraction> million was included within “Other receivables” in the accompanying condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-305" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the six months ended June 30, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-306">7,660</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:IncreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-307">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:DecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-308">5,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-309">2,389</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-310">7,660</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:IncreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-311">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="howl:DecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-312">5,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-313">2,389</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company had not received any milestone or royalty payments under the Collaboration Agreement.</span></div></ix:continuation><div id="i4cadfe64e5d042d7864e5d59b36d7f40_43"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-314" continuedAt="f-314-1" escape="true">Financial Instruments and Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="f-314-1" continuedAt="f-314-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds, classified as cash, cash equivalents and restricted cash and cash equivalents on the Company’s condensed consolidated balance sheets, and a success payment liability pursuant to an amended and restated loan and security agreement (the “Loan Agreement”) with Pacific Western Bank (“PWB”) (see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-315" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June 30, 2023 were as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-316">152,132</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-317">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-318">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-319">152,132</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-320">152,132</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-321">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-322">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-323">152,132</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-324">128,812</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-325">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-326">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-327">128,812</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-328">128,812</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-329">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-330">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-331">128,812</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="howl:SuccessPaymentLiability" format="ixt:fixed-zero" scale="3" id="f-332">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="howl:SuccessPaymentLiability" format="ixt:fixed-zero" scale="3" id="f-333">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="howl:SuccessPaymentLiability" scale="3" id="f-334">570</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="howl:SuccessPaymentLiability" scale="3" id="f-335">570</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-336">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-337">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="f-338">570</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="f-339">570</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The success payment liability was included within “Accrued expenses and other current liabilities” in the accompanying condensed consolidated balance sheets as of December 31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in valuation techniques during the three or six months ended June 30, 2023. There were no liabilities measured at fair value on a recurring basis as of June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Success Payment Liability</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was obligated to pay to PWB a one-time success payment of up to $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="howl:SuccessPaymentLiability" format="ixt:num-dot-decimal" scale="6" id="f-340">1.6</ix:nonFraction> million upon the occurrence of the Company achieving certain conditions defined in the Loan Agreement. The Success Fee Event (as defined in the Loan Agreement) occurred during the second quarter of 2023, resulting in the immediate payment in full of the required Success Fee (as defined in Note 7 below).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><ix:continuation id="f-314-2" continuedAt="f-314-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-341" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the success payment liability during the six months ended June 30, 2023 based on Level 3 inputs (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="f-342">570</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="f-343">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-344">1,030</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment at Success Event</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-345">1,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-346">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-314-3">The success payment liability is stated at fair value and was previously considered Level 3 because its fair value measurement was based, in part, on significant inputs not observed in the market. Upon completion of the Success Fee Event, the Company removed the corresponding financial instrument for the success fee liability and paid the total $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="howl:SuccessFeeLiabilityPaid" format="ixt:num-dot-decimal" scale="6" id="f-347">1.6</ix:nonFraction> million. Prior to repayment, the Company remeasured the liability at fair value with a corresponding increase of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-348">1.0</ix:nonFraction> million recorded to other expense, net for the six months ended June 30, 2023.</ix:continuation> </span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_46"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="f-349" continuedAt="f-349-1" escape="true">Restricted Cash and Cash Equivalents</ix:nonNumeric></span></div><ix:continuation id="f-349-1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintained restricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-350">21.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-351">1.2</ix:nonFraction> million at June 30, 2023 and December 31, 2022, respectively. At June 30, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-352">20.0</ix:nonFraction> million of the restricted cash and cash equivalents balance represents an obligation under the term loan facility for the required minimum cash balance in PWB accounts. This became effective upon imminent achievement of the funding goal as required by the terms of the Loan Agreement (see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The remaining restricted cash amounts are comprised solely of letters of credit required pursuant to the Company’s leased office spaces. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-353" continuedAt="f-353-1" escape="true">At June 30, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="f-354">0.2</ix:nonFraction> million of the Company’s restricted cash balance was included within “Prepaid expenses and other current assets” in the accompanying condensed consolidated balance sheets.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="f-353-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-355">129,315</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-356">137,452</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-357">157,531</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-358">145,712</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-359">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-360">208</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-361">91</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-362">91</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-363">1,214</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-364">21,015</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-365">1,208</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-366">1,208</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-367">130,529</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-368">158,675</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-369">158,830</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-370">147,011</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i4cadfe64e5d042d7864e5d59b36d7f40_49"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="howl:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="f-371" continuedAt="f-371-1" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-371-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-372" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June 30, 2023 and December 31, 2022 were comprised as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="howl:AccruedManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="f-373">4,501</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="howl:AccruedManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="f-374">6,674</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="howl:AccruedContractResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="f-375">2,212</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="howl:AccruedContractResearchCurrent" format="ixt:num-dot-decimal" scale="3" id="f-376">2,990</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-377">2,222</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-378">3,135</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-379">458</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-380">613</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="howl:SuccessPaymentLiability" format="ixt:fixed-zero" scale="3" id="f-381">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="howl:SuccessPaymentLiability" scale="3" id="f-382">570</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-383">547</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-384">170</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-385">9,940</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-386">14,152</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4cadfe64e5d042d7864e5d59b36d7f40_52"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-387" continuedAt="f-387-1" escape="true">Term Loan </ix:nonNumeric></span></div><ix:continuation id="f-387-1" continuedAt="f-387-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company entered into the Loan Agreement with PWB. Under the terms of the Loan Agreement, PWB made available a term loan in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="howl:DebtInstrumentMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-388">20.0</ix:nonFraction> million (“Tranche I Loan”) available at any time after the closing date until February 28, 2024 as extended to August 31, 2024 upon the satisfaction of certain conditions set forth in the Loan Agreement (such date, the “Amortization Date”). Based on the satisfaction of certain conditions defined in the Loan Agreement, PWB was also obligated to make available an additional term loan in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="howl:DebtInstrumentMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-389">20.0</ix:nonFraction> million (“Tranche II Loan”, or collectively with the Tranche I Loan, the “Term Loans”) available at any time after the closing date until the Amortization Date upon the acceptance by the U.S. Food and Drug Administration (the “FDA”) of two investigational new drug (“IND”) submissions on or before March 31, 2023. As of June 30, 2023, the Company has drawn down $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-390">40.0</ix:nonFraction> million of the Term Loans.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-391" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outstanding notes payable balance under the Term Loans as of June 30, 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-392">40,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="f-393">858</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-394">39,142</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><ix:continuation id="f-387-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to the interest-only period, which ends on August 31, 2024, the Company is required to make equal monthly principal payments plus interest until the Term Loans mature on August 31, 2026. The Term Loans will bear interest on the outstanding daily balance at a floating annual rate equal to greater of: (i) <ix:nonFraction unitRef="number" contextRef="c-67" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-395">0.5</ix:nonFraction>% above the prime rate then in effect or (ii) <ix:nonFraction unitRef="number" contextRef="c-68" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-396">4.5</ix:nonFraction>%. If the prime rate changes throughout the term, the interest rate will be adjusted effective on the date of the prime rate change. All interest chargeable under the Loan Agreement is computed on a 360-day year for the actual number of days elapsed, with interest payable monthly. The Company recognized interest expense related to the Loan Agreement of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-397">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-398">1.0</ix:nonFraction> million during the three and six months ended June 30, 2023, respectively. The Company did <ix:nonFraction unitRef="usd" contextRef="c-71" decimals="INF" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-399"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="INF" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-400">not</ix:nonFraction></ix:nonFraction> incur interest expense during the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was obligated to pay PWB a one-time fee in the event of certain corporate transactions equal to either (i) the greater of (a) $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityFee" format="ixt:num-dot-decimal" scale="6" id="f-401">0.2</ix:nonFraction> million and (b) <ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="howl:DebtInstrumentConditionalFeePercentageOfAmountDrawn" scale="-2" id="f-402">2.0</ix:nonFraction>% of the amount drawn under the Term Loans, for a transaction occurring on or before March 31, 2023, or (ii) for any transaction occurring thereafter, the greater of (a) $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:DebtInstrumentUnusedBorrowingCapacityFee" format="ixt:num-dot-decimal" scale="6" id="f-403">0.4</ix:nonFraction> million and (b) <ix:nonFraction unitRef="number" contextRef="c-76" decimals="3" name="howl:DebtInstrumentConditionalFeePercentageOfAmountDrawn" scale="-2" id="f-404">4.0</ix:nonFraction>% of the amount drawn under the Term Loans (the “Success Fee”). The Success Fee Event occurred during the second quarter of 2023, resulting in the immediate payment in full of the $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="howl:SuccessFeeLiabilityPaid" format="ixt:num-dot-decimal" scale="6" id="f-405">1.6</ix:nonFraction> million required Success Fee, and resulting in a total of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="howl:DebtInstrumentConditionalFeeLiability" format="ixt:fixed-zero" scale="6" id="f-406">0.0 million</ix:nonFraction> as a success fee liability as of June 30, 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All outstanding obligations under the Loan Agreement are secured by the Company’s personal property (exclusive of any intellectual property) and are subject to acceleration in the event of default. In the event of a late payment or default, the Company is obligated to pay a fee equal to <ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="howl:DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" scale="-2" id="f-407">5.0</ix:nonFraction>% of such unpaid amounts. In connection with the Loan Agreement, the Company is required to comply with certain negative covenants, which among other things, restrict the Company from (i) incurring future debt or granting liens, (ii) effectuating a merger or consolidation with or into any other business organization, (iii) paying dividends or making certain other distributions, (iv) selling or otherwise transferring its assets, (v) making investments in any entities or instruments other than certain investments specified in the Loan Agreement and (vi) making capitalized expenditures in excess of <ix:nonFraction unitRef="number" contextRef="c-77" decimals="INF" name="howl:DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" scale="-2" id="f-408">125</ix:nonFraction>% of the amount provided for in the annual budget approved by the board of directors. The Loan Agreement also contains standard affirmative covenants, including with respect to the issuance of audited consolidated financial statements, insurance, and maintenance of good standing and government compliance in the Company’s state of formation. On or before September 30, 2023, the Company was required to raise aggregate gross cash process of at least $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-409">50.0</ix:nonFraction> million from the sale or issuance of the Company’s equity or from strategic partnerships or any similar transaction. From after receipt of those proceeds, the Company is required to maintain at all times at least $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="f-410">20.0</ix:nonFraction> million of otherwise unrestricted cash in accounts with PWB, which is included within “Restricted cash and cash equivalents” on our Balance Sheets. On April 17, 2023, the Company achieved the $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-411">50.0</ix:nonFraction> million funding milestone, triggering the corresponding $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="f-412">20.0</ix:nonFraction> million cash covenant, full payment of the Success Fee of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="howl:SuccessFeeLiabilityPaid" format="ixt:num-dot-decimal" scale="6" id="f-413">1.6</ix:nonFraction> million, and the updated Amortization Date of August 31, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PWB has the right to accelerate all outstanding obligations of the Company under the Loan Agreement or terminate any remaining Term Loan commitments in the event of a material adverse effect on (i) the operations, business or financial condition of the Company, (ii) the Company’s ability to repay any portion of the Term Loans or perform any of its other obligations under the Loan Agreement, and (iii) the Company’s interest in, or the value, perfection or priority of PWB’s security interest in the collateral. As of June 30, 2023, the Company had drawn both Term Loans and had $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-414">40.0</ix:nonFraction> million outstanding principal.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_55"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-415" continuedAt="f-415-1" escape="true">Common and Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="f-415-1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-416">200.0</ix:nonFraction> million shares of common stock. Common stockholders are entitled to dividends if and when declared by the Company’s board of directors. As of June 30, 2023, <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="f-417">no</ix:nonFraction> dividends on common stock had been declared by the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 10, 2022, the Company entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB”), pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="howl:CommonStockAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-418">50.0</ix:nonFraction> million (the “ATM Offering”). The Sales Agreement provides that SVB will be entitled to a sales commission equal to <ix:nonFraction unitRef="number" contextRef="c-81" decimals="3" name="howl:SalesCommissionsPercentage" scale="-2" id="f-419">3.0</ix:nonFraction>% of the gross sales price per share of all shares sold under the ATM Offering. As of June 30, 2023, the Company had sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-420">7,923,848</ix:nonFraction> shares under the ATM Offering at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-421">3.33</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-422">25.0</ix:nonFraction> million after deducting sales commissions and offering expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-423">5.0</ix:nonFraction> million shares of undesignated preferred stock in one or more series. As of June 30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-424"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-425">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="f-426" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-84" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-427">6,746</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-85" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-428">5,244</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-429">317</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-430">323</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-431">59</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-432">59</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-433">530</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-434">244</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-435">1,017</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-436">939</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-437">8,669</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-438">6,809</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-439" continuedAt="f-439-1" escape="true">Stock-based Compensation </ix:nonNumeric></span></div><ix:continuation id="f-439-1" continuedAt="f-439-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2017, the Company adopted the 2017 Stock Incentive Plan (the “2017 Plan”), as amended and restated, under which it could grant incentive stock options (“ISOs”), non-qualified stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and other stock-based awards to eligible employees, officers, directors and consultants. The terms of stock options and RSAs, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2017 Plan. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, the board of directors adopted and the Company’s stockholders approved the 2021 Stock Incentive Plan (the “2021 Plan”), which became effective immediately prior to the effectiveness of the Company’s initial public offering (“IPO”). As a result of the adoption of the 2021 Plan, no further awards will be made under the 2017 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2021 Plan provides for the grant of ISOs, non-qualified stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. The Company’s employees, officers, directors, consultants and advisors are eligible to receive awards under the 2021 Plan. The terms of awards, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2021 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company initially registered <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-440">3,352,725</ix:nonFraction> shares of common stock under the 2021 Plan, pursuant to a Registration Statement on Form S-8 filed with the SEC on April 30, 2021, which was comprised of (i) <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-441">2,843,116</ix:nonFraction> shares of common stock reserved for issuance under the 2021 Plan, (ii) <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-442">31,884</ix:nonFraction> shares of common stock originally reserved for issuance under the 2017 Plan that became available for issuance under the 2021 Plan upon the completion of the IPO, and (iii) <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-443">477,725</ix:nonFraction> shares of unvested restricted stock subject to repurchase by the Company that may become issuable under the 2021 Plan following such repurchase. The 2021 Plan also provides that an additional number of shares will be added annually to the shares authorized for issuance under the 2021 Plan on the first day of each fiscal year, beginning with the fiscal year ended December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031. The number of shares added each year will be equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-98" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-444">5</ix:nonFraction>% of the number of outstanding common stock on such date and (ii) such amount as determined by the board of directors. Effective January 1, 2022 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-445">1,380,397</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-446">1,575,753</ix:nonFraction> additional shares, respectively, were automatically added to the shares reserved for issuance under the 2021 Plan pursuant to this evergreen provision.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-447">1,017,062</ix:nonFraction> shares available for future issuance under the 2021 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, the board of directors adopted and the Company’s stockholders approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective immediately prior to the effectiveness of the IPO. The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-448">244,000</ix:nonFraction> shares of common stock for future issuance under the 2021 ESPP. The 2021 ESPP provides that an additional number of shares will automatically be added to the shares reserved for issuance on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing for each fiscal year until, and including, the fiscal year ending on December 31, 2032. The number of shares added each year will be equal to the lowest of (i) <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-449">488,000</ix:nonFraction> shares of common stock, (ii) <ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-450">1</ix:nonFraction>% of the number of shares of outstanding common stock on such date, and (iii) such amount as determined by the board of directors. Effective January 1, 2023, <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-451">315,150</ix:nonFraction> additional shares were automatically added to the shares reserved for issuance under the 2021 ESPP pursuant to the evergreen provision. The Company initiated its first offering period under the 2021 ESPP in December 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2021 ESPP provides that eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-452">15</ix:nonFraction>% of their eligible earnings toward the semi-annual purchase of the Company’s common stock. The 2021 ESPP is qualified under Section 423 of the Internal Revenue Code. The employee’s purchase price is derived from a formula based on the closing price of the common stock on the first day of the offering period versus the closing price on the last date of purchase (or, if not a trading day, on the immediately preceding trading day). The offering period under the 2021 ESPP has a duration of <ix:nonNumeric contextRef="c-106" name="howl:EmployeeStockOwnershipPlanOfferingPeriod" format="ixt-sec:durwordsen" id="f-453">six months</ix:nonNumeric>, and the purchase price with respect to each offering period beginning on or after such date is, until otherwise amended, equal to <ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="howl:EmployeeStockOwnershipPlanPurchasePricePercent" scale="-2" id="f-454">85</ix:nonFraction>% of the lesser of (i) the fair market value of the Company’s common stock at the commencement of the applicable <ix:nonNumeric contextRef="c-106" name="howl:EmployeeStockOwnershipPlanOfferingPeriod" format="ixt-sec:durwordsen" id="f-455">six-month</ix:nonNumeric> offering period or (ii) the fair market value of the Company’s common stock on the purchase date. The Company estimates the fair value of the common stock under the 2021 ESPP using a Black-Scholes valuation model. The fair value was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following assumptions: risk-free interest rate (<ix:nonFraction unitRef="number" contextRef="c-106" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-456">3.8</ix:nonFraction>%); expected term (<ix:nonNumeric contextRef="c-106" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-457">0.5</ix:nonNumeric> years); expected volatility (<ix:nonFraction unitRef="number" contextRef="c-106" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-458">92.7</ix:nonFraction>%); and an expected dividend yield (<ix:nonFraction unitRef="number" contextRef="c-106" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-459">0</ix:nonFraction>%). The Company recorded less than $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-460"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-461">0.1</ix:nonFraction></ix:nonFraction> million of stock-based compensation under the 2021 ESPP for the three and six months ended June 30, 2023. As of June 30, 2023, there was unrecognized stock-based compensation expense of less than $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-462">0.1</ix:nonFraction> million related to the most recent ESPP offering period, which ended May 31, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-463" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-464">1,019</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-465">806</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-466">2,039</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-467">1,587</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-468">911</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-469">971</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-470">1,999</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-471">1,936</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-472">1,930</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-473">1,777</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-474">4,038</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-475">3,523</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><ix:continuation id="f-439-2" continuedAt="f-439-3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">RSA Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may, at its discretion, repurchase unvested shares of restricted stock issued pursuant to the 2017 Plan at the initial purchase price if the employees or non-employees terminate their service relationship with the Company.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-476" continuedAt="f-476-1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSA activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-477">81</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-478">1.38</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="f-479">—</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-480">—</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-120" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-481">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-482">1.38</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-483">—</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-484">—</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-485">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-486">1.38</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested RSAs of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-487">0</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate fair value of RSAs that vested during the three months ended June 30, 2023 and 2022, based upon the fair values of the stock underlying the RSAs on the day of vesting, was $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-488">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-489">0.3</ix:nonFraction> million, respectively. The aggregate fair value of RSAs that vested during the six months ended June 30, 2023 and 2022, based upon the fair values of the stock underlying the RSAs on the day of vesting, was $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-490">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-491">0.8</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has also granted RSUs to its employees under the 2021 Plan. <ix:continuation id="f-476-1" continuedAt="f-476-2">The following table summarizes RSU activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </ix:continuation></span></div><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="f-476-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-492">323</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-493">4.32</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="f-494">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-495">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="f-496">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-497">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-498">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-499">4.97</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-500">317</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-501">4.32</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested RSUs of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-502">0.6</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-126" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-503">0.7</ix:nonNumeric> year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-504"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-505">No</ix:nonFraction></ix:nonFraction> RSUs vested during the three or six months ended June 30, 2023 or 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company granted performance-based stock options to certain executive officers for the purchase of an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-506">883,352</ix:nonFraction> shares of common stock with a grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-507">3.36</ix:nonFraction> per share. These stock options vest only upon achievement of specified performance targets related to certain business objectives. As of June 30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-508">none</ix:nonFraction> of these options were vested because none of the specified performance targets had been achieved. Because achievement of the specified performance targets was not deemed probable as of June 30, 2023, the Company did not record any expense for these stock options from the date of issuance through June 30, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-509" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of stock options granted during the three and six months ended June 30, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-510">3.8</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-511">3.0</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-512">3.9</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-513">1.9</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-131" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-514">5.7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-515">5.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-516">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-517">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-518">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-519">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-520">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-521">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-522">82.6</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-523">77.5</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-524">82.6</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-525">76.3</ix:nonFraction> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the three months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-526">2.24</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-527">2.48</ix:nonFraction> per share, respectively. Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the six months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-528">1.55</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-529">6.25</ix:nonFraction> per share, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><ix:continuation id="f-439-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-530" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-531">5,244</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-532">7.86</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-533">8.34</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-534">1,560</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-535">2.14</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-536">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-537">2.05</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-538">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-539">9.06</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-540">6,746</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-541">6.53</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-542">8.37</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-543">2,457</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-544">7.58</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-545">7.96</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic fair value of stock options exercised during the three months ended June 30, 2023 and 2022 was less than $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-546"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-547"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-548">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million in both periods. The aggregate intrinsic fair value of stock options exercised during the six months ended June 30, 2023 and 2022 was less than $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-549"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-550"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-551">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-552">0.3</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-553">16.9</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-133" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-554">1.9</ix:nonNumeric> years.</span></div></ix:continuation><div id="i4cadfe64e5d042d7864e5d59b36d7f40_61"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-555" continuedAt="f-555-1" escape="true">Related Parties </ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-555-1">In May 2022, the Company entered into a sublease agreement with Crossbow Therapeutics, Inc. (“Crossbow”), for which entities affiliated with MPM Capital (“MPM Capital”) are also beneficial owners, to sublease the entirety of its office and laboratory space in Cambridge, Massachusetts. Luke Evnin, Ph.D., the chair of the Company’s board of directors, co-founded MPM Capital and serves as Managing Director of MPM Capital. Briggs Morrison, who serves on the Company’s board of directors, serves as Executive Partner of MPM Capital and Chief Executive Officer of Crossbow. The term of the sublease agreement commenced in June 2022 and ends in March 2024, with no option to extend. The Company received cash payments under its sublease of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-556">0.8</ix:nonFraction> million during the six months ended June 30, 2023. In addition, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:SecurityDepositLiability" format="ixt:num-dot-decimal" scale="6" id="f-557">0.2</ix:nonFraction> million from Crossbow in June 2022 as a security deposit that is included within “Accrued expenses and other current liabilities” in the accompanying condensed consolidated balance sheets as of June 30, 2023.</ix:continuation></span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_64"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-558" continuedAt="f-558-1" escape="true">Net Loss Attributable to Common Stockholders per Share</ix:nonNumeric></span></div><ix:continuation id="f-558-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-559" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For purposes of the diluted net loss attributable to common stockholders per share calculation, outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, however the following weighted-average amounts were excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-560">6,746</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-561">4,383</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="f-562">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-563">178</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-564">317</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-565">236</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-566">59</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-567">59</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-568">7,122</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-569">4,856</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amounts and uncertainties of cash flows from operations and from outside resources, so as to allow investors to better view our company from management’s perspective. The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q, or Quarterly Report, and our Annual Report on Form 10-K for the year ended December 31, 2022, or the Annual Report on Form 10-K, that was filed with the United States Securities and Exchange Commission, or SEC, on March 23, 2023. In addition to historical information, the discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors we believe could cause or contribute to these differences below and elsewhere in this Quarterly Report, including those factors set forth in the section entitled “Cautionary Note Regarding Forward-Looking Statements and Industry Data” and in the section entitled “Risk Factors” in Part II, Item 1A of this Quarterly Report. You should carefully read the section entitled “Risk Factors” in Part II, Item 1A of this Quarterly Report.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_73"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINE molecules, are intended to activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12, respectively, INDUKINE molecules for the treatment of multiple tumor types. In the second quarter of 2022, we received clearance from the U.S. Food and Drug Administration, or the FDA, for our investigational new drug application, or IND, for WTX-124. In the third quarter of 2022, the first patient was dosed in a Phase 1/1b clinical trial to evaluate WTX-124 as a monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) in patients with advanced or metastatic solid tumors, with initial data anticipated in the fourth quarter of 2023. In the fourth quarter of 2022, we received clearance from the FDA for our IND for WTX-330. In the first quarter of 2023, the first patient was dosed in a Phase 1 clinical trial to evaluate the safety and tolerability of WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, we entered into a collaboration and license agreement, or the Collaboration Agreement, with Jazz Pharmaceuticals Ireland Limited, or Jazz, pursuant to which we granted Jazz certain licenses to develop and commercialize products containing our Interferon alpha (IFNα) INDUKINE molecule, JZP898 (formerly WTX-613), as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria which we refer to as the Licensed Products. Under the Collaboration Agreement, we are initially responsible for certain pre-clinical development activities with respect to JZP898 and other development activities specified in mutually agreed upon development plans. Jazz will generally reimburse us for the cost of such activities. Jazz is responsible for all other development and commercialization activities conducted to exploit the Licensed Products, including submission of an IND to the FDA. Jazz received IND application clearance for JZP898 in July 2023. Under the terms of the Collaboration Agreement, we received an upfront payment of $15.0 million in April 2022, and we are eligible to receive cost reimbursements for research services performed under the Collaboration Agreement. We are also eligible to receive up to $520.0 million in development and regulatory milestones, and up to $740.0 million in sales-based milestones for all Licensed Products. In addition, we are eligible to receive tiered mid-single digit royalties based on Jazz’s, and any of its affiliates’ and sublicensees’, annual net sales of Licensed Products, subject to reduction in specified circumstances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We were incorporated and commenced operations in 2017. Since inception, we have devoted substantially all of our time and efforts to performing research and development activities, raising capital and recruiting management and technical staff to support these operations. To date, we have financed our operations primarily with proceeds from the sales of our convertible promissory notes and equity securities and from the upfront payment that we received from Jazz pursuant to the terms of the Collaboration Agreement. From December 2017 to August 2018, we issued convertible promissory notes for aggregate gross cash proceeds of $11.0 million. From August 2019 to June 2020, we issued an aggregate of 80,246,565 shares of Series A preferred stock for aggregate gross cash proceeds of $44.2 million, together with conversion of all of our previously issued convertible promissory notes. In December 2020, we issued 78,222,173 shares of Series B preferred stock at a price of $0.92 per share, resulting in gross cash proceeds of $72.1 million. On May 4, 2021, we completed our initial public offering, or IPO, pursuant to which we issued and sold 7,500,000 shares of our common stock at a public offering price of $16.00 per share. We received net proceeds of approximately $109.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. On May 10, 2022, we entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, or SVB, pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $50.0 million, which we refer to as the ATM Offering. As of June 30, 2023, we had sold an aggregate of 7,923,848 shares under the ATM Offering at an average price of $3.33 per share for net proceeds of $25.0 million after deducting sales commissions and offering expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to our significant research and development expenditures, we have accumulated substantial net losses since our inception. As of June 30, 2023, we had an accumulated deficit of $323.8 million. We expect to continue to incur substantial and increasing expenses and net losses for the foreseeable future, as we continue to advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">failure to raise capital or enter into such agreements as and when needed could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to raise capital, maintain our research and development efforts, expand our business or continue our operations at planned levels, and as a result we may be forced to substantially reduce or terminate our operations.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_76"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have not generated any revenue to date from product sales and do not expect to do so in the near future. For the six months ended June 30, 2023, we recognized $12.5 million of revenue related to the Collaboration Agreement, of which $5.3 million related to the $15.0 million upfront payment received in April 2022 and $7.3 million related to costs incurred for research services to be reimbursed by Jazz. We had $2.4 million of deferred revenue as of June 30, 2023, which is classified as either current or net of current portion in our condensed consolidated balance sheets based on the period over which the revenue is expected to be recognized. As of June 30, 2023, we had not received any milestone or royalty payments under the Collaboration Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the future, we expect to continue to generate revenue from the Collaboration Agreement and may generate revenue from product sales or other collaboration agreements, strategic alliances and licensing arrangements. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year based upon our pattern of performance under the Collaboration Agreement and as a result of the timing and amount of milestones, reimbursement of costs incurred and other payments and product sales, to the extent any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">expenses incurred under agreements with third parties that conduct research, preclinical and clinical activities on our behalf; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of performance of the individual arrangements, which may differ from the pattern of billings incurred, and are reflected in our condensed consolidated financial statements as prepaid or accrued research and development expenses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We typically use our employee and infrastructure resources across our development programs. We track external development costs by product candidate or development program, but generally we do not allocate personnel costs, license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our external development costs (credits) for the three and six months ended June 30, 2023 and 2022 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:46.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WTX-124</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WTX-330</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">JZP898 (formerly WTX-613)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WTX-712</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-development candidates</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total external development costs</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,785 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,442 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,420 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we progress our clinical trials of WTX-124 and WTX-330, complete pre-clinical requirements for WTX-712, and continue to discover and develop additional product candidates. As a result of our entry into the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration Agreement, which commenced in April 2022, our external preclinical development costs for JZP898 will generally be reimbursed by Jazz. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in development costs in the three months ended June 30, 2023, for WTX-124 and WTX-330 is primarily due to a decrease in manufacturing costs incurred with contract manufacturing organizations to support the production of preclinical, current, and future clinical trial materials, and favorable adjustments recognized during the quarter upon the closeout of completed purchase orders, as more fully described below under “Results of Operations – Research and Development Expenses.” </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. We cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete development of our current or future product candidates. The actual probability of success for our product candidates will depend on a variety of factors, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the scope, rate of progress and expenses of our ongoing research activities as well as any preclinical studies and clinical trials, including our ongoing Phase 1/1b clinical trial for WTX-124 and Phase 1 clinical trial for WTX-330, and other research and development activities; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">establishing an appropriate safety profile; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">successful enrollment in and completion of clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">whether our product candidates show safety and efficacy in our clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">receipt of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">continued acceptable safety profile of the products following any regulatory approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly change the costs and timing associated with the development of those product candidates and we may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development activities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel in our executive, finance, people operations, business development, legal, IT and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support the increasing size and complexity of our research, development and manufacturing activities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net consists primarily of remeasurement gains or losses attributable to changes in the fair value of the success payment liability associated with our debt agreement with Pacific Western Bank, or PWB, and amortization of debt issuance costs related to our debt agreement with PWB. For more information see “Liquidity and Capital Resources” below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income, net consists of interest income earned from our cash and cash equivalents, net of interest expense incurred from our Loan Agreement with PWB.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2023 and 2022 </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,972)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,905 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,098)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,594)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,496 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue was $8.1 million for the three months ended June 30, 2023, which is comprised of amortization of the $15.0 million upfront payment received in April 2022 upon the execution of the Collaboration Agreement with Jazz and costs incurred for research services to be reimbursed by Jazz. There was $4.1 million in collaboration revenue in the three months ended June 30, 2022. This $3.9 million increase in collaboration revenue is driven by an increase in reimbursable costs, pertaining to consumable materials used in research and development activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Personnel</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,897 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lab consumables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,583 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,887 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,304)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended June 30, 2023 were $9.6 million, compared to $13.9 million for the three months ended June 30, 2022. The decrease of $4.3 million was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$4.2 million of decreased manufacturing costs driven by a decrease of $3.1 million to costs incurred with contract manufacturing organizations to support the production of preclinical, current, and future clinical trial materials associated with candidates WTX-124, WTX-330, WTX-712, and JZP898, and $1.1 million of favorable adjustments recognized during the quarter upon the closeout of completed purchase orders; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.8 million of decreased contract research costs, driven by significant proof-of-concept (or “POC”) costs in the prior year for WTX-330 and JZP898 compared to current period POC costs for WTX-712; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.4 million of increased lab consumables costs primarily related to expanded discovery efforts and headcount; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.4 million of increased clinical trial costs, primarily related to expansion of sites for both WTX-124 and WTX-330.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the three months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Personnel</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IT costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,565 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses were $4.6 million for the three months ended June 30, 2023, compared to $5.2 million for the three months ended June 30, 2022. The decrease of $0.7 million was primarily due to a reduction in insurance premiums in the current period and less utilization of advisory/legal costs in maintaining day-to-day operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, other income (expense), net decreased to less than $(0.1) million from $0.3 million for the three months ended June 30, 2022. This decrease was primarily due to the final fair value adjustment of the success payment liability during the three months ended June 30, 2023, immediately preceding the payment to PWB upon the Success Fee Event (as described below under “Liquidity and Capital Resources – Term Loan Facility”).</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income was $1.0 million for the three months ended June 30, 2023, compared to less than $0.1 million for the three months ended June 30, 2022. This increase in interest income was primarily as a result of higher interest rates in 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_82"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2023 and 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,543)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,651)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating loss</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,290)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,338)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,080)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,937)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue was $12.5 million for the six months ended June 30, 2023, which is comprised of amortization of the $15.0 million upfront payment received in April 2022 upon the execution of the Collaboration Agreement with Jazz and costs incurred for research services to be reimbursed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">by Jazz. There was $4.1 million in collaboration revenue in the six months ended June 30, 2022. This $8.4 million increase in collaboration revenue is driven by an increase in reimbursable costs, pertaining to consumable materials used in research and development activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,243)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract research organization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lab consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,289 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,832 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,543)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses for the six months ended June 30, 2023 were $21.3 million, compared to $24.8 million for the six months ended June 30, 2022. The decrease of $3.5 million was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$5.2 million of decreased manufacturing costs driven by a decrease of $3.8 million in costs incurred with contract manufacturing organizations to support the production of preclinical, current, and future clinical trial materials associated with candidates WTX-124, WTX-330, WTX-712, and JZP898, and $1.4 million of favorable adjustments recognized during the quarter upon the closeout of completed purchase orders;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.7 million of increased lab consumables costs primarily related to expanded discovery efforts and headcount;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.6 million of increased personnel costs, including $0.5 million of increased stock-based compensation expense, primarily due to increased headcount associated with expanded discovery efforts as well as the hiring of a clinical development team; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.6 million of increased clinical trial costs due to expansion of clinical sites for WTX-124 and WTX-330.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Personnel</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,775 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,206 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IT costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,546 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,654 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses were $9.5 million for the six months ended June 30, 2023, compared to $9.7 million for the six months ended June 30, 2022. The decrease of $0.1 million was primarily due to </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.3 million of decreased corporate insurance costs, driven by reduction in associated premiums; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">$0.3 million of increased personnel costs, including less than $0.1 million of increased stock-based compensation expense, due to increased headcount to support operating as a public company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June 30, 2023, other expense, net decreased to $(1.1) million from $0.3 million for the six months ended June 30, 2022. This decrease was primarily due to the loss on fair value adjustments of the success payment liability incurred during the six months ended June 30, 2023</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest income was $2.3 million the six months ended June 30, 2023, compared to $0.1 million for the six months ended June 30, 2022. This increase in interest income was primarily as a result of higher interest rates in 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have funded our operations through June 30, 2023 primarily through aggregate cash proceeds from convertible promissory notes of $11.0 million, gross proceeds from private placements of our convertible preferred stock of $116.3 million, net proceeds from our IPO of $109.2 million, a non-refundable upfront payment of $15.0 million received in connection with the Collaboration Agreement, $11.2 million of expense reimbursements from Jazz pursuant to the Collaboration Agreement, net proceeds from our ATM Offering of $25.0 million and the drawdown of $40.0 million of Term Loans.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Jazz Collaboration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, we entered into the Collaboration Agreement with Jazz. Under the terms of the Collaboration Agreement, we received an upfront payment of $15.0 million in April 2022, and we are eligible to receive cost reimbursements for research services performed under the Collaboration Agreement. In addition, we are eligible to receive up to $520.0 million in development and regulatory milestones, and up to $740.0 million in sales-based milestones for all Licensed Products. In addition, we are eligible to receive tiered mid-single digit royalties based on Jazz’s, and any of its affiliates’ and sublicensees’, annual net sales of Licensed Products, subject to reduction in specified circumstances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan Facility</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, we entered into an amended and restated loan and security agreement, or the Loan Agreement, with PWB, which amended and restated in its entirety our previous loan and security agreement with PWB.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Loan Agreement, PWB made available term loans in an aggregate principal amount of up to $40.0 million, or the Term Loans, consisting of (i) a term loan in the aggregate principal amount of up to $20.0 million available at any time until February 28, 2024 (which was extended to August 31, 2024 upon the satisfaction of certain conditions set forth in the Loan Agreement), or the Amortization Date, and (ii) a term loan in the aggregate principal amount of up to $20.0 million available at any time until the Amortization Date upon the acceptance by the FDA of two IND submissions on or before March 31, 2023. On March 15, 2023, we drew down $40.0 million of the Term Loans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Term Loans bear interest on the outstanding daily balance at a floating annual rate equal to greater of: (i) 0.5% above the prime rate then in effect or (ii) 4.50%. If the prime rate changes throughout the term, the interest rate is adjusted effective on the date of the prime rate change. All interest chargeable under the Loan Agreement is computed on a 360-day year for the actual number of days elapsed, with interest payable monthly. The Loan Agreement provides for interest-only payments until the Amortization Date, at which time the aggregate outstanding principal balance of the Term Loans is required to be repaid in monthly installments on a 24-month repayment schedule. All unpaid principal and accrued and unpaid interest with respect to the Term Loans is due and payable in full on August 31, 2026. At our option, we may elect to prepay all, or any part, of the outstanding Term Loans at any time without premium or penalty.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We were obligated to pay PWB a one-time fee in the event of certain corporate transactions equal to either (i) the greater of (a) $200,000 and (b) 2.00% of the amount drawn under the Term Loans for a transaction occurring on or prior to March 31, 2023, or (ii) for any transaction occurring thereafter, the greater of (a) $400,000 and (b) 4.00% of the amount drawn under the Term Loans, which fee is referred to as a Success Fee, upon the occurrence of a Success Fee Event (as defined in the Loan Agreement). In April 2023, the Success Fee Event occurred and, as such, we became obligated to pay the corresponding Success Fee to PWB, in accordance with the terms of the Loan Agreement. We removed the corresponding financial instrument for the Success Fee liability and paid the total $1.6 million upon occurrence of the Success Fee Event. Upon occurrence of the Success Fee Event, the Amortization Date was extended to August 31, 2024, thereby extending the due date for all unpaid principal and accrued and unpaid interest with respect to the Term Loans to August 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Loan Agreement, we are required to comply with certain negative covenants, which among other things, restrict us from incurring future debt or granting liens, effectuating a merger or consolidation with or into any other business organization, paying dividends or making certain other distributions, selling or otherwise transferring our assets, and making investments in any entities or instruments, subject, in each case, to certain exceptions specified in the Loan Agreement. The Loan Agreement also contains standard affirmative covenants, including with respect to the issuance of audited consolidated financial statements, insurance, maintenance of good standing and government compliance in our state of formation. We maintain at least $20.0 million of cash in PWB accounts, included within “Restricted cash and cash equivalents” on our Balance Sheets, which we are required to maintain at all times pursuant to the terms of the Loan Agreement. Our failure to comply with any of the foregoing covenants would result in an event of default under the Loan Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 10, 2022, we entered the Sales Agreement with SVB, pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $50.0 million, which we refer to as the ATM Offering. The Sales Agreement provides that SVB will be entitled to a sales commission equal to 3.0% of the gross sales price per share of all shares sold under the ATM Offering. As of June 30, 2023, we had sold an aggregate of 7,923,848 shares under the ATM Offering at an average price of $3.33 per share for net proceeds of $25.0 million after deducting sales commissions and offering expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operation and Future Funding Requirements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We use our capital resources primarily to fund operating expenses, primarily research and development expenditures. We plan to increase our research and development expenses for the foreseeable future as we continue the preclinical and clinical development of our product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of our product candidates, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval and commercialize our current product candidates or any future product candidates, if at all. For the same reasons, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. Further, inflation generally affects us by increasing our cost of labor and certain services. We do not believe that inflation had a material effect on our financial statements included elsewhere in this Quarterly Report; however, our operations may be adversely affected by inflation in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to our significant research and development expenditures, we have accumulated substantial net losses in each period since inception. We have incurred an accumulated deficit of $323.8 million through June 30, 2023. We expect to continue to incur substantial and increasing expenses and net losses for the foreseeable future, as we continue to advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, we had cash and cash equivalents of $137.5 million. We expect that our existing cash and cash equivalents, together with anticipated collaboration revenue, will be sufficient to fund our operational expenses and capital expenditure requirements through at least the fourth quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, however, and we could use our capital resources sooner than we expect. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The timing and amount of our operating expenditures will depend largely on: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the scope, progress, timing, costs and results of researching and developing our current product candidates or any future product candidates, including with respect to our clinical trials of WTX-124 and WTX-330 and the costs associated with attracting, hiring and retaining skilled personnel and consultants as our preclinical and clinical activities increase; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the cost of manufacturing our product candidates WTX-124, WTX-330, and any future product candidates for clinical trials and, if we are able to obtain marketing approval, for commercial sale; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs of any third-party products used in our combination clinical trials that are not covered by such third parties or other sources; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the success of our collaboration with Jazz;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the timing of, and the cost involved in, obtaining marketing approval for WTX-124 and WTX-330, or any future product candidates, and our ability to obtain marketing approval and generate revenue from any potential commercial sales of such product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the cost of building a sales force in anticipation of product commercialization and the cost of commercialization activities for WTX-124, WTX-330, or any future product candidates if we receive marketing approval, including marketing, sales and distribution costs; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the potential emergence of competing therapies and other adverse market developments; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the amount and timing of any payments we may be required to make pursuant to our license agreement with Harpoon Therapeutics, Inc., or Harpoon, or other future license agreements or collaboration agreements; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our ability to establish future collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any product liability or other lawsuits related to our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the extent to which we in-license or acquire other products and technologies; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs of operating as a public company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our existing cash and cash equivalents will not be sufficient to complete development of WTX-124, WTX-330 or any other product candidate. Accordingly, we will be required to obtain further funding to achieve our business objectives.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity may result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations, cash flows and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">six months ended June 30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and 2022 (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June 30, 2023 was $20.8 million, compared to $14.3 million for the six months ended June 30, 2022. This increase of $6.6 million was primarily attributable to the $18.3 million difference in the change to deferred revenue during each period. For the six months ended June 30, 2023, deferred revenue decreased $5.2 million due to the continued progress in Jazz collaboration research, compared to an increase of $13.1 million for six months ended June 30, 2022 related to the non-refundable upfront cash payment at the inception of the Collaboration Agreement. This was partially offset by a decrease in net loss for the comparable periods of $12.9 million, primarily driven by increased revenue recorded under the Collaboration Agreement for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June 30, 2023 was $0.4 million, compared to $1.1 million for the six months ended June 30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This decrease was driven by high capital expenditures in the second quarter of 2022 related to leasehold improvements for our new headquarters, which was established in May 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June 30, 2023 was $49.3 million, compared to $3.6 million for the six months ended June 30, 2022. Cash provided by financing activities for the six months ended June 30, 2023 primarily consisted of proceeds from the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $40.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> drawdown of the Term Loans and proceeds from our ATM Offering during the period, which included $5.7 million of additional ATM offering proceeds in comparison to those for the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements with CROs, contact manufacturers, vendors and other third parties for preclinical studies and clinical trials, manufacturing services and other services and products for operating purposes. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan Facility </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See “Liquidity and Capital Resources – Sources of Liquidity – Term Loan Facility”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for a description of our Loan Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, we had drawn the Term Loans for a total principal of $40.0 million. Upon achievement of the Loan Agreement’s funding milestone, the maturity date of the Term Loans was extended to August 31, 2026. Interest-only payments are to be made until August 31, 2024, at which point the interest-only period lapses and consecutive equal payments of principal are due along with interest. The Term Loans bear interest at a floating annual rate equal to the greater of: (i) 0.5% above the prime rate then in effect or (ii) 4.5%. If the prime rate changes throughout the term, the interest rate will be adjusted effective on the date of the prime rate change. All interest chargeable under the Loan Agreement is computed on a 360-day year for the actual number of days elapsed, with interest payable monthly.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total estimated base rent payments over the remaining term of the lease for office and laboratory space that we entered into in April 2019 as our prior headquarters are approximately $0.7 million. In May 2022, we entered into a sublease agreement with Crossbow Therapeutics, Inc., or Crossbow, to sublease the entirety of this space. The annual rent from the subleased premises will be approximately $1.1 million in the first year and $1.0 million in the second year, which is greater than the annual rent paid by us to the landlord for the leased premises. Crossbow is obligated to pay all real estate taxes and costs related to the subleased premises, including cost of operations, maintenance, repair, replacement, and property management.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The lease for office and laboratory space that we entered into in June 2021 commenced in May 2022. Total estimated base rent payments over the remaining term of the lease are approximately $16.9 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates which include, but are not limited to, accrued expenses, stock-based compensation expense and income taxes. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 23, 2023. During the three and six months ended June 30, 2023, there were no material changes to our critical accounting policies from those previously disclosed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election and Smaller Reporting Company Implications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act. Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company,” which would allow us to continue to take advantage of reduced disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act if we are a smaller reporting company with less than $100.0 million in annual revenue.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_91"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and are not required to provide the information under this item.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were not effective due to a material weakness in our internal control over financial reporting as discussed below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Based on our assessment as of June 30, 2023, management concluded that our internal control over financial reporting was not effective due to a material weakness relating to design and operating deficiencies in our purchasing process, specifically related to the application of invoices to purchase orders and processes to estimate progress on open purchase orders and to identify inaccurate expense estimates within purchase orders.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notwithstanding this material weakness, our management, including our chief executive officer and chief financial officer, has concluded that our financial statements in this Quarterly Report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America. The material weakness did not result in any restatements of consolidated financial statements previously reported by us, nor were there any changes to previously released financial results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Remediation Plan </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have implemented, and are continuing to implement, measures designed to improve internal control over financial reporting to remediate the control deficiencies that led to the material weakness by, among other things, expanding managerial oversight of, and adding process controls to, our purchasing process, including approval and ongoing management of purchase orders and related invoices, and assessment of progress and estimated expenses. We have utilized and will continue to utilize financial consultants to assist with the evaluation and documentation of process controls. We expect to complete the remediation of the material weakness in the near future by hiring additional finance personnel and the continued adoption of incremental financial policies, procedures, and internal controls.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the most recent financial quarter covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Subsequent to the identification of the material weakness described above, management has taken actions to remediate the deficiency that resulted in that material weakness.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_97"></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II—OTHER INFORMATION</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider the risks described below, as well as the other information in this Quarterly Report, including our condensed consolidated financial statements and the related notes and Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations and future growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. This Quarterly Report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are an early-stage biopharmaceutical company with a limited operating history upon which our business and prospects can be evaluated. We commenced operations in 2017. To date, we have focused primarily on organizing and staffing our company; business planning; raising capital; developing and optimizing our platform technology; identifying potential product candidates; enhancing our intellectual property portfolio; undertaking research, preclinical studies, and clinical trials; and enabling manufacturing for our development programs. Our approach to the discovery and development of product candidates based on our PREDATOR platform is unproven, and we do not know whether we will be able to develop any approved products of commercial value. In addition, we currently only have two product candidates that we are developing independently, WTX-124 and WTX-330, and all of our other development programs are in discovery or preclinical stages. We have not yet demonstrated an ability to successfully complete any Phase 1, Phase 2 or pivotal clinical trials, obtain regulatory approvals, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct the sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have incurred significant operating losses since our inception and have not yet generated any product revenue. If our product candidates are not successfully developed and approved, we may never generate any product revenue. Our net loss was $5.1 million for the three months ended June 30, 2023 . As of June 30, 2023, we had an accumulated deficit of $323.8 million. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as WTX-124 and WTX-330 advance through development, and any future product candidates advance through preclinical studies and into and through clinical trials, and as we expand our clinical, regulatory, quality and manufacturing capabilities and incur additional costs associated with operating as a public company. If we obtain marketing approval for any of our product candidates, we will incur significant commercialization expenses for marketing, sales, manufacturing and distribution. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to develop commercial capabilities, and we may not be successful in doing so. The net losses we incur may fluctuate significantly from quarter to quarter and year to year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from our product candidates or product sales, we do not expect to generate any revenue from the sale of products for a number of years and we may never generate revenue from the sale of products. Our ability to generate product revenue depends on a number of factors, including, but not limited to, our ability to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">successfully complete our ongoing and planned preclinical studies;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">successfully submit INDs to the FDA for any future product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">successfully complete clinical trials for WTX-124 and WTX-330;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">successfully enroll subjects in and complete future clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">initiate and successfully complete all safety and efficacy studies to obtain U.S. and foreign regulatory approval for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">establish clinical and commercial manufacturing capabilities or make arrangements with third party manufacturers for clinical supply and commercial manufacturing;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">obtain and maintain acceptance of the products, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">effectively compete with other therapies;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">obtain and maintain healthcare coverage and adequate reimbursement;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">enforce and defend intellectual property rights and claims; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">maintain a continued acceptable safety profile of our products following approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of expenses we may incur in connection with these activities prior to generating product revenue. In addition, we may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We will need to obtain substantial additional funding to finance our operations and complete the development and any commercialization of WTX-124, WTX-330 and any future product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate one or more of our research and development programs or other operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect to incur increasing expenses and operating losses over the next several years as we pursue clinical development of our product candidates and implement the additional infrastructure necessary to support our operations as a public reporting company. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for a number of years, if at all. If we obtain marketing approval for WTX-124, WTX-330 or any other product candidates that we develop, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. Some of these expenses may be incurred in advance of marketing approval and could be substantial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, we had cash and cash equivalents of $137.5 million. We expect that our existing cash and cash equivalents will allow us to complete the development of WTX-124 through dose escalation and expansion as a monotherapy or in combination with Merck’s anti-PD-1 therapy KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) and the development of WTX-330 through dose escalation and expansion as a monotherapy. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our cash and cash equivalents will not be sufficient to complete development of WTX-124, WTX-330 or any other product candidate. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed, on attractive terms or at all, would have a negative effect on our financial condition and our ability to develop and commercialize our current and any future product candidates, and otherwise pursue our business strategy and we may be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our cash forecasts are based on assumptions that may prove to be wrong, and we could use our available capital resources earlier than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional financing sooner than planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future capital requirements, both short-term and long-term, will depend on many factors, including:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the scope, progress, timing, costs and results of researching and developing our current product candidates or any future product candidates, including with respect to WTX-124 and WTX-330; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs associated with attracting, hiring and retaining skilled personnel and consultants as our preclinical and clinical activities increase; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the cost of manufacturing our lead product candidates, WTX-124 and WTX-330, and any future product candidates for clinical trials and, if we are able to obtain marketing approval, for commercial sale; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs of any third-party products used in our combination clinical trials that are not covered by such third parties or other sources; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the timing of, and the cost involved in, obtaining marketing approval for WTX-124, WTX-330 or any future product candidates, and our ability to obtain marketing approval and generate revenue from any potential commercial sales of such product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the cost of building a sales force in anticipation of product commercialization and the cost of commercialization activities for WTX-124, WTX-330 or any future product candidates if we receive marketing approval, including marketing, sales and distribution costs; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the potential emergence of competing therapies and other adverse market developments; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the amount and timing of any payments we may be required to make pursuant to our license agreement with Harpoon Therapeutics, Inc., or Harpoon, or other future license agreements or collaboration agreements; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our ability to establish future collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any product liability or other lawsuits related to our product candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the extent to which we in-license or acquire other products and technologies; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the costs of operating as a public company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We do not have any committed external source of funds, and adequate additional financing may not be available to us on acceptable terms, or at all. In addition, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions both inside and outside the U.S. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts or other operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our platform technology or product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless and until we can generate a substantial amount of product revenue, we expect to seek additional capital through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Our issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common stock to decline, and our stockholders may not agree with our financing plans or the terms of such financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. The incurrence of indebtedness would result in payment obligations and could require us to comply with certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to declare dividends, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Further, our ability to obtain additional debt financing may be limited by covenants we have made under our Loan Agreement, including our pledge to PWB of substantially all of our assets, other than our intellectual property, as collateral. If we raise additional funds through collaborations and licensing arrangements with third parties, we may have to relinquish valuable rights to our platform technology or product candidates or grant licenses on terms unfavorable to us. In addition, securing additional financing would require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management’s ability to oversee the development of our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have a term loan facility that requires us to comply with certain operating covenants and places restrictions on our operating and financial flexibility.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All outstanding obligations under the Loan Agreement are secured by our personal property (exclusive of any intellectual property), and are subject to acceleration upon an event of default. Under the Loan Agreement, we are required to comply with certain negative covenants, which among other things, restrict us from incurring future debt or granting liens, effectuating a merger or consolidation with or into any other business organization, paying dividends or making certain other distributions, selling or otherwise transferring our assets, and making investments in any entities or instruments, subject, in each case, to certain exceptions specified in the Loan Agreement. The Loan Agreement also contains standard affirmative covenants, including with respect to the issuance of audited consolidated financial statements, insurance, and maintenance of good standing and government compliance in our state of formation. We are required to maintain at all times at least $20.0 million of otherwise unrestricted cash in accounts with PWB. Our failure to comply with any of the foregoing covenants would result in an event of default under the Loan Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our financial obligations and contractual commitments under the Loan Agreement could have significant adverse consequences, including:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under our Loan Agreement, the occurrence of an event that would reasonably be expected to have a material adverse effect on our business, operations, assets or condition is an event of default. If an event of default occurs and the lenders accelerate the amounts due, we may not be able to make accelerated payments, and the lenders could seek to enforce security interests in the collateral securing such indebtedness, which includes substantially all of our assets other than our intellectual property. In addition, the covenants under our Loan Agreement, the pledge of our assets as collateral and the negative pledge with respect to our intellectual property could limit our ability to obtain additional debt financing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in tax laws or in their implementation or interpretation may adversely affect our business or financial condition. The Tax Cuts and Jobs Act of 2017, or TCJA, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, significantly revises the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such net operating losses may be carried forward indefinitely and, as a result of amendments made by the CARES Act, such net operating losses arising in taxable years beginning before January 1, 2021 are generally eligible to be carried back up to five years), one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the CARES Act, as part of Congress’s response to the COVID-19 pandemic, economic relief legislation was enacted in 2020 and 2021 containing tax provisions. Regulatory guidance under the TCJA and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen their impact on our business and financial condition. Also, as a result of the changes in the U.S. presidential administration and control of the U.S. Senate in 2021, additional tax legislation may be enacted; any such additional legislation could have an impact on us. In addition, it is uncertain if and to what extent various states will conform to the TCJA and additional tax legislation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history. We do not anticipate generating revenue from sales of products for the foreseeable future, if ever, and we may never achieve profitability. As of December 31, 2022, we had federal and state net operating loss carryforwards of $92.1 million and $86.1 million, respectively. Under Section 382 of the Code, if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain stockholders over a three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. As a result of our prior private placement financings or other transactions, we have experienced ownership changes on June 10, 2019, August 2, 2019 and August 31, 2022, and we may in the future experience ownership changes as a result of subsequent changes in our stock ownership for purposes of Section 382. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset U.S. federal taxable income are subject to limitations, which could result in increased future tax liability to us and could have an adverse effect on our future results of operations. There is also a risk that due to regulatory changes, such as suspension of the use of net operating losses, or for other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. As described above in “Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition,” the TCJA, as amended by the CARES Act, includes changes to U.S. federal tax rates and rules governing net operating loss carryforwards that may significantly impact our ability to utilize net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons, we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_106"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development, Regulatory Approval and Commercialization of Our Product Candidates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We are early in our development efforts and our current product candidates will require successful completion of preclinical and clinical development before we can seek regulatory approval for any product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are early in our development efforts and have invested substantially all of our efforts and financial resources in building our PREDATOR platform and developing our initial INDUKINE molecules by leveraging our PREDATOR platform. Our lead product candidates are at or near the beginning of the clinical trial stage. Additionally, we have a portfolio of programs that are in even earlier stages of preclinical development and may never advance to clinical-stage development. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our business is highly dependent on the success of our initial INDUKINE molecules, which are in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and launch a product commercially. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business and future success is highly dependent on our ability to obtain regulatory approval of and then successfully launch and commercialize our initial INDUKINE molecules, including our most advanced product candidates, WTX-124 and WTX-330. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA requests prior to commencing clinical trials, the start of a clinical trial may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may experience issues surrounding preliminary trial execution, such as delays in FDA acceptance of our INDs, revisions in trial design and finalization of trial protocols, difficulties with patient recruitment and enrollment, quality and provision of clinical supplies, or early safety signals. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are not permitted to market any biological product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar marketing application to comparable foreign regulatory authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. A BLA must also include significant information regarding the chemistry, manufacturing and controls for the product, and the manufacturing facilities must complete a successful pre-license inspection. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">FDA approval of a BLA is not guaranteed, and the review and approval process is expensive and uncertain and may take several years. The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for BLA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidate that we develop based on the completed clinical trials. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on our ability to successfully develop and commercialize WTX-124, WTX-330 and any future product candidates. The success of our product candidates will depend on several factors, including the following: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">completion of preclinical studies and clinical trials with favorable results; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">acceptance of INDs by the FDA or similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">receipt of marketing approvals from applicable regulatory authorities, including BLAs from the FDA and maintaining such approvals; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">maintaining an acceptable safety profile of our products following approval; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">maintaining and growing an organization of scientists and business people who can develop our products and technology. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally, public concern regarding the safety of biopharmaceutical products could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling or require us to undertake other activities that may entail additional costs. We have not obtained FDA approval for any product. This lack of experience may impede our ability to obtain FDA approval in a timely manner, if at all, for WTX-124, WTX-330 or any future product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of WTX-124, WTX-330 and any future product candidates, which may never occur. Given our early stage of development, it will be years before we are able to demonstrate the safety and efficacy of a treatment sufficient to warrant approval for commercialization, and we may never be able to do so. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our current or any future product candidates, we may not be able to generate sufficient revenue to continue our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of product candidates based on our PREDATOR platform is unproven, and we do not know whether we will be able to develop any products of commercial value. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to discover, develop and commercialize products based on our novel PREDATOR platform. While we have had favorable preclinical study results related to WTX-124 and WTX-330, both of which we are developing by leveraging our PREDATOR platform, we have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. We have no assurance that our PREDATOR platform will be able to produce product candidates that will successfully progress from preclinical studies into clinical development and ultimately marketing approval. We have invested substantially all of our efforts and financial resources in building our PREDATOR platform and developing our initial INDUKINE molecules by leveraging our PREDATOR platform, and our future success is highly dependent on the continued successful development of our platform and product candidates that we develop by leveraging our platform. Because all of our product candidates are based upon our PREDATOR platform, any development problems we may experience in the future related to any of our product candidates has the potential to impact the development of our other product candidates and any such development problems have the potential to cause significant delays or unanticipated costs and may ultimately not be able to be solved. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate may vary according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. As a result, we may face a greater regulatory burden to initiate clinical trials or to obtain regulatory approval of our product candidates as compared to product candidates based on more established technology. In addition, any product candidates for which we may be able to obtain marketing approval may be subject to extensive post-approval regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">requirements, including requirements pertaining to manufacturing, distribution and promotion. We may need to devote significant time and resources to compliance with these requirements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing INDUKINE molecules is subject to risk since they are a novel class of multi-domain biologics that include protease cleavable linkers, and they have never been produced on a clinical or commercial scale. We may be unable to manufacture INDUKINE molecules at the scale needed for clinical development and commercial production on a timely basis or at all, which would adversely affect our ability to conduct clinical trials and seek regulatory approvals or commercialize our programs, which would have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The manufacturing cell line currently in use to develop INDUKINE manufacturing processes has not been used to manufacture multi-domain proteins that include our protease cleavable linkers. The presence of these linkers presents a risk that unintended proteolysis may occur during the manufacture of INDUKINE molecules and that undesired fragments may not be able to be sufficiently removed by the purification process. The novel multi-domain composition of INDUKINE molecules may present a risk due to its complexity and challenges inherent to the manufacture of biologics. As a result, the risk of delays or failure in the manufacture of our INDUKINE molecules is high. Before we can commence clinical trials for a product candidate, the manufactured INDUKINE molecules must complete extensive analytical testing and be qualified for use in human studies. We cannot be certain of the timely completion or outcome of our analytical testing and suitability for human studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical material or if the outcome of our analytical testing will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our product candidates or any future preclinical programs on the timelines we expect, if at all, and we cannot be sure that the submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. In addition, we cannot be certain that we will be able to produce product candidates at the scale required for our clinical trials and, for any approved products, commercial production on a timely basis or at all, which could also have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have chosen to initially develop our lead product candidates, WTX-124 and WTX-330, for the treatment of advanced solid tumors and the treatment of relapsed or refractory advanced or metastatic tumors or lymphoma, respectively. Nevertheless, our development efforts will be limited to a small number of cancer types and we may forego or delay pursuit of opportunities in other cancer types that may prove to have greater potential. Likewise, we may forego or delay the pursuit of opportunities with other potential product candidates that may prove to have greater commercial potential. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk of failure for preclinical product candidates is high. Before we can commence clinical trials for our preclinical product candidates, we must complete extensive preclinical testing and studies that support INDs in the United States, or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to successfully submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Preclinical studies and clinical trials are expensive, time-consuming and difficult to design and implement, and involve uncertain outcomes. Furthermore, results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies or clinical trials. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The risk of failure for our current and any future product candidates is high. It is impossible to predict when or if any of our future product candidates will successfully complete preclinical studies, or if any of our current or future product candidates will complete clinical trials evaluating their safety and effectiveness in humans or will ultimately receive regulatory approval. To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the preclinical or clinical trial process. The outcome of preclinical testing and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. In particular, while we have conducted certain preclinical studies of WTX-124 and WTX-330, we do not know whether either of these product candidates will perform in our clinical trials as it has performed in these prior preclinical studies. Additionally, if we successfully commence clinical trials there can be no assurance that success in early clinical trials will lead to success in later clinical trials. Many companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in clinical trial procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other clinical trial protocols, and the rate of dropout among clinical trial participants. If we fail to produce positive results in our planned preclinical studies or clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects, would be materially and adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate for its intended indications. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We may experience numerous unforeseen events during or as a result of clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our current or future product candidates, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may be unable to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to obtain regulatory authorizations to commence a clinical trial; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may experience issues in reaching a consensus with regulatory authorities on trial design; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">clinical trial sites may deviate from a trial protocol or drop out of a trial or fail to conduct the trial in accordance with regulatory requirements; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the number of subjects required for clinical trials of our product candidates may be larger than we anticipate or subjects may fail to enroll or remain in clinical trials at the rate we expect; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">subjects that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the subject from the trial, increase the needed enrollment size for the clinical trial or extend its duration; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">subjects may choose an alternative treatment for the indication for which we are developing our product candidates, or participate in competing clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">subjects may experience severe or unexpected drug-related adverse effects; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">clinical trials of our product candidates may produce unfavorable, inconclusive, or clinically insignificant results; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may decide to, or regulators or IRBs or ethics committees may require us to, make changes to a clinical trial protocol or conduct additional preclinical studies or clinical trials, or we may decide to abandon product development programs; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may need to add new or additional clinical trial sites; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may experience manufacturing delays, and any changes to manufacturing processes or third party contractors that may be necessary or desired could result in other delays; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we or our third party contractors may experience delays due to complications associated with the COVID-19 pandemic or any future pandemic; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the cost of preclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate or greater than our available financial resources; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or we may not be able to obtain sufficient quantities of combination therapies for use in clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond the clinical trials and testing that we contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results of these clinical trials or tests are unfavorable or are only modestly favorable or if there are safety concerns associated with any of product candidates, we may: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">incur additional unplanned costs; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">be required to suspend or terminate ongoing clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">be delayed in obtaining marketing approval, if at all; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">be subject to additional post-marketing testing or other requirements; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">be required to perform additional clinical trials to support approval; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">have the product removed from the market after obtaining marketing approval; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">be subject to lawsuits; or </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">experience damage to our reputation. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the FDA’s and other regulatory authorities’ policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022 with the passage of the Food and Drug Omnibus Reform Act of 2022, Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other “pivotal study” of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, actions plans must include the sponsor’s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similarly, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state’s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. If we are not able to adapt to these and other changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the factors above, we may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions, which may be costly, time consuming and may not be successful at all. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our failure to successfully initiate and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business. We cannot provide assurances that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our clinical trials. Significant preclinical study or clinical trial delays could also shorten any periods during which we may have the exclusive right to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the severity of the disease under investigation; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the patient eligibility and the inclusion and exclusion criteria defined in the protocol; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the size and health of the patient population required for analysis of the trial’s primary endpoints; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the proximity of patients to trial sites; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the design of the trial; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">clinicians’ and patients’ perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our ability to obtain and maintain patient consents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our ability to monitor patients adequately during and after treatment; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">factors we may not be able to control, including the impacts of the COVID-19 pandemic, that may limit the availability of patients, principal investigators or staff or clinical sites. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial site. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing, if needed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable or unexpectedly severe side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Undesirable or unexpectedly severe side effects caused by our product candidates could cause us to interrupt, delay or halt preclinical studies or could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. It is likely that, as is the case with many treatments for cancer, there may be side effects associated with the use of our product candidates. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, by design, clinical trials rely on a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered when a significantly larger number of patients is exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates after such approval, a number of potentially significant negative consequences could result, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">regulatory authorities may require a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may be subject to regulatory investigations and government enforcement actions; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">regulatory authorities may withdraw or limit their approval of such product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may decide to remove such product candidates from the marketplace; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may suffer reputational harm. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic or any future surges, including as a result of new variants and subvariants of the virus, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Public health crises such as the COVID-19 pandemic or similar outbreaks could adversely impact our business. In response to the COVID-19 pandemic, governments throughout the world implemented a variety of quarantines, travel restrictions and other public health and safety measures that have impacted, and may continue to impact, our operations. The ultimate extent to which COVID-19 or any future surges, including as a result of new variants and subvariants of the virus, impacts our operations, including our preclinical studies and clinical trials, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and the actions taken to contain COVID-19 or treat its impact, among others. Any negative impact COVID-19 has on the execution of our product development plans could adversely affect our ability to timely submit INDs for product candidates, negatively affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effects of the COVID-19 pandemic that may delay or otherwise adversely affect our ongoing and planned preclinical activities and clinical trials as well as our business generally, include: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delays related to COVID-19 disruptions at CROs and contract manufacturers, or in the supply chain; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delays in receiving approval from regulatory authorities to initiate our planned clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff who, as healthcare providers, may have heightened exposure to COVID-19; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delays or difficulties in enrolling and retaining patients in clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delays in clinical sites receiving the supplies and materials needed to conduct clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">difficulties interpreting data from clinical trials due to the possible effects of COVID-19 on patients; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">interruptions, difficulties or delays arising in our existing operations and company culture as a result of many of our employees working remotely, including those hired during the COVID-19 pandemic. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these effects, and other effects of the COVID-19 pandemic, including future outbreaks, the emergence of new variants and subvariants of the virus, and any future pandemic, could have a material adverse effect on our business and our results of operations and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or “top-line” data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We are developing WTX-124, and could potentially develop WTX-330 and future product candidates, in combination with third-party drugs, some of which may still be in development, and we will have limited or no control over the safety, supply, regulatory status or regulatory approval of such drugs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are developing WTX-124, and could potentially develop WTX-330 and other future product candidates, in combination with third-party cancer drugs, which may be either approved or unapproved. For example, we are conducting a clinical trial of WTX-124 both as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab). Our ability to develop and ultimately commercialize our current product candidates, and any future product candidates, used in combination with third-party drugs will depend on our ability to access such drugs on commercially reasonable terms for clinical trials and their availability for use with our commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all. Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing such third-party drugs in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, operating results, or prospects may be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. For example, our clinical trial for WTX-124 in combination with KEYTRUDA may result in adverse events based on the combination therapy that may negatively impact the reported safety profile of the monotherapy in such clinical trials. Checkpoint inhibitors have been shown to have adverse events, including immune-related adverse events involving the lung, liver and other organ systems, which may limit the maximum dose in our clinical trials or otherwise negatively impact our combination clinical trials. In addition, the FDA or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the third-party drug and not our product candidate. Developments related to the third-party drug may also impact our clinical trials for the combination as well as our commercial prospects should we receive regulatory approval. Such developments may include changes to the third-party drug’s safety or efficacy profile, changes to the availability of the third-party drug, quality, and manufacturing and supply issues with respect to the third-party drug. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are able to obtain marketing approval, the FDA or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the third-party drug, this may require us to work with such third party to satisfy such a requirement. We would also continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the third-party drug used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with such drug. Similarly, if the third-party drugs we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we intend to explore other therapeutic opportunities in addition to the product candidates that we are currently developing, we may fail to identify or discover viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our current product candidates or to develop suitable additional product candidates through internal research programs, which could materially adversely affect our future growth and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or following commercial sale, and any product liability insurance we may obtain may not cover all damages from such claims. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are exposed to potential product liability risks that are inherent in the research, development, manufacturing, marketing and use of biopharmaceutical products. The use of product candidates by us in clinical trials, and any sale of approved products in the future, may expose us to liability claims. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval thereof, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the development or commercialization of our product candidates or any products for which we may have received marketing approval. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delay or termination of clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">decreased demand for any product candidates or products that we may develop; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">injury to our reputation and significant negative media attention; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">withdrawal of clinical trial participants or difficulties in recruiting new trial participants; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">initiation of investigations by regulators; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">costs to defend or settle the related litigation; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">a diversion of management’s time and our resources; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">significant negative financial impact; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the inability to commercialize any of our product candidates, if approved. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we will seek to procure and maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any products that receive regulatory approval, either on our own or together with collaborators. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have never commercialized a product candidate. We currently have no sales force or marketing or distribution capabilities. To achieve commercial success of our product candidates, if any are approved, we will have to develop our own sales, marketing and supply capabilities or outsource these activities to one or more third parties. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Factors that may affect our ability to commercialize our product candidates on our own include our ability to recruit and retain adequate numbers of effective sales and marketing personnel and obtain access to or persuade adequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization in the United States, the European Union or other key global markets. To the extent we need to rely upon one or more third parties, we may have little or no control over the marketing and sales efforts of those third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We will also face competition in any search for third parties to assist us with sales and marketing efforts for our product candidates. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may have difficulties generating revenue from them. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies among others. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. There are other companies working to develop immunotherapies for the treatment of cancer including divisions of pharmaceutical and biotechnology companies of various sizes. Some of these competitive therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are developing our initial product candidates for the treatment of cancer and have not received marketing approval for any of our product candidates. There are already a variety of available therapies marketed for cancer and some of the currently approved therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved therapies are well-established and widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic products. This </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates. Competition may further increase with advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are aware of a number of companies that are developing cytokines as immunotherapies, as well as different modalities, including monoclonal antibodies, cell therapies, oncolytic viruses and vaccines. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our lead product candidate, WTX-124, if approved, may face competition from other Interleukin-2, or IL-2, based cancer therapies. Proleukin (aldesleukin), a synthetic protein very similar to IL-2, is approved and marketed for the treatment of metastatic renal cell carcinoma and melanoma. In addition, we are aware that a number of other companies have modified IL-2 programs in development for the treatment of cancer, including Alkermes Plc, Anaveon AG, Anwita Biosciences, Inc., Ascendis Pharma A/S, Asher Biotherapeutics, Inc., Aulos Bioscience, Inc., BioNTech SE, Cue Biopharma, Inc., Merck & Co., Medicenna Therapeutics Corp., F. Hoffmann-La Roche AG, or Roche, Synthekine, Inc., and Xilio Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are no approved IL-12 therapies currently on the market for the treatment of cancer. However, if approved, WTX-330 may face competition from other IL-12 cytokine programs in clinical and preclinical development for oncology indications, including programs from Sanofi S.A. (Amunix), DragonFly Therapeutics, Inc., Juno Therapeutics, Inc. (Bristol-Myers Squibb Company), Turnstone Biologics Corp. (partnered with Takeda Pharmaceutical Company Limited), Philogen S.p.A., OncoSec Medical Incorporated, Sonnet BioTherapeutics, Inc., Xilio Therapeutics, Inc., and Zymeworks Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. We also compete with these organizations in establishing clinical trial sites and patient registration for clinical trials, as well as in recruiting and retaining qualified scientific and management personnel, which could negatively affect our level of expertise and our ability to execute our business plan. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel product candidates or to in-license novel product candidates that could make our product candidates less competitive or obsolete. Smaller or early-stage companies may also prove to be significant competitors, including through collaborative arrangements with large and established companies. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. The availability of competing products could limit the demand and the price we are able to charge for product candidates we commercialize, if any. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The sizes of the potential markets for our product candidates are difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The potential market opportunities for our product candidates are difficult to estimate and, if our product candidates are approved, will ultimately depend on, among other things, the indications for which our product candidates are approved for sale, any drugs with which our product candidates are co-administered, the success of competing therapies and therapeutic approaches, acceptance by the medical community, patient access, product pricing and reimbursement. Our estimates of the potential market opportunities for our product candidates are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports and other surveys. Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which we obtain and maintain favorable coverage, adequate reimbursement levels and pricing policies with third party payors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The availability and adequacy of coverage and reimbursement by third-party payors, including governmental healthcare programs such as Medicare and Medicaid, managed care organizations, and private health insurers, are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by third-party payors will have an effect on our ability to successfully commercialize our product candidates. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates, if approved, or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates, if approved. Even if our product candidates are approved and we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Interim reimbursement levels for new medicines, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Net prices for medicines may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved, and may not be able to obtain a satisfactory financial return on our product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. The regulations that govern marketing approvals, pricing and reimbursement for new medicines vary widely from country to country. In the United States, third-party payors play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how third-party payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates, if approved. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor and coverage and reimbursement by one payor does not guarantee coverage and reimbursement by another payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community necessary for commercial success. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If any product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, hospitals, cancer treatment centers, third-party payors, and others in the medical community. For example, cancer treatments like chemotherapy, radiation therapy and certain existing immunotherapies are well established in the medical community, and doctors may continue to rely on these therapies. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The degree of market acceptance of any product, if approved for commercial sale, will depend on a number of factors, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">its efficacy, safety and potential advantages compared to alternative treatments; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the prevalence and severity of any side effects; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the product’s convenience and ease of administration compared to alternative treatments; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the clinical indications for which the product is approved; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the willingness of the target patient population to try a novel treatment and of physicians to prescribe such treatments; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the recommendations with respect to the product in guidelines published by scientific organizations; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the ability to obtain sufficient third-party insurance coverage and adequate reimbursement, including, if applicable, with respect to the use of the product as a combination therapy; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the strength of marketing, sales and distribution support; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the effectiveness of our sales and marketing efforts; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the approval of other new products for the same indications; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our ability to offer the product for sale at competitive prices. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we obtain marketing approval for a product but such product does not achieve an adequate level of market acceptance, we may not generate or derive significant revenue from that product and our business, financial condition and results of operations may be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, a reference biological product is granted 12 years of non-patent exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company’s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If competitors are able to obtain regulatory approval for biosimilars referencing our product candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_109"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We depend, and expect to continue to depend, upon third parties, including independent investigators and CROs, to conduct preclinical studies and clinical trials. We expect to have to negotiate budgets and contracts with CROs and trial sites, and any of these third parties may terminate their engagements with us at any time, any of which may result in delays to our development timelines and increased costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with current Good Clinical Practices, or cGCP, requirements for clinical trials, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these cGCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the cGCP requirements. In addition, our clinical trials must be conducted with biologic product produced under current Good Manufacturing Practice, or cGMP, requirements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our failure or any failure by these third parties to comply with the applicable regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which could materially impact our ability to meet our desired clinical development timelines. Though we plan to carefully manage our relationships with CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing of biologics is complex and we do not have our own clinical manufacturing capabilities. We will rely on third parties to produce preclinical, clinical and commercial supplies of all current and any future product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To date, we have produced limited quantities of our product candidates at our own facilities for preclinical evaluation. However, going forward we will rely on third-party contract manufacturers to manufacture some of our preclinical supply and all of our clinical trial supply. We do not own manufacturing facilities capable of producing drug products at clinical scale. We have in the past experienced delays in receiving preclinical product supplies from third-party manufacturers and there can be no assurance that our preclinical and clinical development product supplies from third parties will not in the future be limited or interrupted, or be of satisfactory quality or continue to be available at acceptable prices. Additionally, the process of manufacturing biologics is complex, highly regulated, and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, other supply disruptions and higher costs. If microbial, viral or other contaminations are discovered at the facilities of our contract manufacturing organizations, or CMOs, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials, result in higher costs of drug product and adversely affect our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have engaged CMOs to provide certain services to support our clinical and preclinical development. Pursuant to the terms of separate contract manufacturing services agreements, we have engaged one CMO to provide drug substance manufacturing process development and to manufacture WTX-124 and WTX-330 drug substance to cGMP specifications for use in the further manufacture of clinical supply, a second CMO to provide drug product manufacturing process development and to manufacture clinical supply of WTX-124 and WTX-330 vialled drug product to cGMP specifications, and additional CMOs to provide drug substance and drug product manufacturing for JZP898 (formerly WTX-613). To support the manufacture of drug substance and drug product, our CMOs will conduct substantial analytical testing of drug substance and vialled drug product. If our CMOs are unable to supply us with sufficient clinical grade quantities of WTX-124 or WTX-330, and we are unable to timely establish an alternate supply from one or more third-party contract manufacturers, we will experience delays in our development efforts as we seek to locate and qualify new manufacturers. In particular, any replacement of our CMOs could require significant effort and expertise because there may be a limited number of qualified replacements or capacity could be limited at each of the qualified replacements. Additionally, contract manufacturers may rely on single source suppliers for certain of the raw materials for our preclinical and clinical product supplies. If current or future suppliers are delayed or unable to supply sufficient raw materials to manufacture product for our preclinical studies and clinical trials, we may experience delays in our development efforts as materials are obtained or we locate and qualify new raw material manufacturers. Further, for our planned combination clinical trial of WTX-124 with KEYTRUDA (pembrolizumab), an immune checkpoint inhibitor, we will need to procure supply of KEYTRUDA for use in the clinical trials. If we are unable to procure sufficient supply from third-party manufacturers or other sources, we may be required to purchase our supply of checkpoint inhibitors on the open market, which may result in significant additional expense. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The manufacturing process for a clinical candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with their standards, such as cGMPs. In the event that any of our CMOs fail to comply with such requirements or to perform their obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. The transfer of the manufacturing of biologic products to a new CMO and any additional process development that may be necessary can be lengthy and involve significant additional costs. If we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new CMO would negatively affect our ability to develop product candidates in a timely manner or within budget. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, our reliance on third-party manufacturers exposes us to risks beyond our control, including the: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">inability to meet our drug specifications and quality requirements consistently; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">inability to initiate or continue preclinical studies or clinical trials of product candidates under development; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delay or inability to procure or expand sufficient manufacturing capacity; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">manufacturing and drug quality issues, including related to scale-up of manufacturing; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">failure to comply with cGMP and similar foreign standards; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">reliance on a limited number of sources, and in some cases, single sources for drug components and raw materials, such that if we are unable to secure a sufficient supply of these drug components and raw materials, we will be unable to manufacture and sell our future product candidate in a timely fashion, in sufficient quantities or under acceptable terms; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">lack of qualified backup suppliers for those components and raw materials that are purchased from a sole or single source supplier; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">disruption of operations by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or the issuance of an FDA Form 483 notice or warning letter, or as a result of the effects of the COVID-19 pandemic on third-party manufacturers; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">carrier disruptions or increased costs that are beyond our control; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">failure to deliver our drugs under specified storage conditions and in a timely manner; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production, any of which could result in a failure to begin our clinical trials or having to stop ongoing clinical trials. In addition, our CMOs and suppliers are subject to FDA inspection from time to time. Failure by our CMOs and suppliers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidate may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses. In addition, our CMOs and suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws and regulations could result in significant costs associated with civil or criminal fines </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and penalties for such third parties. Based on the severity of the regulatory action, our clinical or commercial supply of drug and packaging and other services could be interrupted or limited, which could harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our CMOs are or may be engaged with other companies to supply and manufacture materials or products for such companies, which also exposes our suppliers and CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier’s or CMO’s facility, which could impact the contract supplier’s or CMO’s ability to manufacture drug product for us. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have entered into, and may in the future seek to enter into, collaborations or other similar arrangements for our product candidates. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A part of our strategy is to strategically evaluate and, as deemed appropriate, enter into collaborations in the future on an asset-by-asset basis to maximize the value of each of our programs. For example, in April 2022, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Jazz Pharmaceuticals Ireland Limited, or Jazz, pursuant to which we granted Jazz certain licenses to develop and commercialize products containing our Interferon alpha (“IFNα”) INDUKINE™ molecule, JZP898 (formerly WTX-613), as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria. We may also enter into collaborations in connection with our platform technology in order to advance the development of programs beyond our initial focus in cytokines. Such collaborations may include the development and commercialization of any of our product candidates or the commercialization of any of our product candidates that are approved for marketing outside the United States. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may enter into collaborations with other companies to provide us with important technologies and funding for our programs and platform technology. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for any product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view such product candidates as having the requisite potential to demonstrate safety and efficacy. We may also be restricted under future license agreements from entering into agreements on certain terms or at all with potential collaborators.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Existing and future collaborations involving our product candidates may pose significant risks to us, including the following: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators may not perform their obligations as expected; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborators may not provide us with timely and accurate information regarding development, regulatory or commercialization status or results, which could adversely impact our ability to manage our own development efforts, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accurately forecast financial results or provide timely information to our stockholders regarding our out-licensed product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">collaborations may be terminated, including for the convenience of the collaborator, and, if terminated, we may find it more difficult to enter into future collaborations or be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. In addition, all of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report will apply to the activities of any of our collaborators. </span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_112"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for any product candidates we develop or for our PREDATOR platform and other proprietary technologies we may develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates and technology similar or identical to our product candidates and technology, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our PREDATOR platform, our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment and development that are important to our business. If we do not adequately protect our intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our PREDATOR platform and our product candidates that are important to our business; we also license and may in the future license or purchase additional patents and patent applications filed by others. If we are unable to secure or maintain patent protection with respect to our PREDATOR platform, our product candidates and any proprietary products and technology we develop, our business, financial condition, results of operations and prospects could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the scope of the patent protection we or our potential licensors obtain is not sufficiently broad, we may not be able to prevent others from developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that any of our pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect our current and future product candidates or otherwise provide any competitive advantage. In addition, to the extent that we license intellectual property in the future, we cannot provide assurances that those licenses will remain in force. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to one or more of our product candidates but that uses a formulation and/or a device that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patent positions of life sciences companies can be uncertain and involve complex factual and legal questions. No consistent policy governing the scope of claims allowable in the field of engineered therapeutic proteins has emerged in the United States. The scope of patent protection in jurisdictions outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of our intellectual property, including the narrowing of the scope of our patents and any that we may license. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patent prosecution process is complex, expensive, time-consuming and inconsistent across jurisdictions. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is possible that we will fail to identify important patentable aspects of our research and development efforts in time to obtain appropriate or any patent protection. While we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development efforts, including for example, our employees, external academic scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose our confidential or proprietary information before a patent application is filed, thereby endangering our ability to seek patent protection. In addition, publications of discoveries in the scientific and scholarly literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Consequently, we cannot be certain that we were the first to file for patent protection on the inventions claimed in our patents or pending patent applications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Pending patent applications cannot be enforced against third parties unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or any patent applications that we may license in the future will result in patents being issued. Further, the scope of the invention claimed in a patent application can be significantly reduced before the patent is issued, and this scope can be reinterpreted after issuance. Even if patent applications we currently own or that we may license in the future issue as patents, they may not issue in a form that will provide us with adequate protection to prevent competitors or other third parties from competing with us, or otherwise provide us with a competitive advantage. Any patents that eventually issue may be challenged, narrowed or invalidated by third parties. Consequently, we do not know whether our PREDATOR platform or any of our product candidates will be protectable or remain protected by valid and enforceable patent rights. Our competitors or other third parties may be able to evade our patent rights by developing new products that are similar to our product candidates, biosimilars of our product candidates, or alternative technologies or products in a non-infringing manner. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The issuance or grant of a patent is not irrefutable as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. We may in the future, become subject to a third-party pre-issuance submission of prior art or opposition, derivation, revocation, re-examination, post-grant and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review, or interference proceeding and other similar proceedings challenging our patent rights or the patent rights of others in the U.S. Patent and Trademark Office, or USPTO, or other foreign patent office. An unfavorable determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or extinguish our ability to manufacture or commercialize products without infringing third-party patent rights. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our owned and in-licensed patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we or our licensors may need the cooperation of any such co-owners of our owned and in-licensed patents in order to enforce such patents against third parties, and such cooperation may not be provided to us or our licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We rely on the Harpoon Agreement for patent rights with respect to our product candidates and may in the future acquire additional third-party intellectual property rights on which we may similarly rely. We face risks with respect to such reliance, including the risk that we could lose these rights that are important to our business if we fail to comply with our obligations under these licenses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely on our Second Amended and Restated Assignment and License Agreement, or the Harpoon Agreement, with Harpoon, pursuant to which we have non-exclusive and exclusive rights to technology that is incorporated into our PREDATOR platform, development programs and product candidates. The Harpoon Agreement gives us non-exclusive, sublicensable, worldwide rights to develop, manufacture, and commercialize products containing certain of Harpoon’s patented technology and exclusive, irrevocable rights to certain other Harpoon inventions that may be made during a limited collaboration period. The Harpoon Agreement imposes disclosure, royalty payment and other obligations on us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, the growth of our business may depend in part on our ability to acquire, in-license or use additional third-party intellectual property rights. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Licenses to additional third-party intellectual property, technology and materials that may be required for the development and commercialization of our product candidates or technology may not be available at all or on commercially reasonable terms. In that event, we may be required to expend significant time and resources to redesign our product candidates or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize our future product candidates or technologies, which could materially harm our business, financial condition, results of operations and growth prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Harpoon Agreement, Harpoon is responsible for prosecution and maintenance of the licensed patents and any future third party from whom we may license patent rights may similarly be responsible for prosecution and maintenance of such patents. We have limited control over the activities that are the responsibility of Harpoon and would have limited control over the activities that are the responsibility of any future licensor, and it is possible that prosecution and maintenance of licensed patents by Harpoon or any future licensor may be less vigorous than had we conducted such activities ourselves. Furthermore, the Harpoon Agreement is subject to, and we expect our future license agreements may also be subject to, a reservation of rights by the licensor and/or one or more third parties. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to the Harpoon Agreement or any future license agreements of ours, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our or our licensor’s ability to defend intellectual property and to enforce intellectual property rights against third parties; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the extent to which our technology, product candidates and processes infringe, misappropriate or otherwise violate any intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the sublicensing of patent and other rights under the license agreement; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and any partners of ours; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the priority of invention of patented technology. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks described in this Quarterly Report with respect to protection of intellectual property that we license as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Harpoon and any potential future licensors might conclude that we have materially breached our license agreements and might therefore terminate the relevant license agreements, thereby removing our ability to develop and commercialize products and technology covered by such license agreements. If any of our current or future inbound license agreements are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products that are covered by such license agreements and underlying patents, which might be identical to our products or product candidates. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects. Our business also would suffer if any current or future licensors fail to abide by the terms of the license or fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor’s rights. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any licensor of ours may have relied on third-party consultants or collaborators or on funds from third parties, such as the United States government, such that such licensor is not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to our technologies and product candidates are not adequate, we may not be able to compete effectively in our market. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biotechnology and pharmaceutical companies generally, and we in particular, compete in a crowded competitive space characterized by rapidly evolving technologies and aggressive defense of intellectual property. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Our or our licensor’s failure to comply with all such provisions during the patent process could result in abandonment or lapse of a patent or patent application that we own or license, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market and compete with us earlier than would otherwise have been the case. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely upon a combination of patents, confidentiality agreements, trade secret protection and license agreements to protect the intellectual property related to our technologies and our product candidates. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements and product candidates, thus eroding our competitive position in our market. We, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We seek or plan to seek patent protection for our PREDATOR platform and product candidates by filing and prosecuting patent applications in the United States and other countries as appropriate. However, we cannot predict: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">if and when patents will issue; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">if patents will issue with claims that cover our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">whether any of our intellectual property will provide any competitive advantage; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">whether any of our patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">whether we will need to initiate or defend litigation or administrative proceedings which may be costly regardless of whether we win or lose. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, we cannot be certain that the claims in our pending patent applications covering our product candidates, PREDATOR platform and research programs will be considered patentable by the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or technology or uses thereof in the United States or in other foreign countries. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates or technology is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. Various post-grant review proceedings, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review, post-grant review and derivation proceedings, are available and may be pursued by any interested third party in the USPTO to challenge the patentability of claims issued in patents to us or our licensors. No assurance can be given as to the outcome of any such post-grant review proceedings. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor’s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In March 2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a “first to invent” to a “first-to-file” system. Under a “first-to-file” system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a USPTO-administered post-grant review system that has affected patent litigation. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">others may be able to make or use polypeptides or nucleic acids that are similar to our product candidates or components of our product candidates but that are not covered by the claims of our patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">others may independently develop similar or alternative technologies or duplicate any of our technologies; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it is possible that our pending patent applications will not result in issued patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it is possible that there are prior public disclosures that could invalidate our or our licensors’ patents, as the case may be, or parts of our or their patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it is possible that others may circumvent our owned or in-licensed patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the laws of foreign countries may not protect our or our licensors’, as the case may be, proprietary rights to the same extent as the laws of the United States; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates or technology; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we have engaged in scientific collaborations in the past and will continue to do so in the future, and such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may not develop additional proprietary technologies for which we can obtain patent protection; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">it is possible that product candidates or technology we develop may be covered by third parties’ patents or other exclusive rights; or </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the patents of others may have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our proprietary position in part depends upon patents that are manufacturing, formulation or method-of-use patents, which may not prevent a competitor or other third party from using the same product candidate for another use.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Composition of matter patents for biological and pharmaceutical products are generally considered to be the strongest form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of making or method of use. We have issued patents with certain composition of matter claims with respect to WTX-124 and IL-12 INDUKINE molecules and also have pending patent applications with other composition of matter claims with respect to our product candidates. We cannot be certain, however, that the claims in our pending patent applications, including those claims covering the composition of matter of our product candidates, will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our patents that have issued or may issue will be considered valid and enforceable by courts in the United States or foreign countries. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions of matter relating to our product candidates, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture. Method of use patents protect a specified method of using a product, such as a method of use for treating a particular medical indication. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their products for our targeted indications, physicians may prescribe these products “off-label” for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent by enforcing patent rights or otherwise. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our product candidates could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we seek to rely on trade secret protection, confidentiality agreements, and license and other agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For example, significant elements of our product candidates and PREDATOR platform, including aspects of sample preparation, methods of manufacturing, cell culturing conditions, computational-biological algorithms and related processes are based on unpatented trade secrets that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. However, we cannot provide assurance that these agreements and policies will not be breached by our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors and that our trade secrets and other proprietary and confidential information will not be disclosed to publicly or to competitors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and post-grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management’s attention from our core business; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party’s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner’s attorneys’ fees; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">redesigning our product candidates or processes so they do not infringe third party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting preclinical and clinical trials and other development activities in the United States is not considered an act of infringement. If WTX-124, WTX-330, JZP898 (formerly WTX-613), WTX-712 or another product candidate is approved by the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. For example, we have received, and we may in the future receive, correspondence from third parties or their legal counsel disclosing that such third party owns patents that may encompass one or more of our product candidates. It is also possible that a third party may file a lawsuit against us alleging infringement of its patents. The outcome of any such proceeding is uncertain and would likely result in the expenditure of significant financial resources and the diversion of management’s time and resources, which could harm our business. While we do not believe that any claims that could otherwise have a materially adverse effect on the commercialization of our product candidates are valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is “clear and convincing,” a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Patent applications can take many years to issue. There may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available on commercially reasonable terms or at all. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presently we have certain intellectual property rights, under patents and patent applications that we own or will own and under the Harpoon Agreement, related to WTX-124, WTX-330, JZP898 (formerly WTX-613), WTX-712 and other product candidates we may develop in the future. Our development of additional product candidates may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, while we have patent rights directed to certain INDUKINE constructs we may not be able to obtain intellectual property to broad INDUKINE polypeptides or engineered INDUKINE constructs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently, and rights to such formulation technology may be held by others. Similarly, efficient production or delivery of our product candidates may also require specific compositions or methods, and the rights to these may be owned by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Moreover, the specific components, such as linkers and antibody fragments, that will be used with our product candidates may be covered by the intellectual property rights of others. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, we may collaborate with or sponsor research at academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions may provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration or sponsorship. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file lawsuits with infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Post-grant proceedings provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of our patent applications have been granted or may be granted or allowed in the future. We cannot be certain that an allowed patent application will become an issued patent. There may be events that can cause the allowance of a patent application to be withdrawn. For example, after a patent application has been allowed, but prior to being issued, material that could be relevant to patentability may be identified. In such circumstances, the applicant may pull the application from allowance in order for the USPTO to review the application in view of the new material. We cannot be certain that the USPTO will re-allow the application in view of the new material. Further, periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. We rely on our outside counsel and other professionals or our licensing partners to pay these fees due to the USPTO and non-U.S. government patent agencies and to help us comply with other procedural, documentary and other similar requirements and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates or technology could be found invalid or unenforceable if challenged in court or the USPTO. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that the patent covering our product candidate or technology, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review, post-grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates or technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates or technology. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States continues to adapt to wide-ranging patent reform legislation that became effective starting in 2012. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, Congress or the USPTO may impact the value of our patents. Similarly, changes in the patent laws of other jurisdictions could adversely affect our ability to obtain and effectively enforce our patent rights, which would have a material adverse effect on our business and financial condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have obtained granted patents in the United States that we consider to be important for certain of our product candidates, however, we may have less robust intellectual property rights outside the United States, and, in particular, we may not be able to pursue generic coverage of our PREDATOR platform or of our INDUKINE molecules outside of the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Most of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Many countries also limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business and financial condition may be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Many of our employees were previously employed at other pharmaceutical companies, including our competitors or potential competitors, in some cases until recently. We may be subject to claims that we or our employees have inadvertently or otherwise used or disclosed trade secrets or other confidential information of these former employers or competitors. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Any litigation or the threat thereof may adversely affect our ability to hire employees. A </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any of our current or future product candidates, our business may be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any of our current or future product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The factors that may limit any potential competitive advantage provided by our intellectual property rights include: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">pending patent applications that we own or license may not lead to issued patents; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">patents, should they issue, that we own or license, may not provide us with any competitive advantages, or may be challenged and held invalid or unenforceable; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by the claims of any of our owned or in-licensed patents, should any such patents issue; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we (or our licensors) might not have been the first to make the inventions covered by a pending patent application that we own or license; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we (or our licensors) might not have been the first to file patent applications covering a particular invention; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">others may independently develop similar or alternative technologies without infringing our intellectual property rights; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">we may not develop or in-license additional proprietary technologies that are patentable; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the patents of others may have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business and results of operation. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal Compliance Matters </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of an NDA or BLA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could negatively affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we may be granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions and any of our product candidates that may be approved for marketing in a foreign jurisdiction will be subject to risks associated with foreign operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In order to market and sell our products in the European Union and other foreign jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our products in any market. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we fail to obtain the non-U.S. approvals required to market our product candidates outside the United States or if we fail to comply with applicable non-U.S. regulatory requirements, our target markets will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the EU, commonly referred to as Brexit. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom’s withdrawal from the EU. The MHRA may rely on a decision taken by the European Commission on the approval of a new marketing authorization via the centralized procedure until December 31, 2023. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the European Medicines Agency, or EMA, will be precluded from approving another marketing application for the same product for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may seek orphan drug designations for our product candidates and may be unable to obtain such designations. Even if we do secure such designations and orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. Further, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, to be more effective or to make a major contribution to patient care. Finally, orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term “same disease or condition” means the designated “rare disease or condition” and could not be interpreted by the FDA to mean the “indication or use.” Thus, the Court of Appeals concluded that orphan drug exclusivity applies to the entire designated disease or condition rather than the “indication or use.” Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, it will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval is subject to ongoing regulation and could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements, when and if any of our product candidates are approved. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. In addition, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy. Accordingly, if we receive marketing approval for one or more of our product candidates, we will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we fail to comply with these requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any products could be limited, which could adversely affect our ability to achieve or sustain profitability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements, may yield various results, including: </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">restrictions on such products, manufacturers or manufacturing processes; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">restrictions on the labeling or marketing of a product; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">restrictions on distribution or use of a product; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">requirements to conduct post-marketing studies or clinical trials; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">warning letters or untitled letters; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">withdrawal of the products from the market; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">refusal to approve pending applications or supplements to approved applications that we submit; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">recall of products; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">damage to relationships with collaborators; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">unfavorable press coverage and damage to our reputation; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">suspension or withdrawal of marketing approvals; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">refusal to permit the import or export of our products; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">product seizure; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">injunctions or the imposition of civil or criminal penalties; and </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">litigation involving patients using our products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar restrictions apply to the approval of products in the EU. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU’s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer’s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the EU and are also subject to EU Member State laws. The failure to comply with these and other EU requirements can also lead to significant penalties and sanctions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product’s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may seek PRIME Designation in the EU for one or more of our product candidates, but we might not receive such designations and, even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the EU, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA’s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the EU and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in the application process. PRIME designation enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA’s grant of a marketing authorization.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requirements, which could materially harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All entities involved in the preparation of product candidates for clinical trials or commercial sale, including any contract manufacturers, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We or our contract manufacturer must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA’s current Good Laboratory Practice and cGMP regulations enforced through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of any product candidate. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product, or revocation of a pre-existing approval. Any such consequence would severely harm our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We intend in the future to conduct clinical trials for certain of our product candidates at sites outside the United States. The FDA may not accept data from trials conducted in such locations and the conduct of trials outside the United States could subject us to additional delays and expense.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We intend in the future to conduct one or more of our clinical trials with trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with good clinical practice. The FDA must be able to validate the data from the trial through an onsite inspection if necessary. The trial population must also have a similar profile to the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful, except to the extent the disease being studied does not typically occur in the United States. In addition, while these clinical trials are subject to the applicable local laws, the FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the conduct of clinical trials outside the United States could have a significant adverse impact on us or the trial results. Risks inherent in conducting international clinical trials include: </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">clinical practice patterns and standards of care that vary widely among countries; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">foreign exchange rate fluctuations; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">diminished protection of intellectual property in some countries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, including from the COVID-19 pandemic, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA’s inability to complete required inspections for their applications. As of early 2022, the FDA has resumed inspections of domestic and foreign facilities to ensure timely reviews of applications for medical products. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required. In response to the COVID-19 pandemic, the FDA issued numerous guidance documents and took other actions to facilitate research and development of new drug products. The public health emergency declarations related to COVID-19 ended on May 11, 2023. In connection therewith, the FDA ended 22 COVID-19-related policies on May 11, 2023 and allowed 22 to continue for 180 days. The FDA plans to retain 24 COVID-19-related policies with appropriate changes and four whose duration is not tied to the end of the public health emergency. At this point, it is unclear how, if at all, these developments will impact our efforts to develop and commercialize our product candidates. Regulatory authorities outside the U.S. have adopted or may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accordingly, if a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for any of our candidate products that do receive marketing approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ACA substantially changed the way healthcare is financed by both governmental and private insurers and continues to significantly impact the U.S. pharmaceutical industry. Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the TCJA in 2017, Congress repealed the “individual mandate.” The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, in December 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. In June 2021, the U.S. Supreme Court dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2032 under the CARES Act. These Medicare sequester reductions were suspended and reduced through the end of June 2022, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010, or PAYGO, sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act’s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans’ access to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. This Executive Order also directs the U.S. Department of Health and Human Services, or HHS, to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislative efforts may limit the costs for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the IRA has been delayed by Congress to January 1, 2032.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The Order directs HHS to create a plan within 45 days to combat “excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.” On September 9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b) improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">More recently, on August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap, imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or “catastrophic period” of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 6, 2023, Merck & Co., or Merck, filed a lawsuit against HHS and CMS asserting that, among other things, the IRA’s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, other parties, including the U.S. Chamber of Commerce, Bristol Myers Squibb Company, the Pharmaceutical Research and Manufacturers of America, Astellas and Johnson & Johnson, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS and/or seeking to stop implementation of the drug pricing provisions of the IRA. We expect that litigation involving the IRA will continue, with unpredictable and uncertain results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finally, outside the United States, in some nations, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to certain healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare providers, third-party payors and others will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our current and future arrangements with healthcare providers and third-party payors will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research as well as market, sell and distribute any products for which we obtain marketing approval. Potentially applicable U.S. federal and state healthcare laws and regulations include the following: </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Anti-Kickback Statute</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">False Claims Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including those from civil whistleblower or qui tam actions against individuals or entities for knowingly presenting, or causing to be presented to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">HIPAA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">HIPAA and HITECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, also imposes obligations on certain types of individuals and entities, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">False Statements Statute</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Transparency Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to report annually to HHS information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests by physicians and their immediate family members. As of January 1, 2022, applicable manufacturers are also required to report such information regarding its payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Analogous State and Foreign Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Analogous state laws and regulations, such as state anti-kickback and false claims laws, and transparency laws, may apply to sales or marketing arrangements, and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Many state laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Foreign laws also govern the privacy and security of health information in many circumstances. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, and reputational harm, any of which could substantially disrupt our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Compliance with state, national and international privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to a variety of harms, including significant fines and penalties, litigation and reputational damage, any of which may have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to data privacy and protection laws and regulations, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the U.S., EU and United Kingdom. The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the United States, there are numerous federal and state laws and regulations related to the privacy and security of personal information that may be applicable to our current and future activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission, or FTC, and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be “unfair” under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The agency is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC’s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to existing laws, a broad range of legislative measures have been introduced at both the federal and state levels. For example, the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020, imposed many requirements on businesses that process the personal information of California residents, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">personal information and, in certain cases, request the erasure of such personal information. Additionally, in November 2020, California voters approved a new privacy law, the California Privacy Rights Act, or CPRA, which expands the CCPA to incorporate additional provisions, including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions took effect on January 1, 2023, though the obligations apply to any personal information collected after January 1, 2022. In addition, other states, including Virginia, Colorado, Utah, and Connecticut, already have passed state privacy laws, and other states are considering similar legislation. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. Failure to comply with federal and state laws regarding privacy and security of personal information could expose us to fines and penalties under such laws.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A wide range of enforcement agencies at both the state and federal levels can review companies for privacy and data security concerns based on general consumer protection laws. For example, the Federal Trade Commission and state Attorneys General are aggressive in reviewing privacy and data security protections for consumers. In addition to the risks associated with enforcement activities, there also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated the law, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. For example, the collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or the EEA, is subject to the EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the EEA in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including strict rules on the transfer of personal data to countries outside the European Union, including the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of annual global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. As a result, there is increased scrutiny on the extent to which clinical trial sites located in the EEA should apply the GDPR to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. There are also open questions about how personal data will be protected in the United Kingdom and whether personal information can transfer from the EU to the United Kingdom. Following the withdrawal of the United Kingdom from the EU, the United Kingdom Data Protection Act of 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the United Kingdom Data Protection Act of 2018 “implements” and complements the GDPR, and has achieved Royal Assent and is effective in the United Kingdom, it is unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The United Kingdom government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom as being “essentially adequate” for purposes of data transfer from the EU to the United Kingdom, although this decision may be re-evaluated in the future. Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws may impact our ability to conduct our business activities, including clinical trials and any eventual sale and distribution of commercial products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These evolving compliance and operational requirements impose significant costs that are likely to increase over time. Preparing for and complying with such requirements is rigorous and time intensive. It requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data, and may require us to modify our data processing practices and policies, divert resources from other initiatives and projects, and restrict the way products and services involving data are offered. Further, current and future laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us. Any of these events could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export control, import, sanctions, anti-corruption, and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. In addition, we may engage third party </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncompliance with the laws and regulations described above could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management’s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, however this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, CROs, consultants, commercial partners, vendors and principal investigators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, CROs, consultants, commercial partners, vendors and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Even with appropriate policies and procedures, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent such activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions. </span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_118"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, as well as the other members of our scientific and clinical teams. Although we have employment offer letters which outline the terms of employment with each of our executive officers, each of them may terminate their employment with us at any time. As such, these employment offer letters do not guarantee our retention of our executive officers for any period of time. We do not maintain “key person” insurance for any of our employees. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific and clinical personnel and, if we are successful in obtaining marketing approval for our product candidates, sales and marketing personnel, is critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our product candidates. We are based in the Boston area, a region that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. Furthermore, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited, and could harm our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We expect to grow our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, we had 48 employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory affairs, finance and, if any of our product candidates receive marketing approval, sales, marketing and distribution. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities to devote time to managing these growth activities. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Our inability to effectively manage the expansion of our operations may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our potential ability to generate revenue could be reduced and we may not be able to implement our business strategy. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, inability to access systems, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality, availability and integrity of such confidential information. Our internal information technology systems and infrastructure, and those of our contractors, consultants, vendors and other third parties on which we rely, are vulnerable to damage or unauthorized access or use resulting from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, denial or degradation of service attacks, ransomware, hacking, phishing and other social engineering attacks, attachments to emails, intentional or accidental actions or inactions by persons inside our organization or by persons with access to systems inside our organization. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, supply chain attacks foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of lost or stolen devices, security incidents and data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we have experienced increases in remote and hybrid working since March 2020 and as a result, have increasingly relied upon teleconferencing and cloud-based means of communication and data storage. In addition, many of our internal systems operate on cloud-based platforms. There have been numerous publicized attempts of bad actors attempting to intercept proprietary communications and cloud-based systems. We may be similarly susceptible to those kinds of threats. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. In addition, if a ransomware attack or other cybersecurity incident occurs, either internally or at our vendors or third-party technology service providers, we could be prevented from accessing our data or systems, which may cause interruptions or delays in our business operations, cause us to incur remediation costs, subject us to demands to pay a ransom, or damage our reputation, regardless of whether we pay the ransom amount. Any such event, or other loss of information, could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations, and damage our reputation, any of which could adversely affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the foregoing, any breach of privacy laws or data security laws, particularly resulting in a significant security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, could have a material adverse effect on our business, reputation and financial condition. As a data controller, we will be accountable for any third-party service providers we engage to process personal data on our behalf, including our CROs. There is no assurance that privacy and security-related safeguards we implement will protect us from all risks associated with the third-party processing, storage and transmission of such information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws, as applicable, such as HIPAA, CCPA, HITECH and GDPR), it could result in a material disruption of our discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We would also be exposed to a risk of loss, governmental investigations or enforcement, or litigation and potential liability, any of which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions and unfavorable economic conditions could seriously harm our business, future revenue and financial condition, and could increase our costs and expenses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We depend on our employees, consultants, contract manufacturers, and CROs, and other parties, for the continued operation of our business. Our or their operations could be significantly disrupted by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, ice and snowstorms, extreme weather conditions, medical epidemics or pandemics, wars or other armed conflicts, geopolitical tensions or trade wars, terrorist attacks, and other natural or manmade disasters or business interruptions, for which we are, and they may be, predominantly self-insured. Because we rely on third-party contract manufacturers to produce our product candidates, our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, unfavorable economic conditions both inside and outside the U.S., including, without limitation, heightened inflation, capital market volatility, interest rate and currency rate fluctuations, any potential economic slowdown or recession, banking disruptions, the COVID-19 pandemic (including variants of COVID-19) and geopolitical events, including trade wars or civil or political unrest (such as the ongoing war between Ukraine and Russia), have resulted in a significant disruption of global financial markets. If the disruption persists or deepens, we could experience an increase in our costs and expenses, including an increase in financing costs, and restrictions on our access to potential sources of future capital. If we are unable to raise additional capital when needed or on attractive terms, our business, financial condition, stock price and results of operations could be adversely affected, and we could be forced to delay, reduce or altogether terminate one or more current or future research and development programs. Further, we hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts at multiple financial institutions, and if a financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of any uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive such difficult economic times, which could directly affect our ability to attain our operating goals. Any of the foregoing could harm our business, future revenue and financial condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally, if approved, could materially adversely affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">regulatory requirements in foreign countries that differ from those in the United States; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">difficulties staffing and managing foreign operations; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">potential liability under the FCPA or comparable foreign regulations; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">business interruptions resulting from geo-political actions, including war and terrorism. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these factors could harm our future international expansion and operations and, consequently, our results of operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_121"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock and Our Status as a Public Company </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not continue to develop or be sustained and our stockholders may not be able to resell their shares of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our common stock began trading on the Nasdaq Global Select Market, or Nasdaq, on April 30, 2021. Prior to April 30, 2021, there was no public market for our common stock. We cannot predict the extent to which an active market for our common stock will continue to develop or be sustained, or how the development of such a market might affect the market price for our common stock. As a result, it may be difficult for our stockholders to sell their shares of our common stock at an attractive price or at all. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock could be subject to volatility related or unrelated to our operations. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our stock price is likely be volatile. For example, from April 30, 2021, when our stock first began trading on Nasdaq until August 4, 2023, our stock price has ranged </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">from $1.39 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $23.99. The stock market in general and the market for biotechnology and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at an attractive price or at all. The market price for our common stock may be influenced by many factors, including: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">adverse results from preclinical studies; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">the commencement, enrollment or results of any clinical trials we may conduct, or changes in the development status of our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">adverse results from, delays in initiating or completing, or termination of clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">unanticipated serious safety concerns related to the use of our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">clinical trial results from, or regulatory approval of, a competitor’s product candidate; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">lower than expected market acceptance of our product candidates following approval for commercialization; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">adverse developments concerning our manufacturers; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">introduction of new products or services by our competitors; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">changes in financial estimates by us or by any securities analysts who might cover our stock; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">conditions or trends in our industry; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">our cash position; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">sales of our common stock by us or our stockholders in the future; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">adoption of new accounting standards; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">ineffectiveness of our internal controls; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">changes in the market valuations of similar companies; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biotechnology and pharmaceutical industry; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">investors’ general perception of our company and our business; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">recruitment or departure of key personnel; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">overall performance of the equity markets; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">trading volume of our common stock; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies and product candidates; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">significant lawsuits, including patent or stockholder litigation; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">proposed changes to healthcare laws or pharmaceutical pricing in the United States or foreign jurisdictions, or speculation regarding such changes; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">developments with respect to the COVID-19 pandemic; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">general political and economic conditions; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">other events or factors, many of which are beyond our control. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies’ stock. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and resources from our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish or cease publishing research or reports about our company, or if they issue unfavorable or inaccurate research regarding our business, our share price and trading volume could decline. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trading market for our common stock relies, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have research control over these analysts. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analysts with provide favorable coverage. Although we have obtained coverage, if one or more of the analysts covering us downgrades our stock or publishes unfavorable or inaccurate research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our common stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our executive officers, directors, holders of 5% or more of our common stock and their respective affiliates beneficially own a significant portion of our outstanding common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of their share ownership, these stockholders, if they act together, have the ability to influence our management and policies and are able to significantly affect the outcome of matters requiring stockholder approval such as elections of directors, amendments of our organizational documents or approvals of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, this concentration of ownership might adversely affect the market price of our common stock by: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">delaying, deferring or preventing a change of control of us; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">impeding a merger, consolidation, takeover or other business combination involving us; or </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion regarding use of our cash and cash equivalents, and we may use them in ways that do not enhance our operating results or the market price of our common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash and cash equivalents. We could utilize our cash and cash equivalents in ways our stockholders may not agree with or that do not yield a favorable return, if any, and our management might not apply our cash and cash equivalents in ways that ultimately increase the value of our stockholders’ investments. If we do not utilize our cash and cash equivalents in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the Loan Agreement and any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited in the foreseeable future to the appreciation of their stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we did not previously incur as a private company. The Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, Nasdaq listing requirements, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel have and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements and will make some activities more time-consuming and costly compared to when we were a private company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company or a smaller reporting company with less than $100.0 million in annual revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting, and that weakness has led to a conclusion that our internal control over financial reporting and disclosure controls and procedures were not effective as of June 30, 2023. Our inability to remediate the material weakness, our discovery of additional weaknesses, and our inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting could adversely affect our results of operations, our stock price and investor confidence.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Section 404 requires that companies evaluate and report on the effectiveness of their internal control over financial reporting. Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Failure to have effective internal control over financial reporting and disclosure controls and procedures can impair our ability to produce accurate financial statements on a timely basis and could lead to a restatement of our financial statements. If, as a result of the ineffectiveness of our internal control over financial reporting and disclosure controls and procedures, we cannot provide reliable financial statements, our business decision processes may be adversely affected, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and our ability to obtain additional financing, or additional financing on favorable terms, could be adversely affected.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have identified a material weakness as of June 30, 2023 in our internal control over financial reporting. The material weakness that we identified related to design and operating deficiencies in our purchasing process, specifically related to the application of invoices to purchase orders and processes to estimate progress on open purchase orders and to identify inaccurate expense estimates within purchase orders. Due to the material weakness in our internal control over financial reporting, we have also concluded that our disclosure controls and procedures were not effective as of June 30, 2023. We have implemented, and are continuing to implement, measures designed to improve internal control over financial reporting to remediate the control deficiencies that led to the material weakness by, among other things, expanding managerial oversight of, and adding process controls to, our purchasing process, including approval and ongoing management of purchase orders and related invoices, and assessment of progress and estimated expenses. We have utilized and will continue to utilize financial consultants to assist with the evaluation and documentation of process controls. We expect to complete the remediation of the material weakness in the near future by hiring additional finance personnel and the continued adoption of incremental financial policies, procedures, and internal controls. We will incur additional costs to remediate these weaknesses, primarily personnel costs and external consulting fees. We cannot provide assurances that the measures we have taken to date, together with any measures we may take in the future, will be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sufficient to remediate the control deficiencies that led to our material weakness in our internal control over financial reporting or to avoid potential future material weaknesses. If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company under the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012 or a smaller reporting company with less than $100.0 million in annual revenue, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We could be an emerging growth company for up to five years. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation, which could have a negative effect on the trading price of our stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal control over financial reporting, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">establish a classified board of directors such that only one of three classes of directors is elected each year; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">limit the manner in which stockholders can remove directors from our board of directors; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">limit who may call stockholder meetings; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees and increase the costs to our stockholders of bringing such claims. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any derivative action or proceeding brought on our behalf; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:19.35pt">any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, and increase the costs to such stockholders of bringing such a claim, either of which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the either exclusive forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and operating results. </span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_124"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Proceeds from Registered Securities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 4, 2021, we closed our initial public offering, or IPO, of common stock under a registration statement on Form S-1 (File No. 333-255132) that was declared effective on April 29, 2021. Information related to our intended use of the proceeds from our IPO is included in the “Use of Proceeds” section of the final prospectus dated April 29, 2021, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act. There has been no material change in the planned use of proceeds from our IPO as described in the final prospectus.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, we have used all proceeds from the IPO.</span></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_127"></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1785530/000119312521150361/d209398dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1785530/000119312521150361/d209398dex31.htm">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 5, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1785530/000119312523176190/d506849dex31.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1785530/000119312523176190/d506849dex31.htm">Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 27, 2023). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a06302023ex311.htm">31.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a06302023ex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a06302023ex312.htm">31.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a06302023ex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="a06302023ex321.htm">32.1†</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a06302023ex321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">†</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications attached as Exhibit 32.1 that accompany this Quarterly Report, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Werewolf Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i4cadfe64e5d042d7864e5d59b36d7f40_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4cadfe64e5d042d7864e5d59b36d7f40_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.766%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WEREWOLF THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy W. Trost</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy W. Trost</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer <br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a06302023ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3a16ac9308f44950a6cbd4c5b7f57e82_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel J. Hicklin, certify that:</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q of Werewolf Therapeutics, Inc.;</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:10pt;padding-left:24.5pt;text-align:justify;text-indent:-24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel J. Hicklin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Hicklin, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a06302023ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6b4084135e874ef682bfc24dc981cf80_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Timothy W. Trost, certify that:</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q of Werewolf Therapeutics, Inc.;</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="margin-top:10pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:10pt;padding-left:24.5pt;text-align:justify;text-indent:-24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy W. Trost</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy W. Trost</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a06302023ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i61d6eee77c29411b8d8c0d72af9b7c61_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-align:justify;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Werewolf Therapeutics, Inc. (the “Company”) for the period ending June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:10pt;padding-left:24.5pt;text-align:justify;text-indent:-24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel J. Hicklin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel J. Hicklin, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 10, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy W. Trost</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy W. Trost</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>howl-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:553e33e0-2e01-4068-99ee-43b139347fc6,g:d188e74b-5927-4b57-8b22-a41aa0482b0b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:howl="http://werewolftx.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://werewolftx.com/20230630">
<xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
<xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
<xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xs:annotation>
<xs:appinfo>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="howl-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="howl-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="howl-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="howl-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:roleType id="Cover" roleURI="http://werewolftx.com/role/Cover">
<link:definition>0000001 - Document - Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited">
<link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
<link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofOperationsunaudited" roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited">
<link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityunaudited" roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited">
<link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals" roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals">
<link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
<link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NatureofBusiness" roleURI="http://werewolftx.com/role/NatureofBusiness">
<link:definition>0000008 - Disclosure - Nature of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://werewolftx.com/role/SummaryofSignificantAccountingPolicies">
<link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="JazzCollaborationandLicenseAgreement" roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreement">
<link:definition>0000010 - Disclosure - Jazz Collaboration and License Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FinancialInstrumentsandFairValueMeasurements" roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements">
<link:definition>0000011 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RestrictedCashandCashEquivalents" roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalents">
<link:definition>0000012 - Disclosure - Restricted Cash and Cash Equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities">
<link:definition>0000013 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="TermLoan" roleURI="http://werewolftx.com/role/TermLoan">
<link:definition>0000014 - Disclosure - Term Loan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommonandPreferredStock" roleURI="http://werewolftx.com/role/CommonandPreferredStock">
<link:definition>0000015 - Disclosure - Common and Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensation" roleURI="http://werewolftx.com/role/StockbasedCompensation">
<link:definition>0000016 - Disclosure - Stock-based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RelatedParties" roleURI="http://werewolftx.com/role/RelatedParties">
<link:definition>0000017 - Disclosure - Related Parties</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossAttributabletoCommonStockholdersperShare" roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare">
<link:definition>0000018 - Disclosure - Net Loss Attributable to Common Stockholders per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
<link:definition>9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="JazzCollaborationandLicenseAgreementTables" roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementTables">
<link:definition>9954702 - Disclosure - Jazz Collaboration and License Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables">
<link:definition>9954703 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RestrictedCashandCashEquivalentsTables" roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsTables">
<link:definition>9954704 - Disclosure - Restricted Cash and Cash Equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
<link:definition>9954705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="TermLoanTables" roleURI="http://werewolftx.com/role/TermLoanTables">
<link:definition>9954706 - Disclosure - Term Loan (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommonandPreferredStockTables" roleURI="http://werewolftx.com/role/CommonandPreferredStockTables">
<link:definition>9954707 - Disclosure - Common and Preferred Stock (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensationTables" roleURI="http://werewolftx.com/role/StockbasedCompensationTables">
<link:definition>9954708 - Disclosure - Stock-based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossAttributabletoCommonStockholdersperShareTables" roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareTables">
<link:definition>9954709 - Disclosure - Net Loss Attributable to Common Stockholders per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NatureofBusinessDetails" roleURI="http://werewolftx.com/role/NatureofBusinessDetails">
<link:definition>9954710 - Disclosure - Nature of Business (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="JazzCollaborationandLicenseAgreementNarrativeDetails" roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails">
<link:definition>9954711 - Disclosure - Jazz Collaboration and License Agreement - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails" roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails">
<link:definition>9954712 - Disclosure - Jazz Collaboration and License Agreement - Contract with Customer, Contract Asset, Contract Liability, and Receivable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails">
<link:definition>9954713 - Disclosure - Financial Instruments and Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails">
<link:definition>9954714 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
<link:definition>9954715 - Disclosure - Financial Instruments and Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RestrictedCashandCashEquivalentsNarrativeDetails" roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails">
<link:definition>9954716 - Disclosure - Restricted Cash and Cash Equivalents - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails" roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails">
<link:definition>9954717 - Disclosure - Restricted Cash and Cash Equivalents - Summary of Restricted Cash (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
<link:definition>9954718 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="TermLoanNarrativeDetails" roleURI="http://werewolftx.com/role/TermLoanNarrativeDetails">
<link:definition>9954719 - Disclosure - Term Loan - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="TermLoanScheduleofLongTermDebtInstrumentsDetails" roleURI="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails">
<link:definition>9954720 - Disclosure - Term Loan - Schedule of Long-Term Debt Instruments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommonandPreferredStockNarrativeDetails" roleURI="http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails">
<link:definition>9954721 - Disclosure - Common and Preferred Stock - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails" roleURI="http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails">
<link:definition>9954722 - Disclosure - Common and Preferred Stock - Schedule of Common Stock Reserved for Issuance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://werewolftx.com/role/StockbasedCompensationNarrativeDetails">
<link:definition>9954723 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensationExpenseRecognizedDetails" roleURI="http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails">
<link:definition>9954724 - Disclosure - Stock-based Compensation - Expense Recognized (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensationRestrictedStockAwardActivityDetails" roleURI="http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails">
<link:definition>9954725 - Disclosure - Stock-based Compensation - Restricted Stock Award Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails">
<link:definition>9954726 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockbasedCompensationStockOptionActivityDetails" roleURI="http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails">
<link:definition>9954727 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RelatedPartiesDetails" roleURI="http://werewolftx.com/role/RelatedPartiesDetails">
<link:definition>9954728 - Disclosure - Related Parties (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails" roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails">
<link:definition>9954729 - Disclosure - Net Loss Attributable to Common Stockholders per Share - Antidilutive Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
</xs:appinfo>
</xs:annotation>
<xs:element id="howl_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="howl_IncreaseInContractWithCustomerLiability" abstract="false" name="IncreaseInContractWithCustomerLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_EmployeeStockOwnershipPlanPurchasePricePercent" abstract="false" name="EmployeeStockOwnershipPlanPurchasePricePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
<xs:element id="howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" abstract="false" name="DebtInstrumentConditionalFeePercentageOfAmountDrawn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
<xs:element id="howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" abstract="true" name="EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="howl_DebtInstrumentCovenantPeriodTwoMember" abstract="true" name="DebtInstrumentCovenantPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" abstract="false" name="DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="howl_DebtInstrumentCovenantPeriodOneMember" abstract="true" name="DebtInstrumentCovenantPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_ATMOfferingMember" abstract="true" name="ATMOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_DebtInstrumentCovenantPeriodDomain" abstract="true" name="DebtInstrumentCovenantPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_DebtInstrumentMaximumBorrowingCapacity" abstract="false" name="DebtInstrumentMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_AccruedContractResearchCurrent" abstract="false" name="AccruedContractResearchCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_SalesCommissionsPercentage" abstract="false" name="SalesCommissionsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
<xs:element id="howl_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_SuccessFeeLiabilityPaid" abstract="false" name="SuccessFeeLiabilityPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_CollaborationAgreementEstimatedFutureReimbursableCosts" abstract="false" name="CollaborationAgreementEstimatedFutureReimbursableCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_DevelopmentAndRegulatoryMilestones" abstract="false" name="DevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_DebtInstrumentConditionalFeeLiability" abstract="false" name="DebtInstrumentConditionalFeeLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_A2017StockIncentivePlanMember" abstract="true" name="A2017StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_JazzCollaborationAgreementMember" abstract="true" name="JazzCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_A2021StockEmployeeStockPurchasePlanMember" abstract="true" name="A2021StockEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_EmployeeStockOwnershipPlanOfferingPeriod" abstract="false" name="EmployeeStockOwnershipPlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="howl_AccruedManufacturingCurrent" abstract="false" name="AccruedManufacturingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_TermLoansMember" abstract="true" name="TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_SalesBasedMilestonesUpTo" abstract="false" name="SalesBasedMilestonesUpTo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_TrancheIILoanMember" abstract="true" name="TrancheIILoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" abstract="false" name="DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
<xs:element id="howl_DebtInstrumentCovenantPeriodAxis" abstract="true" name="DebtInstrumentCovenantPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
<xs:element id="howl_TrancheILoanMember" abstract="true" name="TrancheILoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_DecreaseInContractWithCustomerLiability" abstract="false" name="DecreaseInContractWithCustomerLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_SuccessPaymentLiability" abstract="false" name="SuccessPaymentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_CommonStockAmountAuthorized" abstract="false" name="CommonStockAmountAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_StockIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_NonRefundableUpfrontCashPaymentReceived" abstract="false" name="NonRefundableUpfrontCashPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="howl_A2021StockIncentivePlanMember" abstract="true" name="A2021StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>howl-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:553e33e0-2e01-4068-99ee-43b139347fc6,g:d188e74b-5927-4b57-8b22-a41aa0482b0b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_edf83db6-11fa-4a10-a787-968593d16e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b333fcd-b3e4-481d-8fa4-3400d79b83b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_edf83db6-11fa-4a10-a787-968593d16e17" xlink:to="loc_us-gaap_StockholdersEquity_3b333fcd-b3e4-481d-8fa4-3400d79b83b7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_be46502a-d88d-415c-bae4-f18cfc8bc5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_edf83db6-11fa-4a10-a787-968593d16e17" xlink:to="loc_us-gaap_Liabilities_be46502a-d88d-415c-bae4-f18cfc8bc5c9" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_822f5777-9631-4c44-9c28-02895db84255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_edf83db6-11fa-4a10-a787-968593d16e17" xlink:to="loc_us-gaap_CommitmentsAndContingencies_822f5777-9631-4c44-9c28-02895db84255" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7f7456d6-73da-4519-a4e2-9257593a7e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6da8013a-03bd-4780-890c-675eea6f1462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7f7456d6-73da-4519-a4e2-9257593a7e84" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6da8013a-03bd-4780-890c-675eea6f1462" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5963319c-d4a5-4e22-9bd7-b6bcd6dc1b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7f7456d6-73da-4519-a4e2-9257593a7e84" xlink:to="loc_us-gaap_LiabilitiesCurrent_5963319c-d4a5-4e22-9bd7-b6bcd6dc1b76" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_db5b8dba-542d-4cb8-8a35-d92f86362b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7f7456d6-73da-4519-a4e2-9257593a7e84" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_db5b8dba-542d-4cb8-8a35-d92f86362b59" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_e66d4df2-fcf0-4b19-829d-476d91964e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7f7456d6-73da-4519-a4e2-9257593a7e84" xlink:to="loc_us-gaap_LongTermNotesPayable_e66d4df2-fcf0-4b19-829d-476d91964e0d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa097b0b-1954-4fe1-9945-04542658c769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7f7456d6-73da-4519-a4e2-9257593a7e84" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa097b0b-1954-4fe1-9945-04542658c769" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a168eb29-e12d-4465-9fb1-5118112579c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_628111e8-93d4-4374-879e-00de5e0972ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a168eb29-e12d-4465-9fb1-5118112579c3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_628111e8-93d4-4374-879e-00de5e0972ac" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4e9c92ae-1f54-46c2-9578-4ee3dd891087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a168eb29-e12d-4465-9fb1-5118112579c3" xlink:to="loc_us-gaap_CommonStockValue_4e9c92ae-1f54-46c2-9578-4ee3dd891087" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1ae278bd-6cd1-4942-8afa-843548b6f865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a168eb29-e12d-4465-9fb1-5118112579c3" xlink:to="loc_us-gaap_PreferredStockValue_1ae278bd-6cd1-4942-8afa-843548b6f865" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e07edb8-bbfb-4d3d-ab02-a46fad8a5a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a168eb29-e12d-4465-9fb1-5118112579c3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2e07edb8-bbfb-4d3d-ab02-a46fad8a5a1a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a1b045a3-8816-4694-b81e-1ad5440de307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e1b74a4d-19cb-4511-8832-031c9766b1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1b045a3-8816-4694-b81e-1ad5440de307" xlink:to="loc_us-gaap_AccountsPayableCurrent_e1b74a4d-19cb-4511-8832-031c9766b1d5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7ea27cf7-0d11-40ae-972f-30a7604e58ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1b045a3-8816-4694-b81e-1ad5440de307" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7ea27cf7-0d11-40ae-972f-30a7604e58ff" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4bc967c8-2d8a-4d64-b642-11954e7f66c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1b045a3-8816-4694-b81e-1ad5440de307" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4bc967c8-2d8a-4d64-b642-11954e7f66c0" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_34b16144-b32f-4e66-80eb-492e697b2938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a1b045a3-8816-4694-b81e-1ad5440de307" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_34b16144-b32f-4e66-80eb-492e697b2938" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4d074749-2ced-4e93-9e0b-ade3681ffee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_96cbf0ed-8294-4935-b163-34eb56e9ae95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4d074749-2ced-4e93-9e0b-ade3681ffee3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_96cbf0ed-8294-4935-b163-34eb56e9ae95" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_570b07bd-4ae4-47ba-ab20-7136817b5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4d074749-2ced-4e93-9e0b-ade3681ffee3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_570b07bd-4ae4-47ba-ab20-7136817b5f76" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_61589654-c6ea-49d8-802b-0cbf6c9cabce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4d074749-2ced-4e93-9e0b-ade3681ffee3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_61589654-c6ea-49d8-802b-0cbf6c9cabce" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0bc8e3f0-4ac1-40ff-99e6-f293e46cae08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4d074749-2ced-4e93-9e0b-ade3681ffee3" xlink:to="loc_us-gaap_AssetsCurrent_0bc8e3f0-4ac1-40ff-99e6-f293e46cae08" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8dab5acd-b2d0-49ed-8f1e-2eac08a872f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4d074749-2ced-4e93-9e0b-ade3681ffee3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8dab5acd-b2d0-49ed-8f1e-2eac08a872f9" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3218d637-eeef-4fbb-928e-88d56d5171e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33018c36-bcca-4cb1-b612-3a3a4525a591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3218d637-eeef-4fbb-928e-88d56d5171e5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33018c36-bcca-4cb1-b612-3a3a4525a591" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_e365f06b-5bef-4960-9259-9468d5cf0c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3218d637-eeef-4fbb-928e-88d56d5171e5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_e365f06b-5bef-4960-9259-9468d5cf0c2d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1059ced6-07f7-417e-8a05-c770bfbd9e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3218d637-eeef-4fbb-928e-88d56d5171e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1059ced6-07f7-417e-8a05-c770bfbd9e8e" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a36e374b-a413-47e8-be6a-0bcfdaec388b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c5bf6634-08bf-4db2-95aa-80f252f96433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a36e374b-a413-47e8-be6a-0bcfdaec388b" xlink:to="loc_us-gaap_OperatingExpenses_c5bf6634-08bf-4db2-95aa-80f252f96433" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_834c7b22-4904-45a2-abe4-28fce24a6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a36e374b-a413-47e8-be6a-0bcfdaec388b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_834c7b22-4904-45a2-abe4-28fce24a6cdb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_add69b1c-1f3e-4c26-9f02-f484abc86e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2f974ba4-fbd3-4b80-b6ca-41c51acfe581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_add69b1c-1f3e-4c26-9f02-f484abc86e34" xlink:to="loc_us-gaap_OperatingIncomeLoss_2f974ba4-fbd3-4b80-b6ca-41c51acfe581" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_225fc468-d414-4868-bafd-f8b6e6f2ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_add69b1c-1f3e-4c26-9f02-f484abc86e34" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_225fc468-d414-4868-bafd-f8b6e6f2ad3c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5e605ad-4306-4fa4-b477-1e3efb3a5cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_937a3f6e-a017-4ee0-b109-43104b36f3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5e605ad-4306-4fa4-b477-1e3efb3a5cb5" xlink:to="loc_us-gaap_InvestmentIncomeNet_937a3f6e-a017-4ee0-b109-43104b36f3c9" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c6474473-9375-4691-90d3-eec60b9eabe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5e605ad-4306-4fa4-b477-1e3efb3a5cb5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c6474473-9375-4691-90d3-eec60b9eabe6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_76aa0c06-d562-4416-af27-a97b4f7c3086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_123c6ed0-1ec5-45ec-8861-cb165719550d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76aa0c06-d562-4416-af27-a97b4f7c3086" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_123c6ed0-1ec5-45ec-8861-cb165719550d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ad5b8d4b-4b19-4358-837d-4cd3d8e6c308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76aa0c06-d562-4416-af27-a97b4f7c3086" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ad5b8d4b-4b19-4358-837d-4cd3d8e6c308" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_730938e2-4d12-40a2-9eb5-59416603cd93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_559ceec9-d99b-4a79-bca1-12ee942365f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_730938e2-4d12-40a2-9eb5-59416603cd93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_559ceec9-d99b-4a79-bca1-12ee942365f2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6f0a8186-06e9-48b1-930c-ba8e25b6ce52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_730938e2-4d12-40a2-9eb5-59416603cd93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6f0a8186-06e9-48b1-930c-ba8e25b6ce52" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_896fd80d-8e6d-4d11-adfd-bcc511fbbf75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_730938e2-4d12-40a2-9eb5-59416603cd93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_896fd80d-8e6d-4d11-adfd-bcc511fbbf75" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_12a53acc-8930-474b-8910-726cea41857e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_ShareBasedCompensation_12a53acc-8930-474b-8910-726cea41857e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c51f24be-91ec-4c18-bb46-f980a4ba48e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c51f24be-91ec-4c18-bb46-f980a4ba48e2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7564611b-407e-42e6-b0a2-7578ffe5152c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7564611b-407e-42e6-b0a2-7578ffe5152c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e427037-e941-458d-8415-d9bfab4167b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_NetIncomeLoss_8e427037-e941-458d-8415-d9bfab4167b2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f13b9482-7238-4ed6-9094-7fbdc06b73a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f13b9482-7238-4ed6-9094-7fbdc06b73a2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6f3c6066-8040-4b41-8884-82dba5b5c228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6f3c6066-8040-4b41-8884-82dba5b5c228" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_72705333-ffc1-4319-a4c4-ab2aee874a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_Depreciation_72705333-ffc1-4319-a4c4-ab2aee874a27" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_61bdeaed-9cb9-4650-a8ee-866c8fae92f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_61bdeaed-9cb9-4650-a8ee-866c8fae92f0" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_4d51b84b-e458-46ed-96da-5b2515d542c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
<link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_4d51b84b-e458-46ed-96da-5b2515d542c6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ec03c1c9-8d9e-478c-8c45-55bea46a2c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ec03c1c9-8d9e-478c-8c45-55bea46a2c42" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c96be063-bdda-4377-b65b-1f03de658d36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
<link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c96be063-bdda-4377-b65b-1f03de658d36" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5e0d90dd-238d-42b3-ab5e-f41e0d5dc2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5e0d90dd-238d-42b3-ab5e-f41e0d5dc2d8" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_bbcabf00-24c9-4962-8b6c-3fb1a17ff65b" xlink:href="howl-20230630.xsd#howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset"/>
<link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_bbcabf00-24c9-4962-8b6c-3fb1a17ff65b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f25d97b2-4ea4-48e1-b340-70083dfb2351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
<link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f25d97b2-4ea4-48e1-b340-70083dfb2351" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_NonCashInterestExpense_0183edb2-022b-4dca-899a-724f72309bce" xlink:href="howl-20230630.xsd#howl_NonCashInterestExpense"/>
<link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_04d48334-4d9a-42dc-82ac-5d9dfda5e7dc" xlink:to="loc_howl_NonCashInterestExpense_0183edb2-022b-4dca-899a-724f72309bce" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6b6ee61-6bba-4995-a1bc-c67dc87b176a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_0232905f-8ebf-46af-bc24-a15a576244e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6b6ee61-6bba-4995-a1bc-c67dc87b176a" xlink:to="loc_us-gaap_ProceedsFromStockPlans_0232905f-8ebf-46af-bc24-a15a576244e6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b0cd8b6c-03f9-44a6-9a9d-ccda77942046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6b6ee61-6bba-4995-a1bc-c67dc87b176a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b0cd8b6c-03f9-44a6-9a9d-ccda77942046" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9abd09cd-c346-4622-ba78-a567491f9d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6b6ee61-6bba-4995-a1bc-c67dc87b176a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9abd09cd-c346-4622-ba78-a567491f9d71" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_95f7a879-ec83-40e5-9bd2-40f2c17bd180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6b6ee61-6bba-4995-a1bc-c67dc87b176a" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_95f7a879-ec83-40e5-9bd2-40f2c17bd180" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_756cda12-7a67-4441-84a7-31f480a48e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6b6ee61-6bba-4995-a1bc-c67dc87b176a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_756cda12-7a67-4441-84a7-31f480a48e4f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_260fc8f2-7d76-49d9-b2b3-3235c21b57c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a99930b-4e6b-4ad8-a935-3b6b807bb68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_260fc8f2-7d76-49d9-b2b3-3235c21b57c1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a99930b-4e6b-4ad8-a935-3b6b807bb68c" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_578484ae-df23-4a98-a227-c58daff83cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_a7a4b49e-5796-44e3-922c-7fee30b0532f" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_578484ae-df23-4a98-a227-c58daff83cf0" xlink:to="loc_howl_SuccessPaymentLiability_a7a4b49e-5796-44e3-922c-7fee30b0532f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_16a12ad6-7bda-4e12-b912-96d8fa5a6c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8dad0298-d56f-4c15-bfe8-00f55172b0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_16a12ad6-7bda-4e12-b912-96d8fa5a6c1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8dad0298-d56f-4c15-bfe8-00f55172b0f1" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfa5890b-fe28-4a34-b146-6940d71c7316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_5f30fde2-8344-4f73-83b8-65421d859fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfa5890b-fe28-4a34-b146-6940d71c7316" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_5f30fde2-8344-4f73-83b8-65421d859fb8" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0daaf172-e5f1-4500-bf1e-fcdcf03bc973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfa5890b-fe28-4a34-b146-6940d71c7316" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0daaf172-e5f1-4500-bf1e-fcdcf03bc973" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_12ba4c84-9b46-46d2-82ca-1449e38265ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfa5890b-fe28-4a34-b146-6940d71c7316" xlink:to="loc_us-gaap_RestrictedCashCurrent_12ba4c84-9b46-46d2-82ca-1449e38265ca" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dd7925bc-89a3-4a62-bbe3-c253ec1c6e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dd7925bc-89a3-4a62-bbe3-c253ec1c6e92" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ac95228d-e51a-47de-a3e4-e3b514a5113f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ac95228d-e51a-47de-a3e4-e3b514a5113f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedManufacturingCurrent_edcccd17-189d-4832-8aa4-438b36458b04" xlink:href="howl-20230630.xsd#howl_AccruedManufacturingCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:to="loc_howl_AccruedManufacturingCurrent_edcccd17-189d-4832-8aa4-438b36458b04" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedContractResearchCurrent_9f295a83-08db-474b-a87e-3fa73d2ceaaa" xlink:href="howl-20230630.xsd#howl_AccruedContractResearchCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:to="loc_howl_AccruedContractResearchCurrent_9f295a83-08db-474b-a87e-3fa73d2ceaaa" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0dfbaa2-7c85-43bd-bd5f-469f699f1752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0dfbaa2-7c85-43bd-bd5f-469f699f1752" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_468d55b6-7e8d-4be9-8764-5ee1d1d2b8e8" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ba7aa31-7cc7-49c1-99b8-a25ff7085cfc" xlink:to="loc_howl_SuccessPaymentLiability_468d55b6-7e8d-4be9-8764-5ee1d1d2b8e8" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoanScheduleofLongTermDebtInstrumentsDetails"/>
<link:calculationLink xlink:role="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3710372f-2f53-4140-ad5b-277fb25401d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4b2dd5bb-d7e9-4f8e-977e-42847eb4a8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3710372f-2f53-4140-ad5b-277fb25401d4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4b2dd5bb-d7e9-4f8e-977e-42847eb4a8a6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_67d18234-7f0b-4ce2-9b34-01e1cd741e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3710372f-2f53-4140-ad5b-277fb25401d4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_67d18234-7f0b-4ce2-9b34-01e1cd741e89" xlink:type="arc"/>
</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>howl-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:553e33e0-2e01-4068-99ee-43b139347fc6,g:d188e74b-5927-4b57-8b22-a41aa0482b0b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fe9f7959-f3ac-4314-ad87-5040a8bfbb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fe9f7959-f3ac-4314-ad87-5040a8bfbb5c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_69e69f53-23ed-4b2b-8420-b7817b2eacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_SharesOutstanding_69e69f53-23ed-4b2b-8420-b7817b2eacd4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f7df68b5-0dc1-49c0-b517-ec5a9ee496ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockholdersEquity_f7df68b5-0dc1-49c0-b517-ec5a9ee496ea" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e17d77cb-f40e-4c89-ad07-3c5d3f62754b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e17d77cb-f40e-4c89-ad07-3c5d3f62754b" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0ccfc2e-cec8-4f02-82a4-ed7b744d4b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0ccfc2e-cec8-4f02-82a4-ed7b744d4b31" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ccafecdc-116c-4b04-85e1-edd3c3193562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ccafecdc-116c-4b04-85e1-edd3c3193562" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8881425e-0c30-4315-8d18-b61a2d472c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8881425e-0c30-4315-8d18-b61a2d472c0b" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_beb5d470-df17-40d8-8e9d-ae26b9e9a9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_beb5d470-df17-40d8-8e9d-ae26b9e9a9c2" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1feaa159-9450-4d4b-9f54-5d785081f447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1feaa159-9450-4d4b-9f54-5d785081f447" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_90a282aa-ed92-4950-85a3-2577f5705d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_90a282aa-ed92-4950-85a3-2577f5705d9e" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15fe0639-4098-49d9-97c3-f40123aeadc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_NetIncomeLoss_15fe0639-4098-49d9-97c3-f40123aeadc4" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1d1698d1-2713-4afb-82c1-e306802a8a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_857e6eb1-728c-4bba-a67f-3d877822998a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fe9f7959-f3ac-4314-ad87-5040a8bfbb5c" xlink:to="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0528a0a7-27ce-44da-bde2-befa6fff46db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:to="loc_us-gaap_EquityComponentDomain_0528a0a7-27ce-44da-bde2-befa6fff46db_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:to="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d27faa48-ae59-4c42-8ed9-cf3130fb20cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:to="loc_us-gaap_CommonStockMember_d27faa48-ae59-4c42-8ed9-cf3130fb20cc" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_92e448a9-5d43-455d-a809-6d3e8d4474b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_92e448a9-5d43-455d-a809-6d3e8d4474b9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_09866bad-bf62-4c29-b719-62f16a319df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:to="loc_us-gaap_RetainedEarningsMember_09866bad-bf62-4c29-b719-62f16a319df4" xlink:type="arc" order="2"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#JazzCollaborationandLicenseAgreementNarrativeDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_NonRefundableUpfrontCashPaymentReceived_ce394596-0af6-4326-bd4f-6e4cd04c11d4" xlink:href="howl-20230630.xsd#howl_NonRefundableUpfrontCashPaymentReceived"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_NonRefundableUpfrontCashPaymentReceived_ce394596-0af6-4326-bd4f-6e4cd04c11d4" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DevelopmentAndRegulatoryMilestones_34aa2ca9-53db-4a77-9754-66d7d28b5e4c" xlink:href="howl-20230630.xsd#howl_DevelopmentAndRegulatoryMilestones"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_DevelopmentAndRegulatoryMilestones_34aa2ca9-53db-4a77-9754-66d7d28b5e4c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SalesBasedMilestonesUpTo_60901c49-8171-4976-833d-55fccfab84d9" xlink:href="howl-20230630.xsd#howl_SalesBasedMilestonesUpTo"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_SalesBasedMilestonesUpTo_60901c49-8171-4976-833d-55fccfab84d9" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborativeAgreementTransactionPrice_bfea5af5-df58-4c64-8558-3cac321d00d7" xlink:href="howl-20230630.xsd#howl_CollaborativeAgreementTransactionPrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_CollaborativeAgreementTransactionPrice_bfea5af5-df58-4c64-8558-3cac321d00d7" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_ff9f575d-cac8-4472-b5ad-37c28eea15f8" xlink:href="howl-20230630.xsd#howl_CollaborationAgreementEstimatedFutureReimbursableCosts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_ff9f575d-cac8-4472-b5ad-37c28eea15f8" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborationAgreementTerm_7a25f670-0a48-4f1a-b254-e7a57ff14887" xlink:href="howl-20230630.xsd#howl_CollaborationAgreementTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_CollaborationAgreementTerm_7a25f670-0a48-4f1a-b254-e7a57ff14887" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c347fadc-2a10-4062-8946-3a2659e9bb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c347fadc-2a10-4062-8946-3a2659e9bb6d" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2a30fa8a-c501-49e5-9773-8d0399c29847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2a30fa8a-c501-49e5-9773-8d0399c29847" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ae372f04-1fad-4258-a93e-60ee778bcdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ae372f04-1fad-4258-a93e-60ee778bcdf3" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_3fd0b5a8-4996-49eb-8e01-70f4bf331650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_3fd0b5a8-4996-49eb-8e01-70f4bf331650" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c294170-97ab-4d4f-9271-139e961215d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2c294170-97ab-4d4f-9271-139e961215d0_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5283bdd9-4e50-4c17-9dc0-31d8910ef050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5283bdd9-4e50-4c17-9dc0-31d8910ef050" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_JazzCollaborationAgreementMember_12f45643-7401-49a7-915d-d5d32da6df54" xlink:href="howl-20230630.xsd#howl_JazzCollaborationAgreementMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5283bdd9-4e50-4c17-9dc0-31d8910ef050" xlink:to="loc_howl_JazzCollaborationAgreementMember_12f45643-7401-49a7-915d-d5d32da6df54" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c26684-5531-4034-81d6-f7a1c4a08c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c26684-5531-4034-81d6-f7a1c4a08c69" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3c9ae997-a162-44c5-93d9-e658335f69bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3c9ae997-a162-44c5-93d9-e658335f69bd" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_722434cd-4be8-478e-855e-d7e43adc9fb6" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_howl_SuccessPaymentLiability_722434cd-4be8-478e-855e-d7e43adc9fb6" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_cb86c167-3cdc-4063-88d3-43e5145e02cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_cb86c167-3cdc-4063-88d3-43e5145e02cd" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7de096f7-5bd5-4a48-9d40-c39878f327dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7de096f7-5bd5-4a48-9d40-c39878f327dc_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8008915-552e-47b7-b2d1-1a30388e381d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8008915-552e-47b7-b2d1-1a30388e381d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_87e6f0e4-2606-43a7-9eb7-91ac15cd0696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_87e6f0e4-2606-43a7-9eb7-91ac15cd0696" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d8178517-2a37-4fa0-b85f-5dbed73c0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d8178517-2a37-4fa0-b85f-5dbed73c0d3f" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2498bd30-5d9d-4392-ab5b-b87f731802d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2498bd30-5d9d-4392-ab5b-b87f731802d0_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb1b651c-e9ee-4aaf-8a1e-32ed96a2e54d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb1b651c-e9ee-4aaf-8a1e-32ed96a2e54d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7c47137e-271c-44c0-96ce-5717306ae7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb1b651c-e9ee-4aaf-8a1e-32ed96a2e54d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7c47137e-271c-44c0-96ce-5717306ae7ba" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e04397c2-d9c6-430a-99af-0b123dd27ce6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e04397c2-d9c6-430a-99af-0b123dd27ce6_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a9f87a15-ce4e-4c80-9eaf-61166d74fab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a9f87a15-ce4e-4c80-9eaf-61166d74fab1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b51ba146-3d9f-4581-aa5b-4db6c5f0bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a9f87a15-ce4e-4c80-9eaf-61166d74fab1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b51ba146-3d9f-4581-aa5b-4db6c5f0bedd" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_b917ecdf-9d5b-4bcd-9e0d-b3271b77625e" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_howl_SuccessPaymentLiability_b917ecdf-9d5b-4bcd-9e0d-b3271b77625e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessFeeLiabilityPaid_4f10d130-4a67-4d90-8d84-5e0b1f41f7f7" xlink:href="howl-20230630.xsd#howl_SuccessFeeLiabilityPaid"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_howl_SuccessFeeLiabilityPaid_4f10d130-4a67-4d90-8d84-5e0b1f41f7f7" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_95c8a60b-63ab-422f-8548-c99d40c060a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_95c8a60b-63ab-422f-8548-c99d40c060a5" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f7a597e-0631-4d0d-a97a-b037f436d3d2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:to="loc_srt_RangeMember_2f7a597e-0631-4d0d-a97a-b037f436d3d2_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26b2fa76-c11c-4cc5-b253-d11591e2eb9a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:to="loc_srt_RangeMember_26b2fa76-c11c-4cc5-b253-d11591e2eb9a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfc51689-0619-4beb-9169-822066cc4553" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26b2fa76-c11c-4cc5-b253-d11591e2eb9a" xlink:to="loc_srt_MaximumMember_dfc51689-0619-4beb-9169-822066cc4553" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b9f507c-ecad-4e06-97b8-05fe202c200b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b9f507c-ecad-4e06-97b8-05fe202c200b_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9654c38c-cc15-431f-a684-2e231c721690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9654c38c-cc15-431f-a684-2e231c721690" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_212f45f1-e044-46e6-9171-4e162ba9f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9654c38c-cc15-431f-a684-2e231c721690" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_212f45f1-e044-46e6-9171-4e162ba9f52d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ebb58031-871f-4ae8-b4b6-2574bbb56f91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ebb58031-871f-4ae8-b4b6-2574bbb56f91_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e280118-216b-48e5-97d0-c1019dc10aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e280118-216b-48e5-97d0-c1019dc10aae" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3e460ed0-3372-41b2-8e9a-6c23495b48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e280118-216b-48e5-97d0-c1019dc10aae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3e460ed0-3372-41b2-8e9a-6c23495b48b3" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c9b8d1e8-17d5-4517-8b10-3ae51445c956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c9b8d1e8-17d5-4517-8b10-3ae51445c956" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_67520dd1-fbd5-4103-b67f-baeddcfdf789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_67520dd1-fbd5-4103-b67f-baeddcfdf789" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7b0f9061-bfef-42ec-a707-1e00c3cfe5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7b0f9061-bfef-42ec-a707-1e00c3cfe5bb" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_27a03082-0024-47c5-8174-b832cb3bf568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_27a03082-0024-47c5-8174-b832cb3bf568" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_666e0627-3d92-4254-a725-4ea7aa207634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_666e0627-3d92-4254-a725-4ea7aa207634" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_946dc6f6-0f9e-4bc5-9556-59be3acd5aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c9b8d1e8-17d5-4517-8b10-3ae51445c956" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_888a1ad0-35ab-47f2-a8c7-1299c362846e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_888a1ad0-35ab-47f2-a8c7-1299c362846e_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_338333f3-bc56-43fa-a3c2-035bd6eb1a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_338333f3-bc56-43fa-a3c2-035bd6eb1a51" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3cbd0883-0f31-4275-8d64-dde39aa2891d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_338333f3-bc56-43fa-a3c2-035bd6eb1a51" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3cbd0883-0f31-4275-8d64-dde39aa2891d" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3b8b884-4b11-4fc4-8167-649282ed0547_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3b8b884-4b11-4fc4-8167-649282ed0547_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_baf25163-aed3-403a-ac7e-d855f3d8a76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_baf25163-aed3-403a-ac7e-d855f3d8a76f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b57b88a7-a1fc-44d7-84c5-ffdb3b011707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_baf25163-aed3-403a-ac7e-d855f3d8a76f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b57b88a7-a1fc-44d7-84c5-ffdb3b011707" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#RestrictedCashandCashEquivalentsNarrativeDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_33719822-6258-4cfc-9bd6-db4e10cabb54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:to="loc_us-gaap_RestrictedCash_33719822-6258-4cfc-9bd6-db4e10cabb54" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_b3bc08bc-57b2-4f60-9725-2007e420f82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:to="loc_us-gaap_RestrictedCashCurrent_b3bc08bc-57b2-4f60-9725-2007e420f82c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46d63161-9a38-457b-8f70-a6380508bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46d63161-9a38-457b-8f70-a6380508bb5b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember_6ab3910d-182d-4c08-b670-3af95a69a5fb" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46d63161-9a38-457b-8f70-a6380508bb5b" xlink:to="loc_howl_TermLoansMember_6ab3910d-182d-4c08-b670-3af95a69a5fb" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb18bd1e-10b7-4a9a-8b82-12d893a1539f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb18bd1e-10b7-4a9a-8b82-12d893a1539f_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9427e882-506b-4fe8-9e33-be9a75bcae37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9427e882-506b-4fe8-9e33-be9a75bcae37" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e370c0dc-ea93-46d9-89ec-3e8f4c88ecad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9427e882-506b-4fe8-9e33-be9a75bcae37" xlink:to="loc_us-gaap_LoansPayableMember_e370c0dc-ea93-46d9-89ec-3e8f4c88ecad" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoanNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoanNarrativeDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/TermLoanNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentMaximumBorrowingCapacity_523621a7-61a9-4b79-9b43-65bc05f88e2e" xlink:href="howl-20230630.xsd#howl_DebtInstrumentMaximumBorrowingCapacity"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentMaximumBorrowingCapacity_523621a7-61a9-4b79-9b43-65bc05f88e2e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11aae1da-22b9-48af-8041-e05062084efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11aae1da-22b9-48af-8041-e05062084efb" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba486281-8cee-4cd4-9c56-bb3d89ffbf10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba486281-8cee-4cd4-9c56-bb3d89ffbf10" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a0975cb0-e3f9-4db0-bbe0-1b99675f7bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_InterestExpense_a0975cb0-e3f9-4db0-bbe0-1b99675f7bf1" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee_16c473e0-dc44-4ec3-a295-c6750ecfa7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityFee"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee_16c473e0-dc44-4ec3-a295-c6750ecfa7d3" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_619fbe29-e965-471d-a58f-2561cdc424f7" xlink:href="howl-20230630.xsd#howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_619fbe29-e965-471d-a58f-2561cdc424f7" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessFeeLiabilityPaid_521d8ba8-5a1a-449d-80f6-edd58b20cb44" xlink:href="howl-20230630.xsd#howl_SuccessFeeLiabilityPaid"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_SuccessFeeLiabilityPaid_521d8ba8-5a1a-449d-80f6-edd58b20cb44" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentConditionalFeeLiability_3f608460-d997-469e-9417-e4676d6b2687" xlink:href="howl-20230630.xsd#howl_DebtInstrumentConditionalFeeLiability"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentConditionalFeeLiability_3f608460-d997-469e-9417-e4676d6b2687" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_592c5225-d571-4922-b15a-93352dcb1ebe" xlink:href="howl-20230630.xsd#howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_592c5225-d571-4922-b15a-93352dcb1ebe" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_eee1065e-08d8-4b04-8d16-ecd3eb8da30f" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_eee1065e-08d8-4b04-8d16-ecd3eb8da30f" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_79816cd5-cb82-4cd2-8290-7b14b5f570d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_79816cd5-cb82-4cd2-8290-7b14b5f570d0" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_8f107b15-a9a6-49bc-b74d-13fbadd0786f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_Cash_8f107b15-a9a6-49bc-b74d-13fbadd0786f" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c358f9d1-b3a9-47a4-be4e-0eb0d54bde57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c358f9d1-b3a9-47a4-be4e-0eb0d54bde57" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2bdef250-2b42-4c6b-98a5-170c3d2422c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2bdef250-2b42-4c6b-98a5-170c3d2422c7_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9b4229fd-ec48-48db-a0e7-3fb4607287c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9b4229fd-ec48-48db-a0e7-3fb4607287c0" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1f99b7c2-ec69-4147-b88a-fe3baab06b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9b4229fd-ec48-48db-a0e7-3fb4607287c0" xlink:to="loc_us-gaap_LoansPayableMember_1f99b7c2-ec69-4147-b88a-fe3baab06b83" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86072de7-1fdd-4f27-806b-6803a92c7ce8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86072de7-1fdd-4f27-806b-6803a92c7ce8_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TrancheILoanMember_f2c73e67-47f2-42bb-a2ca-206df8b016f9" xlink:href="howl-20230630.xsd#howl_TrancheILoanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:to="loc_howl_TrancheILoanMember_f2c73e67-47f2-42bb-a2ca-206df8b016f9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TrancheIILoanMember_aea979a4-dc5a-495c-8a3d-d8948f2b9bef" xlink:href="howl-20230630.xsd#howl_TrancheIILoanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:to="loc_howl_TrancheIILoanMember_aea979a4-dc5a-495c-8a3d-d8948f2b9bef" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember_24737381-24e5-4fab-9300-1c34945ebe68" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:to="loc_howl_TermLoansMember_24737381-24e5-4fab-9300-1c34945ebe68" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:to="loc_us-gaap_VariableRateDomain_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_59b4c207-c451-44ea-90f1-935f1189d1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:to="loc_us-gaap_VariableRateDomain_59b4c207-c451-44ea-90f1-935f1189d1f1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_14d09992-a771-42fc-97e6-5769b31be4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_59b4c207-c451-44ea-90f1-935f1189d1f1" xlink:to="loc_us-gaap_PrimeRateMember_14d09992-a771-42fc-97e6-5769b31be4cb" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodDomain_c5e4fd35-2b61-4044-9acc-4688434e103a_default" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:to="loc_howl_DebtInstrumentCovenantPeriodDomain_c5e4fd35-2b61-4044-9acc-4688434e103a_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:to="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodOneMember_476a931f-ff39-4d58-b1ad-7200f6f07318" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodOneMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:to="loc_howl_DebtInstrumentCovenantPeriodOneMember_476a931f-ff39-4d58-b1ad-7200f6f07318" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodTwoMember_53d3f80d-7e5a-46da-a04d-dc4811796ede" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodTwoMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:to="loc_howl_DebtInstrumentCovenantPeriodTwoMember_53d3f80d-7e5a-46da-a04d-dc4811796ede" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoanScheduleofLongTermDebtInstrumentsDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_43be981b-e1af-41fe-bae3-80b5a3fbaddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_43be981b-e1af-41fe-bae3-80b5a3fbaddf" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1c9e91ed-161e-4c6a-bbfd-2247ee119f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1c9e91ed-161e-4c6a-bbfd-2247ee119f52" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cda22ed8-2683-4527-998f-8b4defed3c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_LongTermDebt_cda22ed8-2683-4527-998f-8b4defed3c99" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07aef090-fa69-471f-9fc2-970e88e669ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07aef090-fa69-471f-9fc2-970e88e669ba_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99050be9-69e6-45fd-a94a-d289abfa0e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99050be9-69e6-45fd-a94a-d289abfa0e3f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember_56203dfd-d0b6-47a8-a41e-49d3cfaae791" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99050be9-69e6-45fd-a94a-d289abfa0e3f" xlink:to="loc_howl_TermLoansMember_56203dfd-d0b6-47a8-a41e-49d3cfaae791" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c62a02b-f4ef-42f7-968b-b271b2cb4630_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c62a02b-f4ef-42f7-968b-b271b2cb4630_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb64fe49-666a-4ab2-ac24-50dc67c00506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb64fe49-666a-4ab2-ac24-50dc67c00506" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_405cfd11-0103-4373-9171-95610e0e5dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb64fe49-666a-4ab2-ac24-50dc67c00506" xlink:to="loc_us-gaap_LoansPayableMember_405cfd11-0103-4373-9171-95610e0e5dae" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#CommonandPreferredStockNarrativeDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cfe3c33f-d559-454a-8e47-2ae495de68df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cfe3c33f-d559-454a-8e47-2ae495de68df" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_568a6a77-d397-4122-9dfd-480740226a88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_568a6a77-d397-4122-9dfd-480740226a88" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CommonStockAmountAuthorized_9540f738-7ae7-4aef-8c79-dd34a177f455" xlink:href="howl-20230630.xsd#howl_CommonStockAmountAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_howl_CommonStockAmountAuthorized_9540f738-7ae7-4aef-8c79-dd34a177f455" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SalesCommissionsPercentage_498731c0-26dd-4d02-adbd-328cff2c548e" xlink:href="howl-20230630.xsd#howl_SalesCommissionsPercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_howl_SalesCommissionsPercentage_498731c0-26dd-4d02-adbd-328cff2c548e" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_441eb5b0-b5ad-4f4a-919f-843f7e9a6056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_441eb5b0-b5ad-4f4a-919f-843f7e9a6056" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_62630ec6-8ed3-4fa4-af65-5cfa1a7028ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_62630ec6-8ed3-4fa4-af65-5cfa1a7028ee" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5bf613dd-3ea5-4c60-abd3-9bbd27ba77c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5bf613dd-3ea5-4c60-abd3-9bbd27ba77c1" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4e7314b6-d67c-4d72-aa21-f3c1de7e933d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4e7314b6-d67c-4d72-aa21-f3c1de7e933d" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b8ee0a33-154f-4b49-abf9-14295e786b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b8ee0a33-154f-4b49-abf9-14295e786b85" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_484d095e-5fed-4ac3-a315-9725b8c07722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_484d095e-5fed-4ac3-a315-9725b8c07722" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:to="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4069175e-d961-4413-b7fc-28aa11eafee8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:to="loc_srt_RangeMember_4069175e-d961-4413-b7fc-28aa11eafee8_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c97e059a-a2ad-4ed0-b345-cd5e9128cf56" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:to="loc_srt_RangeMember_c97e059a-a2ad-4ed0-b345-cd5e9128cf56" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d5018d3-7338-422a-a42c-886bae36589f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c97e059a-a2ad-4ed0-b345-cd5e9128cf56" xlink:to="loc_srt_MaximumMember_5d5018d3-7338-422a-a42c-886bae36589f" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c270336-1104-47d1-8d53-2799a75588ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c270336-1104-47d1-8d53-2799a75588ce_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44ac0480-ef4f-48a1-a57c-a6322d26e260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44ac0480-ef4f-48a1-a57c-a6322d26e260" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_ATMOfferingMember_762b20a0-ab19-4050-aba1-aee85d8d6b79" xlink:href="howl-20230630.xsd#howl_ATMOfferingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44ac0480-ef4f-48a1-a57c-a6322d26e260" xlink:to="loc_howl_ATMOfferingMember_762b20a0-ab19-4050-aba1-aee85d8d6b79" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_53ed73ae-1f36-4820-9c5b-cb2eb31b04da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3faa166-d442-4338-8650-7bffee1245d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53ed73ae-1f36-4820-9c5b-cb2eb31b04da" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3faa166-d442-4338-8650-7bffee1245d1" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_53ed73ae-1f36-4820-9c5b-cb2eb31b04da" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ebcddaa-b82c-430a-8b85-368cd120d29f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:to="loc_us-gaap_ClassOfStockDomain_1ebcddaa-b82c-430a-8b85-368cd120d29f_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:to="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_0a9bfb12-4f3c-4bdf-b3b0-92a7bfd74bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_StockOptionMember_0a9bfb12-4f3c-4bdf-b3b0-92a7bfd74bb6" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_16ad2761-1fd5-42a9-a59b-8deffd26b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_16ad2761-1fd5-42a9-a59b-8deffd26b8bc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_37cf8783-1bfb-4f86-9ffd-3255c6b28346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_WarrantMember_37cf8783-1bfb-4f86-9ffd-3255c6b28346" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockEmployeeStockPurchasePlanMember_794d5c6d-f8a1-4ae3-b1e3-d99f105c8b07" xlink:href="howl-20230630.xsd#howl_A2021StockEmployeeStockPurchasePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_howl_A2021StockEmployeeStockPurchasePlanMember_794d5c6d-f8a1-4ae3-b1e3-d99f105c8b07" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_adb186ae-da09-4662-8e21-8f6d3a3f47fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_adb186ae-da09-4662-8e21-8f6d3a3f47fc" xlink:type="arc" order="4"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationNarrativeDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd8e0bc2-bec9-47c9-bf7b-fdb79bd6495e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd8e0bc2-bec9-47c9-bf7b-fdb79bd6495e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a8228475-b42c-4074-bbdd-78e7e552f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a8228475-b42c-4074-bbdd-78e7e552f5f5" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_da49d0b8-773f-4038-bddb-7fe94ca98dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_da49d0b8-773f-4038-bddb-7fe94ca98dbc" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7336a898-5ff5-4570-9ca8-6deafb17b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7336a898-5ff5-4570-9ca8-6deafb17b87b" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4f35c29-e5fe-43dc-bed8-1bb0c5ac15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4f35c29-e5fe-43dc-bed8-1bb0c5ac15aa" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_EmployeeStockOwnershipPlanOfferingPeriod_82bf1bcc-8e6a-4091-8219-517b0ef5b2dd" xlink:href="howl-20230630.xsd#howl_EmployeeStockOwnershipPlanOfferingPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_howl_EmployeeStockOwnershipPlanOfferingPeriod_82bf1bcc-8e6a-4091-8219-517b0ef5b2dd" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_EmployeeStockOwnershipPlanPurchasePricePercent_39acb262-68ab-4359-8fcd-467e47b163a0" xlink:href="howl-20230630.xsd#howl_EmployeeStockOwnershipPlanPurchasePricePercent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_howl_EmployeeStockOwnershipPlanPurchasePricePercent_39acb262-68ab-4359-8fcd-467e47b163a0" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e1a1775c-3e1d-4b5c-8c0a-fcb1300eccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e1a1775c-3e1d-4b5c-8c0a-fcb1300eccbc" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d98a0c11-2f49-492a-911f-cc28d33d8ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d98a0c11-2f49-492a-911f-cc28d33d8ce0" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_17f00b07-5f6e-4835-9e42-bc1f352757dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_17f00b07-5f6e-4835-9e42-bc1f352757dc" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a6fb4dd8-523c-4d55-9398-ba47103a6c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a6fb4dd8-523c-4d55-9398-ba47103a6c32" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3329e95e-0bd5-4bae-9fd5-20fecb9230ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3329e95e-0bd5-4bae-9fd5-20fecb9230ce" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5e7fa758-53b2-4001-a259-07745b0b4062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5e7fa758-53b2-4001-a259-07745b0b4062" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_27530d2d-6eab-493c-9067-a05a8cb0c648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_27530d2d-6eab-493c-9067-a05a8cb0c648" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_06183210-12ef-4d86-a611-d4e6ea4384d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_06183210-12ef-4d86-a611-d4e6ea4384d4" xlink:type="arc" order="14"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3c5d8e6d-774f-4d69-b40b-a082cfc941b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3c5d8e6d-774f-4d69-b40b-a082cfc941b0" xlink:type="arc" order="15"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_de08c1af-74fd-4cc9-8205-8be9f70c2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_de08c1af-74fd-4cc9-8205-8be9f70c2e2e" xlink:type="arc" order="16"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b9ed2e0-c596-4911-972c-0ae4cd4b195c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b9ed2e0-c596-4911-972c-0ae4cd4b195c" xlink:type="arc" order="17"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa7b8a79-40ac-440d-a7e7-5eb7c37ea215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa7b8a79-40ac-440d-a7e7-5eb7c37ea215" xlink:type="arc" order="18"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_272ef50c-269c-44b7-aaf0-596f61a7b618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_272ef50c-269c-44b7-aaf0-596f61a7b618" xlink:type="arc" order="19"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46bc7574-3fe4-44ee-8311-a8d62da39cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46bc7574-3fe4-44ee-8311-a8d62da39cb2" xlink:type="arc" order="20"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27b3c65d-76fb-4a18-bb02-db24270d44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27b3c65d-76fb-4a18-bb02-db24270d44d6" xlink:type="arc" order="21"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_20c27a3d-fb27-4cc4-802a-311030db1efd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:to="loc_us-gaap_EquityComponentDomain_20c27a3d-fb27-4cc4-802a-311030db1efd_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e634eefd-d269-4fd5-b974-f84bc3c90977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:to="loc_us-gaap_EquityComponentDomain_e634eefd-d269-4fd5-b974-f84bc3c90977" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3d646b9d-8b98-41de-8bef-0b85c8302568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e634eefd-d269-4fd5-b974-f84bc3c90977" xlink:to="loc_us-gaap_CommonStockMember_3d646b9d-8b98-41de-8bef-0b85c8302568" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:to="loc_us-gaap_PlanNameDomain_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:to="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember_716f4f4d-c875-4ac2-82e3-0fd6f4d574b0" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:to="loc_howl_A2021StockIncentivePlanMember_716f4f4d-c875-4ac2-82e3-0fd6f4d574b0" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember_c466307d-1bd9-49da-9d34-ff86107eac1d" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:to="loc_howl_A2017StockIncentivePlanMember_c466307d-1bd9-49da-9d34-ff86107eac1d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockEmployeeStockPurchasePlanMember_bf27dca9-7953-47a2-aefd-6452ba94fca0" xlink:href="howl-20230630.xsd#howl_A2021StockEmployeeStockPurchasePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:to="loc_howl_A2021StockEmployeeStockPurchasePlanMember_bf27dca9-7953-47a2-aefd-6452ba94fca0" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8304f4d-96bc-46ac-94a5-f4bb35cd6850_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f8304f4d-96bc-46ac-94a5-f4bb35cd6850_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d210cd2b-924a-4e06-a349-adbcee75ec35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_RestrictedStockMember_d210cd2b-924a-4e06-a349-adbcee75ec35" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3f6f6e16-f471-4509-8f5b-8daeb2113cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_EmployeeStockMember_3f6f6e16-f471-4509-8f5b-8daeb2113cc8" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_437760ce-b872-4aff-82a2-b4470cf6bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_437760ce-b872-4aff-82a2-b4470cf6bc26" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1331bbac-3f4d-4167-88d0-01f09115ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_PerformanceSharesMember_1331bbac-3f4d-4167-88d0-01f09115ff3c" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0afb1fd5-df05-4c60-8f89-52ab6889c1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0afb1fd5-df05-4c60-8f89-52ab6889c1d3" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83703f02-f58d-4d27-ad27-e479d103c079_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:to="loc_srt_RangeMember_83703f02-f58d-4d27-ad27-e479d103c079_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0bb1f74-b1a5-4e8e-a3f9-86000f165ec0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:to="loc_srt_RangeMember_d0bb1f74-b1a5-4e8e-a3f9-86000f165ec0" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_83f34aba-49c4-49a5-89c8-1a1e36080b48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0bb1f74-b1a5-4e8e-a3f9-86000f165ec0" xlink:to="loc_srt_MinimumMember_83f34aba-49c4-49a5-89c8-1a1e36080b48" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c9cca73a-0d29-442a-b211-79bc7b0e6a2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_c9cca73a-0d29-442a-b211-79bc7b0e6a2b_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember_da33ef80-4e4c-43e1-9e54-0b8c62b01f63" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:to="loc_howl_A2017StockIncentivePlanMember_da33ef80-4e4c-43e1-9e54-0b8c62b01f63" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember_bc6eb4a7-5efc-4d68-b0e8-88224c1c6473" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:to="loc_howl_A2021StockIncentivePlanMember_bc6eb4a7-5efc-4d68-b0e8-88224c1c6473" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationExpenseRecognizedDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1d622313-69b9-4dd6-bcbb-caf0df629759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_58136c02-15f3-419d-9455-a941affc217b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1d622313-69b9-4dd6-bcbb-caf0df629759" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_58136c02-15f3-419d-9455-a941affc217b" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1d622313-69b9-4dd6-bcbb-caf0df629759" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5575d4b5-d1a1-47b4-ab08-11db451d87e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5575d4b5-d1a1-47b4-ab08-11db451d87e3_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9711ed8-af46-4272-9506-88b761c598ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9711ed8-af46-4272-9506-88b761c598ba" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_36e048db-d0b7-46b7-b57f-b2077c7b5da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_36e048db-d0b7-46b7-b57f-b2077c7b5da6" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationRestrictedStockAwardActivityDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af3c451c-cd8d-4df2-ba5b-b1662eb53ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af3c451c-cd8d-4df2-ba5b-b1662eb53ec4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cb092ab5-5aa5-4aae-b6e3-23934bbf589c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cb092ab5-5aa5-4aae-b6e3-23934bbf589c" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4630c2bd-ea67-410c-b4e6-f40721411445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4630c2bd-ea67-410c-b4e6-f40721411445" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6687d218-a770-41dc-9aa6-e8619edf1b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6687d218-a770-41dc-9aa6-e8619edf1b1a" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114d0103-d40e-478d-bbe0-df78787870b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b635c0de-e4b4-4c07-ac9f-99707a2eb842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b635c0de-e4b4-4c07-ac9f-99707a2eb842" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bbcabbb-80f0-4097-9a2c-dd146038b38e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bbcabbb-80f0-4097-9a2c-dd146038b38e" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa1a91c2-3358-4604-a4ca-44758dbc4363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa1a91c2-3358-4604-a4ca-44758dbc4363" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a1a49f8-524a-4495-88d2-13bca5ccae84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a1a49f8-524a-4495-88d2-13bca5ccae84" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b781bf8b-2fa1-44d9-94b4-e2f75e95141a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:to="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d602439-aacb-452b-8eb0-5ac7cb01ac84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d602439-aacb-452b-8eb0-5ac7cb01ac84_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c55e7ab6-a01d-4a96-9b0d-423c5d6ba8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:to="loc_us-gaap_RestrictedStockMember_c55e7ab6-a01d-4a96-9b0d-423c5d6ba8f2" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8df090b3-31d0-4717-b463-f1406ffa25e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8df090b3-31d0-4717-b463-f1406ffa25e8" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember_1c673661-1ca2-485c-b7e2-49cd56afe441" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:to="loc_howl_A2017StockIncentivePlanMember_1c673661-1ca2-485c-b7e2-49cd56afe441" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember_cfb34613-5048-41e9-b924-647dba967fe4" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:to="loc_howl_A2021StockIncentivePlanMember_cfb34613-5048-41e9-b924-647dba967fe4" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationWeightedAverageAssumptionsDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b550112c-0022-4fd1-a86f-3d6d27513cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b550112c-0022-4fd1-a86f-3d6d27513cd0" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad3e8a03-3cf8-49d3-a4ac-07b8de23e7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad3e8a03-3cf8-49d3-a4ac-07b8de23e7a4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfad0aac-c747-4fde-89f5-cfff901e0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfad0aac-c747-4fde-89f5-cfff901e0d9b" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f2cf62e4-8ddc-4294-ba65-fe1b5b9db98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f2cf62e4-8ddc-4294-ba65-fe1b5b9db98b" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:to="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbfc046e-eb58-45df-bd58-1ecbf26c58c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fbfc046e-eb58-45df-bd58-1ecbf26c58c9_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08f3255f-572b-4e27-889e-3d2febad2ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08f3255f-572b-4e27-889e-3d2febad2ec3" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d6faaf7f-fc20-4522-9f77-adf924c4aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08f3255f-572b-4e27-889e-3d2febad2ec3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d6faaf7f-fc20-4522-9f77-adf924c4aeed" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationStockOptionActivityDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06d2217e-8179-4e3d-b744-a35544d41a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06d2217e-8179-4e3d-b744-a35544d41a18" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c8ecf627-3525-4d6f-bb97-e1c37569f067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c8ecf627-3525-4d6f-bb97-e1c37569f067" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60fe42e0-972f-4087-8577-84b2a1b62b27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60fe42e0-972f-4087-8577-84b2a1b62b27" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1b31d0d-7e3f-4e11-908a-2196b2416813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1b31d0d-7e3f-4e11-908a-2196b2416813" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6626b370-08ae-49c7-a661-6a1c0dde0c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9d25d2a8-7d77-4f30-86b9-cc5e91339c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9d25d2a8-7d77-4f30-86b9-cc5e91339c4e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c076057-0c45-4c42-b455-526ce22dd2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c076057-0c45-4c42-b455-526ce22dd2e9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc451812-86b3-48be-b483-7bb6400392c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc451812-86b3-48be-b483-7bb6400392c3" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_65e90262-7c92-4b8e-8f88-0f2b1ef2121a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_65e90262-7c92-4b8e-8f88-0f2b1ef2121a" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c529a38-5a33-40d3-8a05-d1a48a84a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c529a38-5a33-40d3-8a05-d1a48a84a5db" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89024188-5f51-49ba-b7dc-6584941e4d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b512a571-0a41-4463-bc22-89f027ac7e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b512a571-0a41-4463-bc22-89f027ac7e5b" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_42a98c9c-81b2-40e4-95b5-d726467c85b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_42a98c9c-81b2-40e4-95b5-d726467c85b3" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_279094c9-bdb8-4b69-93d7-64270c266de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_279094c9-bdb8-4b69-93d7-64270c266de9" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:to="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_525ebe68-3008-43e2-9b51-309ea22d6595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_525ebe68-3008-43e2-9b51-309ea22d6595_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9410c580-54b6-40ad-9573-4492071aee90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9410c580-54b6-40ad-9573-4492071aee90" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_172778df-e888-4314-9169-e8fcd061985f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9410c580-54b6-40ad-9573-4492071aee90" xlink:to="loc_us-gaap_EmployeeStockOptionMember_172778df-e888-4314-9169-e8fcd061985f" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"/>
<link:definitionLink xlink:role="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d3e405-ef60-4dd4-acf4-200ccc223e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_06d0650d-0fbb-4059-aaad-22d604a14dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d3e405-ef60-4dd4-acf4-200ccc223e21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_06d0650d-0fbb-4059-aaad-22d604a14dee" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d3e405-ef60-4dd4-acf4-200ccc223e21" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d950f891-2ab3-4bb6-95b4-4477223a505d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d950f891-2ab3-4bb6-95b4-4477223a505d_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3264523f-8f08-4354-a711-074a325fe66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3264523f-8f08-4354-a711-074a325fe66e" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9b184297-458e-4150-8f1b-1a10a9f10b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_RestrictedStockMember_9b184297-458e-4150-8f1b-1a10a9f10b9a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4fd3943-8bb3-49d2-ac3e-5244ccf2c21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4fd3943-8bb3-49d2-ac3e-5244ccf2c21a" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_69ee6954-05ad-4b76-ba7d-9f4f9e803acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_WarrantMember_69ee6954-05ad-4b76-ba7d-9f4f9e803acb" xlink:type="arc" order="3"/>
</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>howl-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:553e33e0-2e01-4068-99ee-43b139347fc6,g:d188e74b-5927-4b57-8b22-a41aa0482b0b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_96ca3a65-bde2-49c8-959d-e9274080c605_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
<link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4bd5713c-4aa5-4c80-9836-94f70d388642_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_howl_A2017StockIncentivePlanMember_cb13b297-f573-4e05-b77c-d5d10404d0da_terseLabel_en-US" xlink:label="lab_howl_A2017StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Stock Incentive Plan</link:label>
<link:label id="lab_howl_A2017StockIncentivePlanMember_label_en-US" xlink:label="lab_howl_A2017StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Stock Incentive Plan [Member]</link:label>
<link:label id="lab_howl_A2017StockIncentivePlanMember_documentation_en-US" xlink:label="lab_howl_A2017StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Stock Incentive Plan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_A2017StockIncentivePlanMember" xlink:to="lab_howl_A2017StockIncentivePlanMember" xlink:type="arc" order="1"/>
<link:label id="lab_howl_TrancheIILoanMember_199daa96-71a8-4a5b-bf19-d3337bcf151b_terseLabel_en-US" xlink:label="lab_howl_TrancheIILoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche II Loan</link:label>
<link:label id="lab_howl_TrancheIILoanMember_label_en-US" xlink:label="lab_howl_TrancheIILoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche II Loan [Member]</link:label>
<link:label id="lab_howl_TrancheIILoanMember_documentation_en-US" xlink:label="lab_howl_TrancheIILoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche II Loan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_TrancheIILoanMember" xlink:href="howl-20230630.xsd#howl_TrancheIILoanMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_TrancheIILoanMember" xlink:to="lab_howl_TrancheIILoanMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VariableRateDomain_d10b00e6-83dc-45e1-9c85-f697713fe919_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
<link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
<link:label id="lab_howl_SalesBasedMilestonesUpTo_c7a0e8a8-9465-417e-99f4-b1d24dd2b8f3_terseLabel_en-US" xlink:label="lab_howl_SalesBasedMilestonesUpTo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones (up to)</link:label>
<link:label id="lab_howl_SalesBasedMilestonesUpTo_label_en-US" xlink:label="lab_howl_SalesBasedMilestonesUpTo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones (up to)</link:label>
<link:label id="lab_howl_SalesBasedMilestonesUpTo_documentation_en-US" xlink:label="lab_howl_SalesBasedMilestonesUpTo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones (up to)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_SalesBasedMilestonesUpTo" xlink:href="howl-20230630.xsd#howl_SalesBasedMilestonesUpTo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_SalesBasedMilestonesUpTo" xlink:to="lab_howl_SalesBasedMilestonesUpTo" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_67586b1b-232d-4684-8602-a60448f2dce6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
<link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1219dbf2-a754-4d55-a9c5-d7a6f2228e9d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3ef97f10-c6ec-49a7-8b54-c1ae27d6f7b2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RangeMember_6320aeb5-da93-4820-bae2-f8f9a6e9485e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsCurrent_edc3c36e-9515-42ee-b7fd-faf0b5ee7206_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
<link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InvestmentIncomeNet_db25682d-66d5-42bd-a290-3f0b565dc071_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
<link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0306b34c-7c58-4833-885d-797242af84be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9df1e85f-94db-44f7-ae2f-7e78ccc44b0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCash_864c8229-a594-4c90-b426-1aed222bcdce_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
<link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_649ba404-3880-4421-97a4-df55a5c5f777_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9122cd50-95a0-4b01-b3b8-4e2d49827947_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c603eb16-eca0-4220-a2a8-c5aac338e7b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_58ae30d7-33d8-46eb-9f27-0c496b13dbdc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2817169b-a996-4186-a500-d6a22f719fc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityFilerCategory_558bc23c-3994-4fd8-a1a5-899b080daa9a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
<link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_4a4ac155-a92c-4599-b8b0-b52a2f3a7a8a_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual capital expenditures</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_label_en-US" xlink:label="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Annual Capital Expenditure</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_documentation_en-US" xlink:label="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Maximum Annual Capital Expenditure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" xlink:to="lab_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure" xlink:type="arc" order="1"/>
<link:label id="lab_howl_SuccessPaymentLiability_76419878-92b0-4f53-a975-2602e4e95e93_terseLabel_en-US" xlink:label="lab_howl_SuccessPaymentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success payment liability</link:label>
<link:label id="lab_howl_SuccessPaymentLiability_label_en-US" xlink:label="lab_howl_SuccessPaymentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability</link:label>
<link:label id="lab_howl_SuccessPaymentLiability_documentation_en-US" xlink:label="lab_howl_SuccessPaymentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Payment Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_SuccessPaymentLiability" xlink:to="lab_howl_SuccessPaymentLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementTable_581253f9-39d0-4948-a29a-756fc4f38307_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
<link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CurrentFiscalYearEndDate_af1885e8-d81e-4709-9d44-593279b666db_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PerformanceSharesMember_c2b1575e-5383-4adf-9785-9dd6f29365f2_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
<link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountsPayableCurrent_df24e3b9-d21b-4275-9d70-00cd4bfb4eb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
<link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f1673ff0-6ae1-4c02-881f-258db9fd0ccd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life - Exercisable</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_928020c0-991a-40db-b96e-efce8a1a883d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
<link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NonoperatingIncomeExpense_57f08bb4-1d01-4047-8cd3-5549805f32dd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
<link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f0e8caaa-c364-4b4d-80ba-8714835721c4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_568d3951-fe7c-4e6d-a92e-a5127dc43fc9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_87a00ca4-b109-4e0e-bb68-d7f58f7c20c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value - Granted (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCashCurrent_d4995263-a0cb-4993-8de2-912bf1354816_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in "Prepaid expenses and other current assets"</link:label>
<link:label id="lab_us-gaap_RestrictedCashCurrent_c2d4eff2-4c8a-43a5-9231-9552769c9a02_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents, current</link:label>
<link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_64198a68-bbe5-4b66-9869-6043c3d469d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_50e7e10b-4fb6-4e31-a869-af2cf72c38e6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
<link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8b58b7fe-4b5e-4ddc-a1fc-d0c768014cdd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_howl_TermLoansMember_17812bce-a112-4c32-99a5-a40b9d376462_terseLabel_en-US" xlink:label="lab_howl_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
<link:label id="lab_howl_TermLoansMember_label_en-US" xlink:label="lab_howl_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans [Member]</link:label>
<link:label id="lab_howl_TermLoansMember_documentation_en-US" xlink:label="lab_howl_TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_TermLoansMember" xlink:to="lab_howl_TermLoansMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_9adfef15-8400-4edb-a59a-c735f5b03c2b_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards Activity</link:label>
<link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DecreaseInContractWithCustomerLiability_d4b6c6c5-7cf5-41c0-8a9e-ca2c433d1abf_negatedTerseLabel_en-US" xlink:label="lab_howl_DecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
<link:label id="lab_howl_DecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_howl_DecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Contract With Customer, Liability</link:label>
<link:label id="lab_howl_DecreaseInContractWithCustomerLiability_documentation_en-US" xlink:label="lab_howl_DecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Contract With Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DecreaseInContractWithCustomerLiability" xlink:href="howl-20230630.xsd#howl_DecreaseInContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DecreaseInContractWithCustomerLiability" xlink:to="lab_howl_DecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_becfeff8-4355-48ec-97ef-ac8797b566ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common and Preferred Stock</link:label>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_37356095-1abd-458b-96eb-43a3c9ef9fc2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_92f53b60-ab10-4c79-867e-04ad9a4cd986_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at the market offering of common stock</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementClassOfStockAxis_7a6353d7-34bc-4442-86c7-6020d073886e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_10b788fb-5980-454e-8720-95c6f3ec1173_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
<link:label id="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_4d9bf6bb-e367-4db6-adeb-41cdd5dc5e91_terseLabel_en-US" xlink:label="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic and diluted</link:label>
<link:label id="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_label_en-US" xlink:label="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic And Diluted Other Disclosures1 [Abstract]</link:label>
<link:label id="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_documentation_en-US" xlink:label="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic And Diluted Other Disclosures1</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:href="howl-20230630.xsd#howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:to="lab_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_6c8bb539-793a-44aa-b754-78acc47472a0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_2a444bde-a395-4775-aad5-08ddf7faa956_periodStartLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, beginning balance</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_677dbd28-eff8-4db7-bbe7-238b3df1f545_periodEndLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, ending balance</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TypeOfArrangementAxis_df141d15-2fba-4f1a-9d17-33814fb84d1c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
<link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromStockPlans_1ed56160-bc34-48d6-b85f-28b4e8653542_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances under Employee Stock Purchase Plan</link:label>
<link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
<link:label id="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_2d9e0de6-9488-4595-a212-24b63e551632_terseLabel_en-US" xlink:label="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
<link:label id="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities Disclosure [Text Block]</link:label>
<link:label id="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_documentation_en-US" xlink:label="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:href="howl-20230630.xsd#howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="lab_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_149bfa15-2309-4ce6-8867-db4b4ab1546d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6776a53f-5dd0-4a91-b78b-a821b92dd671_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
<link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7eb4702-42b2-4f8b-931e-849025e58476_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_410fcede-8653-4b8c-9c86-261b30e3ac26_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
<link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4664a0ce-903d-4bb0-965c-9997478be8de_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ed681634-cb68-4c53-bc23-40384d8ef757_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (usd per share)</link:label>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquity_2263385c-664e-42b8-9fee-6b476bfda564_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders’ equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_c593fe91-08e7-41be-a1eb-712afbf6cb67_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, beginning balance</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_5683f809-684d-4272-ae91-7ad9ac650b22_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, ending balance</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockValue_18a43eb5-19c4-4b4c-b612-0e7d8c3e98d6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value, 5,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued or outstanding as of June 30, 2023 and December 31, 2022, respectively</link:label>
<link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_22fee8e9-efbe-422c-9f9b-5f3d7b43b289_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value Per Share</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareDiluted_d528f245-6e47-4170-a7bb-d06afa2a4283_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (usd per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedStockMember_da3b366a-b94c-472e-ba44-3671b6809159_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSAs</link:label>
<link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_howl_TrancheILoanMember_34362ba7-95e8-44b6-bf81-fd0acf0f2ca0_terseLabel_en-US" xlink:label="lab_howl_TrancheILoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche I Loan</link:label>
<link:label id="lab_howl_TrancheILoanMember_label_en-US" xlink:label="lab_howl_TrancheILoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche I Loan [Member]</link:label>
<link:label id="lab_howl_TrancheILoanMember_documentation_en-US" xlink:label="lab_howl_TrancheILoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche I Loan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_TrancheILoanMember" xlink:href="howl-20230630.xsd#howl_TrancheILoanMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_TrancheILoanMember" xlink:to="lab_howl_TrancheILoanMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ffed952d-eba6-4dc2-95fc-de4d2e2d9bcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_794db2e8-90b5-4669-9fea-177c1ea7e316_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentMaximumBorrowingCapacity_a8c65dd9-abb6-4b22-afbc-896b7391b45d_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan available</link:label>
<link:label id="lab_howl_DebtInstrumentMaximumBorrowingCapacity_label_en-US" xlink:label="lab_howl_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
<link:label id="lab_howl_DebtInstrumentMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_howl_DebtInstrumentMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Borrowing Capacity</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentMaximumBorrowingCapacity" xlink:href="howl-20230630.xsd#howl_DebtInstrumentMaximumBorrowingCapacity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentMaximumBorrowingCapacity" xlink:to="lab_howl_DebtInstrumentMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueInputsLevel3Member_fc74d836-1b51-4499-95d3-77317c206c0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
<link:label id="lab_howl_NonCashInterestExpense_3789677c-3caf-4526-bf1b-90d0a8ea3fe6_terseLabel_en-US" xlink:label="lab_howl_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
<link:label id="lab_howl_NonCashInterestExpense_label_en-US" xlink:label="lab_howl_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
<link:label id="lab_howl_NonCashInterestExpense_documentation_en-US" xlink:label="lab_howl_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_NonCashInterestExpense" xlink:href="howl-20230630.xsd#howl_NonCashInterestExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_NonCashInterestExpense" xlink:to="lab_howl_NonCashInterestExpense" xlink:type="arc" order="1"/>
<link:label id="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_5556061f-28f4-4cf4-83cf-5039f14b5083_terseLabel_en-US" xlink:label="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
<link:label id="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_label_en-US" xlink:label="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability and Right of Use Asset</link:label>
<link:label id="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_documentation_en-US" xlink:label="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability and Right of Use Asset</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:href="howl-20230630.xsd#howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:to="lab_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ce6107c3-8a10-402a-813e-95fe1aa857e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4aa5277f-3c7e-4ed3-808b-72458f8411b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
<link:label id="lab_howl_JazzCollaborationAgreementMember_532f845b-4acc-4541-b4e2-255fe91ebb71_terseLabel_en-US" xlink:label="lab_howl_JazzCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jazz Collaboration Agreement</link:label>
<link:label id="lab_howl_JazzCollaborationAgreementMember_label_en-US" xlink:label="lab_howl_JazzCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jazz Collaboration Agreement [Member]</link:label>
<link:label id="lab_howl_JazzCollaborationAgreementMember_documentation_en-US" xlink:label="lab_howl_JazzCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jazz Collaboration Agreement</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_JazzCollaborationAgreementMember" xlink:href="howl-20230630.xsd#howl_JazzCollaborationAgreementMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_JazzCollaborationAgreementMember" xlink:to="lab_howl_JazzCollaborationAgreementMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a5204470-14b6-4d45-a9c7-e29a77effd45_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
<link:label id="lab_dei_TradingSymbol_b03961c3-4641-4a46-a5c5-cdbc8dfe2daa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
<link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_460dbcce-0661-43f6-bcd9-1914743e383b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_d2b40945-38c3-4c20-8ee6-885e9237bc43_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ddf54fb6-0e27-4fce-a741-29e3bd701379_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price - Granted (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6d49115-4151-4053-b9ac-8525f001c730_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of awards (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueInputsLevel2Member_c19db1ce-486f-47ae-aa33-c03581d85e04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetIncomeLoss_0fe233ab-688f-46d9-8fc5-ad83d10d2e92_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_ee7e5c3f-1495-414a-8fa9-bc37dca7dedd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesCurrent_9ac9002b-f7d3-493b-8139-c2e966554653_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityEmergingGrowthCompany_8c82c7fd-c133-4bd8-a64f-399b6ac6956a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
<link:label id="lab_howl_NonRefundableUpfrontCashPaymentReceived_02a0066d-582e-4c8e-9956-c400f86663bc_terseLabel_en-US" xlink:label="lab_howl_NonRefundableUpfrontCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront cash payment received</link:label>
<link:label id="lab_howl_NonRefundableUpfrontCashPaymentReceived_label_en-US" xlink:label="lab_howl_NonRefundableUpfrontCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Refundable Upfront Cash Payment Received</link:label>
<link:label id="lab_howl_NonRefundableUpfrontCashPaymentReceived_documentation_en-US" xlink:label="lab_howl_NonRefundableUpfrontCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Refundable Upfront Cash Payment Received</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_NonRefundableUpfrontCashPaymentReceived" xlink:href="howl-20230630.xsd#howl_NonRefundableUpfrontCashPaymentReceived"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_NonRefundableUpfrontCashPaymentReceived" xlink:to="lab_howl_NonRefundableUpfrontCashPaymentReceived" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1ea1bee-af58-4376-930c-991b096222a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders’ Equity:</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityExTransitionPeriod_9ec03741-41b4-44cc-91eb-19f963ad67b1_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
<link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockMember_594202c1-781c-407a-80d8-4e9ec1a70e28_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock</link:label>
<link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cd88619e-ace8-44fd-abda-09aafbca5040_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
<link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
<link:label id="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_3ef84eda-8397-464e-8277-5a363c41717c_terseLabel_en-US" xlink:label="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercise receivables in prepaid expenses and other current assets</link:label>
<link:label id="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets</link:label>
<link:label id="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:href="howl-20230630.xsd#howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_495ba8f0-df32-47a0-9b78-05fac1a5877e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_14363e36-9464-4a64-bda6-4297a8feca11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_f97aab95-32da-489a-ad7b-fb38c97cc7e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, ending balance</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65126e8b-7cd5-4e09-9a58-0003706372c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises (shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11d33d18-7a13-4bc5-9d1f-885ac4806603_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_46fb2a49-414f-4e67-83fc-7bea1b550d7a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e358f4d8-8b6c-4e07-b9ae-820b29e11ca4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodTwoMember_87cbe7b2-eeb3-4d0b-a2ef-4db104fa5574_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodTwoMember_label_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period Two [Member]</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodTwoMember_documentation_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodTwoMember" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodTwoMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentCovenantPeriodTwoMember" xlink:to="lab_howl_DebtInstrumentCovenantPeriodTwoMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_735a5062-fbfd-4991-9b0c-358b89850437_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price - Outstanding at beginning of period (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d672035f-875f-4f47-aac8-687e7235b33b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price - Outstanding at end of period (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensation_e965708a-8e74-4ee2-9746-9f2f9b2c9fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2d4d1040-484c-4aee-aa4d-69a5dc2fb681_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
<link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermNotesPayable_e00881a4-f372-4cc8-8d52-15f6fe7deda8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, net of discount and issuance costs</link:label>
<link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_55fa7fa8-7fbd-4baf-be0e-fe4ad347be68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares/Units</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1cafd3b3-cd48-4385-bcaa-ca1d62d2b9a4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
<link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockMember_af39b97e-d552-4441-94d8-49d1fecf556d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
<link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_323fb2b4-5c50-48ba-a809-49c159de163c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price - Exercised (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueInputsLevel1Member_71f616eb-9d54-4b5c-823b-9dde9eba876e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Price in Active Markets (Level 1)</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CityAreaCode_e3d6e94a-d78f-4fc2-994a-2f2d94ba952f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
<link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressPostalZipCode_e81cc733-4f56-45c0-8ee3-c342796d5595_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareTextBlock_c0247f41-0b82-4034-a958-6ec2ec425cac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Attributable to Common Stockholders per Share</link:label>
<link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementLocationDomain_6e9e99c5-c0c8-476e-b1fb-0cba2a1350d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
<link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_9a21d2bf-1fde-41d6-adc5-654db60945b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7f757aca-7859-4c92-83d0-c270b8b9d0dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f0817528-e508-419a-91ed-a18b0546c653_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Measured at Fair Value on a Recurring Basis</link:label>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentFiscalYearFocus_449a5b7d-d473-4183-a7e5-3c0dea3f6be6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_17511f43-e57a-4626-9af3-b966628bb8c7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntitySmallBusiness_b381d9d6-8d34-467f-a565-63e3facf69c5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
<link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
<link:label id="lab_howl_A2021StockIncentivePlanMember_df96d830-0076-4fa0-82d4-425fbecb1fb8_terseLabel_en-US" xlink:label="lab_howl_A2021StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Incentive Plan</link:label>
<link:label id="lab_howl_A2021StockIncentivePlanMember_label_en-US" xlink:label="lab_howl_A2021StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Incentive Plan [Member]</link:label>
<link:label id="lab_howl_A2021StockIncentivePlanMember_documentation_en-US" xlink:label="lab_howl_A2021StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Incentive Plan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_A2021StockIncentivePlanMember" xlink:to="lab_howl_A2021StockIncentivePlanMember" xlink:type="arc" order="1"/>
<link:label id="lab_srt_MinimumMember_fa82ac67-187f-426c-815c-d892205eb8b0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
<link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_LocalPhoneNumber_16690108-db8a-40a1-8bca-7444125d7033_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
<link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e714da8b-9d8a-4c5a-9c00-dfbbf82cada6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1bd24f7e-dc48-4ae6-be31-cec04e9d961e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Cash_f1395629-edcf-4732-9432-148fdc3317d9_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash</link:label>
<link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ae9471f1-d151-4137-8d26-d407d83a20ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment at Success Event</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
<link:label id="lab_howl_A2021StockEmployeeStockPurchasePlanMember_a164eae5-0829-4d38-a081-8c1c01433183_verboseLabel_en-US" xlink:label="lab_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</link:label>
<link:label id="lab_howl_A2021StockEmployeeStockPurchasePlanMember_8cded8e0-c205-45b1-a8b9-60a8c4258bae_terseLabel_en-US" xlink:label="lab_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Employee Stock Purchase Plan</link:label>
<link:label id="lab_howl_A2021StockEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Employee Stock Purchase Plan [Member]</link:label>
<link:label id="lab_howl_A2021StockEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Employee Stock Purchase Plan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:href="howl-20230630.xsd#howl_A2021StockEmployeeStockPurchasePlanMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:to="lab_howl_A2021StockEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2f5e2440-f9d7-41b6-a962-1b00e864f4f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WarrantMember_28ecbbc3-b481-4417-982e-6ef0cfa7bec7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
<link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsAbstract_1bc0aea9-b23a-4860-92d1-af66d35f1191_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
<link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3603ad41-f03e-41f5-8171-a7417f16ba92_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7fa6121b-c5bf-4c74-97ad-23677d52e55b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drawings on term loans</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_24bce09a-8a50-4ce3-8b94-4b909baffaee_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for vesting of restricted stock units</link:label>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_beaebaa1-9007-4191-957d-198fe25c7f13_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_50d207af-bc69-4260-8462-5c08bf8dd22f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_d36816ee-e20a-4c19-b64d-3cb7a21b31b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of equity issuance costs</link:label>
<link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_3f2ed5f8-a09f-4a4f-9017-f980464017fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Depreciation_45d7897a-6b90-4454-8cba-3d729e703fc8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
<link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee_11d53fba-e071-48b2-9a3b-f80103d4d3d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed draw fee</link:label>
<link:label id="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Fee</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityFee"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_76ce1710-32a5-4240-85f7-c87e73fde5f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_cd3913f3-f6dc-4a6b-8199-c6daddce0216_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default payment fee (percent)</link:label>
<link:label id="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_label_en-US" xlink:label="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default or Late Payment Fee, Percent of Unpaid Amount</link:label>
<link:label id="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_documentation_en-US" xlink:label="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default or Late Payment Fee, Percent of Unpaid Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" xlink:href="howl-20230630.xsd#howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" xlink:to="lab_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_c9590c27-631c-480e-a47d-dba5b9ce0097_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Fee (percent)</link:label>
<link:label id="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_label_en-US" xlink:label="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conditional Fee, Percentage Of Amount Drawn</link:label>
<link:label id="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_documentation_en-US" xlink:label="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conditional Fee, Percentage Of Amount Drawn</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" xlink:href="howl-20230630.xsd#howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" xlink:to="lab_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_0ea2c72e-3417-4e31-81db-190ba4a71f39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementLocationAxis_cf1f9298-eb71-420a-8639-c5ca6af572a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
<link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DevelopmentAndRegulatoryMilestones_53fd0833-b999-42de-b907-f889d937436e_terseLabel_en-US" xlink:label="lab_howl_DevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones (up to)</link:label>
<link:label id="lab_howl_DevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_howl_DevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestones</link:label>
<link:label id="lab_howl_DevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_howl_DevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestones</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DevelopmentAndRegulatoryMilestones" xlink:href="howl-20230630.xsd#howl_DevelopmentAndRegulatoryMilestones"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DevelopmentAndRegulatoryMilestones" xlink:to="lab_howl_DevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_95557dde-83a7-40fb-8b08-50093ef514d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
<link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5daf2f7f-f5fa-4285-8f9c-ae5fdbf189a0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
<link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RetainedEarningsMember_e7a03fa5-382d-42d2-937e-0847f70005ed_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d0c7fdc8-22d2-44e9-927b-801806980a71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
<link:label id="lab_howl_SuccessFeeLiabilityPaid_041a45b9-2c9a-43fe-88a2-25d2df280327_terseLabel_en-US" xlink:label="lab_howl_SuccessFeeLiabilityPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success fee liability paid</link:label>
<link:label id="lab_howl_SuccessFeeLiabilityPaid_label_en-US" xlink:label="lab_howl_SuccessFeeLiabilityPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Fee Liability Paid</link:label>
<link:label id="lab_howl_SuccessFeeLiabilityPaid_documentation_en-US" xlink:label="lab_howl_SuccessFeeLiabilityPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success Fee Liability Paid</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessFeeLiabilityPaid" xlink:href="howl-20230630.xsd#howl_SuccessFeeLiabilityPaid"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_SuccessFeeLiabilityPaid" xlink:to="lab_howl_SuccessFeeLiabilityPaid" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b0f5730-c2d7-4ddf-9c11-94e0382dbdd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Expense Recognized</link:label>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1d306c20-053d-48e3-9c09-894d451c611c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders’ equity</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5d1b2648-2e69-4552-83c1-596605ab9f25_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
<link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_f76dbb0e-da3d-4f56-9a10-f8850feda167_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8ade5665-fb0f-4295-9319-142d709cdd79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareBasic_741371d7-170f-4f7a-b454-930012972eed_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (usd per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_67948cf0-e698-4a3c-b30e-e557ba7276e8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use asset</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_004fd74e-397a-4bc0-a0e7-fb955a3934c6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense not yet recognized (less than)</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentTable_0ef30792-270d-47b9-be64-bb8722a92b3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_06258cd6-2bec-420d-8625-8d8e4004b6ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockOptionMember_8d9daf49-08a8-441e-ac4d-01202ca004c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for exercises of outstanding stock options</link:label>
<link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e87713c7-c679-4f35-b324-c5d0de3b336c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
<link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_32fb0f86-5574-4f35-8f68-cf235c106cfd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e2a53f61-8d76-4f3c-9427-1170fcdb44ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic fair value of options exercised</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodOneMember_1a915086-c886-4ad9-9e48-e3e72487fedf_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodOneMember_label_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period One [Member]</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodOneMember_documentation_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodOneMember" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodOneMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentCovenantPeriodOneMember" xlink:to="lab_howl_DebtInstrumentCovenantPeriodOneMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_26632c24-6978-45d2-98d1-bf087fd53338_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of (Loss) Income per Share</link:label>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressCityOrTown_d2bc7a2e-190a-4343-9ae6-a4ca7ed65591_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e074d14e-b873-44d5-b2ac-cf85989ed35d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
<link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentConditionalFeeLiability_199447b1-34b0-4b63-9d43-e95cc32fa23f_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentConditionalFeeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, conditional fee, liability</link:label>
<link:label id="lab_howl_DebtInstrumentConditionalFeeLiability_label_en-US" xlink:label="lab_howl_DebtInstrumentConditionalFeeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conditional Fee, Liability</link:label>
<link:label id="lab_howl_DebtInstrumentConditionalFeeLiability_documentation_en-US" xlink:label="lab_howl_DebtInstrumentConditionalFeeLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Conditional Fee, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentConditionalFeeLiability" xlink:href="howl-20230630.xsd#howl_DebtInstrumentConditionalFeeLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentConditionalFeeLiability" xlink:to="lab_howl_DebtInstrumentConditionalFeeLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d21455a4-2520-4b51-9ad6-25e157c33e76_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_abe309cf-aa45-470b-9b5d-9db5be12f639_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_bf8406ef-a035-4ac7-9e7e-56c6559f3004_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1b04b357-fbad-4473-a84f-1dcd892d1153_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (shares)</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AwardTypeAxis_dc775c7a-38a2-4333-81a4-2b76ac8bdea1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
<link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_efbf5cf9-6a5e-4f63-b28b-2934bc8ef9ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PlanNameDomain_52d14375-169f-4b79-a66e-647d75ebea09_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
<link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_8ce226c9-dd7a-453c-a2b6-d74341441570_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of success payment liability</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentQuarterlyReport_3811c9d8-a353-408a-82b0-deb0ef38d7c1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
<link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_49c112e3-9560-4615-a971-3394492959fb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
<link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestExpense_9618d208-4593-4605-ac29-98396919f75b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
<link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1ffed04f-73e6-4f4d-ba58-9dd9411f0660_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense not yet recognized, excluding option</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_50cd9d0c-b4e3-4b55-ba8d-16a90fccf80a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
<link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1e48746-018b-4718-a74b-103308d1afb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentTransitionReport_7eb5f7d8-5ea4-4f6b-ab60-c56c798b92ee_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
<link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4ca7fe4a-450b-43fb-9473-7db92c06dc09_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_f1b0aff9-1e3b-4653-a787-14d982fc5593_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized to be issued (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cde473aa-4952-41a3-87fd-e7db1a39f788_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life - Outstanding</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_df9093d8-3a3c-4fd0-8e7b-45fd3e3e3796_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
<link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_UseOfEstimates_0cb4f331-ba4a-428f-9d5f-91953ae7520b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
<link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_96977f6f-6190-42ad-95b3-14687bc4d7c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_d9d074a0-1b4c-42e5-ad34-ac32b85448e6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityFileNumber_a77f72bc-9d5c-4c40-a3dc-a6591aa9e1ac_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
<link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_334b6e0e-9ad2-4610-acf4-f5fddc5c21ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
<link:label id="lab_howl_AccruedContractResearchCurrent_3611e210-83d8-4081-8d5d-4edf9dca0209_terseLabel_en-US" xlink:label="lab_howl_AccruedContractResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract research</link:label>
<link:label id="lab_howl_AccruedContractResearchCurrent_label_en-US" xlink:label="lab_howl_AccruedContractResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research, Current</link:label>
<link:label id="lab_howl_AccruedContractResearchCurrent_documentation_en-US" xlink:label="lab_howl_AccruedContractResearchCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Research, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedContractResearchCurrent" xlink:href="howl-20230630.xsd#howl_AccruedContractResearchCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_AccruedContractResearchCurrent" xlink:to="lab_howl_AccruedContractResearchCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ec99b04b-3263-4d77-ac9d-8d76be030c83_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_27e4449c-272d-4d13-8857-1d7f702bfdf8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityShellCompany_9ac519e1-7ecf-4372-9d8c-3520bf75c478_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
<link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ae47dd75-3074-41a2-b897-58550010747b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_43086d51-87c5-4e3b-babe-e3401292a3c1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SecurityDepositLiability_de8ce111-e2b5-4dec-87e4-6cbc9a104bee_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDepositLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit liability</link:label>
<link:label id="lab_us-gaap_SecurityDepositLiability_label_en-US" xlink:label="lab_us-gaap_SecurityDepositLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDepositLiability" xlink:to="lab_us-gaap_SecurityDepositLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_864c6558-b379-46d3-8eaf-158de45c394b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_UnbilledReceivablesCurrent_f7fb6c3d-c4d8-44af-b119-b4cfe120b1f3_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
<link:label id="lab_us-gaap_UnbilledReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_31062168-532d-4bc1-87bb-c84d20246924_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_3271367b-6f44-4729-b400-70f0451f9e88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be added annually, as a percentage of outstanding shares (percent)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_343beb05-4269-4720-83be-206182898ad1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash and cash equivalents—beginning of period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb88e1ac-c7e1-4aca-b9e8-3479ec5b3100_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash and cash equivalents—end of period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a251728c-d9ad-40a6-a964-73c6156f3861_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_ffd5812e-d52d-454e-bd2f-a0b306527233_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
<link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_5dc07772-d57e-423f-b1b0-f7e1d2d8a927_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
<link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ff0a616f-3904-46e2-8194-4b52c97d1ec2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of awards that vested</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SaleOfStockPricePerShare_900063c7-d17f-43a3-9a60-24ce9885b222_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in usd per share)</link:label>
<link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LoansPayableMember_4ab7dd01-a04c-4bb4-b067-561ca2ace7b2_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
<link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalPaidInCapital_b58ab3f1-cce4-4e08-a11a-b0c22ed9cfbc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesIssued_99cc4d1d-7dc2-4eb7-9e8e-8d75d6b8cf76_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5680afe6-7444-4a25-a7a7-9521e483c139_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_43590997-8a2f-4014-9051-fd31b9a3d628_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bc4e99e9-fb41-4249-8c64-7d64b10ea816_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted -average Valuation Assumptions</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dfea5dc5-dafd-4133-9980-e1651662b4c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value - Forfeited (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_dei_SecurityExchangeName_3f929c88-bf93-445e-b755-54f6ba119e3f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
<link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_f1773acd-f08d-435a-a14f-313517a6c51e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebt_e3785dc8-0f6b-4f15-9d32-e1b63a7e8547_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
<link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsFairValueDisclosure_6c0e7ad4-27d2-4962-acb1-6bdf1f57c81a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
<link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_50952dae-8c8e-4e5e-84a1-6de44d1897b9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
<link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2f30ff65-c634-4e26-9f29-26608434c7da_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jazz Collaboration and License Agreement</link:label>
<link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_0faf1cc2-d407-4a47-a6cf-763c2a60cab2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_2e4d269f-0a2a-4c5b-a016-dfe4015877ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance under the 2021 Stock Incentive Plan</link:label>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_15b9cbbe-6fab-40df-99d8-21e4939bf225_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_e191e4f8-cd7f-4d31-ae6e-c5c0f3d635f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
<link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cda82ee0-e41f-499c-8ee7-6fb198bd2e34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9450459e-437a-4bd9-88ec-a076430dc6ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price - Cancelled (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6b4753bc-f56c-4f67-8ecb-301c822bc589_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5dcfc86b-c21a-47f1-ac39-3e2004719675_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdea0fac-ec1e-47e5-baed-064ca933f40e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation not yet recognized, recognition period</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
<link:label id="lab_howl_ATMOfferingMember_f32c02eb-76b8-474f-a8f8-5f20e81e65c0_terseLabel_en-US" xlink:label="lab_howl_ATMOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering</link:label>
<link:label id="lab_howl_ATMOfferingMember_label_en-US" xlink:label="lab_howl_ATMOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering [Member]</link:label>
<link:label id="lab_howl_ATMOfferingMember_documentation_en-US" xlink:label="lab_howl_ATMOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_ATMOfferingMember" xlink:href="howl-20230630.xsd#howl_ATMOfferingMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_ATMOfferingMember" xlink:to="lab_howl_ATMOfferingMember" xlink:type="arc" order="1"/>
<link:label id="lab_srt_MaximumMember_563bc6a9-8618-42aa-8c4f-60107cce29de_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
<link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentType_31ac3c9b-5bb7-4121-a214-c30a07bb8ee9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
<link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressAddressLine1_2c1d8db9-ee83-46cf-9eff-6b674bc81aeb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressAddressLine2_01e25997-e0f8-42e2-9ac6-349d36326dbd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
<link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityRegistrantName_7de03c08-40b2-4799-8460-fbec7fc9091b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
<link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b3dd2873-abac-4767-912c-d88de5733488_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9b16c883-2a78-4538-a39d-b5717ff8d858_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0e3dcd30-9c8a-4ef8-beab-42bd1801bc3d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentPeriodEndDate_5c1f7173-53db-4955-a604-9b426147bd14_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
<link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d76eed5c-06e0-4f95-a3a0-155db538206b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
<link:label id="lab_howl_SalesCommissionsPercentage_e3977131-74d0-4b3d-944a-e53b7997877d_terseLabel_en-US" xlink:label="lab_howl_SalesCommissionsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales commissions, percentage</link:label>
<link:label id="lab_howl_SalesCommissionsPercentage_label_en-US" xlink:label="lab_howl_SalesCommissionsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Commissions, Percentage</link:label>
<link:label id="lab_howl_SalesCommissionsPercentage_documentation_en-US" xlink:label="lab_howl_SalesCommissionsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Commissions, Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_SalesCommissionsPercentage" xlink:href="howl-20230630.xsd#howl_SalesCommissionsPercentage"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_SalesCommissionsPercentage" xlink:to="lab_howl_SalesCommissionsPercentage" xlink:type="arc" order="1"/>
<link:label id="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod_dae55b06-f54d-47c6-a44a-e49fd4839bdf_terseLabel_en-US" xlink:label="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
<link:label id="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod_label_en-US" xlink:label="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan, Offering Period</link:label>
<link:label id="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod_documentation_en-US" xlink:label="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan, Offering Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_EmployeeStockOwnershipPlanOfferingPeriod" xlink:href="howl-20230630.xsd#howl_EmployeeStockOwnershipPlanOfferingPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_EmployeeStockOwnershipPlanOfferingPeriod" xlink:to="lab_howl_EmployeeStockOwnershipPlanOfferingPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3bdc4dec-175e-485c-94e9-8210b8fedf09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price - Exercisable at end of period (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e65cbff8-df23-442f-8cf7-540e568116dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
<link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCentralIndexKey_33013147-0c68-40af-8159-2b1b881c5421_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
<link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCashNoncurrent_fa22ac63-40ff-4254-ae06-1d485702da43_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_RestrictedCashNoncurrent_9fd1933b-63f3-4c60-9f81-e29e825139fa_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents, non-current</link:label>
<link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f7143113-8024-464a-8a74-41c51bc3fc05_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation (less than)</link:label>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9501b392-5756-4153-b23a-ab941edfa362_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherLiabilitiesCurrent_793df986-b216-40fb-8386-bd7d1a0b38c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VariableRateAxis_f906b0ec-66f3-4f52-bfd6-bbc658424234_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
<link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a7143af0-b3bd-4879-8975-6a4eb02052a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1d903527-fbf5-4d4f-bccb-1fdff8da2644_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from at the market offering, net of issuance costs (shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a598cdd3-77ab-4369-8f62-ff9a287ddf9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_dei_Security12bTitle_e3a4c211-e2b4-466f-bdd4-96f8afb68628_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b3d7f0b7-c95b-40c5-9d99-e0759f83bc13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
<link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_540b3d88-3576-42b3-ba08-08d1988a2877_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Fair Value Measurements</link:label>
<link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_howl_IncreaseInContractWithCustomerLiability_2b7a6886-a7da-4ac6-93c2-f3abbd52333e_terseLabel_en-US" xlink:label="lab_howl_IncreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
<link:label id="lab_howl_IncreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_howl_IncreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Contract With Customer, Liability</link:label>
<link:label id="lab_howl_IncreaseInContractWithCustomerLiability_documentation_en-US" xlink:label="lab_howl_IncreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Contract With Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_IncreaseInContractWithCustomerLiability" xlink:href="howl-20230630.xsd#howl_IncreaseInContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_IncreaseInContractWithCustomerLiability" xlink:to="lab_howl_IncreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_28ee889a-16c4-4248-84b4-18345177ef2f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubleaseIncome_b193bc8c-f7ae-418b-9147-54d8bbb0981f_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
<link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_07f5090f-ea4f-4439-a509-68c9b52fe354_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from at the market offering, net of issuance costs</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1a63fbd0-fe49-485a-8738-a53a838c1457_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value - Unvested at beginning of period (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c41afd43-2624-421b-82e8-afccb50fbfee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value - Unvested at end of period (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_80019969-1075-4577-95fe-3f274e81b8f1_terseLabel_en-US" xlink:label="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future reimbursable costs</link:label>
<link:label id="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_label_en-US" xlink:label="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Estimated Future Reimbursable Costs</link:label>
<link:label id="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_documentation_en-US" xlink:label="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Estimated Future Reimbursable Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborationAgreementEstimatedFutureReimbursableCosts" xlink:href="howl-20230630.xsd#howl_CollaborationAgreementEstimatedFutureReimbursableCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_CollaborationAgreementEstimatedFutureReimbursableCosts" xlink:to="lab_howl_CollaborationAgreementEstimatedFutureReimbursableCosts" xlink:type="arc" order="1"/>
<link:label id="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent_b4585a6f-38a0-4963-b6b0-fbfc212abd0b_terseLabel_en-US" xlink:label="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock ownership plan, purchase price, percent</link:label>
<link:label id="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent_label_en-US" xlink:label="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan, Purchase Price, Percent</link:label>
<link:label id="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent_documentation_en-US" xlink:label="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan, Purchase Price, Percent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_EmployeeStockOwnershipPlanPurchasePricePercent" xlink:href="howl-20230630.xsd#howl_EmployeeStockOwnershipPlanPurchasePricePercent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_EmployeeStockOwnershipPlanPurchasePricePercent" xlink:to="lab_howl_EmployeeStockOwnershipPlanPurchasePricePercent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherReceivablesNetCurrent_adb4a957-220c-4660-a737-b34252dea19c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
<link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ClassOfStockLineItems_b91b154f-eef0-4101-807a-0c929e626590_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
<link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_cd83ad96-f290-4cba-9ac0-40f685fd3424_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_dei_AmendmentFlag_ffb46b05-d6d0-4473-a58f-f2cac84c37b6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
<link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodAxis_5cf6abdc-83a5-48d6-9958-b44f7280276d_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period [Axis]</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodAxis_label_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period [Axis]</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodAxis_documentation_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodAxis" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentCovenantPeriodAxis" xlink:to="lab_howl_DebtInstrumentCovenantPeriodAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MoneyMarketFundsMember_f642d209-75f2-43a4-9c39-9c6f871fd199_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
<link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_74b8fd14-1fa8-4fcf-adbe-26f3e13ced4b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityTaxIdentificationNumber_895bffa6-0364-4d26-a856-ba3d0e2d7431_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb79b4d-a95e-4fab-9c48-ebcc1c0cb6a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_6d83ec53-85e3-41f0-97ad-056b3081bd27_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
<link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestPaidNet_93dfee21-6a74-480d-a9ef-886fbb87abb7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
<link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RangeAxis_83b3e388-2f0c-4c69-a32f-e32cb7e15496_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityInteractiveDataCurrent_ab178424-45cc-4087-91f1-f67ffb860b19_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2e906922-38c9-4b9a-847c-f238bd634551_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating rate spread in effect (greater than) (percent)</link:label>
<link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_e3a3078b-640c-4ad0-820c-82ddb5c123e7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_482f4fc9-fe4b-4d6f-8a4f-0cea4db7ca2b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_howl_StockIssuanceCostsIncurredButNotYetPaid_f1fc208f-9c70-4624-897a-ba7558820135_terseLabel_en-US" xlink:label="lab_howl_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs in accounts payable and accrued expenses</link:label>
<link:label id="lab_howl_StockIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_howl_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not yet Paid</link:label>
<link:label id="lab_howl_StockIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_howl_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not yet Paid</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_StockIssuanceCostsIncurredButNotYetPaid" xlink:href="howl-20230630.xsd#howl_StockIssuanceCostsIncurredButNotYetPaid"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_howl_StockIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c6f7ac99-cac1-4da6-8fa5-9b3ea533ebc8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cbb3d54f-5a79-44b0-9ff5-d673413cb9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_d3a32b16-6d7f-4ff2-9280-40a6341d0c36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Issuance</link:label>
<link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_howl_CollaborativeAgreementTransactionPrice_79593551-013c-4ffb-9661-c18cb6201fe8_terseLabel_en-US" xlink:label="lab_howl_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
<link:label id="lab_howl_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_howl_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Transaction Price</link:label>
<link:label id="lab_howl_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_howl_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Transaction Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborativeAgreementTransactionPrice" xlink:href="howl-20230630.xsd#howl_CollaborativeAgreementTransactionPrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_CollaborativeAgreementTransactionPrice" xlink:to="lab_howl_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fca24b2b-4237-460b-b0df-1b3ad41e6083_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_faf0a1a7-015b-4e2a-9389-8ea223e83472_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares to be added annually, as a percentage of outstanding shares (shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingExpensesAbstract_e950bda2-f657-4be5-9bc3-08e9bc1aa0c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
<link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79562074-0a5d-4b36-81bf-5deba6e54043_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_32419cf8-483b-4d0c-9c28-53a653256ce7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_305a1d09-3a70-4c22-adf5-153a77c5cf2b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsCurrentAbstract_214a7eed-c186-4cc9-8a83-bc53a4f52cd3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
<link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Assets_90ffddb6-6e1e-41e1-b72c-08b54699f5c2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
<link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressStateOrProvince_39d8d551-bc4b-4b1f-bc9c-e8938ccd8a24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3cc887da-53a9-4d3e-91e3-d196652bf1a7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e9db670e-78c3-4903-8acf-c0c57cc299b2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7faf084c-4f0f-415f-8403-dbe7451f1e55_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AmortizationOfFinancingCosts_529d55bd-f663-4307-b7e5-948e2b6e4421_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
<link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
<link:label id="lab_howl_AccruedManufacturingCurrent_13e49b57-1221-4026-a471-0ee0548a0a01_terseLabel_en-US" xlink:label="lab_howl_AccruedManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing</link:label>
<link:label id="lab_howl_AccruedManufacturingCurrent_label_en-US" xlink:label="lab_howl_AccruedManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing, Current</link:label>
<link:label id="lab_howl_AccruedManufacturingCurrent_documentation_en-US" xlink:label="lab_howl_AccruedManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedManufacturingCurrent" xlink:href="howl-20230630.xsd#howl_AccruedManufacturingCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_AccruedManufacturingCurrent" xlink:to="lab_howl_AccruedManufacturingCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a56b28e8-d8cd-4c52-9a98-9c8797c6f5cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_62cef689-78ec-4e9b-b596-8ddfbdb7fc1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a94afea8-b96a-4ae2-b61c-06391c94a433_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_38a68a0f-8692-42cc-8270-62a483238699_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value - Vested (in usd per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_howl_CommonStockAmountAuthorized_c07e0190-ec76-4dfc-9725-04c24c6cf036_terseLabel_en-US" xlink:label="lab_howl_CommonStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, amount authorized</link:label>
<link:label id="lab_howl_CommonStockAmountAuthorized_label_en-US" xlink:label="lab_howl_CommonStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Amount Authorized</link:label>
<link:label id="lab_howl_CommonStockAmountAuthorized_documentation_en-US" xlink:label="lab_howl_CommonStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Amount Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_CommonStockAmountAuthorized" xlink:href="howl-20230630.xsd#howl_CommonStockAmountAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_CommonStockAmountAuthorized" xlink:to="lab_howl_CommonStockAmountAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_420122da-0632-43f6-ac27-548db5d43ea4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5c1a069a-b8cf-4cfe-acb6-d7c93fff74db_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
<link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingExpenses_bbafd82d-7c60-432d-8761-6c890c70b952_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
<link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrimeRateMember_92c61474-3ec9-4a4c-ad36-a317bc771833_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
<link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_aab2da56-6bb6-4c9a-be74-788d5c33e935_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharesOutstanding_5582c5da-f230-4625-8dee-c343508c9c82_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, beginning balance (shares)</link:label>
<link:label id="lab_us-gaap_SharesOutstanding_5f7eb45c-6977-47d8-8acb-40a53c3e5dd8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity, ending balance (shares)</link:label>
<link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5f90edf5-ee22-49ab-8d46-e2a7bd1de02b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
<link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodDomain_be3e2c3c-b5d4-41a6-82a7-7b68665938d5_terseLabel_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period [Domain]</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodDomain_label_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period [Domain]</link:label>
<link:label id="lab_howl_DebtInstrumentCovenantPeriodDomain_documentation_en-US" xlink:label="lab_howl_DebtInstrumentCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodDomain" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_DebtInstrumentCovenantPeriodDomain" xlink:to="lab_howl_DebtInstrumentCovenantPeriodDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_10e412be-0e64-4ea4-89ed-96b9b52d0a6f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35fed505-e355-41bd-8a7e-9730656bea37_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_70fd370a-9ff9-4955-9bfa-37a029b8aa43_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (usd per share)</link:label>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8e360c64-eaf5-4ad0-9255-ee4f13cb8078_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, maximum annual contributions per employee, percent</link:label>
<link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_09a6c315-c48c-46fb-993a-e8da7d31b491_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
<link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
<link:label id="lab_howl_CollaborationAgreementTerm_bc3e6045-2eef-4fd4-b837-b2faa609e09f_terseLabel_en-US" xlink:label="lab_howl_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, term</link:label>
<link:label id="lab_howl_CollaborationAgreementTerm_label_en-US" xlink:label="lab_howl_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
<link:label id="lab_howl_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_howl_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborationAgreementTerm" xlink:href="howl-20230630.xsd#howl_CollaborationAgreementTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_howl_CollaborationAgreementTerm" xlink:to="lab_howl_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EquityComponentDomain_e80b8491-54d6-4609-9df5-cfb3bc56c201_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ClassOfStockDomain_26d8fd04-eb03-4476-959d-2ac247188c03_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57e4b23-e73d-42af-b6c2-cda82316773a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_916662b4-7bba-4849-920a-060d58556e8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentAxis_3dcad03c-ac79-4967-8f05-103d3e4e17fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_65e306be-24a5-4547-9c92-9a767eafffa8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a54b0d29-abb5-47dd-94a5-acfc89799a5b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCurrentReportingStatus_b1a5731f-23b2-4e94-9eca-863e369a92b0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingIncomeLoss_3c8199a2-ab52-4969-9cbb-3ddc321a5e37_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
<link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Liabilities_41ad2a9a-42a3-488d-976f-ed9aeb75ccd3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
<link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f1b71aeb-feef-4b73-a13e-cdb97a10c546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_989a2f6d-768c-430f-8a2e-83e4c8894201_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_07cb6be2-6771-4ef2-ba64-b50c5b0b5bde_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from drawdown of term loans</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba7654f2-dfa3-440c-a321-7140bba753ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenuesAbstract_9a54c415-ccb6-4a2c-93ba-a437f0e5774c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
<link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7048f9ea-c4f4-4d87-b0c2-7568a1c484a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7c8ce012-7c3e-4020-b077-ae35043bf16e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for issuance (shares)</link:label>
<link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ee1ea6e0-6567-4482-94c7-84a9ecf87780_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_efa6e9d7-0b67-4227-bc10-b1dec3dfa0d5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementLineItems_9c397a23-5abd-4711-bf5c-efcf242950da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
<link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PlanNameAxis_eacfef0a-dc88-4737-bfed-dc14ab444992_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
<link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8e546169-81dd-4d39-9257-d50cd284fe65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining
Contractual Life
(in years)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareAbstract_935995de-63a6-4c96-8324-50a4455d662d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic and diluted</link:label>
<link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockValue_ba53528d-54d8-44c9-892c-1a3502ca28a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 200,000 shares authorized as of June 30, 2023 and December 31, 2022; 35,642 and 31,515 shares issued as of June 30, 2023 and December 31, 2022, respectively; 35,642 and 31,434 shares outstanding as of June 30, 2023 and December 31, 2022, respectively</link:label>
<link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f4e8d450-78d8-48c3-8cd6-e83e2b46f0b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders’ equity:</link:label>
<link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_14ce5880-d918-40c2-9ca9-3228714977b3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>howl-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:553e33e0-2e01-4068-99ee-43b139347fc6,g:d188e74b-5927-4b57-8b22-a41aa0482b0b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://werewolftx.com/role/Cover" xlink:type="simple" xlink:href="howl-20230630.xsd#Cover"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/Cover" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b7b777c3-83e4-4618-869c-92fce19a0ee2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_DocumentType_b7b777c3-83e4-4618-869c-92fce19a0ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_05b747f6-3837-491b-a131-6a6e740ec51b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_DocumentQuarterlyReport_05b747f6-3837-491b-a131-6a6e740ec51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f067efed-687f-4523-a54b-1bbfe4c3ebde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_DocumentPeriodEndDate_f067efed-687f-4523-a54b-1bbfe4c3ebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_cf6132b0-dd50-4240-ab64-bcd89ef862ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_DocumentTransitionReport_cf6132b0-dd50-4240-ab64-bcd89ef862ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1311af15-5261-4e96-897a-95a2a87de11c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e1980dd7-949c-4a2a-8c59-e8ec05531618" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityFileNumber_e1980dd7-949c-4a2a-8c59-e8ec05531618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_115d06af-0946-4a59-b87c-7c3b2bb6016e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityRegistrantName_115d06af-0946-4a59-b87c-7c3b2bb6016e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8a1d1b56-f818-45c4-9b9b-124e865097b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8a1d1b56-f818-45c4-9b9b-124e865097b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1781ef3a-5845-445d-bf3a-f1648000853f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityTaxIdentificationNumber_1781ef3a-5845-445d-bf3a-f1648000853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_35bf8fb5-724e-45af-9eeb-9b9103fac20e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityAddressAddressLine1_35bf8fb5-724e-45af-9eeb-9b9103fac20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1de404ed-14a9-4fdb-8008-71d06606cb74" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityAddressAddressLine2_1de404ed-14a9-4fdb-8008-71d06606cb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c2131b14-695c-4ea6-bb57-d44ecb4acab5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityAddressCityOrTown_c2131b14-695c-4ea6-bb57-d44ecb4acab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b03c07b7-47d9-4b43-9cea-b7125970e2ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityAddressStateOrProvince_b03c07b7-47d9-4b43-9cea-b7125970e2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9b8a90ce-ff96-4f83-af16-2c2af8d74d10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityAddressPostalZipCode_9b8a90ce-ff96-4f83-af16-2c2af8d74d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c7bfb8ef-32de-4b83-afec-0e53a2b0e3ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_CityAreaCode_c7bfb8ef-32de-4b83-afec-0e53a2b0e3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7b604947-3384-44b3-993e-5e9e6c1f9f88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_LocalPhoneNumber_7b604947-3384-44b3-993e-5e9e6c1f9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2158835a-1c98-4a92-8586-6e23bcaf8c02" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_Security12bTitle_2158835a-1c98-4a92-8586-6e23bcaf8c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5afe0824-15f0-4c33-8580-7b449f7df0d8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
<link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_TradingSymbol_5afe0824-15f0-4c33-8580-7b449f7df0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5f15d023-292f-40b8-9be8-ae1324028ec7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
<link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_SecurityExchangeName_5f15d023-292f-40b8-9be8-ae1324028ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6a1028b6-39ee-4cc1-bc58-9ff2bd7a91e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
<link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityCurrentReportingStatus_6a1028b6-39ee-4cc1-bc58-9ff2bd7a91e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_13c7948e-8b21-4f7a-875f-e96918b0f1b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
<link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityInteractiveDataCurrent_13c7948e-8b21-4f7a-875f-e96918b0f1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4a5b051f-a818-40b1-9d87-854f6da4cdb4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
<link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityFilerCategory_4a5b051f-a818-40b1-9d87-854f6da4cdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bf3fe255-0689-41be-9dd1-3e1954dc8e66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
<link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntitySmallBusiness_bf3fe255-0689-41be-9dd1-3e1954dc8e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4da3ec07-bb68-47e7-9106-97954511843f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
<link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityEmergingGrowthCompany_4da3ec07-bb68-47e7-9106-97954511843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_728a794a-6470-4576-8b30-387432fb6536" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
<link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityExTransitionPeriod_728a794a-6470-4576-8b30-387432fb6536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5ea8d17b-2568-4464-bc7f-d8d2dfcdf656" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
<link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityShellCompany_5ea8d17b-2568-4464-bc7f-d8d2dfcdf656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_32219ca6-9744-42cc-86e8-c0972419fd3d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
<link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_32219ca6-9744-42cc-86e8-c0972419fd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2021427e-fcf7-450a-a142-a223d70aa38e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
<link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_EntityCentralIndexKey_2021427e-fcf7-450a-a142-a223d70aa38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1585d81b-6afe-44e8-b7d1-f9146aec727b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
<link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_CurrentFiscalYearEndDate_1585d81b-6afe-44e8-b7d1-f9146aec727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f1d58bb3-05c6-410f-bdaa-71474c291bab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
<link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_DocumentFiscalYearFocus_f1d58bb3-05c6-410f-bdaa-71474c291bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8f1c742c-0e51-442a-8a64-8dfb8b7e83fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
<link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8f1c742c-0e51-442a-8a64-8dfb8b7e83fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_76679d8f-c618-4be8-9e84-7a024775bb43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
<link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29343bbe-944a-44a7-bcb6-f9b264a4049f" xlink:to="loc_dei_AmendmentFlag_76679d8f-c618-4be8-9e84-7a024775bb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_30e86084-61b9-475c-8f2b-b95134253f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_30e86084-61b9-475c-8f2b-b95134253f96" xlink:to="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d6ae0ad1-ddb4-4335-937b-8678f8e239b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d6ae0ad1-ddb4-4335-937b-8678f8e239b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf7553da-c5ca-4949-8ef7-8c7e070e99c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6ae0ad1-ddb4-4335-937b-8678f8e239b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf7553da-c5ca-4949-8ef7-8c7e070e99c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea46ef7e-d362-4b6f-8b4b-7160e31bf098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6ae0ad1-ddb4-4335-937b-8678f8e239b3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ea46ef7e-d362-4b6f-8b4b-7160e31bf098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_91d80d4c-eb0a-4b2e-876e-3184a3915b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6ae0ad1-ddb4-4335-937b-8678f8e239b3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_91d80d4c-eb0a-4b2e-876e-3184a3915b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4e25dca-e6cd-4ee2-bfea-299576a4bb63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6ae0ad1-ddb4-4335-937b-8678f8e239b3" xlink:to="loc_us-gaap_AssetsCurrent_c4e25dca-e6cd-4ee2-bfea-299576a4bb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12a5a721-2896-4110-a1f1-db00dbe258fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12a5a721-2896-4110-a1f1-db00dbe258fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_dc3f8f3b-2f58-4993-87c5-1db02b2b42f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_dc3f8f3b-2f58-4993-87c5-1db02b2b42f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9a9dc5fd-343b-47e4-aaff-f28f4868d61a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9a9dc5fd-343b-47e4-aaff-f28f4868d61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a75d1219-a2ce-46d8-b385-220ab0ddb731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a75d1219-a2ce-46d8-b385-220ab0ddb731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9a6c53e2-784a-46fd-bd9a-655360ce95ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4d7df2-d25a-4a9c-993c-573291e3c171" xlink:to="loc_us-gaap_Assets_9a6c53e2-784a-46fd-bd9a-655360ce95ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_30e86084-61b9-475c-8f2b-b95134253f96" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a71040d8-ec93-457c-a767-61eb31329e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:to="loc_us-gaap_AccountsPayableCurrent_a71040d8-ec93-457c-a767-61eb31329e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_76d41153-0529-41da-8aae-d82cfb274870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_76d41153-0529-41da-8aae-d82cfb274870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d98f0031-3253-4981-8d65-cb271432aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d98f0031-3253-4981-8d65-cb271432aba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_930ab105-49bb-468f-9c39-653d3b006b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_930ab105-49bb-468f-9c39-653d3b006b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5bbcbcdf-017f-4553-bbb6-a8f095dab6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cf036296-df60-49d7-b40c-d534b69a8e1a" xlink:to="loc_us-gaap_LiabilitiesCurrent_5bbcbcdf-017f-4553-bbb6-a8f095dab6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_540cabda-32ee-4a2c-8a69-c0ad73d8bb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_540cabda-32ee-4a2c-8a69-c0ad73d8bb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_698df674-159e-4581-a268-467c1e60c8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_698df674-159e-4581-a268-467c1e60c8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_f1d49017-4061-47a8-b430-93b8f7911602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_LongTermNotesPayable_f1d49017-4061-47a8-b430-93b8f7911602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_61ee2c69-8d27-4775-9d4b-511bd4f456d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_61ee2c69-8d27-4775-9d4b-511bd4f456d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d3ec045a-38f4-4bef-a546-658eff64da96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_Liabilities_d3ec045a-38f4-4bef-a546-658eff64da96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_97c5769a-4385-47dc-a3d4-b00b34abc951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_CommitmentsAndContingencies_97c5769a-4385-47dc-a3d4-b00b34abc951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_16c5aa3e-3e74-4f23-a6bc-ae19b71a0ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:to="loc_us-gaap_PreferredStockValue_16c5aa3e-3e74-4f23-a6bc-ae19b71a0ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_756c4e3b-2bfd-401c-8c67-74eb7334c608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:to="loc_us-gaap_CommonStockValue_756c4e3b-2bfd-401c-8c67-74eb7334c608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1e89f4a0-69c8-424b-93dd-e1d92adb1f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1e89f4a0-69c8-424b-93dd-e1d92adb1f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fff9c3a-b206-4f9c-9a20-e51b8f124ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1fff9c3a-b206-4f9c-9a20-e51b8f124ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1851e371-40b1-4f25-822c-554eadc6dc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_80efaa02-8d91-4459-a21f-059c23173863" xlink:to="loc_us-gaap_StockholdersEquity_1851e371-40b1-4f25-822c-554eadc6dc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_00d59761-cac8-428a-9296-6e3a1929ec01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23087a5f-a38c-4917-ba91-8bd851667b86" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_00d59761-cac8-428a-9296-6e3a1929ec01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0a82f6e-4a57-4252-ae61-096a42f69004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b0a82f6e-4a57-4252-ae61-096a42f69004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_01172871-32f5-4932-aa0d-c791bf84fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_01172871-32f5-4932-aa0d-c791bf84fdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_71aa7b3d-7fd8-45be-b234-5b4a92dad4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_PreferredStockSharesIssued_71aa7b3d-7fd8-45be-b234-5b4a92dad4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c5f7b29f-31d1-433b-ae4e-d601ca478cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c5f7b29f-31d1-433b-ae4e-d601ca478cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d61e2bb2-71d5-4c4a-a6db-246c74727a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d61e2bb2-71d5-4c4a-a6db-246c74727a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3cc3d2d2-39c7-4849-83aa-449097da08bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3cc3d2d2-39c7-4849-83aa-449097da08bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ef93c202-a08a-42ee-b2eb-1ecbd7ab4707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_CommonStockSharesIssued_ef93c202-a08a-42ee-b2eb-1ecbd7ab4707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd2489b1-3aef-409b-8164-8146f4ed2e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fd8d0ea5-4b63-49fe-9bf4-fa0141583442" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd2489b1-3aef-409b-8164-8146f4ed2e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_85ed3347-a073-4211-9933-92068276218b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_us-gaap_RevenuesAbstract_85ed3347-a073-4211-9933-92068276218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_b6dc90f8-063d-49a5-8af2-1150a67a9e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_85ed3347-a073-4211-9933-92068276218b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_b6dc90f8-063d-49a5-8af2-1150a67a9e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_67a7f880-5e8d-4a9d-b169-aa671dc07ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_67a7f880-5e8d-4a9d-b169-aa671dc07ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_da7c6269-9771-40c7-954f-d730058b02ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_67a7f880-5e8d-4a9d-b169-aa671dc07ce4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_da7c6269-9771-40c7-954f-d730058b02ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_43e946cc-bedb-4833-b014-f95bec6ba890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_67a7f880-5e8d-4a9d-b169-aa671dc07ce4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_43e946cc-bedb-4833-b014-f95bec6ba890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_75ce6ce0-8640-46b5-8d1f-729606e4e7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_67a7f880-5e8d-4a9d-b169-aa671dc07ce4" xlink:to="loc_us-gaap_OperatingExpenses_75ce6ce0-8640-46b5-8d1f-729606e4e7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d799d68f-2b59-4b44-bf74-3f3154eaac95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_us-gaap_OperatingIncomeLoss_d799d68f-2b59-4b44-bf74-3f3154eaac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_03f97168-c731-4e05-8de0-e7f19c0e981b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_03f97168-c731-4e05-8de0-e7f19c0e981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_485a8ed7-0b67-4efb-b14f-5e3900b678b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_03f97168-c731-4e05-8de0-e7f19c0e981b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_485a8ed7-0b67-4efb-b14f-5e3900b678b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7aea79ab-ca31-42af-85e5-368990a80edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNet"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_03f97168-c731-4e05-8de0-e7f19c0e981b" xlink:to="loc_us-gaap_InvestmentIncomeNet_7aea79ab-ca31-42af-85e5-368990a80edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_261439a6-6b9f-4b46-86e4-6e4aa97a108a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_03f97168-c731-4e05-8de0-e7f19c0e981b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_261439a6-6b9f-4b46-86e4-6e4aa97a108a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85f86182-603c-42cd-ad36-9d2e1e8913f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_us-gaap_NetIncomeLoss_85f86182-603c-42cd-ad36-9d2e1e8913f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b1cf4224-9089-4244-83ba-16f5ddb5e161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b1cf4224-9089-4244-83ba-16f5ddb5e161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9cd1475f-a007-4b22-8ec0-449c88913127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b1cf4224-9089-4244-83ba-16f5ddb5e161" xlink:to="loc_us-gaap_EarningsPerShareBasic_9cd1475f-a007-4b22-8ec0-449c88913127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aa1290fe-10b3-4b4e-b835-7206e6b658be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b1cf4224-9089-4244-83ba-16f5ddb5e161" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aa1290fe-10b3-4b4e-b835-7206e6b658be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_acf4785f-5b0f-48f9-890e-1d48d17743db" xlink:href="howl-20230630.xsd#howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c43bf8f2-5e7e-4d47-b735-17613db10f6b" xlink:to="loc_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_acf4785f-5b0f-48f9-890e-1d48d17743db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd6bbd86-222b-40c9-b952-6743c7988ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_acf4785f-5b0f-48f9-890e-1d48d17743db" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dd6bbd86-222b-40c9-b952-6743c7988ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_77367fc5-3555-4b9b-9f7a-9dadd2566a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_acf4785f-5b0f-48f9-890e-1d48d17743db" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_77367fc5-3555-4b9b-9f7a-9dadd2566a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cf724631-f02f-4960-a091-f6bda64eb0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cf724631-f02f-4960-a091-f6bda64eb0a8" xlink:to="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0528a0a7-27ce-44da-bde2-befa6fff46db" xlink:to="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d27faa48-ae59-4c42-8ed9-cf3130fb20cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:to="loc_us-gaap_CommonStockMember_d27faa48-ae59-4c42-8ed9-cf3130fb20cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_92e448a9-5d43-455d-a809-6d3e8d4474b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_92e448a9-5d43-455d-a809-6d3e8d4474b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_09866bad-bf62-4c29-b719-62f16a319df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0db86a55-7bec-458a-bf89-fb9c74846428" xlink:to="loc_us-gaap_RetainedEarningsMember_09866bad-bf62-4c29-b719-62f16a319df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fe9f7959-f3ac-4314-ad87-5040a8bfbb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90191068-754f-466e-a86c-0027ecd99db4" xlink:to="loc_us-gaap_StatementLineItems_fe9f7959-f3ac-4314-ad87-5040a8bfbb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fe9f7959-f3ac-4314-ad87-5040a8bfbb5c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_69e69f53-23ed-4b2b-8420-b7817b2eacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_SharesOutstanding_69e69f53-23ed-4b2b-8420-b7817b2eacd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f7df68b5-0dc1-49c0-b517-ec5a9ee496ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockholdersEquity_f7df68b5-0dc1-49c0-b517-ec5a9ee496ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e17d77cb-f40e-4c89-ad07-3c5d3f62754b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e17d77cb-f40e-4c89-ad07-3c5d3f62754b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0ccfc2e-cec8-4f02-82a4-ed7b744d4b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0ccfc2e-cec8-4f02-82a4-ed7b744d4b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ccafecdc-116c-4b04-85e1-edd3c3193562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ccafecdc-116c-4b04-85e1-edd3c3193562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8881425e-0c30-4315-8d18-b61a2d472c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8881425e-0c30-4315-8d18-b61a2d472c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_beb5d470-df17-40d8-8e9d-ae26b9e9a9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_beb5d470-df17-40d8-8e9d-ae26b9e9a9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1feaa159-9450-4d4b-9f54-5d785081f447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1feaa159-9450-4d4b-9f54-5d785081f447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_90a282aa-ed92-4950-85a3-2577f5705d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_90a282aa-ed92-4950-85a3-2577f5705d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15fe0639-4098-49d9-97c3-f40123aeadc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_NetIncomeLoss_15fe0639-4098-49d9-97c3-f40123aeadc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1d1698d1-2713-4afb-82c1-e306802a8a13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_SharesOutstanding_1d1698d1-2713-4afb-82c1-e306802a8a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_857e6eb1-728c-4bba-a67f-3d877822998a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a27a0179-b591-4cf8-ac30-0266b6ea1041" xlink:to="loc_us-gaap_StockholdersEquity_857e6eb1-728c-4bba-a67f-3d877822998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0a3ab40e-1d26-48c4-9eea-df572352d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f2af2dc5-5ce3-4ce6-b481-3efedb67b7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0a3ab40e-1d26-48c4-9eea-df572352d7ce" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f2af2dc5-5ce3-4ce6-b481-3efedb67b7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="howl-20230630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e225742f-885d-4b72-9d23-1f49b1a6f33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e225742f-885d-4b72-9d23-1f49b1a6f33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff349378-7aa9-4739-a342-faa1cba9485f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e225742f-885d-4b72-9d23-1f49b1a6f33f" xlink:to="loc_us-gaap_NetIncomeLoss_ff349378-7aa9-4739-a342-faa1cba9485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e225742f-885d-4b72-9d23-1f49b1a6f33f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_53ecad56-8651-4e76-9ce3-c2885d9c4b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:to="loc_us-gaap_ShareBasedCompensation_53ecad56-8651-4e76-9ce3-c2885d9c4b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9eddf3d3-5aed-4fac-b6a8-b5be3930e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:to="loc_us-gaap_Depreciation_9eddf3d3-5aed-4fac-b6a8-b5be3930e4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_NonCashInterestExpense_4f53d296-2cc3-4677-8541-8940758ea192" xlink:href="howl-20230630.xsd#howl_NonCashInterestExpense"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:to="loc_howl_NonCashInterestExpense_4f53d296-2cc3-4677-8541-8940758ea192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d69c6000-7dc2-4bcd-95df-6cb3854a9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d69c6000-7dc2-4bcd-95df-6cb3854a9e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_863e7d98-478a-40a9-b347-813e5ea6a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_863e7d98-478a-40a9-b347-813e5ea6a14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_874ea392-fcca-4453-b9a5-17755a137367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c105c403-e2cd-44fb-b0f3-105294048081" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_874ea392-fcca-4453-b9a5-17755a137367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e225742f-885d-4b72-9d23-1f49b1a6f33f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bb4f08ee-0590-450d-a154-152416de4925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bb4f08ee-0590-450d-a154-152416de4925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_cdb5d944-2eca-41a0-8156-6adbe9ab3663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_cdb5d944-2eca-41a0-8156-6adbe9ab3663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f3f674ed-cb70-48c8-a778-4749f010a5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f3f674ed-cb70-48c8-a778-4749f010a5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_6527c1ae-5844-4d11-9484-d00302cacc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_6527c1ae-5844-4d11-9484-d00302cacc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6b141ba8-a2a4-4acd-8d33-8c388bd9e538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6b141ba8-a2a4-4acd-8d33-8c388bd9e538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_21d33bdf-de03-453a-9cf1-0715acdc3cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_21d33bdf-de03-453a-9cf1-0715acdc3cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_e8f870ed-d5bf-48c3-a9c7-b190cedc4048" xlink:href="howl-20230630.xsd#howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_e8f870ed-d5bf-48c3-a9c7-b190cedc4048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5ffb31f8-6289-4213-900d-bd7cf468d721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a38587e7-0646-44d6-83aa-e1e45cbae902" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5ffb31f8-6289-4213-900d-bd7cf468d721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0efee42d-78df-48a5-9b59-f07129b97337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e225742f-885d-4b72-9d23-1f49b1a6f33f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0efee42d-78df-48a5-9b59-f07129b97337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c69c102-f037-4c59-a4ae-c47961f2e40f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c69c102-f037-4c59-a4ae-c47961f2e40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_58cf00fb-b14f-493f-9068-d241a4cff658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c69c102-f037-4c59-a4ae-c47961f2e40f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_58cf00fb-b14f-493f-9068-d241a4cff658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1ac77fa-c1f9-4b34-97d7-a1b24f61566a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c69c102-f037-4c59-a4ae-c47961f2e40f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e1ac77fa-c1f9-4b34-97d7-a1b24f61566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1d738248-d12b-4ab1-88d2-8ec726dc49c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1d738248-d12b-4ab1-88d2-8ec726dc49c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2a90dd9e-a923-4fd4-9822-3976db5caf54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2a90dd9e-a923-4fd4-9822-3976db5caf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a3e4197d-b018-46d2-a5e9-f3e21b8b8e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a3e4197d-b018-46d2-a5e9-f3e21b8b8e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c735f4c9-e216-49b6-a7f7-d215379841c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c735f4c9-e216-49b6-a7f7-d215379841c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b2f59f3e-7f43-417c-ba2e-7cea17518286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b2f59f3e-7f43-417c-ba2e-7cea17518286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb53ab4d-1595-4936-81ee-038dcf3182e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_25d46d14-fc6f-4dff-ba77-2db8f483da39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb53ab4d-1595-4936-81ee-038dcf3182e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1736524b-db0c-454a-8e4b-4409e5b54488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1736524b-db0c-454a-8e4b-4409e5b54488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bd9363c-22bf-4491-8e44-4a3d282e4af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bd9363c-22bf-4491-8e44-4a3d282e4af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0709f64a-bc61-42b2-9d46-8cbf343936af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0709f64a-bc61-42b2-9d46-8cbf343936af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4365e6f7-85f4-4357-9d49-3c7bef89c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8cb28ac-d25a-4678-b4f3-dd5212bd561a" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4365e6f7-85f4-4357-9d49-3c7bef89c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6003b5e6-779f-4ec0-b3a2-23aa0aea9fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4365e6f7-85f4-4357-9d49-3c7bef89c58e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6003b5e6-779f-4ec0-b3a2-23aa0aea9fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_StockIssuanceCostsIncurredButNotYetPaid_200caa8b-48c3-4192-867a-dc80c2964472" xlink:href="howl-20230630.xsd#howl_StockIssuanceCostsIncurredButNotYetPaid"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4365e6f7-85f4-4357-9d49-3c7bef89c58e" xlink:to="loc_howl_StockIssuanceCostsIncurredButNotYetPaid_200caa8b-48c3-4192-867a-dc80c2964472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1414c58c-bffb-4294-98f4-05a716b43c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4365e6f7-85f4-4357-9d49-3c7bef89c58e" xlink:to="loc_us-gaap_InterestPaidNet_1414c58c-bffb-4294-98f4-05a716b43c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_e66beb8a-b311-4a97-aa90-f0e607060f1b" xlink:href="howl-20230630.xsd#howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4365e6f7-85f4-4357-9d49-3c7bef89c58e" xlink:to="loc_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_e66beb8a-b311-4a97-aa90-f0e607060f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/NatureofBusiness" xlink:type="simple" xlink:href="howl-20230630.xsd#NatureofBusiness"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/NatureofBusiness" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93151e1a-d873-4a7e-bb96-116e1fd6020e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f17e70d4-4341-4be9-a1a9-121ba5646a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93151e1a-d873-4a7e-bb96-116e1fd6020e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f17e70d4-4341-4be9-a1a9-121ba5646a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="howl-20230630.xsd#SummaryofSignificantAccountingPolicies"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6e32f32-b874-49bd-9564-96120ce32730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f63f1a0c-c177-4ecb-a7c7-636ac5bdecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6e32f32-b874-49bd-9564-96120ce32730" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f63f1a0c-c177-4ecb-a7c7-636ac5bdecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="howl-20230630.xsd#JazzCollaborationandLicenseAgreement"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/JazzCollaborationandLicenseAgreement" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4bec917f-7b44-458a-9c03-53690bab4b27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b237c511-d5fb-4d9a-89c6-d03e821df200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4bec917f-7b44-458a-9c03-53690bab4b27" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b237c511-d5fb-4d9a-89c6-d03e821df200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurements"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_084936b6-54fe-4352-b982-d32f12da078a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8c70f527-01bf-4be0-8ea7-ec5c04d1ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_084936b6-54fe-4352-b982-d32f12da078a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8c70f527-01bf-4be0-8ea7-ec5c04d1ce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalents" xlink:type="simple" xlink:href="howl-20230630.xsd#RestrictedCashandCashEquivalents"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/RestrictedCashandCashEquivalents" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_4ad775f5-df39-484e-a517-0f583b931953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_13c22289-f45c-4954-b941-632fb929caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4ad775f5-df39-484e-a517-0f583b931953" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_13c22289-f45c-4954-b941-632fb929caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="howl-20230630.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_729d0e3d-77d5-4b9c-b0e1-d143f8e2ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_dccf0a65-80d4-449f-98b5-74f7f98f3665" xlink:href="howl-20230630.xsd#howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_729d0e3d-77d5-4b9c-b0e1-d143f8e2ad94" xlink:to="loc_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_dccf0a65-80d4-449f-98b5-74f7f98f3665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoan" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoan"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/TermLoan" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9697dae2-c009-44e2-842d-3e25cd95dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4e446372-978b-495a-a1d7-4e6c208dcab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9697dae2-c009-44e2-842d-3e25cd95dee5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4e446372-978b-495a-a1d7-4e6c208dcab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CommonandPreferredStock" xlink:type="simple" xlink:href="howl-20230630.xsd#CommonandPreferredStock"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CommonandPreferredStock" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b4daf48b-5cf0-465c-a178-a9a6958e3e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_56b4d7ee-4b46-498b-a91f-643194c7a53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b4daf48b-5cf0-465c-a178-a9a6958e3e05" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_56b4d7ee-4b46-498b-a91f-643194c7a53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensation"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensation" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f17fe399-9a97-42e5-9abe-31eae1d66feb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9284160e-8d49-426f-9b73-ff45de643bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f17fe399-9a97-42e5-9abe-31eae1d66feb" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9284160e-8d49-426f-9b73-ff45de643bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RelatedParties" xlink:type="simple" xlink:href="howl-20230630.xsd#RelatedParties"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/RelatedParties" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5847f63f-83f5-44e2-a221-8789a7edf2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ef77a26c-53d2-4a19-9e73-71a7a890f219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5847f63f-83f5-44e2-a221-8789a7edf2aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ef77a26c-53d2-4a19-9e73-71a7a890f219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare" xlink:type="simple" xlink:href="howl-20230630.xsd#NetLossAttributabletoCommonStockholdersperShare"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7da8b012-35b9-4322-ad13-e5fef715a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_143c43fe-f39f-44eb-92c6-026b90d7cb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7da8b012-35b9-4322-ad13-e5fef715a2a1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_143c43fe-f39f-44eb-92c6-026b90d7cb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="howl-20230630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8ec5fe59-406c-47b7-8a30-4c904c1d5078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_88fb71fa-2fe2-48fe-9d25-86f9401b182f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ec5fe59-406c-47b7-8a30-4c904c1d5078" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_88fb71fa-2fe2-48fe-9d25-86f9401b182f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6d6060ed-cae5-45c9-87a1-1b8edc21879f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ec5fe59-406c-47b7-8a30-4c904c1d5078" xlink:to="loc_us-gaap_UseOfEstimates_6d6060ed-cae5-45c9-87a1-1b8edc21879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c3c76da7-2476-4cf1-b340-8f1cbcde92b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ec5fe59-406c-47b7-8a30-4c904c1d5078" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c3c76da7-2476-4cf1-b340-8f1cbcde92b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_9e5cd8cb-08b3-4adf-ad72-357f03023802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ec5fe59-406c-47b7-8a30-4c904c1d5078" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_9e5cd8cb-08b3-4adf-ad72-357f03023802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementTables" xlink:type="simple" xlink:href="howl-20230630.xsd#JazzCollaborationandLicenseAgreementTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c365559f-1f55-4bda-ab68-560b35246e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5e8113b4-63ee-45f2-843d-5e46f0575765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c365559f-1f55-4bda-ab68-560b35246e0c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5e8113b4-63ee-45f2-843d-5e46f0575765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6265e49b-6798-4842-b6ef-1d60045eb6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7a9de1d1-8c8c-4cef-92bc-079cf891e1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6265e49b-6798-4842-b6ef-1d60045eb6e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7a9de1d1-8c8c-4cef-92bc-079cf891e1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c3b93442-cd13-44f5-afdf-4464af16cefb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6265e49b-6798-4842-b6ef-1d60045eb6e9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c3b93442-cd13-44f5-afdf-4464af16cefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsTables" xlink:type="simple" xlink:href="howl-20230630.xsd#RestrictedCashandCashEquivalentsTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/RestrictedCashandCashEquivalentsTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_82785526-84a4-4b2f-8fab-3001819531a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b0f09a3e-80cc-422e-a911-f1ab826707cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_82785526-84a4-4b2f-8fab-3001819531a3" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b0f09a3e-80cc-422e-a911-f1ab826707cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="howl-20230630.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c305bf19-4670-4e2c-82fc-28cfbba1220d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8d329a02-e033-4776-8eb2-8b7b528e38e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c305bf19-4670-4e2c-82fc-28cfbba1220d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8d329a02-e033-4776-8eb2-8b7b528e38e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoanTables" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoanTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/TermLoanTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f18f4a21-d7d0-4859-a8a8-e432a15c4d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5e2b8c8a-20f2-4323-a5a1-9839d9ad8388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f18f4a21-d7d0-4859-a8a8-e432a15c4d62" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5e2b8c8a-20f2-4323-a5a1-9839d9ad8388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CommonandPreferredStockTables" xlink:type="simple" xlink:href="howl-20230630.xsd#CommonandPreferredStockTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CommonandPreferredStockTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dd01d877-2e1c-4016-9ba9-7d1ecef0734a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_329cc392-76de-4b09-a98a-3328467ffccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd01d877-2e1c-4016-9ba9-7d1ecef0734a" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_329cc392-76de-4b09-a98a-3328467ffccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensationTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4bd081a-80ad-48d3-a392-d8fb729976e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8fbb6278-18cf-45b2-868c-436d3aa28fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4bd081a-80ad-48d3-a392-d8fb729976e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8fbb6278-18cf-45b2-868c-436d3aa28fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f62cc703-b1e7-4cd8-b257-81126be18361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4bd081a-80ad-48d3-a392-d8fb729976e5" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_f62cc703-b1e7-4cd8-b257-81126be18361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d7e6f13a-ebb6-4a7f-87e5-b7221a42bddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4bd081a-80ad-48d3-a392-d8fb729976e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d7e6f13a-ebb6-4a7f-87e5-b7221a42bddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_66bf8daf-2714-4268-9af7-7941dab9af6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4bd081a-80ad-48d3-a392-d8fb729976e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_66bf8daf-2714-4268-9af7-7941dab9af6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareTables" xlink:type="simple" xlink:href="howl-20230630.xsd#NetLossAttributabletoCommonStockholdersperShareTables"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_40ba7e8d-155a-4a42-b742-11ef918a2e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e7aaa740-53c3-4945-8d35-22a3f8543f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_40ba7e8d-155a-4a42-b742-11ef918a2e7e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e7aaa740-53c3-4945-8d35-22a3f8543f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#NatureofBusinessDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/NatureofBusinessDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0666291-32a1-4bec-b422-ab45d239549b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_519b9d6e-4417-4071-a265-aeda6d2cfe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0666291-32a1-4bec-b422-ab45d239549b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_519b9d6e-4417-4071-a265-aeda6d2cfe5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#JazzCollaborationandLicenseAgreementNarrativeDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aa31de45-53f2-4511-bd65-c32922a748c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aa31de45-53f2-4511-bd65-c32922a748c4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5283bdd9-4e50-4c17-9dc0-31d8910ef050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2c294170-97ab-4d4f-9271-139e961215d0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5283bdd9-4e50-4c17-9dc0-31d8910ef050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_JazzCollaborationAgreementMember_12f45643-7401-49a7-915d-d5d32da6df54" xlink:href="howl-20230630.xsd#howl_JazzCollaborationAgreementMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5283bdd9-4e50-4c17-9dc0-31d8910ef050" xlink:to="loc_howl_JazzCollaborationAgreementMember_12f45643-7401-49a7-915d-d5d32da6df54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ef672ae8-5363-4272-aa6f-e25f7780bb10" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_NonRefundableUpfrontCashPaymentReceived_ce394596-0af6-4326-bd4f-6e4cd04c11d4" xlink:href="howl-20230630.xsd#howl_NonRefundableUpfrontCashPaymentReceived"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_NonRefundableUpfrontCashPaymentReceived_ce394596-0af6-4326-bd4f-6e4cd04c11d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DevelopmentAndRegulatoryMilestones_34aa2ca9-53db-4a77-9754-66d7d28b5e4c" xlink:href="howl-20230630.xsd#howl_DevelopmentAndRegulatoryMilestones"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_DevelopmentAndRegulatoryMilestones_34aa2ca9-53db-4a77-9754-66d7d28b5e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SalesBasedMilestonesUpTo_60901c49-8171-4976-833d-55fccfab84d9" xlink:href="howl-20230630.xsd#howl_SalesBasedMilestonesUpTo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_SalesBasedMilestonesUpTo_60901c49-8171-4976-833d-55fccfab84d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborativeAgreementTransactionPrice_bfea5af5-df58-4c64-8558-3cac321d00d7" xlink:href="howl-20230630.xsd#howl_CollaborativeAgreementTransactionPrice"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_CollaborativeAgreementTransactionPrice_bfea5af5-df58-4c64-8558-3cac321d00d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_ff9f575d-cac8-4472-b5ad-37c28eea15f8" xlink:href="howl-20230630.xsd#howl_CollaborationAgreementEstimatedFutureReimbursableCosts"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_CollaborationAgreementEstimatedFutureReimbursableCosts_ff9f575d-cac8-4472-b5ad-37c28eea15f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CollaborationAgreementTerm_7a25f670-0a48-4f1a-b254-e7a57ff14887" xlink:href="howl-20230630.xsd#howl_CollaborationAgreementTerm"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_howl_CollaborationAgreementTerm_7a25f670-0a48-4f1a-b254-e7a57ff14887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c347fadc-2a10-4062-8946-3a2659e9bb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c347fadc-2a10-4062-8946-3a2659e9bb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2a30fa8a-c501-49e5-9773-8d0399c29847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2a30fa8a-c501-49e5-9773-8d0399c29847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ae372f04-1fad-4258-a93e-60ee778bcdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ae372f04-1fad-4258-a93e-60ee778bcdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_3fd0b5a8-4996-49eb-8e01-70f4bf331650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnbilledReceivablesCurrent"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_64663278-64c5-4fd1-84fd-655a5284ca31" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_3fd0b5a8-4996-49eb-8e01-70f4bf331650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6e30286d-e5a2-4f75-9b8b-0e634b0e972d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_9daf8f97-09ad-488f-86a1-4413090f6017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6e30286d-e5a2-4f75-9b8b-0e634b0e972d" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_9daf8f97-09ad-488f-86a1-4413090f6017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f0262cfd-e093-415e-824f-a86bee13907d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_9daf8f97-09ad-488f-86a1-4413090f6017" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f0262cfd-e093-415e-824f-a86bee13907d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_24ebbfd5-bb17-44f9-895a-84c2a9402afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f0262cfd-e093-415e-824f-a86bee13907d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_24ebbfd5-bb17-44f9-895a-84c2a9402afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_IncreaseInContractWithCustomerLiability_b5ec5924-ded8-48ce-ac01-6cf1df68d178" xlink:href="howl-20230630.xsd#howl_IncreaseInContractWithCustomerLiability"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f0262cfd-e093-415e-824f-a86bee13907d" xlink:to="loc_howl_IncreaseInContractWithCustomerLiability_b5ec5924-ded8-48ce-ac01-6cf1df68d178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DecreaseInContractWithCustomerLiability_a846098e-bd98-4a67-8826-b5138b857040" xlink:href="howl-20230630.xsd#howl_DecreaseInContractWithCustomerLiability"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f0262cfd-e093-415e-824f-a86bee13907d" xlink:to="loc_howl_DecreaseInContractWithCustomerLiability_a846098e-bd98-4a67-8826-b5138b857040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7d2a4e4a-7a94-4300-b2f4-39404cbcdb10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f0262cfd-e093-415e-824f-a86bee13907d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7d2a4e4a-7a94-4300-b2f4-39404cbcdb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc5e9414-4bf3-43d0-b628-fd6849b60e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc5e9414-4bf3-43d0-b628-fd6849b60e61" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7de096f7-5bd5-4a48-9d40-c39878f327dc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8008915-552e-47b7-b2d1-1a30388e381d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8008915-552e-47b7-b2d1-1a30388e381d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_87e6f0e4-2606-43a7-9eb7-91ac15cd0696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_87e6f0e4-2606-43a7-9eb7-91ac15cd0696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d8178517-2a37-4fa0-b85f-5dbed73c0d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a7685ec5-aa7e-4662-aa48-8dc818dd0d08" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d8178517-2a37-4fa0-b85f-5dbed73c0d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb1b651c-e9ee-4aaf-8a1e-32ed96a2e54d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2498bd30-5d9d-4392-ab5b-b87f731802d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb1b651c-e9ee-4aaf-8a1e-32ed96a2e54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7c47137e-271c-44c0-96ce-5717306ae7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cb1b651c-e9ee-4aaf-8a1e-32ed96a2e54d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7c47137e-271c-44c0-96ce-5717306ae7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a9f87a15-ce4e-4c80-9eaf-61166d74fab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e04397c2-d9c6-430a-99af-0b123dd27ce6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a9f87a15-ce4e-4c80-9eaf-61166d74fab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b51ba146-3d9f-4581-aa5b-4db6c5f0bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a9f87a15-ce4e-4c80-9eaf-61166d74fab1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b51ba146-3d9f-4581-aa5b-4db6c5f0bedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_be53d404-0f9e-4da3-bbbc-ff4abd29d9d6" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c26684-5531-4034-81d6-f7a1c4a08c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_72c26684-5531-4034-81d6-f7a1c4a08c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3c9ae997-a162-44c5-93d9-e658335f69bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3c9ae997-a162-44c5-93d9-e658335f69bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_722434cd-4be8-478e-855e-d7e43adc9fb6" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_howl_SuccessPaymentLiability_722434cd-4be8-478e-855e-d7e43adc9fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_cb86c167-3cdc-4063-88d3-43e5145e02cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_77e1b43d-b04c-4a9b-b0b0-1879d3c8f093" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_cb86c167-3cdc-4063-88d3-43e5145e02cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e6a3e15-efd5-4382-878d-17550e9f2e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e6a3e15-efd5-4382-878d-17550e9f2e76" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26b2fa76-c11c-4cc5-b253-d11591e2eb9a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f7a597e-0631-4d0d-a97a-b037f436d3d2" xlink:to="loc_srt_RangeMember_26b2fa76-c11c-4cc5-b253-d11591e2eb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dfc51689-0619-4beb-9169-822066cc4553" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26b2fa76-c11c-4cc5-b253-d11591e2eb9a" xlink:to="loc_srt_MaximumMember_dfc51689-0619-4beb-9169-822066cc4553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9654c38c-cc15-431f-a684-2e231c721690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b9f507c-ecad-4e06-97b8-05fe202c200b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9654c38c-cc15-431f-a684-2e231c721690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_212f45f1-e044-46e6-9171-4e162ba9f52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9654c38c-cc15-431f-a684-2e231c721690" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_212f45f1-e044-46e6-9171-4e162ba9f52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e280118-216b-48e5-97d0-c1019dc10aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ebb58031-871f-4ae8-b4b6-2574bbb56f91" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e280118-216b-48e5-97d0-c1019dc10aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3e460ed0-3372-41b2-8e9a-6c23495b48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e280118-216b-48e5-97d0-c1019dc10aae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3e460ed0-3372-41b2-8e9a-6c23495b48b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b3d934da-a677-484c-af16-b19ad593793d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_b917ecdf-9d5b-4bcd-9e0d-b3271b77625e" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_howl_SuccessPaymentLiability_b917ecdf-9d5b-4bcd-9e0d-b3271b77625e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessFeeLiabilityPaid_4f10d130-4a67-4d90-8d84-5e0b1f41f7f7" xlink:href="howl-20230630.xsd#howl_SuccessFeeLiabilityPaid"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_howl_SuccessFeeLiabilityPaid_4f10d130-4a67-4d90-8d84-5e0b1f41f7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_95c8a60b-63ab-422f-8548-c99d40c060a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bfba8b0b-981b-41f9-94d8-ea73d173535a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_95c8a60b-63ab-422f-8548-c99d40c060a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aa3c921d-427f-4f8e-a18e-5746fdbe6008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aa3c921d-427f-4f8e-a18e-5746fdbe6008" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_338333f3-bc56-43fa-a3c2-035bd6eb1a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888a1ad0-35ab-47f2-a8c7-1299c362846e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_338333f3-bc56-43fa-a3c2-035bd6eb1a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3cbd0883-0f31-4275-8d64-dde39aa2891d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_338333f3-bc56-43fa-a3c2-035bd6eb1a51" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3cbd0883-0f31-4275-8d64-dde39aa2891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_baf25163-aed3-403a-ac7e-d855f3d8a76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d3b8b884-4b11-4fc4-8167-649282ed0547" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_baf25163-aed3-403a-ac7e-d855f3d8a76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b57b88a7-a1fc-44d7-84c5-ffdb3b011707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_baf25163-aed3-403a-ac7e-d855f3d8a76f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b57b88a7-a1fc-44d7-84c5-ffdb3b011707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c9b8d1e8-17d5-4517-8b10-3ae51445c956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8664b9fe-d471-4ff4-af0d-13bbfe87ddbd" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c9b8d1e8-17d5-4517-8b10-3ae51445c956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c9b8d1e8-17d5-4517-8b10-3ae51445c956" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_67520dd1-fbd5-4103-b67f-baeddcfdf789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_67520dd1-fbd5-4103-b67f-baeddcfdf789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7b0f9061-bfef-42ec-a707-1e00c3cfe5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_7b0f9061-bfef-42ec-a707-1e00c3cfe5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_27a03082-0024-47c5-8174-b832cb3bf568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_27a03082-0024-47c5-8174-b832cb3bf568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_666e0627-3d92-4254-a725-4ea7aa207634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_666e0627-3d92-4254-a725-4ea7aa207634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_946dc6f6-0f9e-4bc5-9556-59be3acd5aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e80cddfa-483b-44c7-9001-ca57cd664425" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_946dc6f6-0f9e-4bc5-9556-59be3acd5aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#RestrictedCashandCashEquivalentsNarrativeDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_05cffa51-ea0c-42bc-9962-f9224c461c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_05cffa51-ea0c-42bc-9962-f9224c461c47" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46d63161-9a38-457b-8f70-a6380508bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1b0527c-68db-49fa-8d1e-3179a3f0c3cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46d63161-9a38-457b-8f70-a6380508bb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember_6ab3910d-182d-4c08-b670-3af95a69a5fb" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_46d63161-9a38-457b-8f70-a6380508bb5b" xlink:to="loc_howl_TermLoansMember_6ab3910d-182d-4c08-b670-3af95a69a5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9427e882-506b-4fe8-9e33-be9a75bcae37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bb18bd1e-10b7-4a9a-8b82-12d893a1539f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9427e882-506b-4fe8-9e33-be9a75bcae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e370c0dc-ea93-46d9-89ec-3e8f4c88ecad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9427e882-506b-4fe8-9e33-be9a75bcae37" xlink:to="loc_us-gaap_LoansPayableMember_e370c0dc-ea93-46d9-89ec-3e8f4c88ecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_50b0bbe3-c1b3-4a0f-b4a0-d387a630aada" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_33719822-6258-4cfc-9bd6-db4e10cabb54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:to="loc_us-gaap_RestrictedCash_33719822-6258-4cfc-9bd6-db4e10cabb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_b3bc08bc-57b2-4f60-9725-2007e420f82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_5a730552-9b5b-4cad-bce3-54bd1807fd48" xlink:to="loc_us-gaap_RestrictedCashCurrent_b3bc08bc-57b2-4f60-9725-2007e420f82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2b41e2e1-3289-43b4-baf0-29f56ef67c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a33eda1-e36d-4e7c-a115-787075642ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2b41e2e1-3289-43b4-baf0-29f56ef67c8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a33eda1-e36d-4e7c-a115-787075642ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1de325c7-a1e6-47ef-8778-e62f397e9f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2b41e2e1-3289-43b4-baf0-29f56ef67c8c" xlink:to="loc_us-gaap_RestrictedCashCurrent_1de325c7-a1e6-47ef-8778-e62f397e9f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d58fd901-bb64-4c6c-9b33-94058cee5526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2b41e2e1-3289-43b4-baf0-29f56ef67c8c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d58fd901-bb64-4c6c-9b33-94058cee5526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7201727d-c9a3-4567-ab9e-855e896ed1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2b41e2e1-3289-43b4-baf0-29f56ef67c8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7201727d-c9a3-4567-ab9e-855e896ed1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedManufacturingCurrent_33e6ba29-e157-48c1-b047-4182ab077c4d" xlink:href="howl-20230630.xsd#howl_AccruedManufacturingCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_howl_AccruedManufacturingCurrent_33e6ba29-e157-48c1-b047-4182ab077c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_AccruedContractResearchCurrent_0c8b374d-0bf8-45ad-9f80-7bf29ac247d7" xlink:href="howl-20230630.xsd#howl_AccruedContractResearchCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_howl_AccruedContractResearchCurrent_0c8b374d-0bf8-45ad-9f80-7bf29ac247d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a4c816cb-6820-4cbc-b973-85815aae98f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a4c816cb-6820-4cbc-b973-85815aae98f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_11d0d084-16e8-4a79-9f67-dd17bbfd6df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_11d0d084-16e8-4a79-9f67-dd17bbfd6df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessPaymentLiability_191bd579-99dc-4a77-a486-ea859103d24b" xlink:href="howl-20230630.xsd#howl_SuccessPaymentLiability"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_howl_SuccessPaymentLiability_191bd579-99dc-4a77-a486-ea859103d24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_679ce53b-1db1-4dfc-b84f-2d45947b58d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_679ce53b-1db1-4dfc-b84f-2d45947b58d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03fe2713-df2d-43e6-9f85-82b1ad0bec41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a21b0302-5a1e-4a53-b546-819bfe629751" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_03fe2713-df2d-43e6-9f85-82b1ad0bec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoanNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoanNarrativeDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/TermLoanNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_27dd75c4-1ff7-463e-864f-d4807dd4d6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27dd75c4-1ff7-463e-864f-d4807dd4d6d1" xlink:to="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9b4229fd-ec48-48db-a0e7-3fb4607287c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2bdef250-2b42-4c6b-98a5-170c3d2422c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9b4229fd-ec48-48db-a0e7-3fb4607287c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1f99b7c2-ec69-4147-b88a-fe3baab06b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9b4229fd-ec48-48db-a0e7-3fb4607287c0" xlink:to="loc_us-gaap_LoansPayableMember_1f99b7c2-ec69-4147-b88a-fe3baab06b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_86072de7-1fdd-4f27-806b-6803a92c7ce8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TrancheILoanMember_f2c73e67-47f2-42bb-a2ca-206df8b016f9" xlink:href="howl-20230630.xsd#howl_TrancheILoanMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:to="loc_howl_TrancheILoanMember_f2c73e67-47f2-42bb-a2ca-206df8b016f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TrancheIILoanMember_aea979a4-dc5a-495c-8a3d-d8948f2b9bef" xlink:href="howl-20230630.xsd#howl_TrancheIILoanMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:to="loc_howl_TrancheIILoanMember_aea979a4-dc5a-495c-8a3d-d8948f2b9bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember_24737381-24e5-4fab-9300-1c34945ebe68" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8047d03c-29da-4251-b47e-0eaad8b665de" xlink:to="loc_howl_TermLoansMember_24737381-24e5-4fab-9300-1c34945ebe68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_59b4c207-c451-44ea-90f1-935f1189d1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_98ea4f29-6a8e-45ae-8cf0-3639b0d72cbc" xlink:to="loc_us-gaap_VariableRateDomain_59b4c207-c451-44ea-90f1-935f1189d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_14d09992-a771-42fc-97e6-5769b31be4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_59b4c207-c451-44ea-90f1-935f1189d1f1" xlink:to="loc_us-gaap_PrimeRateMember_14d09992-a771-42fc-97e6-5769b31be4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodAxis"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_howl_DebtInstrumentCovenantPeriodAxis_c5e4fd35-2b61-4044-9acc-4688434e103a" xlink:to="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodOneMember_476a931f-ff39-4d58-b1ad-7200f6f07318" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodOneMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:to="loc_howl_DebtInstrumentCovenantPeriodOneMember_476a931f-ff39-4d58-b1ad-7200f6f07318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantPeriodTwoMember_53d3f80d-7e5a-46da-a04d-dc4811796ede" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantPeriodTwoMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_howl_DebtInstrumentCovenantPeriodDomain_8315276f-04f5-4481-8019-3e343b49d22d" xlink:to="loc_howl_DebtInstrumentCovenantPeriodTwoMember_53d3f80d-7e5a-46da-a04d-dc4811796ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_882da533-1773-450b-b376-22f3f884f993" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentMaximumBorrowingCapacity_523621a7-61a9-4b79-9b43-65bc05f88e2e" xlink:href="howl-20230630.xsd#howl_DebtInstrumentMaximumBorrowingCapacity"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentMaximumBorrowingCapacity_523621a7-61a9-4b79-9b43-65bc05f88e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11aae1da-22b9-48af-8041-e05062084efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11aae1da-22b9-48af-8041-e05062084efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba486281-8cee-4cd4-9c56-bb3d89ffbf10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba486281-8cee-4cd4-9c56-bb3d89ffbf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a0975cb0-e3f9-4db0-bbe0-1b99675f7bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_InterestExpense_a0975cb0-e3f9-4db0-bbe0-1b99675f7bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee_16c473e0-dc44-4ec3-a295-c6750ecfa7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityFee"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee_16c473e0-dc44-4ec3-a295-c6750ecfa7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_619fbe29-e965-471d-a58f-2561cdc424f7" xlink:href="howl-20230630.xsd#howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn_619fbe29-e965-471d-a58f-2561cdc424f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SuccessFeeLiabilityPaid_521d8ba8-5a1a-449d-80f6-edd58b20cb44" xlink:href="howl-20230630.xsd#howl_SuccessFeeLiabilityPaid"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_SuccessFeeLiabilityPaid_521d8ba8-5a1a-449d-80f6-edd58b20cb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentConditionalFeeLiability_3f608460-d997-469e-9417-e4676d6b2687" xlink:href="howl-20230630.xsd#howl_DebtInstrumentConditionalFeeLiability"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentConditionalFeeLiability_3f608460-d997-469e-9417-e4676d6b2687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_592c5225-d571-4922-b15a-93352dcb1ebe" xlink:href="howl-20230630.xsd#howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount_592c5225-d571-4922-b15a-93352dcb1ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_eee1065e-08d8-4b04-8d16-ecd3eb8da30f" xlink:href="howl-20230630.xsd#howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure_eee1065e-08d8-4b04-8d16-ecd3eb8da30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_79816cd5-cb82-4cd2-8290-7b14b5f570d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_79816cd5-cb82-4cd2-8290-7b14b5f570d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_8f107b15-a9a6-49bc-b74d-13fbadd0786f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_Cash_8f107b15-a9a6-49bc-b74d-13fbadd0786f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c358f9d1-b3a9-47a4-be4e-0eb0d54bde57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aa7d7708-2bdc-490e-b90d-c99caffb7b93" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c358f9d1-b3a9-47a4-be4e-0eb0d54bde57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#TermLoanScheduleofLongTermDebtInstrumentsDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ab9ba419-776d-435a-bcfd-daf34b5a96be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ab9ba419-776d-435a-bcfd-daf34b5a96be" xlink:to="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:to="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99050be9-69e6-45fd-a94a-d289abfa0e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_07aef090-fa69-471f-9fc2-970e88e669ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99050be9-69e6-45fd-a94a-d289abfa0e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_TermLoansMember_56203dfd-d0b6-47a8-a41e-49d3cfaae791" xlink:href="howl-20230630.xsd#howl_TermLoansMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_99050be9-69e6-45fd-a94a-d289abfa0e3f" xlink:to="loc_howl_TermLoansMember_56203dfd-d0b6-47a8-a41e-49d3cfaae791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bb64fe49-666a-4ab2-ac24-50dc67c00506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1c62a02b-f4ef-42f7-968b-b271b2cb4630" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bb64fe49-666a-4ab2-ac24-50dc67c00506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_405cfd11-0103-4373-9171-95610e0e5dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bb64fe49-666a-4ab2-ac24-50dc67c00506" xlink:to="loc_us-gaap_LoansPayableMember_405cfd11-0103-4373-9171-95610e0e5dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4637c9ba-59b3-48bf-ac37-2730488348e2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_43be981b-e1af-41fe-bae3-80b5a3fbaddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_43be981b-e1af-41fe-bae3-80b5a3fbaddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1c9e91ed-161e-4c6a-bbfd-2247ee119f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1c9e91ed-161e-4c6a-bbfd-2247ee119f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cda22ed8-2683-4527-998f-8b4defed3c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_900dea24-081b-40db-8c0c-e182fa56216c" xlink:to="loc_us-gaap_LongTermDebt_cda22ed8-2683-4527-998f-8b4defed3c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#CommonandPreferredStockNarrativeDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_93f1d237-755a-47f5-ac64-2519a531a533" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_93f1d237-755a-47f5-ac64-2519a531a533" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:to="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c97e059a-a2ad-4ed0-b345-cd5e9128cf56" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4069175e-d961-4413-b7fc-28aa11eafee8" xlink:to="loc_srt_RangeMember_c97e059a-a2ad-4ed0-b345-cd5e9128cf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d5018d3-7338-422a-a42c-886bae36589f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c97e059a-a2ad-4ed0-b345-cd5e9128cf56" xlink:to="loc_srt_MaximumMember_5d5018d3-7338-422a-a42c-886bae36589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44ac0480-ef4f-48a1-a57c-a6322d26e260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c270336-1104-47d1-8d53-2799a75588ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44ac0480-ef4f-48a1-a57c-a6322d26e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_ATMOfferingMember_762b20a0-ab19-4050-aba1-aee85d8d6b79" xlink:href="howl-20230630.xsd#howl_ATMOfferingMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44ac0480-ef4f-48a1-a57c-a6322d26e260" xlink:to="loc_howl_ATMOfferingMember_762b20a0-ab19-4050-aba1-aee85d8d6b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b6289815-9ecf-44fc-9649-7529c78f05cb" xlink:to="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cfe3c33f-d559-454a-8e47-2ae495de68df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cfe3c33f-d559-454a-8e47-2ae495de68df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_568a6a77-d397-4122-9dfd-480740226a88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_568a6a77-d397-4122-9dfd-480740226a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_CommonStockAmountAuthorized_9540f738-7ae7-4aef-8c79-dd34a177f455" xlink:href="howl-20230630.xsd#howl_CommonStockAmountAuthorized"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_howl_CommonStockAmountAuthorized_9540f738-7ae7-4aef-8c79-dd34a177f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_SalesCommissionsPercentage_498731c0-26dd-4d02-adbd-328cff2c548e" xlink:href="howl-20230630.xsd#howl_SalesCommissionsPercentage"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_howl_SalesCommissionsPercentage_498731c0-26dd-4d02-adbd-328cff2c548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_441eb5b0-b5ad-4f4a-919f-843f7e9a6056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_441eb5b0-b5ad-4f4a-919f-843f7e9a6056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_62630ec6-8ed3-4fa4-af65-5cfa1a7028ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_62630ec6-8ed3-4fa4-af65-5cfa1a7028ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5bf613dd-3ea5-4c60-abd3-9bbd27ba77c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5bf613dd-3ea5-4c60-abd3-9bbd27ba77c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4e7314b6-d67c-4d72-aa21-f3c1de7e933d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4e7314b6-d67c-4d72-aa21-f3c1de7e933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b8ee0a33-154f-4b49-abf9-14295e786b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b8ee0a33-154f-4b49-abf9-14295e786b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_484d095e-5fed-4ac3-a315-9725b8c07722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7ba478f7-195b-42ed-b6fc-37b9c25876d9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_484d095e-5fed-4ac3-a315-9725b8c07722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e41b530a-f886-449a-9102-2d397574903c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e41b530a-f886-449a-9102-2d397574903c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1ebcddaa-b82c-430a-8b85-368cd120d29f" xlink:to="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_0a9bfb12-4f3c-4bdf-b3b0-92a7bfd74bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_StockOptionMember_0a9bfb12-4f3c-4bdf-b3b0-92a7bfd74bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_16ad2761-1fd5-42a9-a59b-8deffd26b8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_16ad2761-1fd5-42a9-a59b-8deffd26b8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_37cf8783-1bfb-4f86-9ffd-3255c6b28346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_WarrantMember_37cf8783-1bfb-4f86-9ffd-3255c6b28346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockEmployeeStockPurchasePlanMember_794d5c6d-f8a1-4ae3-b1e3-d99f105c8b07" xlink:href="howl-20230630.xsd#howl_A2021StockEmployeeStockPurchasePlanMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_howl_A2021StockEmployeeStockPurchasePlanMember_794d5c6d-f8a1-4ae3-b1e3-d99f105c8b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_adb186ae-da09-4662-8e21-8f6d3a3f47fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b93646f8-e69a-4583-a99c-501cdfefcbad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_adb186ae-da09-4662-8e21-8f6d3a3f47fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_53ed73ae-1f36-4820-9c5b-cb2eb31b04da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f414dde7-99bf-4155-97e1-546a8736a386" xlink:to="loc_us-gaap_ClassOfStockLineItems_53ed73ae-1f36-4820-9c5b-cb2eb31b04da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3faa166-d442-4338-8650-7bffee1245d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53ed73ae-1f36-4820-9c5b-cb2eb31b04da" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c3faa166-d442-4338-8650-7bffee1245d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationNarrativeDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c758c38-cbe6-431a-a40e-0f14f2c47f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c758c38-cbe6-431a-a40e-0f14f2c47f71" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e634eefd-d269-4fd5-b974-f84bc3c90977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_20c27a3d-fb27-4cc4-802a-311030db1efd" xlink:to="loc_us-gaap_EquityComponentDomain_e634eefd-d269-4fd5-b974-f84bc3c90977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3d646b9d-8b98-41de-8bef-0b85c8302568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e634eefd-d269-4fd5-b974-f84bc3c90977" xlink:to="loc_us-gaap_CommonStockMember_3d646b9d-8b98-41de-8bef-0b85c8302568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_86f4402a-b1a4-4c7c-afe2-77ef5333b1ab" xlink:to="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember_716f4f4d-c875-4ac2-82e3-0fd6f4d574b0" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:to="loc_howl_A2021StockIncentivePlanMember_716f4f4d-c875-4ac2-82e3-0fd6f4d574b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember_c466307d-1bd9-49da-9d34-ff86107eac1d" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:to="loc_howl_A2017StockIncentivePlanMember_c466307d-1bd9-49da-9d34-ff86107eac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockEmployeeStockPurchasePlanMember_bf27dca9-7953-47a2-aefd-6452ba94fca0" xlink:href="howl-20230630.xsd#howl_A2021StockEmployeeStockPurchasePlanMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5fc71d3b-68b1-4634-b317-d0f6fa9dcd87" xlink:to="loc_howl_A2021StockEmployeeStockPurchasePlanMember_bf27dca9-7953-47a2-aefd-6452ba94fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f8304f4d-96bc-46ac-94a5-f4bb35cd6850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d210cd2b-924a-4e06-a349-adbcee75ec35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_RestrictedStockMember_d210cd2b-924a-4e06-a349-adbcee75ec35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3f6f6e16-f471-4509-8f5b-8daeb2113cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_EmployeeStockMember_3f6f6e16-f471-4509-8f5b-8daeb2113cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_437760ce-b872-4aff-82a2-b4470cf6bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_437760ce-b872-4aff-82a2-b4470cf6bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1331bbac-3f4d-4167-88d0-01f09115ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_PerformanceSharesMember_1331bbac-3f4d-4167-88d0-01f09115ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0afb1fd5-df05-4c60-8f89-52ab6889c1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca4e1816-e9ee-4bd3-b786-95e3b3803059" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0afb1fd5-df05-4c60-8f89-52ab6889c1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0bb1f74-b1a5-4e8e-a3f9-86000f165ec0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83703f02-f58d-4d27-ad27-e479d103c079" xlink:to="loc_srt_RangeMember_d0bb1f74-b1a5-4e8e-a3f9-86000f165ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_83f34aba-49c4-49a5-89c8-1a1e36080b48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0bb1f74-b1a5-4e8e-a3f9-86000f165ec0" xlink:to="loc_srt_MinimumMember_83f34aba-49c4-49a5-89c8-1a1e36080b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_c9cca73a-0d29-442a-b211-79bc7b0e6a2b" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember_da33ef80-4e4c-43e1-9e54-0b8c62b01f63" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:to="loc_howl_A2017StockIncentivePlanMember_da33ef80-4e4c-43e1-9e54-0b8c62b01f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember_bc6eb4a7-5efc-4d68-b0e8-88224c1c6473" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_13aaba9a-4599-4c8c-9f84-6b37213bb368" xlink:to="loc_howl_A2021StockIncentivePlanMember_bc6eb4a7-5efc-4d68-b0e8-88224c1c6473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f9a6ea7a-5433-4f34-a827-b5cee631e232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd8e0bc2-bec9-47c9-bf7b-fdb79bd6495e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd8e0bc2-bec9-47c9-bf7b-fdb79bd6495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a8228475-b42c-4074-bbdd-78e7e552f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_a8228475-b42c-4074-bbdd-78e7e552f5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_da49d0b8-773f-4038-bddb-7fe94ca98dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_da49d0b8-773f-4038-bddb-7fe94ca98dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7336a898-5ff5-4570-9ca8-6deafb17b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7336a898-5ff5-4570-9ca8-6deafb17b87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4f35c29-e5fe-43dc-bed8-1bb0c5ac15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_a4f35c29-e5fe-43dc-bed8-1bb0c5ac15aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_EmployeeStockOwnershipPlanOfferingPeriod_82bf1bcc-8e6a-4091-8219-517b0ef5b2dd" xlink:href="howl-20230630.xsd#howl_EmployeeStockOwnershipPlanOfferingPeriod"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_howl_EmployeeStockOwnershipPlanOfferingPeriod_82bf1bcc-8e6a-4091-8219-517b0ef5b2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_EmployeeStockOwnershipPlanPurchasePricePercent_39acb262-68ab-4359-8fcd-467e47b163a0" xlink:href="howl-20230630.xsd#howl_EmployeeStockOwnershipPlanPurchasePricePercent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_howl_EmployeeStockOwnershipPlanPurchasePricePercent_39acb262-68ab-4359-8fcd-467e47b163a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e1a1775c-3e1d-4b5c-8c0a-fcb1300eccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e1a1775c-3e1d-4b5c-8c0a-fcb1300eccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d98a0c11-2f49-492a-911f-cc28d33d8ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d98a0c11-2f49-492a-911f-cc28d33d8ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_17f00b07-5f6e-4835-9e42-bc1f352757dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_17f00b07-5f6e-4835-9e42-bc1f352757dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a6fb4dd8-523c-4d55-9398-ba47103a6c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a6fb4dd8-523c-4d55-9398-ba47103a6c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3329e95e-0bd5-4bae-9fd5-20fecb9230ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3329e95e-0bd5-4bae-9fd5-20fecb9230ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5e7fa758-53b2-4001-a259-07745b0b4062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5e7fa758-53b2-4001-a259-07745b0b4062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_27530d2d-6eab-493c-9067-a05a8cb0c648" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_27530d2d-6eab-493c-9067-a05a8cb0c648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_06183210-12ef-4d86-a611-d4e6ea4384d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_06183210-12ef-4d86-a611-d4e6ea4384d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3c5d8e6d-774f-4d69-b40b-a082cfc941b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3c5d8e6d-774f-4d69-b40b-a082cfc941b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_de08c1af-74fd-4cc9-8205-8be9f70c2e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_de08c1af-74fd-4cc9-8205-8be9f70c2e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b9ed2e0-c596-4911-972c-0ae4cd4b195c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7b9ed2e0-c596-4911-972c-0ae4cd4b195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa7b8a79-40ac-440d-a7e7-5eb7c37ea215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa7b8a79-40ac-440d-a7e7-5eb7c37ea215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_272ef50c-269c-44b7-aaf0-596f61a7b618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_272ef50c-269c-44b7-aaf0-596f61a7b618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46bc7574-3fe4-44ee-8311-a8d62da39cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_46bc7574-3fe4-44ee-8311-a8d62da39cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27b3c65d-76fb-4a18-bb02-db24270d44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fec28b94-e6d4-42c3-a2d7-01c82187c01a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_27b3c65d-76fb-4a18-bb02-db24270d44d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationExpenseRecognizedDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6ad7ae6-addd-4a90-9a98-a2dfaab26f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6ad7ae6-addd-4a90-9a98-a2dfaab26f7e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5575d4b5-d1a1-47b4-ab08-11db451d87e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9711ed8-af46-4272-9506-88b761c598ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f9711ed8-af46-4272-9506-88b761c598ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_36e048db-d0b7-46b7-b57f-b2077c7b5da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_59919548-45c7-47e2-a25f-70988691b6b9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_36e048db-d0b7-46b7-b57f-b2077c7b5da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1d622313-69b9-4dd6-bcbb-caf0df629759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_09479081-0beb-46fb-b266-7a07c2812593" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1d622313-69b9-4dd6-bcbb-caf0df629759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_58136c02-15f3-419d-9455-a941affc217b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1d622313-69b9-4dd6-bcbb-caf0df629759" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_58136c02-15f3-419d-9455-a941affc217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationRestrictedStockAwardActivityDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_800ba867-4483-4578-980c-756f4c756fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_800ba867-4483-4578-980c-756f4c756fb0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:to="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0d602439-aacb-452b-8eb0-5ac7cb01ac84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c55e7ab6-a01d-4a96-9b0d-423c5d6ba8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:to="loc_us-gaap_RestrictedStockMember_c55e7ab6-a01d-4a96-9b0d-423c5d6ba8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8df090b3-31d0-4717-b463-f1406ffa25e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e3fa552-55a1-4b39-b0ae-6bf54b3e5723" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8df090b3-31d0-4717-b463-f1406ffa25e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_55f6fb3c-1aa3-4587-ba7c-c54bc13a0f1f" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2017StockIncentivePlanMember_1c673661-1ca2-485c-b7e2-49cd56afe441" xlink:href="howl-20230630.xsd#howl_A2017StockIncentivePlanMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:to="loc_howl_A2017StockIncentivePlanMember_1c673661-1ca2-485c-b7e2-49cd56afe441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_howl_A2021StockIncentivePlanMember_cfb34613-5048-41e9-b924-647dba967fe4" xlink:href="howl-20230630.xsd#howl_A2021StockIncentivePlanMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_16619403-cd19-4b9a-a9a1-ce4daf08c517" xlink:to="loc_howl_A2021StockIncentivePlanMember_cfb34613-5048-41e9-b924-647dba967fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b64ea006-0650-4c68-8493-c6438c34924c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af3c451c-cd8d-4df2-ba5b-b1662eb53ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_af3c451c-cd8d-4df2-ba5b-b1662eb53ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cb092ab5-5aa5-4aae-b6e3-23934bbf589c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cb092ab5-5aa5-4aae-b6e3-23934bbf589c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4630c2bd-ea67-410c-b4e6-f40721411445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4630c2bd-ea67-410c-b4e6-f40721411445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6687d218-a770-41dc-9aa6-e8619edf1b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6687d218-a770-41dc-9aa6-e8619edf1b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114d0103-d40e-478d-bbe0-df78787870b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b4c7f83-f736-421f-8ce9-8aadd4cc093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_114d0103-d40e-478d-bbe0-df78787870b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f5bbd82-bdf9-43df-b183-12c8ee1908ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b635c0de-e4b4-4c07-ac9f-99707a2eb842" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b635c0de-e4b4-4c07-ac9f-99707a2eb842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bbcabbb-80f0-4097-9a2c-dd146038b38e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bbcabbb-80f0-4097-9a2c-dd146038b38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa1a91c2-3358-4604-a4ca-44758dbc4363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aa1a91c2-3358-4604-a4ca-44758dbc4363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a1a49f8-524a-4495-88d2-13bca5ccae84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8a1a49f8-524a-4495-88d2-13bca5ccae84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b781bf8b-2fa1-44d9-94b4-e2f75e95141a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6aa98e7d-5887-4bed-882b-2a8b5e9e5ee1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b781bf8b-2fa1-44d9-94b4-e2f75e95141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationWeightedAverageAssumptionsDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e95397de-3c59-48dc-9c8c-9355759909e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e95397de-3c59-48dc-9c8c-9355759909e4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:to="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08f3255f-572b-4e27-889e-3d2febad2ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fbfc046e-eb58-45df-bd58-1ecbf26c58c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08f3255f-572b-4e27-889e-3d2febad2ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d6faaf7f-fc20-4522-9f77-adf924c4aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08f3255f-572b-4e27-889e-3d2febad2ec3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d6faaf7f-fc20-4522-9f77-adf924c4aeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c4d65308-7c27-4883-ba98-244baed51b92" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b550112c-0022-4fd1-a86f-3d6d27513cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b550112c-0022-4fd1-a86f-3d6d27513cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad3e8a03-3cf8-49d3-a4ac-07b8de23e7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ad3e8a03-3cf8-49d3-a4ac-07b8de23e7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfad0aac-c747-4fde-89f5-cfff901e0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bfad0aac-c747-4fde-89f5-cfff901e0d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f2cf62e4-8ddc-4294-ba65-fe1b5b9db98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c4e16d30-bff4-4b08-b461-4fff74316269" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f2cf62e4-8ddc-4294-ba65-fe1b5b9db98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#StockbasedCompensationStockOptionActivityDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edadddf6-439c-435e-83b6-c2f2500f3585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edadddf6-439c-435e-83b6-c2f2500f3585" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:to="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9410c580-54b6-40ad-9573-4492071aee90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_525ebe68-3008-43e2-9b51-309ea22d6595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9410c580-54b6-40ad-9573-4492071aee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_172778df-e888-4314-9169-e8fcd061985f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9410c580-54b6-40ad-9573-4492071aee90" xlink:to="loc_us-gaap_EmployeeStockOptionMember_172778df-e888-4314-9169-e8fcd061985f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d7ef1044-7f88-436b-a6e3-14d5be218d1a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06d2217e-8179-4e3d-b744-a35544d41a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06d2217e-8179-4e3d-b744-a35544d41a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c8ecf627-3525-4d6f-bb97-e1c37569f067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c8ecf627-3525-4d6f-bb97-e1c37569f067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60fe42e0-972f-4087-8577-84b2a1b62b27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60fe42e0-972f-4087-8577-84b2a1b62b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1b31d0d-7e3f-4e11-908a-2196b2416813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1b31d0d-7e3f-4e11-908a-2196b2416813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6626b370-08ae-49c7-a661-6a1c0dde0c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_77d94e30-5288-4e0e-b090-89b85935e781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6626b370-08ae-49c7-a661-6a1c0dde0c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9d25d2a8-7d77-4f30-86b9-cc5e91339c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9d25d2a8-7d77-4f30-86b9-cc5e91339c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c076057-0c45-4c42-b455-526ce22dd2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c076057-0c45-4c42-b455-526ce22dd2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc451812-86b3-48be-b483-7bb6400392c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cc451812-86b3-48be-b483-7bb6400392c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_65e90262-7c92-4b8e-8f88-0f2b1ef2121a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_65e90262-7c92-4b8e-8f88-0f2b1ef2121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c529a38-5a33-40d3-8a05-d1a48a84a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5c529a38-5a33-40d3-8a05-d1a48a84a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89024188-5f51-49ba-b7dc-6584941e4d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85ea463c-ea73-4968-b275-e2934be4812b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89024188-5f51-49ba-b7dc-6584941e4d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b512a571-0a41-4463-bc22-89f027ac7e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b512a571-0a41-4463-bc22-89f027ac7e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0da0d128-fad4-49f9-8226-254bef7db74e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_42a98c9c-81b2-40e4-95b5-d726467c85b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_42a98c9c-81b2-40e4-95b5-d726467c85b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_279094c9-bdb8-4b69-93d7-64270c266de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ba035a4-4191-4935-830c-36bacedc6787" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_279094c9-bdb8-4b69-93d7-64270c266de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#RelatedPartiesDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/RelatedPartiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6389174f-cb30-4d85-9fec-72b744b8cc57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_391b2f2f-c4f2-4627-b515-971536e95341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6389174f-cb30-4d85-9fec-72b744b8cc57" xlink:to="loc_us-gaap_SubleaseIncome_391b2f2f-c4f2-4627-b515-971536e95341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability_f8766491-6415-412e-a1d9-0f10790b40ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6389174f-cb30-4d85-9fec-72b744b8cc57" xlink:to="loc_us-gaap_SecurityDepositLiability_f8766491-6415-412e-a1d9-0f10790b40ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails" xlink:type="simple" xlink:href="howl-20230630.xsd#NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"/>
<link:presentationLink xlink:role="http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_257bea3f-fd6e-49ef-a5e1-8031b9531aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_257bea3f-fd6e-49ef-a5e1-8031b9531aa6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d950f891-2ab3-4bb6-95b4-4477223a505d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3264523f-8f08-4354-a711-074a325fe66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3264523f-8f08-4354-a711-074a325fe66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9b184297-458e-4150-8f1b-1a10a9f10b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_RestrictedStockMember_9b184297-458e-4150-8f1b-1a10a9f10b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4fd3943-8bb3-49d2-ac3e-5244ccf2c21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4fd3943-8bb3-49d2-ac3e-5244ccf2c21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_69ee6954-05ad-4b76-ba7d-9f4f9e803acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_eb147aed-7802-4aef-a1fc-e7c798700143" xlink:to="loc_us-gaap_WarrantMember_69ee6954-05ad-4b76-ba7d-9f4f9e803acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d3e405-ef60-4dd4-acf4-200ccc223e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d2c1d551-ef29-4416-ae82-125aa05c0540" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d3e405-ef60-4dd4-acf4-200ccc223e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_06d0650d-0fbb-4059-aaad-22d604a14dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d3e405-ef60-4dd4-acf4-200ccc223e21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_06d0650d-0fbb-4059-aaad-22d604a14dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031490320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30, 2023<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40366<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WEREWOLF THERAPEUTICS, INC.<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3523180<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Talcott Ave<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952‑0555<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HOWL<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,658,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001785530<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916029442336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 137,452<span></span>
</td>
<td class="nump">$ 129,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,020<span></span>
</td>
<td class="nump">3,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">6,927<span></span>
</td>
<td class="nump">6,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">147,399<span></span>
</td>
<td class="nump">140,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,381<span></span>
</td>
<td class="nump">8,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">21,015<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">7,788<span></span>
</td>
<td class="nump">8,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">185,235<span></span>
</td>
<td class="nump">160,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,940<span></span>
</td>
<td class="nump">14,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="nump">2,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">6,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,006<span></span>
</td>
<td class="nump">23,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">11,705<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of discount and issuance costs</a></td>
<td class="nump">39,142<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">66,636<span></span>
</td>
<td class="nump">37,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders’ equity:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 5,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued or outstanding as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 200,000 shares authorized as of June 30, 2023 and December 31, 2022; 35,642 and 31,515 shares issued as of June 30, 2023 and December 31, 2022, respectively; 35,642 and 31,434 shares outstanding as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">442,381<span></span>
</td>
<td class="nump">429,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(323,785)<span></span>
</td>
<td class="num">(306,705)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders’ equity</a></td>
<td class="nump">118,599<span></span>
</td>
<td class="nump">122,337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders’ equity</a></td>
<td class="nump">$ 185,235<span></span>
</td>
<td class="nump">$ 160,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030739088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">35,642,000<span></span>
</td>
<td class="nump">31,515,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">35,642,000<span></span>
</td>
<td class="nump">31,434,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030164176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 8,081<span></span>
</td>
<td class="nump">$ 4,148<span></span>
</td>
<td class="nump">$ 12,545<span></span>
</td>
<td class="nump">$ 4,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,583<span></span>
</td>
<td class="nump">13,887<span></span>
</td>
<td class="nump">21,289<span></span>
</td>
<td class="nump">24,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,565<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
<td class="nump">9,546<span></span>
</td>
<td class="nump">9,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,148<span></span>
</td>
<td class="nump">19,120<span></span>
</td>
<td class="nump">30,835<span></span>
</td>
<td class="nump">34,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,067)<span></span>
</td>
<td class="num">(14,972)<span></span>
</td>
<td class="num">(18,290)<span></span>
</td>
<td class="num">(30,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="num">(1,131)<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">969<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,098)<span></span>
</td>
<td class="num">$ (14,594)<span></span>
</td>
<td class="num">$ (17,080)<span></span>
</td>
<td class="num">$ (29,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to common stockholders, basic and diluted</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (usd per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (usd per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract', window );"><strong>Weighted-average common shares outstanding, basic and diluted</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (shares)</a></td>
<td class="nump">35,558<span></span>
</td>
<td class="nump">27,517<span></span>
</td>
<td class="nump">35,173<span></span>
</td>
<td class="nump">27,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (shares)</a></td>
<td class="nump">35,558<span></span>
</td>
<td class="nump">27,517<span></span>
</td>
<td class="nump">35,173<span></span>
</td>
<td class="nump">27,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Basic And Diluted Other Disclosures1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916027186048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,608<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 152,787<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 405,680<span></span>
</td>
<td class="num">$ (252,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,745<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(15,343)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,343)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (shares) at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,654<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Mar. 31, 2022</a></td>
<td class="nump">139,318<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">407,554<span></span>
</td>
<td class="num">(268,238)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,608<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">152,787<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">405,680<span></span>
</td>
<td class="num">(252,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(29,937)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (shares) at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Jun. 30, 2022</a></td>
<td class="nump">129,841<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">412,671<span></span>
</td>
<td class="num">(282,832)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (shares) at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,654<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Mar. 31, 2022</a></td>
<td class="nump">139,318<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">407,554<span></span>
</td>
<td class="num">(268,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs</a></td>
<td class="nump">3,339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(14,594)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (shares) at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Jun. 30, 2022</a></td>
<td class="nump">129,841<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">412,671<span></span>
</td>
<td class="num">(282,832)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (shares) at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,515<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">122,337<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">429,039<span></span>
</td>
<td class="num">(306,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,824<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs</a></td>
<td class="nump">8,610<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,610<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(11,982)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,982)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (shares) at Mar. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Mar. 31, 2023</a></td>
<td class="nump">121,073<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">439,757<span></span>
</td>
<td class="num">(318,687)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (shares) at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,515<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">122,337<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">429,039<span></span>
</td>
<td class="num">(306,705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(17,080)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (shares) at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,642<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Jun. 30, 2023</a></td>
<td class="nump">118,599<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">442,381<span></span>
</td>
<td class="num">(323,785)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, beginning balance (shares) at Mar. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,339<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, beginning balance at Mar. 31, 2023</a></td>
<td class="nump">121,073<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">439,757<span></span>
</td>
<td class="num">(318,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs</a></td>
<td class="nump">644<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">45<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,930<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,930<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(5,098)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,098)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Stockholders' equity, ending balance (shares) at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,642<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity, ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 118,599<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 442,381<span></span>
</td>
<td class="num">$ (323,785)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031924480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders’ Equity (unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030193696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (17,080)<span></span>
</td>
<td class="num">$ (29,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">3,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of success payment liability</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">863<span></span>
</td>
<td class="num">(2,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,171)<span></span>
</td>
<td class="nump">3,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(5,271)<span></span>
</td>
<td class="nump">13,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset', window );">Operating lease liability</a></td>
<td class="num">(1,009)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(191)<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,819)<span></span>
</td>
<td class="num">(14,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(1,139)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(1,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at the market offering of common stock</a></td>
<td class="nump">9,388<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from drawdown of term loans</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of equity issuance costs</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances under Employee Stock Purchase Plan</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">49,315<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">28,146<span></span>
</td>
<td class="num">(11,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents—beginning of period</a></td>
<td class="nump">130,529<span></span>
</td>
<td class="nump">158,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents—end of period</a></td>
<td class="nump">158,675<span></span>
</td>
<td class="nump">147,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_StockIssuanceCostsIncurredButNotYetPaid', window );">Issuance costs in accounts payable and accrued expenses</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets', window );">Stock option exercise receivables in prepaid expenses and other current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liability and Right of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred But Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031664640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business</a></td>
<td class="text">Nature of Business <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Werewolf Therapeutics, Inc. (“Werewolf” or the “Company”) was incorporated in the state of Delaware in October 2017. The Company is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The Company’s headquarters are located in Watertown, Massachusetts. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, raising capital and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents of $137.5 million at June 30, 2023. The Company expects that its cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements for at least twelve months from the filing date of this Quarterly Report. However, additional funding will be necessary beyond this point to fund future preclinical and clinical activities. The Company expects to finance its future cash needs through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034217344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of June 30, 2023 and December 31, 2022, and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States of America (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments which are necessary for a fair presentation of the Company’s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC (the “Annual Report”).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information presented in the condensed consolidated financial statements and related notes as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022, is unaudited. The December 31, 2022 condensed consolidated balance sheet included herein was derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interim results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Werewolf Therapeutics, Inc. and its wholly owned subsidiary, Werewolf Therapeutics Mass Securities, Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant accounting policies and estimates used in the preparation of the condensed consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and the fair value of the success payment liability. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events and transactions that occurred in the period from the balance sheet date to the date that the financial statements were issued. Other than as described in these condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031417936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Jazz Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Jazz Collaboration and License Agreement</a></td>
<td class="text">Jazz Collaboration and License Agreement<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company entered into an exclusive global collaboration and license agreement (the “Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited (“Jazz”) pursuant to which the Company granted Jazz certain licenses to develop and commercialize products containing the Company’s Interferon alpha (“IFNα”) INDUKINE™ molecule, JZP898 (formerly WTX-613), as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria (each such product, a “Licensed Product”). Under the Collaboration Agreement, the Company is responsible for certain pre-clinical development activities with respect to JZP898 and other development activities specified in mutually agreed upon development plans. Jazz will generally reimburse the Company for the cost of such activities. Jazz will be responsible for all other development and commercialization activities conducted to exploit the Licensed Products, including submission of an investigational new drug application (“IND”) to the U.S. Food and Drug Administration (the “FDA”). Jazz received IND application clearance for JZP898 in July 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Collaboration Agreement, the Company received a non-refundable upfront cash payment of $15.0 million in April 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Milestones and Royalties</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $520.0 million in development and regulatory milestones, and up to $740.0 million in sales-based milestones for all Licensed Products. In addition, the Company is eligible to receive tiered mid-single digit royalties based on Jazz’s, and any of its affiliates’ and sublicensees’ annual net sales of Licensed Products, subject to reduction in specified circumstances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis under ASC 606</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Identification of the Contract(s)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assessed the Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Identification of Promises and Performance Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has concluded that the exclusive license to its intellectual property, JZP898, and the non-exclusive corresponding “know-how” are not capable of being distinct from the other promises within the contract, and as such, the Company has determined that the license and “know-how” combined with the other research and development services and supply represent a single combined performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Determination of Transaction Price</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The overall transaction price as of the inception of the contract was determined to be $32.3 million, which is comprised of the nonrefundable upfront payment of $15.0 million and the estimated costs for research services of $17.3 million. Outside of the estimated costs for research services, there is no other variable consideration included in the transaction price at inception. The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential development and regulatory milestone payment under this agreement is zero, as achievement of those milestones is uncertain and highly susceptible to factors outside the Company’s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based royalties, including milestones based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The upfront payment of $15.0 million was recorded as deferred revenue and, along with payments related to the Company’s conduct of research services under the Collaboration Agreement, will be recognized as revenue over approximately 3.7 years using an input-based measurement of actual costs incurred as a percentage of the estimated total costs expected to be incurred over the expected term of conduct of the research services. Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">e Company believes this input-based method to recognize revenue best reflects the transfer of value to Jazz.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recognition of Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, using the cost-to-cost input method, which best depicts the research services performed for the customer, the Company recognized $12.5 million of revenue related to the Collaboration Agreement. As of June 30, 2023, there is $1.6 million and $0.8 million of current and long-term deferred revenue, respectively, related to the Collaboration Agreement. All costs associated with the Collaboration Agreement are recorded in research and development expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">“Unbilled receivables” of $5.2 million and $4.1 million was included within “Other receivables” in the accompanying condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the six months ended June 30, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company had not received any milestone or royalty payments under the Collaboration Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916033118448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text">Financial Instruments and Fair Value Measurements <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds, classified as cash, cash equivalents and restricted cash and cash equivalents on the Company’s condensed consolidated balance sheets, and a success payment liability pursuant to an amended and restated loan and security agreement (the “Loan Agreement”) with Pacific Western Bank (“PWB”) (see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June 30, 2023 were as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The success payment liability was included within “Accrued expenses and other current liabilities” in the accompanying condensed consolidated balance sheets as of December 31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in valuation techniques during the three or six months ended June 30, 2023. There were no liabilities measured at fair value on a recurring basis as of June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Success Payment Liability</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was obligated to pay to PWB a one-time success payment of up to $1.6 million upon the occurrence of the Company achieving certain conditions defined in the Loan Agreement. The Success Fee Event (as defined in the Loan Agreement) occurred during the second quarter of 2023, resulting in the immediate payment in full of the required Success Fee (as defined in Note 7 below).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the success payment liability during the six months ended June 30, 2023 based on Level 3 inputs (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment at Success Event</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The success payment liability is stated at fair value and was previously considered Level 3 because its fair value measurement was based, in part, on significant inputs not observed in the market. Upon completion of the Success Fee Event, the Company removed the corresponding financial instrument for the success fee liability and paid the total $1.6 million. Prior to repayment, the Company remeasured the liability at fair value with a corresponding increase of $1.0 million recorded to other expense, net for the six months ended June 30, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916032807312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text">Restricted Cash and Cash Equivalents<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintained restricted cash and cash equivalents of $21.2 million and $1.2 million at June 30, 2023 and December 31, 2022, respectively. At June 30, 2023, $20.0 million of the restricted cash and cash equivalents balance represents an obligation under the term loan facility for the required minimum cash balance in PWB accounts. This became effective upon imminent achievement of the funding goal as required by the terms of the Loan Agreement (see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The remaining restricted cash amounts are comprised solely of letters of credit required pursuant to the Company’s leased office spaces. At June 30, 2023, $0.2 million of the Company’s restricted cash balance was included within “Prepaid expenses and other current assets” in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,529 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916033007200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June 30, 2023 and December 31, 2022 were comprised as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,501</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,990</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,135</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,940</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,152</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031428160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text">Term Loan <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company entered into the Loan Agreement with PWB. Under the terms of the Loan Agreement, PWB made available a term loan in an aggregate principal amount of up to $20.0 million (“Tranche I Loan”) available at any time after the closing date until February 28, 2024 as extended to August 31, 2024 upon the satisfaction of certain conditions set forth in the Loan Agreement (such date, the “Amortization Date”). Based on the satisfaction of certain conditions defined in the Loan Agreement, PWB was also obligated to make available an additional term loan in the aggregate principal amount of up to $20.0 million (“Tranche II Loan”, or collectively with the Tranche I Loan, the “Term Loans”) available at any time after the closing date until the Amortization Date upon the acceptance by the U.S. Food and Drug Administration (the “FDA”) of two investigational new drug (“IND”) submissions on or before March 31, 2023. As of June 30, 2023, the Company has drawn down $40.0 million of the Term Loans.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outstanding notes payable balance under the Term Loans as of June 30, 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to the interest-only period, which ends on August 31, 2024, the Company is required to make equal monthly principal payments plus interest until the Term Loans mature on August 31, 2026. The Term Loans will bear interest on the outstanding daily balance at a floating annual rate equal to greater of: (i) 0.5% above the prime rate then in effect or (ii) 4.5%. If the prime rate changes throughout the term, the interest rate will be adjusted effective on the date of the prime rate change. All interest chargeable under the Loan Agreement is computed on a 360-day year for the actual number of days elapsed, with interest payable monthly. The Company recognized interest expense related to the Loan Agreement of $0.9 million and $1.0 million during the three and six months ended June 30, 2023, respectively. The Company did not incur interest expense during the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was obligated to pay PWB a one-time fee in the event of certain corporate transactions equal to either (i) the greater of (a) $0.2 million and (b) 2.0% of the amount drawn under the Term Loans, for a transaction occurring on or before March 31, 2023, or (ii) for any transaction occurring thereafter, the greater of (a) $0.4 million and (b) 4.0% of the amount drawn under the Term Loans (the “Success Fee”). The Success Fee Event occurred during the second quarter of 2023, resulting in the immediate payment in full of the $1.6 million required Success Fee, and resulting in a total of $0.0 million as a success fee liability as of June 30, 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All outstanding obligations under the Loan Agreement are secured by the Company’s personal property (exclusive of any intellectual property) and are subject to acceleration in the event of default. In the event of a late payment or default, the Company is obligated to pay a fee equal to 5.0% of such unpaid amounts. In connection with the Loan Agreement, the Company is required to comply with certain negative covenants, which among other things, restrict the Company from (i) incurring future debt or granting liens, (ii) effectuating a merger or consolidation with or into any other business organization, (iii) paying dividends or making certain other distributions, (iv) selling or otherwise transferring its assets, (v) making investments in any entities or instruments other than certain investments specified in the Loan Agreement and (vi) making capitalized expenditures in excess of 125% of the amount provided for in the annual budget approved by the board of directors. The Loan Agreement also contains standard affirmative covenants, including with respect to the issuance of audited consolidated financial statements, insurance, and maintenance of good standing and government compliance in the Company’s state of formation. On or before September 30, 2023, the Company was required to raise aggregate gross cash process of at least $50.0 million from the sale or issuance of the Company’s equity or from strategic partnerships or any similar transaction. From after receipt of those proceeds, the Company is required to maintain at all times at least $20.0 million of otherwise unrestricted cash in accounts with PWB, which is included within “Restricted cash and cash equivalents” on our Balance Sheets. On April 17, 2023, the Company achieved the $50.0 million funding milestone, triggering the corresponding $20.0 million cash covenant, full payment of the Success Fee of $1.6 million, and the updated Amortization Date of August 31, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PWB has the right to accelerate all outstanding obligations of the Company under the Loan Agreement or terminate any remaining Term Loan commitments in the event of a material adverse effect on (i) the operations, business or financial condition of the Company, (ii) the Company’s ability to repay any portion of the Term Loans or perform any of its other obligations under the Loan Agreement, and (iii) the Company’s interest in, or the value, perfection or priority of PWB’s security interest in the collateral. As of June 30, 2023, the Company had drawn both Term Loans and had $40.0 million outstanding principal.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034345168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common and Preferred Stock</a></td>
<td class="text">Common and Preferred Stock<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is authorized to issue 200.0 million shares of common stock. Common stockholders are entitled to dividends if and when declared by the Company’s board of directors. As of June 30, 2023, no dividends on common stock had been declared by the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 10, 2022, the Company entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB”), pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $50.0 million (the “ATM Offering”). The Sales Agreement provides that SVB will be entitled to a sales commission equal to 3.0% of the gross sales price per share of all shares sold under the ATM Offering. As of June 30, 2023, the Company had sold an aggregate of 7,923,848 shares under the ATM Offering at an average price of $3.33 per share for net proceeds of $25.0 million after deducting sales commissions and offering expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is authorized to issue 5.0 million shares of undesignated preferred stock in one or more series. As of June 30, 2023, no shares of preferred stock were issued or outstanding.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">939</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,809</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034274400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2017, the Company adopted the 2017 Stock Incentive Plan (the “2017 Plan”), as amended and restated, under which it could grant incentive stock options (“ISOs”), non-qualified stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and other stock-based awards to eligible employees, officers, directors and consultants. The terms of stock options and RSAs, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2017 Plan. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, the board of directors adopted and the Company’s stockholders approved the 2021 Stock Incentive Plan (the “2021 Plan”), which became effective immediately prior to the effectiveness of the Company’s initial public offering (“IPO”). As a result of the adoption of the 2021 Plan, no further awards will be made under the 2017 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2021 Plan provides for the grant of ISOs, non-qualified stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. The Company’s employees, officers, directors, consultants and advisors are eligible to receive awards under the 2021 Plan. The terms of awards, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2021 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company initially registered 3,352,725 shares of common stock under the 2021 Plan, pursuant to a Registration Statement on Form S-8 filed with the SEC on April 30, 2021, which was comprised of (i) 2,843,116 shares of common stock reserved for issuance under the 2021 Plan, (ii) 31,884 shares of common stock originally reserved for issuance under the 2017 Plan that became available for issuance under the 2021 Plan upon the completion of the IPO, and (iii) 477,725 shares of unvested restricted stock subject to repurchase by the Company that may become issuable under the 2021 Plan following such repurchase. The 2021 Plan also provides that an additional number of shares will be added annually to the shares authorized for issuance under the 2021 Plan on the first day of each fiscal year, beginning with the fiscal year ended December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031. The number of shares added each year will be equal to the lesser of (i) 5% of the number of outstanding common stock on such date and (ii) such amount as determined by the board of directors. Effective January 1, 2022 and 2023, 1,380,397 and 1,575,753 additional shares, respectively, were automatically added to the shares reserved for issuance under the 2021 Plan pursuant to this evergreen provision.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there were 1,017,062 shares available for future issuance under the 2021 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, the board of directors adopted and the Company’s stockholders approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective immediately prior to the effectiveness of the IPO. The Company initially reserved 244,000 shares of common stock for future issuance under the 2021 ESPP. The 2021 ESPP provides that an additional number of shares will automatically be added to the shares reserved for issuance on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing for each fiscal year until, and including, the fiscal year ending on December 31, 2032. The number of shares added each year will be equal to the lowest of (i) 488,000 shares of common stock, (ii) 1% of the number of shares of outstanding common stock on such date, and (iii) such amount as determined by the board of directors. Effective January 1, 2023, 315,150 additional shares were automatically added to the shares reserved for issuance under the 2021 ESPP pursuant to the evergreen provision. The Company initiated its first offering period under the 2021 ESPP in December 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2021 ESPP provides that eligible employees may contribute up to 15% of their eligible earnings toward the semi-annual purchase of the Company’s common stock. The 2021 ESPP is qualified under Section 423 of the Internal Revenue Code. The employee’s purchase price is derived from a formula based on the closing price of the common stock on the first day of the offering period versus the closing price on the last date of purchase (or, if not a trading day, on the immediately preceding trading day). The offering period under the 2021 ESPP has a duration of six months, and the purchase price with respect to each offering period beginning on or after such date is, until otherwise amended, equal to 85% of the lesser of (i) the fair market value of the Company’s common stock at the commencement of the applicable six-month offering period or (ii) the fair market value of the Company’s common stock on the purchase date. The Company estimates the fair value of the common stock under the 2021 ESPP using a Black-Scholes valuation model. The fair value was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following assumptions: risk-free interest rate (3.8%); expected term (0.5 years); expected volatility (92.7%); and an expected dividend yield (0%). The Company recorded less than $0.1 million of stock-based compensation under the 2021 ESPP for the three and six months ended June 30, 2023. As of June 30, 2023, there was unrecognized stock-based compensation expense of less than $0.1 million related to the most recent ESPP offering period, which ended May 31, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,038 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">RSA Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may, at its discretion, repurchase unvested shares of restricted stock issued pursuant to the 2017 Plan at the initial purchase price if the employees or non-employees terminate their service relationship with the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSA activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested RSAs of $0.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate fair value of RSAs that vested during the three months ended June 30, 2023 and 2022, based upon the fair values of the stock underlying the RSAs on the day of vesting, was $0.1 million and $0.3 million, respectively. The aggregate fair value of RSAs that vested during the six months ended June 30, 2023 and 2022, based upon the fair values of the stock underlying the RSAs on the day of vesting, was $0.2 million and $0.8 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has also granted RSUs to its employees under the 2021 Plan. The following table summarizes RSU activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested RSUs of $0.6 million, which the Company expects to recognize over a weighted-average period of approximately 0.7 year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No RSUs vested during the three or six months ended June 30, 2023 or 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company granted performance-based stock options to certain executive officers for the purchase of an aggregate of 883,352 shares of common stock with a grant date fair value of $3.36 per share. These stock options vest only upon achievement of specified performance targets related to certain business objectives. As of June 30, 2023, none of these options were vested because none of the specified performance targets had been achieved. Because achievement of the specified performance targets was not deemed probable as of June 30, 2023, the Company did not record any expense for these stock options from the date of issuance through June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of stock options granted during the three and six months ended June 30, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the three months ended June 30, 2023 and 2022 was $2.24 and $2.48 per share, respectively. Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the six months ended June 30, 2023 and 2022 was $1.55 and $6.25 per share, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic fair value of stock options exercised during the three months ended June 30, 2023 and 2022 was less than $0.1 million in both periods. The aggregate intrinsic fair value of stock options exercised during the six months ended June 30, 2023 and 2022 was less than $0.1 million and $0.3 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $16.9 million, which the Company expects to recognize over a weighted-average period of approximately 1.9 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034345168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties In May 2022, the Company entered into a sublease agreement with Crossbow Therapeutics, Inc. (“Crossbow”), for which entities affiliated with MPM Capital (“MPM Capital”) are also beneficial owners, to sublease the entirety of its office and laboratory space in Cambridge, Massachusetts. Luke Evnin, Ph.D., the chair of the Company’s board of directors, co-founded MPM Capital and serves as Managing Director of MPM Capital. Briggs Morrison, who serves on the Company’s board of directors, serves as Executive Partner of MPM Capital and Chief Executive Officer of Crossbow. The term of the sublease agreement commenced in June 2022 and ends in March 2024, with no option to extend. The Company received cash payments under its sublease of approximately $0.8 million during the six months ended June 30, 2023. In addition, the Company received $0.2 million from Crossbow in June 2022 as a security deposit that is included within “Accrued expenses and other current liabilities” in the accompanying condensed consolidated balance sheets as of June 30, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034347600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Attributable to Common Stockholders per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Attributable to Common Stockholders per Share</a></td>
<td class="text">Net Loss Attributable to Common Stockholders per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For purposes of the diluted net loss attributable to common stockholders per share calculation, outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, however the following weighted-average amounts were excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916023764512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of June 30, 2023 and December 31, 2022, and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States of America (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments which are necessary for a fair presentation of the Company’s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC (the “Annual Report”).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and the fair value of the success payment liability. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events and transactions that occurred in the period from the balance sheet date to the date that the financial statements were issued. Other than as described in these condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034347600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Jazz Collaboration and License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Contract Asset, Contract Liability, and Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the six months ended June 30, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916033068816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June 30, 2023 were as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the success payment liability during the six months ended June 30, 2023 based on Level 3 inputs (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment at Success Event</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034341440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text">At June 30, 2023, $0.2 million of the Company’s restricted cash balance was included within “Prepaid expenses and other current assets” in the accompanying condensed consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,529 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034351024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June 30, 2023 and December 31, 2022 were comprised as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,501</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,990</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,135</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,940</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,152</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031921936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outstanding notes payable balance under the Term Loans as of June 30, 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916034345168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Common Stock Reserved for Issuance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">939</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,809</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030087024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expense Recognized</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,038 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted Stock Awards Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSA activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes RSU activity during the six months ended June 30, 2023 (in thousands, except per share amounts): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted -average Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of stock options granted during the three and six months ended June 30, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916033046384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Attributable to Common Stockholders per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of (Loss) Income per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For purposes of the diluted net loss attributable to common stockholders per share calculation, outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, however the following weighted-average amounts were excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031477984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 137,452<span></span>
</td>
<td class="nump">$ 129,315<span></span>
</td>
<td class="nump">$ 145,712<span></span>
</td>
<td class="nump">$ 157,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916027195952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Jazz Collaboration and License Agreement - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,081<span></span>
</td>
<td class="nump">$ 4,148<span></span>
</td>
<td class="nump">$ 12,545<span></span>
</td>
<td class="nump">$ 4,148<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Deferred revenue, current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=howl_JazzCollaborationAgreementMember', window );">Jazz Collaboration Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_NonRefundableUpfrontCashPaymentReceived', window );">Non-refundable upfront cash payment received</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DevelopmentAndRegulatoryMilestones', window );">Development and regulatory milestones (up to)</a></td>
<td class="nump">520,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SalesBasedMilestonesUpTo', window );">Sales-based milestones (up to)</a></td>
<td class="nump">740,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">32,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_CollaborationAgreementEstimatedFutureReimbursableCosts', window );">Estimated future reimbursable costs</a></td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_CollaborationAgreementTerm', window );">Collaboration agreement, term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_CollaborationAgreementEstimatedFutureReimbursableCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Estimated Future Reimbursable Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_CollaborationAgreementEstimatedFutureReimbursableCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_NonRefundableUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Refundable Upfront Cash Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_NonRefundableUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SalesBasedMilestonesUpTo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-Based Milestones (up to)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SalesBasedMilestonesUpTo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=howl_JazzCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=howl_JazzCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916023752528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Jazz Collaboration and License Agreement - Contract with Customer, Contract Asset, Contract Liability, and Receivable (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, beginning balance</a></td>
<td class="nump">$ 7,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_IncreaseInContractWithCustomerLiability', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DecreaseInContractWithCustomerLiability', window );">Reductions</a></td>
<td class="num">(5,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, ending balance</a></td>
<td class="nump">$ 2,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease In Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_IncreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_IncreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916029543024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">152,132<span></span>
</td>
<td class="nump">128,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">152,132<span></span>
</td>
<td class="nump">128,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Price in Active Markets (Level 1) | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">152,132<span></span>
</td>
<td class="nump">128,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Price in Active Markets (Level 1) | Money market funds | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">152,132<span></span>
</td>
<td class="nump">128,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Money market funds | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Money market funds | Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916031547600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessFeeLiabilityPaid', window );">Success fee liability paid</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,030<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SuccessFeeLiabilityPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Fee Liability Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SuccessFeeLiabilityPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916023790416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Recurring<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment at Success Event</a></td>
<td class="num">(1,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Contract liabilities, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916027969760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash and Cash Equivalents - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Non-current restricted cash</a></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included in "Prepaid expenses and other current assets"</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=howl_TermLoansMember', window );">Term Loans | Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Non-current restricted cash</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=howl_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=howl_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916029542080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash and Cash Equivalents - Summary of Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 137,452<span></span>
</td>
<td class="nump">$ 129,315<span></span>
</td>
<td class="nump">$ 145,712<span></span>
</td>
<td class="nump">$ 157,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash and cash equivalents, non-current</a></td>
<td class="nump">21,015<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">$ 158,675<span></span>
</td>
<td class="nump">$ 130,529<span></span>
</td>
<td class="nump">$ 147,011<span></span>
</td>
<td class="nump">$ 158,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030624432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_AccruedManufacturingCurrent', window );">Manufacturing</a></td>
<td class="nump">$ 4,501<span></span>
</td>
<td class="nump">$ 6,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_AccruedContractResearchCurrent', window );">Contract research</a></td>
<td class="nump">2,212<span></span>
</td>
<td class="nump">2,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">3,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,940<span></span>
</td>
<td class="nump">$ 14,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_AccruedContractResearchCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Contract Research, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_AccruedContractResearchCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_AccruedManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_AccruedManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916024017488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating rate spread in effect (greater than) (percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SuccessFeeLiabilityPaid', window );">Success fee liability paid</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentConditionalFeeLiability', window );">Debt instrument, conditional fee, liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at the market offering of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,388,000<span></span>
</td>
<td class="nump">$ 3,653,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating rate spread in effect (greater than) (percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan | Period One</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee', window );">Delayed draw fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn', window );">Success Fee (percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan | Period Two</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee', window );">Delayed draw fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn', window );">Success Fee (percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan | Tranche I Loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentMaximumBorrowingCapacity', window );">Term loan available</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan | Tranche II Loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentMaximumBorrowingCapacity', window );">Term loan available</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term loan | Term Loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Drawings on term loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount', window );">Default payment fee (percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure', window );">Maximum annual capital expenditures</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at the market offering of common stock</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Unrestricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentConditionalFeeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Conditional Fee, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentConditionalFeeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Conditional Fee, Percentage Of Amount Drawn</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Maximum Annual Capital Expenditure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default or Late Payment Fee, Percent of Unpaid Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SuccessFeeLiabilityPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Fee Liability Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SuccessFeeLiabilityPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment fees for the unused borrowing capacity under the long-term financing arrangement that is available to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentCovenantPeriodAxis=howl_DebtInstrumentCovenantPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentCovenantPeriodAxis=howl_DebtInstrumentCovenantPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_DebtInstrumentCovenantPeriodAxis=howl_DebtInstrumentCovenantPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_DebtInstrumentCovenantPeriodAxis=howl_DebtInstrumentCovenantPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=howl_TrancheILoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=howl_TrancheILoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=howl_TrancheIILoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=howl_TrancheIILoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=howl_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=howl_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916033431040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Schedule of Long-Term Debt Instruments (Details) - Term Loans - Term loan<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 39,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=howl_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=howl_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916028702528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at the market offering of common stock | $</a></td>
<td class="nump">$ 9,388,000<span></span>
</td>
<td class="nump">$ 3,653,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=howl_ATMOfferingMember', window );">ATM Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_SalesCommissionsPercentage', window );">Sales commissions, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from at the market offering, net of issuance costs (shares)</a></td>
<td class="nump">7,923,848<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at the market offering of common stock | $</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ATM Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_CommonStockAmountAuthorized', window );">Common stock, amount authorized | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_CommonStockAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_CommonStockAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_SalesCommissionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Commissions, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_SalesCommissionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=howl_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=howl_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916023778896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common and Preferred Stock - Schedule of Common Stock Reserved for Issuance (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="nump">8,669<span></span>
</td>
<td class="nump">6,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember', window );">Shares reserved for exercises of outstanding stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">5,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares reserved for vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=howl_A2021StockEmployeeStockPurchasePlanMember', window );">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember', window );">Shares reserved for future issuance under the 2021 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=howl_A2021StockEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=howl_A2021StockEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916023026736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,669,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,669,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,809,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation (less than) | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,038<span></span>
</td>
<td class="nump">$ 3,523<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based compensation expense not yet recognized (less than) | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of awards (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic fair value of options exercised | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested RSAs | 2017 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based compensation expense not yet recognized, excluding option | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of awards that vested | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Granted (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Shares reserved for vesting of restricted stock units | 2021 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based compensation expense not yet recognized, excluding option | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation not yet recognized, recognition period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Granted (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">883,352<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Granted (in usd per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.36<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Shares reserved for future issuance under the 2021 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">82.60%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">77.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82.60%<span></span>
</td>
<td class="nump">76.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation not yet recognized, recognition period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=howl_A2021StockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum number of shares to be added annually, as a percentage of outstanding shares (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=howl_A2021StockIncentivePlanMember', window );">2021 Stock Incentive Plan | Unvested RSAs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized to be issued (shares)</a></td>
<td class="nump">477,725<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=howl_A2017StockIncentivePlanMember', window );">2017 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for issuance (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,017,062<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,017,062<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=howl_A2021StockEmployeeStockPurchasePlanMember', window );">2021 Stock Employee Stock Purchase Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual contributions per employee, percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_EmployeeStockOwnershipPlanOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_howl_EmployeeStockOwnershipPlanPurchasePricePercent', window );">Employee stock ownership plan, purchase price, percent</a></td>
<td class="nump">0.85<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.70%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation (less than) | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based compensation expense not yet recognized (less than) | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=howl_A2021StockEmployeeStockPurchasePlanMember', window );">2021 Stock Employee Stock Purchase Plan | Employee stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized to be issued (shares)</a></td>
<td class="nump">244,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">315,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum number of shares to be added annually, as a percentage of outstanding shares (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=howl_A2021StockEmployeeStockPurchasePlanMember', window );">2021 Stock Employee Stock Purchase Plan | Employee stock | Minimum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Maximum number of shares to be added annually, as a percentage of outstanding shares (shares)</a></td>
<td class="nump">488,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized to be issued (shares)</a></td>
<td class="nump">3,352,725<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2021 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized to be issued (shares)</a></td>
<td class="nump">2,843,116<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,575,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,380,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2017 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized to be issued (shares)</a></td>
<td class="nump">31,884<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_EmployeeStockOwnershipPlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Ownership Plan, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_EmployeeStockOwnershipPlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_howl_EmployeeStockOwnershipPlanPurchasePricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Ownership Plan, Purchase Price, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">howl_EmployeeStockOwnershipPlanPurchasePricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>howl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2017StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2017StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2021StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2021StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=howl_A2021StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=howl_A2021StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=howl_A2017StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=howl_A2017StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=howl_A2021StockEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=howl_A2021StockEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916027956416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Expense Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,930<span></span>
</td>
<td class="nump">$ 1,777<span></span>
</td>
<td class="nump">$ 4,038<span></span>
</td>
<td class="nump">$ 3,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 1,999<span></span>
</td>
<td class="nump">$ 1,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916023001344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Award Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested RSAs | 2017 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares/Units</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(81,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Unvested at beginning of period (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Granted (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Vested (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Forfeited (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Unvested at end of period (in usd per share)</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs | 2021 Stock Incentive Plan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares/Units</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">323,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (shares)</a></td>
<td class="nump">317,000<span></span>
</td>
<td class="nump">317,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Unvested at beginning of period (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Granted (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Vested (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Forfeited (in usd per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value - Unvested at end of period (in usd per share)</a></td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2017StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2017StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2021StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=howl_A2021StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916029484832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted Average Assumptions (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.60%<span></span>
</td>
<td class="nump">77.50%<span></span>
</td>
<td class="nump">82.60%<span></span>
</td>
<td class="nump">76.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030049200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details) - Stock options<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (shares) | shares</a></td>
<td class="nump">5,244<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares) | shares</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares) | shares</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (shares) | shares</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (shares) | shares</a></td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">5,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (shares) | shares</a></td>
<td class="nump">2,457<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price - Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 7.86<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price - Granted (in usd per share) | $ / shares</a></td>
<td class="nump">2.14<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price - Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">2.05<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price - Cancelled (in usd per share) | $ / shares</a></td>
<td class="nump">9.06<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price - Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">6.53<span></span>
</td>
<td class="nump">$ 7.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price - Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 7.58<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining
Contractual Life
(in years)</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life - Outstanding</a></td>
<td class="text">8 years 4 months 13 days<span></span>
</td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life - Exercisable</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916033406848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Security deposit liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139916030559920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Attributable to Common Stockholders per Share - Antidilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (shares)</a></td>
<td class="nump">7,122,000<span></span>
</td>
<td class="nump">4,856,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (shares)</a></td>
<td class="nump">6,746,000<span></span>
</td>
<td class="nump">4,383,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested RSAs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (shares)</a></td>
<td class="nump">317,000<span></span>
</td>
<td class="nump">236,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (shares)</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>howl-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
xml:lang="en-US"
xmlns="http://www.xbrl.org/2003/instance"
xmlns:dei="http://xbrl.sec.gov/dei/2023"
xmlns:howl="http://werewolftx.com/20230630"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:srt="http://fasb.org/srt/2023"
xmlns:us-gaap="http://fasb.org/us-gaap/2023"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="howl-20230630.xsd" xlink:type="simple"/>
<context id="c-1">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-2">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2023-08-04</instant>
</period>
</context>
<context id="c-3">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-4">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-5">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-6">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-7">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-8">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-9">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-10">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-11">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-03-31</endDate>
</period>
</context>
<context id="c-12">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-03-31</endDate>
</period>
</context>
<context id="c-13">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-03-31</endDate>
</period>
</context>
<context id="c-14">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-03-31</endDate>
</period>
</context>
<context id="c-15">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-03-31</instant>
</period>
</context>
<context id="c-16">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-03-31</instant>
</period>
</context>
<context id="c-17">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-03-31</instant>
</period>
</context>
<context id="c-18">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2023-03-31</instant>
</period>
</context>
<context id="c-19">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-20">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-21">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-22">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-23">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-24">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-25">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="c-26">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="c-27">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="c-28">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="c-29">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="c-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="c-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="c-32">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="c-33">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="c-34">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="c-35">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="c-36">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="c-37">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-38">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-39">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-40">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="c-41">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="c-42">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="c-43">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="c-44">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">howl:JazzCollaborationAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-04-30</endDate>
</period>
</context>
<context id="c-45">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-46">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-47">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-48">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-49">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-50">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-51">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-52">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-53">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-54">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-55">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-56">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-57">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-58">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-59">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-60">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-61">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-62">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-63">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-64">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TrancheILoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-04-30</instant>
</period>
</context>
<context id="c-65">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TrancheIILoanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-04-30</instant>
</period>
</context>
<context id="c-66">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-67">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-04-30</endDate>
</period>
</context>
<context id="c-68">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-04-30</endDate>
</period>
</context>
<context id="c-69">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-70">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-71">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-72">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-73">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodOneMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-04-30</endDate>
</period>
</context>
<context id="c-74">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodOneMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-04-30</instant>
</period>
</context>
<context id="c-75">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodTwoMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-04-30</endDate>
</period>
</context>
<context id="c-76">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="howl:DebtInstrumentCovenantPeriodAxis">howl:DebtInstrumentCovenantPeriodTwoMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-04-30</instant>
</period>
</context>
<context id="c-77">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-04-30</instant>
</period>
</context>
<context id="c-78">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">howl:TermLoansMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-17</startDate>
<endDate>2023-04-17</endDate>
</period>
</context>
<context id="c-79">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
</entity>
<period>
<startDate>2023-04-17</startDate>
<endDate>2023-04-17</endDate>
</period>
</context>
<context id="c-80">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-05-10</instant>
</period>
</context>
<context id="c-81">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-05-10</instant>
</period>
</context>
<context id="c-82">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-83">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">howl:ATMOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-84">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-85">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-86">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-87">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-88">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-89">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-90">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-91">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-92">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-93">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-94">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-04-30</instant>
</period>
</context>
<context id="c-95">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-04-30</instant>
</period>
</context>
<context id="c-96">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-04-30</instant>
</period>
</context>
<context id="c-97">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-04-30</instant>
</period>
</context>
<context id="c-98">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-04-30</endDate>
</period>
</context>
<context id="c-99">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-01-01</instant>
</period>
</context>
<context id="c-100">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-01-01</instant>
</period>
</context>
<context id="c-101">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-102">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-04-30</instant>
</period>
</context>
<context id="c-103">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-04-30</endDate>
</period>
</context>
<context id="c-104">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-04-30</endDate>
</period>
</context>
<context id="c-105">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-01-01</instant>
</period>
</context>
<context id="c-106">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-04-30</endDate>
</period>
</context>
<context id="c-107">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-04-30</instant>
</period>
</context>
<context id="c-108">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-109">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-110">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">howl:A2021StockEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-111">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-112">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-113">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-114">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-115">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-116">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-117">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-118">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-119">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-120">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-121">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-122">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-123">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-124">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2017StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-125">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-126">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-127">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-128">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">howl:A2021StockIncentivePlanMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-129">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-07-01</startDate>
<endDate>2022-09-30</endDate>
</period>
</context>
<context id="c-130">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-131">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-04-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-132">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-133">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-134">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-135">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-12-31</instant>
</period>
</context>
<context id="c-136">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-12-31</endDate>
</period>
</context>
<context id="c-137">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2023-06-30</instant>
</period>
</context>
<context id="c-138">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-139">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-140">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-141">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-142">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-143">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="c-144">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2023-01-01</startDate>
<endDate>2023-06-30</endDate>
</period>
</context>
<context id="c-145">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001785530</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<unit id="shares">
<measure>shares</measure>
</unit>
<unit id="usd">
<measure>iso4217:USD</measure>
</unit>
<unit id="usdPerShare">
<divide>
<unitNumerator>
<measure>iso4217:USD</measure>
</unitNumerator>
<unitDenominator>
<measure>shares</measure>
</unitDenominator>
</divide>
</unit>
<unit id="number">
<measure>pure</measure>
</unit>
<dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001785530</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2023</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q2</dei:DocumentFiscalPeriodFocus>
<dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
<dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
<dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="c-1" id="f-5">001-40366</dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="c-1" id="f-6">WEREWOLF THERAPEUTICS, INC.</dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">82-3523180</dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">200 Talcott Ave</dei:EntityAddressAddressLine1>
<dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">2nd Floor</dei:EntityAddressAddressLine2>
<dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Watertown</dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MA</dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">02472</dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="c-1" id="f-14">617</dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="c-1" id="f-15">952‑0555</dei:LocalPhoneNumber>
<dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
<dei:TradingSymbol contextRef="c-1" id="f-17">HOWL</dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
<dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
<dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">true</dei:EntityExTransitionPeriod>
<dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
<dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="0" id="f-26" unitRef="shares">35658050</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">137452000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">129315000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">3020000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">3957000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:OtherReceivablesNetCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">6927000</us-gaap:OtherReceivablesNetCurrent>
<us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">6928000</us-gaap:OtherReceivablesNetCurrent>
<us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">147399000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">140200000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">8381000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">8988000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">21015000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">1214000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">7788000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">8463000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">652000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">1380000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">185235000</us-gaap:Assets>
<us-gaap:Assets contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">160245000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">1490000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">1221000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">9940000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">14152000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">1970000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">2084000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">1606000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">6532000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">15006000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">23989000</us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">11705000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">12600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">783000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">1128000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:LongTermNotesPayable contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">39142000</us-gaap:LongTermNotesPayable>
<us-gaap:LongTermNotesPayable contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">0</us-gaap:LongTermNotesPayable>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">191000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">66636000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">37908000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-70" unitRef="usd" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-71" unitRef="usd" xsi:nil="true"/>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="c-4"
decimals="INF"
id="f-72"
unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="c-3"
decimals="INF"
id="f-73"
unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-74" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-75" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-76" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-77" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-78" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="c-4"
decimals="INF"
id="f-82"
unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="c-3"
decimals="INF"
id="f-83"
unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-3" id="f-84" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-85" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-86" unitRef="shares">35642000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-87" unitRef="shares">31515000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-88" unitRef="shares">35642000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-89" unitRef="shares">31434000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">3000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">3000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">442381000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">429039000</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">-323785000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">-306705000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">118599000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">122337000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-98" unitRef="usd">185235000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">160245000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">8081000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
<us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">4148000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
<us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">12545000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
<us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">4148000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
<us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">9583000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">13887000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">21289000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-107" unitRef="usd">24832000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">4565000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">5233000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">9546000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-111" unitRef="usd">9654000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">14148000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">19120000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">30835000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">34486000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">-6067000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">-14972000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">-18290000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-119" unitRef="usd">-30338000</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">-25000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">281000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-1131000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">265000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-124" unitRef="usd">994000</us-gaap:InvestmentIncomeNet>
<us-gaap:InvestmentIncomeNet contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">97000</us-gaap:InvestmentIncomeNet>
<us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">2341000</us-gaap:InvestmentIncomeNet>
<us-gaap:InvestmentIncomeNet contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">136000</us-gaap:InvestmentIncomeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">969000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">378000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">1210000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-131" unitRef="usd">401000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">-5098000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">-14594000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-17080000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">-29937000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareDiluted
contextRef="c-5"
decimals="2"
id="f-136"
unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="c-5"
decimals="2"
id="f-137"
unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="c-6"
decimals="2"
id="f-138"
unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="c-6"
decimals="2"
id="f-139"
unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="c-1"
decimals="2"
id="f-140"
unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="c-1"
decimals="2"
id="f-141"
unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="c-7"
decimals="2"
id="f-142"
unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="c-7"
decimals="2"
id="f-143"
unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-144" unitRef="shares">35558000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-145" unitRef="shares">35558000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-146" unitRef="shares">27517000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-147" unitRef="shares">27517000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-148" unitRef="shares">35173000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-149" unitRef="shares">35173000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-150" unitRef="shares">27455000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-151" unitRef="shares">27455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding contextRef="c-8" decimals="-3" id="f-152" unitRef="shares">31515000</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-153" unitRef="usd">3000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-154" unitRef="usd">429039000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-155" unitRef="usd">-306705000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-156" unitRef="usd">122337000</us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">103000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-12" decimals="-3" id="f-158" unitRef="shares">3824000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-159" unitRef="usd">8610000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="-3" id="f-160" unitRef="usd">8610000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-161" unitRef="usd">2108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-162" unitRef="usd">2108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-163" unitRef="usd">-11982000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-164" unitRef="usd">-11982000</us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="c-15" decimals="-3" id="f-165" unitRef="shares">35339000</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-166" unitRef="usd">3000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-167" unitRef="usd">439757000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-168" unitRef="usd">-318687000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-169" unitRef="usd">121073000</us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-5" decimals="-3" id="f-170" unitRef="usd">31000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-19" decimals="-3" id="f-171" unitRef="shares">272000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">644000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-173" unitRef="usd">644000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-19" decimals="-3" id="f-174" unitRef="shares">29000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-175" unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-3" id="f-176" unitRef="usd">45000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-177" unitRef="usd">1930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">1930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-19" decimals="-3" id="f-179" unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-20" decimals="-3" id="f-180" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-182" unitRef="usd">-5098000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">-5098000</us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="c-22" decimals="-3" id="f-184" unitRef="shares">35642000</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-185" unitRef="usd">3000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-186" unitRef="usd">442381000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-187" unitRef="usd">-323785000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-188" unitRef="usd">118599000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="c-25" decimals="-3" id="f-189" unitRef="shares">27608000</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-190" unitRef="usd">2000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-191" unitRef="usd">405680000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-192" unitRef="usd">-252895000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-193" unitRef="usd">152787000</us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-3" id="f-194" unitRef="usd">1745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-195" unitRef="usd">1745000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-31" decimals="-3" id="f-196" unitRef="shares">46000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-3" id="f-197" unitRef="usd">129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-198" unitRef="usd">129000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-199" unitRef="usd">-15343000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-200" unitRef="usd">-15343000</us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="c-33" decimals="-3" id="f-201" unitRef="shares">27654000</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-202" unitRef="usd">2000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-203" unitRef="usd">407554000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-204" unitRef="usd">-268238000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-205" unitRef="usd">139318000</us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-6" decimals="-3" id="f-206" unitRef="usd">314000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-37" decimals="-3" id="f-207" unitRef="shares">801000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-3" id="f-208" unitRef="usd">3339000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-6" decimals="-3" id="f-209" unitRef="usd">3339000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-3" id="f-210" unitRef="usd">1777000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-211" unitRef="usd">1777000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-37" decimals="-3" id="f-212" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-38" decimals="-3" id="f-213" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-214" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:NetIncomeLoss contextRef="c-39" decimals="-3" id="f-215" unitRef="usd">-14594000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-216" unitRef="usd">-14594000</us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="c-40" decimals="-3" id="f-217" unitRef="shares">28456000</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-218" unitRef="usd">2000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-219" unitRef="usd">412671000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-220" unitRef="usd">-282832000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-221" unitRef="usd">129841000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">-17080000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-223" unitRef="usd">-29937000</us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">4038000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-225" unitRef="usd">3522000</us-gaap:ShareBasedCompensation>
<us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">859000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-227" unitRef="usd">283000</us-gaap:Depreciation>
<howl:NonCashInterestExpense contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">92000</howl:NonCashInterestExpense>
<howl:NonCashInterestExpense contextRef="c-7" decimals="-3" id="f-229" unitRef="usd">0</howl:NonCashInterestExpense>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">675000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-231" unitRef="usd">961000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-1030000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="c-7" decimals="-3" id="f-233" unitRef="usd">262000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">60000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="c-7" decimals="-3" id="f-235" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">-863000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-237" unitRef="usd">2726000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-7" decimals="-3" id="f-239" unitRef="usd">2220000</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-7" decimals="-3" id="f-241" unitRef="usd">1206000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">345000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-7" decimals="-3" id="f-243" unitRef="usd">132000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">-3171000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-245" unitRef="usd">3528000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">-5271000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-247" unitRef="usd">13071000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<howl:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">-1009000</howl:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
<howl:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset contextRef="c-7" decimals="-3" id="f-249" unitRef="usd">-115000</howl:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">-191000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-251" unitRef="usd">191000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">-20819000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-253" unitRef="usd">-14254000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">350000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-255" unitRef="usd">1139000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">-350000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-257" unitRef="usd">-1139000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">9388000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-259" unitRef="usd">3653000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">40000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c-7" decimals="-3" id="f-261" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">123000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-3" id="f-263" unitRef="usd">239000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">45000</us-gaap:ProceedsFromStockPlans>
<us-gaap:ProceedsFromStockPlans contextRef="c-7" decimals="-3" id="f-265" unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-267" unitRef="usd">160000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">49315000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-269" unitRef="usd">3574000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">28146000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-271" unitRef="usd">-11819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-272" unitRef="usd">130529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-3" id="f-273" unitRef="usd">158830000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-274" unitRef="usd">158675000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-43" decimals="-3" id="f-275" unitRef="usd">147011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">13000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-277" unitRef="usd">1881000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<howl:StockIssuanceCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">15000</howl:StockIssuanceCostsIncurredButNotYetPaid>
<howl:StockIssuanceCostsIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-279" unitRef="usd">75000</howl:StockIssuanceCostsIncurredButNotYetPaid>
<us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">742000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:InterestPaidNet>
<howl:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">0</howl:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets>
<howl:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets contextRef="c-7" decimals="-3" id="f-283" unitRef="usd">-30000</howl:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-284">Nature of Business <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Werewolf Therapeutics, Inc. (“Werewolf” or the “Company”) was incorporated in the state of Delaware in October 2017. The Company is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The Company’s headquarters are located in Watertown, Massachusetts. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, raising capital and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had cash and cash equivalents of $137.5 million at June 30, 2023. The Company expects that its cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements for at least twelve months from the filing date of this Quarterly Report. However, additional funding will be necessary beyond this point to fund future preclinical and clinical activities. The Company expects to finance its future cash needs through a combination of equity or debt financings, collaboration agreements, strategic alliances and licensing arrangements.</span></div></us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-285" unitRef="usd">137500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-286">Summary of Significant Accounting Policies <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of June 30, 2023 and December 31, 2022, and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States of America (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments which are necessary for a fair presentation of the Company’s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC (the “Annual Report”).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information presented in the condensed consolidated financial statements and related notes as of June 30, 2023, and for the three and six months ended June 30, 2023 and 2022, is unaudited. The December 31, 2022 condensed consolidated balance sheet included herein was derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interim results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any future period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Werewolf Therapeutics, Inc. and its wholly owned subsidiary, Werewolf Therapeutics Mass Securities, Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The significant accounting policies and estimates used in the preparation of the condensed consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Annual Report. There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and the fair value of the success payment liability. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events and transactions that occurred in the period from the balance sheet date to the date that the financial statements were issued. Other than as described in these condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial statements.</span></div></us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-287"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of June 30, 2023 and December 31, 2022, and for the three and six months ended June 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and generally accepted accounting principles in the United States of America (“GAAP”) as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”) for condensed consolidated financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all normal recurring adjustments which are necessary for a fair presentation of the Company’s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC (the “Annual Report”).</span></div></us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="c-1" id="f-288"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and the fair value of the success payment liability. Actual results could differ from those estimates.</span></div></us-gaap:UseOfEstimates>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-289"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.</span></div></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="c-1" id="f-290"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events and transactions that occurred in the period from the balance sheet date to the date that the financial statements were issued. Other than as described in these condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the financial statements.</span></div></us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-291">Jazz Collaboration and License Agreement<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company entered into an exclusive global collaboration and license agreement (the “Collaboration Agreement”) with Jazz Pharmaceuticals Ireland Limited (“Jazz”) pursuant to which the Company granted Jazz certain licenses to develop and commercialize products containing the Company’s Interferon alpha (“IFNα”) INDUKINE™ molecule, JZP898 (formerly WTX-613), as well as products containing certain isolated recombinant polypeptides comprising IFNα that meet specified criteria (each such product, a “Licensed Product”). Under the Collaboration Agreement, the Company is responsible for certain pre-clinical development activities with respect to JZP898 and other development activities specified in mutually agreed upon development plans. Jazz will generally reimburse the Company for the cost of such activities. Jazz will be responsible for all other development and commercialization activities conducted to exploit the Licensed Products, including submission of an investigational new drug application (“IND”) to the U.S. Food and Drug Administration (the “FDA”). Jazz received IND application clearance for JZP898 in July 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Collaboration Agreement, the Company received a non-refundable upfront cash payment of $15.0 million in April 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Milestones and Royalties</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $520.0 million in development and regulatory milestones, and up to $740.0 million in sales-based milestones for all Licensed Products. In addition, the Company is eligible to receive tiered mid-single digit royalties based on Jazz’s, and any of its affiliates’ and sublicensees’ annual net sales of Licensed Products, subject to reduction in specified circumstances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis under ASC 606</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Identification of the Contract(s)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company assessed the Collaboration Agreement and concluded that it represents a contract with a customer within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Identification of Promises and Performance Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has concluded that the exclusive license to its intellectual property, JZP898, and the non-exclusive corresponding “know-how” are not capable of being distinct from the other promises within the contract, and as such, the Company has determined that the license and “know-how” combined with the other research and development services and supply represent a single combined performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Determination of Transaction Price</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The overall transaction price as of the inception of the contract was determined to be $32.3 million, which is comprised of the nonrefundable upfront payment of $15.0 million and the estimated costs for research services of $17.3 million. Outside of the estimated costs for research services, there is no other variable consideration included in the transaction price at inception. The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential development and regulatory milestone payment under this agreement is zero, as achievement of those milestones is uncertain and highly susceptible to factors outside the Company’s control. Accordingly, all such milestone payments were excluded from the transaction price. Management will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, will adjust the transaction price as necessary. Sales based royalties, including milestones based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate. The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The upfront payment of $15.0 million was recorded as deferred revenue and, along with payments related to the Company’s conduct of research services under the Collaboration Agreement, will be recognized as revenue over approximately 3.7 years using an input-based measurement of actual costs incurred as a percentage of the estimated total costs expected to be incurred over the expected term of conduct of the research services. Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">e Company believes this input-based method to recognize revenue best reflects the transfer of value to Jazz.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recognition of Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, using the cost-to-cost input method, which best depicts the research services performed for the customer, the Company recognized $12.5 million of revenue related to the Collaboration Agreement. As of June 30, 2023, there is $1.6 million and $0.8 million of current and long-term deferred revenue, respectively, related to the Collaboration Agreement. All costs associated with the Collaboration Agreement are recorded in research and development expense in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">“Unbilled receivables” of $5.2 million and $4.1 million was included within “Other receivables” in the accompanying condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the six months ended June 30, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company had not received any milestone or royalty payments under the Collaboration Agreement.</span></div></us-gaap:CollaborativeArrangementDisclosureTextBlock>
<howl:NonRefundableUpfrontCashPaymentReceived contextRef="c-44" decimals="-5" id="f-292" unitRef="usd">15000000</howl:NonRefundableUpfrontCashPaymentReceived>
<howl:DevelopmentAndRegulatoryMilestones contextRef="c-44" decimals="-5" id="f-293" unitRef="usd">520000000</howl:DevelopmentAndRegulatoryMilestones>
<howl:SalesBasedMilestonesUpTo contextRef="c-44" decimals="-5" id="f-294" unitRef="usd">740000000</howl:SalesBasedMilestonesUpTo>
<howl:CollaborativeAgreementTransactionPrice contextRef="c-44" decimals="-5" id="f-295" unitRef="usd">32300000</howl:CollaborativeAgreementTransactionPrice>
<howl:NonRefundableUpfrontCashPaymentReceived contextRef="c-44" decimals="-5" id="f-296" unitRef="usd">15000000</howl:NonRefundableUpfrontCashPaymentReceived>
<howl:CollaborationAgreementEstimatedFutureReimbursableCosts contextRef="c-44" decimals="-5" id="f-297" unitRef="usd">17300000</howl:CollaborationAgreementEstimatedFutureReimbursableCosts>
<howl:NonRefundableUpfrontCashPaymentReceived contextRef="c-44" decimals="-5" id="f-298" unitRef="usd">15000000</howl:NonRefundableUpfrontCashPaymentReceived>
<howl:CollaborationAgreementTerm contextRef="c-44" id="f-299">P3Y8M12D</howl:CollaborationAgreementTerm>
<us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-5" id="f-300" unitRef="usd">12500000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
<us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-5" id="f-301" unitRef="usd">1600000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-5" id="f-302" unitRef="usd">800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:UnbilledReceivablesCurrent contextRef="c-3" decimals="-5" id="f-303" unitRef="usd">5200000</us-gaap:UnbilledReceivablesCurrent>
<us-gaap:UnbilledReceivablesCurrent contextRef="c-4" decimals="-5" id="f-304" unitRef="usd">4100000</us-gaap:UnbilledReceivablesCurrent>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-305"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the six months ended June 30, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Totals</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-306" unitRef="usd">7660000</us-gaap:ContractWithCustomerLiability>
<howl:IncreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">0</howl:IncreaseInContractWithCustomerLiability>
<howl:DecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">5271000</howl:DecreaseInContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-309" unitRef="usd">2389000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-310" unitRef="usd">7660000</us-gaap:ContractWithCustomerLiability>
<howl:IncreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">0</howl:IncreaseInContractWithCustomerLiability>
<howl:DecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">5271000</howl:DecreaseInContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-313" unitRef="usd">2389000</us-gaap:ContractWithCustomerLiability>
<us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-314">Financial Instruments and Fair Value Measurements <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is determined based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect certain market assumptions. As a basis for considering such assumptions, GAAP establishes a three-tier value hierarchy, which prioritizes the inputs used to develop the assumptions and for measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets; (Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds, classified as cash, cash equivalents and restricted cash and cash equivalents on the Company’s condensed consolidated balance sheets, and a success payment liability pursuant to an amended and restated loan and security agreement (the “Loan Agreement”) with Pacific Western Bank (“PWB”) (see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June 30, 2023 were as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The success payment liability was included within “Accrued expenses and other current liabilities” in the accompanying condensed consolidated balance sheets as of December 31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in valuation techniques during the three or six months ended June 30, 2023. There were no liabilities measured at fair value on a recurring basis as of June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Success Payment Liability</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was obligated to pay to PWB a one-time success payment of up to $1.6 million upon the occurrence of the Company achieving certain conditions defined in the Loan Agreement. The Success Fee Event (as defined in the Loan Agreement) occurred during the second quarter of 2023, resulting in the immediate payment in full of the required Success Fee (as defined in Note 7 below).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the success payment liability during the six months ended June 30, 2023 based on Level 3 inputs (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment at Success Event</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The success payment liability is stated at fair value and was previously considered Level 3 because its fair value measurement was based, in part, on significant inputs not observed in the market. Upon completion of the Success Fee Event, the Company removed the corresponding financial instrument for the success fee liability and paid the total $1.6 million. Prior to repayment, the Company remeasured the liability at fair value with a corresponding increase of $1.0 million recorded to other expense, net for the six months ended June 30, 2023.</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-315"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of June 30, 2023 were as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Price in <br/>Active Markets <br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inputs (Level 3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,812 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-45" decimals="-3" id="f-316" unitRef="usd">152132000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-46" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-47" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-48" decimals="-3" id="f-319" unitRef="usd">152132000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-49" decimals="-3" id="f-320" unitRef="usd">152132000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-50" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-51" decimals="-3" id="f-322" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-52" decimals="-3" id="f-323" unitRef="usd">152132000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-53" decimals="-3" id="f-324" unitRef="usd">128812000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-54" decimals="-3" id="f-325" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-326" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-327" unitRef="usd">128812000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-328" unitRef="usd">128812000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-331" unitRef="usd">128812000</us-gaap:AssetsFairValueDisclosure>
<howl:SuccessPaymentLiability contextRef="c-57" decimals="-3" id="f-332" unitRef="usd">0</howl:SuccessPaymentLiability>
<howl:SuccessPaymentLiability contextRef="c-58" decimals="-3" id="f-333" unitRef="usd">0</howl:SuccessPaymentLiability>
<howl:SuccessPaymentLiability contextRef="c-59" decimals="-3" id="f-334" unitRef="usd">570000</howl:SuccessPaymentLiability>
<howl:SuccessPaymentLiability contextRef="c-60" decimals="-3" id="f-335" unitRef="usd">570000</howl:SuccessPaymentLiability>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-57" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-58" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-59" decimals="-3" id="f-338" unitRef="usd">570000</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-60" decimals="-3" id="f-339" unitRef="usd">570000</us-gaap:OtherLiabilitiesFairValueDisclosure>
<howl:SuccessPaymentLiability contextRef="c-61" decimals="-5" id="f-340" unitRef="usd">1600000</howl:SuccessPaymentLiability>
<us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-341"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles the change in fair value of the success payment liability during the six months ended June 30, 2023 based on Level 3 inputs (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment at Success Event</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-59" decimals="-3" id="f-342" unitRef="usd">570000</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-62" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="c-62" decimals="-3" id="f-344" unitRef="usd">1030000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-62" decimals="-3" id="f-345" unitRef="usd">1600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-51" decimals="-3" id="f-346" unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
<howl:SuccessFeeLiabilityPaid contextRef="c-1" decimals="-5" id="f-347" unitRef="usd">1600000</howl:SuccessFeeLiabilityPaid>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="c-62" decimals="-5" id="f-348" unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c-1" id="f-349">Restricted Cash and Cash Equivalents<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintained restricted cash and cash equivalents of $21.2 million and $1.2 million at June 30, 2023 and December 31, 2022, respectively. At June 30, 2023, $20.0 million of the restricted cash and cash equivalents balance represents an obligation under the term loan facility for the required minimum cash balance in PWB accounts. This became effective upon imminent achievement of the funding goal as required by the terms of the Loan Agreement (see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). The remaining restricted cash amounts are comprised solely of letters of credit required pursuant to the Company’s leased office spaces. At June 30, 2023, $0.2 million of the Company’s restricted cash balance was included within “Prepaid expenses and other current assets” in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,529 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
<us-gaap:RestrictedCash contextRef="c-3" decimals="-5" id="f-350" unitRef="usd">21200000</us-gaap:RestrictedCash>
<us-gaap:RestrictedCash contextRef="c-4" decimals="-5" id="f-351" unitRef="usd">1200000</us-gaap:RestrictedCash>
<us-gaap:RestrictedCash contextRef="c-63" decimals="-5" id="f-352" unitRef="usd">20000000</us-gaap:RestrictedCash>
<us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-353">At June 30, 2023, $0.2 million of the Company’s restricted cash balance was included within “Prepaid expenses and other current assets” in the accompanying condensed consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,315 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,529 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,675 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,011 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
<us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-5" id="f-354" unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">129315000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-356" unitRef="usd">137452000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-28" decimals="-3" id="f-357" unitRef="usd">157531000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-43" decimals="-3" id="f-358" unitRef="usd">145712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-360" unitRef="usd">208000</us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashCurrent contextRef="c-28" decimals="-3" id="f-361" unitRef="usd">91000</us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashCurrent contextRef="c-43" decimals="-3" id="f-362" unitRef="usd">91000</us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-363" unitRef="usd">1214000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-364" unitRef="usd">21015000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:RestrictedCashNoncurrent contextRef="c-28" decimals="-3" id="f-365" unitRef="usd">1208000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:RestrictedCashNoncurrent contextRef="c-43" decimals="-3" id="f-366" unitRef="usd">1208000</us-gaap:RestrictedCashNoncurrent>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-367" unitRef="usd">130529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-368" unitRef="usd">158675000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-3" id="f-369" unitRef="usd">158830000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-43" decimals="-3" id="f-370" unitRef="usd">147011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<howl:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-371">Accrued Expenses and Other Current Liabilities<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June 30, 2023 and December 31, 2022 were comprised as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,501</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,990</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,135</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,940</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,152</span></td></tr></table></div></howl:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-372"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities as of June 30, 2023 and December 31, 2022 were comprised as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Manufacturing</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,501</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contract research</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,990</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,135</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Success payment liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,940</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,152</span></td></tr></table></div></us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<howl:AccruedManufacturingCurrent contextRef="c-3" decimals="-3" id="f-373" unitRef="usd">4501000</howl:AccruedManufacturingCurrent>
<howl:AccruedManufacturingCurrent contextRef="c-4" decimals="-3" id="f-374" unitRef="usd">6674000</howl:AccruedManufacturingCurrent>
<howl:AccruedContractResearchCurrent contextRef="c-3" decimals="-3" id="f-375" unitRef="usd">2212000</howl:AccruedContractResearchCurrent>
<howl:AccruedContractResearchCurrent contextRef="c-4" decimals="-3" id="f-376" unitRef="usd">2990000</howl:AccruedContractResearchCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-377" unitRef="usd">2222000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-378" unitRef="usd">3135000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="-3" id="f-379" unitRef="usd">458000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-380" unitRef="usd">613000</us-gaap:AccruedProfessionalFeesCurrent>
<howl:SuccessPaymentLiability contextRef="c-3" decimals="-3" id="f-381" unitRef="usd">0</howl:SuccessPaymentLiability>
<howl:SuccessPaymentLiability contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">570000</howl:SuccessPaymentLiability>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-383" unitRef="usd">547000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-384" unitRef="usd">170000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-385" unitRef="usd">9940000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-386" unitRef="usd">14152000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-387">Term Loan <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the Company entered into the Loan Agreement with PWB. Under the terms of the Loan Agreement, PWB made available a term loan in an aggregate principal amount of up to $20.0 million (“Tranche I Loan”) available at any time after the closing date until February 28, 2024 as extended to August 31, 2024 upon the satisfaction of certain conditions set forth in the Loan Agreement (such date, the “Amortization Date”). Based on the satisfaction of certain conditions defined in the Loan Agreement, PWB was also obligated to make available an additional term loan in the aggregate principal amount of up to $20.0 million (“Tranche II Loan”, or collectively with the Tranche I Loan, the “Term Loans”) available at any time after the closing date until the Amortization Date upon the acceptance by the U.S. Food and Drug Administration (the “FDA”) of two investigational new drug (“IND”) submissions on or before March 31, 2023. As of June 30, 2023, the Company has drawn down $40.0 million of the Term Loans.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outstanding notes payable balance under the Term Loans as of June 30, 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to the interest-only period, which ends on August 31, 2024, the Company is required to make equal monthly principal payments plus interest until the Term Loans mature on August 31, 2026. The Term Loans will bear interest on the outstanding daily balance at a floating annual rate equal to greater of: (i) 0.5% above the prime rate then in effect or (ii) 4.5%. If the prime rate changes throughout the term, the interest rate will be adjusted effective on the date of the prime rate change. All interest chargeable under the Loan Agreement is computed on a 360-day year for the actual number of days elapsed, with interest payable monthly. The Company recognized interest expense related to the Loan Agreement of $0.9 million and $1.0 million during the three and six months ended June 30, 2023, respectively. The Company did not incur interest expense during the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was obligated to pay PWB a one-time fee in the event of certain corporate transactions equal to either (i) the greater of (a) $0.2 million and (b) 2.0% of the amount drawn under the Term Loans, for a transaction occurring on or before March 31, 2023, or (ii) for any transaction occurring thereafter, the greater of (a) $0.4 million and (b) 4.0% of the amount drawn under the Term Loans (the “Success Fee”). The Success Fee Event occurred during the second quarter of 2023, resulting in the immediate payment in full of the $1.6 million required Success Fee, and resulting in a total of $0.0 million as a success fee liability as of June 30, 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All outstanding obligations under the Loan Agreement are secured by the Company’s personal property (exclusive of any intellectual property) and are subject to acceleration in the event of default. In the event of a late payment or default, the Company is obligated to pay a fee equal to 5.0% of such unpaid amounts. In connection with the Loan Agreement, the Company is required to comply with certain negative covenants, which among other things, restrict the Company from (i) incurring future debt or granting liens, (ii) effectuating a merger or consolidation with or into any other business organization, (iii) paying dividends or making certain other distributions, (iv) selling or otherwise transferring its assets, (v) making investments in any entities or instruments other than certain investments specified in the Loan Agreement and (vi) making capitalized expenditures in excess of 125% of the amount provided for in the annual budget approved by the board of directors. The Loan Agreement also contains standard affirmative covenants, including with respect to the issuance of audited consolidated financial statements, insurance, and maintenance of good standing and government compliance in the Company’s state of formation. On or before September 30, 2023, the Company was required to raise aggregate gross cash process of at least $50.0 million from the sale or issuance of the Company’s equity or from strategic partnerships or any similar transaction. From after receipt of those proceeds, the Company is required to maintain at all times at least $20.0 million of otherwise unrestricted cash in accounts with PWB, which is included within “Restricted cash and cash equivalents” on our Balance Sheets. On April 17, 2023, the Company achieved the $50.0 million funding milestone, triggering the corresponding $20.0 million cash covenant, full payment of the Success Fee of $1.6 million, and the updated Amortization Date of August 31, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PWB has the right to accelerate all outstanding obligations of the Company under the Loan Agreement or terminate any remaining Term Loan commitments in the event of a material adverse effect on (i) the operations, business or financial condition of the Company, (ii) the Company’s ability to repay any portion of the Term Loans or perform any of its other obligations under the Loan Agreement, and (iii) the Company’s interest in, or the value, perfection or priority of PWB’s security interest in the collateral. As of June 30, 2023, the Company had drawn both Term Loans and had $40.0 million outstanding principal.</span></div></us-gaap:DebtDisclosureTextBlock>
<howl:DebtInstrumentMaximumBorrowingCapacity contextRef="c-64" decimals="-5" id="f-388" unitRef="usd">20000000</howl:DebtInstrumentMaximumBorrowingCapacity>
<howl:DebtInstrumentMaximumBorrowingCapacity contextRef="c-65" decimals="-5" id="f-389" unitRef="usd">20000000</howl:DebtInstrumentMaximumBorrowingCapacity>
<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-66" decimals="-5" id="f-390" unitRef="usd">40000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-391"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The outstanding notes payable balance under the Term Loans as of June 30, 2023 consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,142 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:ScheduleOfDebtInstrumentsTextBlock>
<us-gaap:DebtInstrumentCarryingAmount contextRef="c-63" decimals="-3" id="f-392" unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-63" decimals="-3" id="f-393" unitRef="usd">858000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
<us-gaap:LongTermDebt contextRef="c-63" decimals="-3" id="f-394" unitRef="usd">39142000</us-gaap:LongTermDebt>
<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-67" decimals="3" id="f-395" unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-68" decimals="3" id="f-396" unitRef="number">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
<us-gaap:InterestExpense contextRef="c-69" decimals="-5" id="f-397" unitRef="usd">900000</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="c-70" decimals="-5" id="f-398" unitRef="usd">1000000</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="c-71" decimals="INF" id="f-399" unitRef="usd">0</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="c-72" decimals="INF" id="f-400" unitRef="usd">0</us-gaap:InterestExpense>
<us-gaap:DebtInstrumentUnusedBorrowingCapacityFee contextRef="c-73" decimals="-5" id="f-401" unitRef="usd">200000</us-gaap:DebtInstrumentUnusedBorrowingCapacityFee>
<howl:DebtInstrumentConditionalFeePercentageOfAmountDrawn contextRef="c-74" decimals="3" id="f-402" unitRef="number">0.020</howl:DebtInstrumentConditionalFeePercentageOfAmountDrawn>
<us-gaap:DebtInstrumentUnusedBorrowingCapacityFee contextRef="c-75" decimals="-5" id="f-403" unitRef="usd">400000</us-gaap:DebtInstrumentUnusedBorrowingCapacityFee>
<howl:DebtInstrumentConditionalFeePercentageOfAmountDrawn contextRef="c-76" decimals="3" id="f-404" unitRef="number">0.040</howl:DebtInstrumentConditionalFeePercentageOfAmountDrawn>
<howl:SuccessFeeLiabilityPaid contextRef="c-5" decimals="-5" id="f-405" unitRef="usd">1600000</howl:SuccessFeeLiabilityPaid>
<howl:DebtInstrumentConditionalFeeLiability contextRef="c-3" decimals="-5" id="f-406" unitRef="usd">0</howl:DebtInstrumentConditionalFeeLiability>
<howl:DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount contextRef="c-77" decimals="3" id="f-407" unitRef="number">0.050</howl:DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount>
<howl:DebtInstrumentCovenantMaximumAnnualCapitalExpenditure
contextRef="c-77"
decimals="INF"
id="f-408"
unitRef="number">1.25</howl:DebtInstrumentCovenantMaximumAnnualCapitalExpenditure>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-66" decimals="-5" id="f-409" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:Cash contextRef="c-63" decimals="-5" id="f-410" unitRef="usd">20000000</us-gaap:Cash>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-78" decimals="-5" id="f-411" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:Cash contextRef="c-63" decimals="-5" id="f-412" unitRef="usd">20000000</us-gaap:Cash>
<howl:SuccessFeeLiabilityPaid contextRef="c-79" decimals="-5" id="f-413" unitRef="usd">1600000</howl:SuccessFeeLiabilityPaid>
<us-gaap:DebtInstrumentCarryingAmount contextRef="c-63" decimals="-5" id="f-414" unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-415">Common and Preferred Stock<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is authorized to issue 200.0 million shares of common stock. Common stockholders are entitled to dividends if and when declared by the Company’s board of directors. As of June 30, 2023, no dividends on common stock had been declared by the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 10, 2022, the Company entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB”), pursuant to which the Company may offer and sell shares of its common stock with an aggregate offering price of up to $50.0 million (the “ATM Offering”). The Sales Agreement provides that SVB will be entitled to a sales commission equal to 3.0% of the gross sales price per share of all shares sold under the ATM Offering. As of June 30, 2023, the Company had sold an aggregate of 7,923,848 shares under the ATM Offering at an average price of $3.33 per share for net proceeds of $25.0 million after deducting sales commissions and offering expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is authorized to issue 5.0 million shares of undesignated preferred stock in one or more series. As of June 30, 2023, no shares of preferred stock were issued or outstanding.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">939</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,809</span></td></tr></table></div></us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="-5" id="f-416" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-3" decimals="INF" id="f-417" unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
<howl:CommonStockAmountAuthorized contextRef="c-80" decimals="-5" id="f-418" unitRef="usd">50000000</howl:CommonStockAmountAuthorized>
<howl:SalesCommissionsPercentage contextRef="c-81" decimals="3" id="f-419" unitRef="number">0.030</howl:SalesCommissionsPercentage>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-82" decimals="0" id="f-420" unitRef="shares">7923848</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SaleOfStockPricePerShare
contextRef="c-83"
decimals="2"
id="f-421"
unitRef="usdPerShare">3.33</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-82" decimals="-5" id="f-422" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="-5" id="f-423" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-424" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-425" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="c-1" id="f-426"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of outstanding stock options</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for vesting of restricted stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for exercises of warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares reserved for future issuance under the 2021 Stock Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">939</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares reserved for future issuance</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,809</span></td></tr></table></div></us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-84" decimals="-3" id="f-427" unitRef="shares">6746000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-85" decimals="-3" id="f-428" unitRef="shares">5244000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-86" decimals="-3" id="f-429" unitRef="shares">317000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-87" decimals="-3" id="f-430" unitRef="shares">323000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-88" decimals="-3" id="f-431" unitRef="shares">59000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-89" decimals="-3" id="f-432" unitRef="shares">59000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-90" decimals="-3" id="f-433" unitRef="shares">530000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-91" decimals="-3" id="f-434" unitRef="shares">244000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-92" decimals="-3" id="f-435" unitRef="shares">1017000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-93" decimals="-3" id="f-436" unitRef="shares">939000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="-3" id="f-437" unitRef="shares">8669000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="-3" id="f-438" unitRef="shares">6809000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-439">Stock-based Compensation <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2017, the Company adopted the 2017 Stock Incentive Plan (the “2017 Plan”), as amended and restated, under which it could grant incentive stock options (“ISOs”), non-qualified stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and other stock-based awards to eligible employees, officers, directors and consultants. The terms of stock options and RSAs, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2017 Plan. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, the board of directors adopted and the Company’s stockholders approved the 2021 Stock Incentive Plan (the “2021 Plan”), which became effective immediately prior to the effectiveness of the Company’s initial public offering (“IPO”). As a result of the adoption of the 2021 Plan, no further awards will be made under the 2017 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2021 Plan provides for the grant of ISOs, non-qualified stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. The Company’s employees, officers, directors, consultants and advisors are eligible to receive awards under the 2021 Plan. The terms of awards, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2021 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company initially registered 3,352,725 shares of common stock under the 2021 Plan, pursuant to a Registration Statement on Form S-8 filed with the SEC on April 30, 2021, which was comprised of (i) 2,843,116 shares of common stock reserved for issuance under the 2021 Plan, (ii) 31,884 shares of common stock originally reserved for issuance under the 2017 Plan that became available for issuance under the 2021 Plan upon the completion of the IPO, and (iii) 477,725 shares of unvested restricted stock subject to repurchase by the Company that may become issuable under the 2021 Plan following such repurchase. The 2021 Plan also provides that an additional number of shares will be added annually to the shares authorized for issuance under the 2021 Plan on the first day of each fiscal year, beginning with the fiscal year ended December 31, 2022 and continuing until, and including, the fiscal year ending December 31, 2031. The number of shares added each year will be equal to the lesser of (i) 5% of the number of outstanding common stock on such date and (ii) such amount as determined by the board of directors. Effective January 1, 2022 and 2023, 1,380,397 and 1,575,753 additional shares, respectively, were automatically added to the shares reserved for issuance under the 2021 Plan pursuant to this evergreen provision.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there were 1,017,062 shares available for future issuance under the 2021 Plan.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, the board of directors adopted and the Company’s stockholders approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective immediately prior to the effectiveness of the IPO. The Company initially reserved 244,000 shares of common stock for future issuance under the 2021 ESPP. The 2021 ESPP provides that an additional number of shares will automatically be added to the shares reserved for issuance on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2022 and continuing for each fiscal year until, and including, the fiscal year ending on December 31, 2032. The number of shares added each year will be equal to the lowest of (i) 488,000 shares of common stock, (ii) 1% of the number of shares of outstanding common stock on such date, and (iii) such amount as determined by the board of directors. Effective January 1, 2023, 315,150 additional shares were automatically added to the shares reserved for issuance under the 2021 ESPP pursuant to the evergreen provision. The Company initiated its first offering period under the 2021 ESPP in December 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2021 ESPP provides that eligible employees may contribute up to 15% of their eligible earnings toward the semi-annual purchase of the Company’s common stock. The 2021 ESPP is qualified under Section 423 of the Internal Revenue Code. The employee’s purchase price is derived from a formula based on the closing price of the common stock on the first day of the offering period versus the closing price on the last date of purchase (or, if not a trading day, on the immediately preceding trading day). The offering period under the 2021 ESPP has a duration of six months, and the purchase price with respect to each offering period beginning on or after such date is, until otherwise amended, equal to 85% of the lesser of (i) the fair market value of the Company’s common stock at the commencement of the applicable six-month offering period or (ii) the fair market value of the Company’s common stock on the purchase date. The Company estimates the fair value of the common stock under the 2021 ESPP using a Black-Scholes valuation model. The fair value was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following assumptions: risk-free interest rate (3.8%); expected term (0.5 years); expected volatility (92.7%); and an expected dividend yield (0%). The Company recorded less than $0.1 million of stock-based compensation under the 2021 ESPP for the three and six months ended June 30, 2023. As of June 30, 2023, there was unrecognized stock-based compensation expense of less than $0.1 million related to the most recent ESPP offering period, which ended May 31, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,038 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">RSA Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may, at its discretion, repurchase unvested shares of restricted stock issued pursuant to the 2017 Plan at the initial purchase price if the employees or non-employees terminate their service relationship with the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSA activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested RSAs of $0.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate fair value of RSAs that vested during the three months ended June 30, 2023 and 2022, based upon the fair values of the stock underlying the RSAs on the day of vesting, was $0.1 million and $0.3 million, respectively. The aggregate fair value of RSAs that vested during the six months ended June 30, 2023 and 2022, based upon the fair values of the stock underlying the RSAs on the day of vesting, was $0.2 million and $0.8 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">RSU Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has also granted RSUs to its employees under the 2021 Plan. The following table summarizes RSU activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested RSUs of $0.6 million, which the Company expects to recognize over a weighted-average period of approximately 0.7 year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No RSUs vested during the three or six months ended June 30, 2023 or 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company granted performance-based stock options to certain executive officers for the purchase of an aggregate of 883,352 shares of common stock with a grant date fair value of $3.36 per share. These stock options vest only upon achievement of specified performance targets related to certain business objectives. As of June 30, 2023, none of these options were vested because none of the specified performance targets had been achieved. Because achievement of the specified performance targets was not deemed probable as of June 30, 2023, the Company did not record any expense for these stock options from the date of issuance through June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of stock options granted during the three and six months ended June 30, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the three months ended June 30, 2023 and 2022 was $2.24 and $2.48 per share, respectively. Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted during the six months ended June 30, 2023 and 2022 was $1.55 and $6.25 per share, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic fair value of stock options exercised during the three months ended June 30, 2023 and 2022 was less than $0.1 million in both periods. The aggregate intrinsic fair value of stock options exercised during the six months ended June 30, 2023 and 2022 was less than $0.1 million and $0.3 million, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2023, there was unrecognized stock-based compensation expense related to unvested stock options of $16.9 million, which the Company expects to recognize over a weighted-average period of approximately 1.9 years.</span></div></us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-94"
decimals="INF"
id="f-440"
unitRef="shares">3352725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-95"
decimals="INF"
id="f-441"
unitRef="shares">2843116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-96"
decimals="INF"
id="f-442"
unitRef="shares">31884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-97"
decimals="INF"
id="f-443"
unitRef="shares">477725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-98" decimals="2" id="f-444" unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-99"
decimals="INF"
id="f-445"
unitRef="shares">1380397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-100"
decimals="INF"
id="f-446"
unitRef="shares">1575753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="c-101"
decimals="INF"
id="f-447"
unitRef="shares">1017062</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-102"
decimals="INF"
id="f-448"
unitRef="shares">244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
contextRef="c-103"
decimals="INF"
id="f-449"
unitRef="shares">488000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-104" decimals="2" id="f-450" unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
contextRef="c-105"
decimals="INF"
id="f-451"
unitRef="shares">315150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
contextRef="c-106"
decimals="INF"
id="f-452"
unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
<howl:EmployeeStockOwnershipPlanOfferingPeriod contextRef="c-106" id="f-453">P6M</howl:EmployeeStockOwnershipPlanOfferingPeriod>
<howl:EmployeeStockOwnershipPlanPurchasePricePercent
contextRef="c-107"
decimals="INF"
id="f-454"
unitRef="number">0.85</howl:EmployeeStockOwnershipPlanPurchasePricePercent>
<howl:EmployeeStockOwnershipPlanOfferingPeriod contextRef="c-106" id="f-455">P6M</howl:EmployeeStockOwnershipPlanOfferingPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-106" decimals="3" id="f-456" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-106" id="f-457">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-106" decimals="3" id="f-458" unitRef="number">0.927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-106" decimals="3" id="f-459" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-108" decimals="-5" id="f-460" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="-5" id="f-461" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-110" decimals="-5" id="f-462" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-463"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">806 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,999 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total stock-based compensation</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,038 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-111" decimals="-3" id="f-464" unitRef="usd">1019000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-112" decimals="-3" id="f-465" unitRef="usd">806000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-113" decimals="-3" id="f-466" unitRef="usd">2039000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-114" decimals="-3" id="f-467" unitRef="usd">1587000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="-3" id="f-468" unitRef="usd">911000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-3" id="f-469" unitRef="usd">971000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-3" id="f-470" unitRef="usd">1999000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-471" unitRef="usd">1936000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-472" unitRef="usd">1930000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-473" unitRef="usd">1777000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-474" unitRef="usd">4038000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-475" unitRef="usd">3523000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-476"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSA activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes RSU activity during the six months ended June 30, 2023 (in thousands, except per share amounts): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares/Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unvested at June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="c-119"
decimals="-3"
id="f-477"
unitRef="shares">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="c-119"
decimals="2"
id="f-478"
unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
contextRef="c-120"
decimals="-3"
id="f-479"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-120"
decimals="2"
id="f-480"
unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="c-120"
decimals="-3"
id="f-481"
unitRef="shares">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
contextRef="c-120"
decimals="2"
id="f-482"
unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="c-120"
decimals="-3"
id="f-483"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="c-120"
decimals="2"
id="f-484"
unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="c-121"
decimals="-3"
id="f-485"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="c-121"
decimals="2"
id="f-486"
unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-121" decimals="-5" id="f-487" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-122" decimals="-5" id="f-488" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-123" decimals="-5" id="f-489" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-120" decimals="-5" id="f-490" unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-124" decimals="-5" id="f-491" unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="c-125"
decimals="-3"
id="f-492"
unitRef="shares">323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="c-125"
decimals="2"
id="f-493"
unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
contextRef="c-126"
decimals="-3"
id="f-494"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-126"
decimals="2"
id="f-495"
unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="c-126"
decimals="-3"
id="f-496"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
contextRef="c-126"
decimals="2"
id="f-497"
unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="c-126"
decimals="-3"
id="f-498"
unitRef="shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="c-126"
decimals="2"
id="f-499"
unitRef="usdPerShare">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="c-127"
decimals="-3"
id="f-500"
unitRef="shares">317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="c-127"
decimals="2"
id="f-501"
unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-127" decimals="-5" id="f-502" unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-126" id="f-503">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="c-126"
decimals="INF"
id="f-504"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="c-128"
decimals="INF"
id="f-505"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
contextRef="c-129"
decimals="INF"
id="f-506"
unitRef="shares">883352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-129"
decimals="2"
id="f-507"
unitRef="usdPerShare">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="c-130"
decimals="INF"
id="f-508"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-509"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of stock options granted during the three and six months ended June 30, 2023 and 2022 was calculated on the date of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected term (in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.65pt;text-align:justify;text-indent:-17.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-131" decimals="3" id="f-510" unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-132" decimals="3" id="f-511" unitRef="number">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-133" decimals="3" id="f-512" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-134" decimals="3" id="f-513" unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-131" id="f-514">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-132" id="f-515">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-133" id="f-516">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-134" id="f-517">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-131" decimals="3" id="f-518" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-132" decimals="3" id="f-519" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-133" decimals="3" id="f-520" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-134" decimals="3" id="f-521" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-131" decimals="3" id="f-522" unitRef="number">0.826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-132" decimals="3" id="f-523" unitRef="number">0.775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-133" decimals="3" id="f-524" unitRef="number">0.826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-134" decimals="3" id="f-525" unitRef="number">0.763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-5"
decimals="2"
id="f-526"
unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-6"
decimals="2"
id="f-527"
unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-1"
decimals="2"
id="f-528"
unitRef="usdPerShare">1.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="c-7"
decimals="2"
id="f-529"
unitRef="usdPerShare">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-530"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the six months ended June 30, 2023 (in thousands, except per share amounts): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outstanding at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="c-135"
decimals="-3"
id="f-531"
unitRef="shares">5244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="c-135"
decimals="2"
id="f-532"
unitRef="usdPerShare">7.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-136" id="f-533">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="c-133"
decimals="-3"
id="f-534"
unitRef="shares">1560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
contextRef="c-133"
decimals="2"
id="f-535"
unitRef="usdPerShare">2.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="c-133"
decimals="-3"
id="f-536"
unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
contextRef="c-133"
decimals="2"
id="f-537"
unitRef="usdPerShare">2.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
contextRef="c-133"
decimals="-3"
id="f-538"
unitRef="shares">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
contextRef="c-133"
decimals="2"
id="f-539"
unitRef="usdPerShare">9.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="c-137"
decimals="-3"
id="f-540"
unitRef="shares">6746000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="c-137"
decimals="2"
id="f-541"
unitRef="usdPerShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-133" id="f-542">P8Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
contextRef="c-137"
decimals="-3"
id="f-543"
unitRef="shares">2457000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
contextRef="c-137"
decimals="2"
id="f-544"
unitRef="usdPerShare">7.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-133" id="f-545">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-546" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-5" id="f-547" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-5" id="f-548" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-549" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-5" id="f-550" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-5" id="f-551" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-7" decimals="-5" id="f-552" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-553" unitRef="usd">16900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-133" id="f-554">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-555">Related Parties In May 2022, the Company entered into a sublease agreement with Crossbow Therapeutics, Inc. (“Crossbow”), for which entities affiliated with MPM Capital (“MPM Capital”) are also beneficial owners, to sublease the entirety of its office and laboratory space in Cambridge, Massachusetts. Luke Evnin, Ph.D., the chair of the Company’s board of directors, co-founded MPM Capital and serves as Managing Director of MPM Capital. Briggs Morrison, who serves on the Company’s board of directors, serves as Executive Partner of MPM Capital and Chief Executive Officer of Crossbow. The term of the sublease agreement commenced in June 2022 and ends in March 2024, with no option to extend. The Company received cash payments under its sublease of approximately $0.8 million during the six months ended June 30, 2023. In addition, the Company received $0.2 million from Crossbow in June 2022 as a security deposit that is included within “Accrued expenses and other current liabilities” in the accompanying condensed consolidated balance sheets as of June 30, 2023.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:SubleaseIncome contextRef="c-1" decimals="-5" id="f-556" unitRef="usd">800000</us-gaap:SubleaseIncome>
<us-gaap:SecurityDepositLiability contextRef="c-43" decimals="-5" id="f-557" unitRef="usd">200000</us-gaap:SecurityDepositLiability>
<us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-558">Net Loss Attributable to Common Stockholders per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For purposes of the diluted net loss attributable to common stockholders per share calculation, outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, however the following weighted-average amounts were excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:EarningsPerShareTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-559"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For purposes of the diluted net loss attributable to common stockholders per share calculation, outstanding stock options, unvested RSAs, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, however the following weighted-average amounts were excluded from the calculation of diluted net loss attributable to common stockholders per share because their effect would be anti-dilutive (in thousands): </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSAs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-138" decimals="0" id="f-560" unitRef="shares">6746000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-139" decimals="0" id="f-561" unitRef="shares">4383000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-140" decimals="0" id="f-562" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-141" decimals="0" id="f-563" unitRef="shares">178000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-142" decimals="0" id="f-564" unitRef="shares">317000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-143" decimals="0" id="f-565" unitRef="shares">236000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-144" decimals="0" id="f-566" unitRef="shares">59000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-145" decimals="0" id="f-567" unitRef="shares">59000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-568" unitRef="shares">7122000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-569" unitRef="shares">4856000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0 ( !@X"E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M " 8. I7/++Z7>T K @ $0 &1O8U!R;W!S+V-O<F4N>&ULS9+!
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MX[.@ZN#77:@O4$L#!!0 ( !@X"E>97)PC$ 8 )PG 3 >&PO=&AE
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @
M&#@*5Y7I+JP.!@ HR !@ !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
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MD,!SP-AXN%,Q[BH''JIOR'E2<)[4[)F2P122S0#5[8A[S5B8&!L2E34$'!2
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MG/E<ZAO@^DP(M3W0/U#\7\+P/U!+ P04 " 8. I72:'RPQ@& 7&@
M& 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;+59;6_;-A#^*X17%"W@Q"*I
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MTWBKA'[+M)Y:7O&ZT)-""Z"O)"]9092^^4A*4N<4W!K#$KQK:M(43+]Y#T[
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M8L9XJNF S="/SG:*^,%T!T<F>(Q<%L(PJF.#@T<B?P<^2=7M"]Q/>B"R;;X
MM26%2=FTN[J<2S=!(9L7<0;#,7TZQ";BC@;N1'[NW'+\D?6-;&(<%PR'",PF
M2C3:VQIZ.:K+PF/HD%T!XAB/L\\AAI,LF%H! \^A(WLZ7E5,F29YRR YKTTN
MTCJ?PNNUY^9EX-S)_KRA0Y\'ZD2AMZ&Y53S_MN9E085\^TN*8'+>]MWJR;U_
M]Q+QBS?PKV3MT/>!=I&?=O7.N"M5TD1A#MX$IT$00%T$!- ;#U.[HKE^ N2:
M"--6-&K-!?M7:Q %/C4UW:+9'<&TJ^9:[UFK.RJZ5]WQRKGNOG=F3!G1)K@
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MZQZPNS'?!OIO0<O_ %!+ P04 " 8. I7"6V50_X" ="@ & 'AL
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MPT$Y3.'\1I4-@.LK*<W3Q)X0ZA-A] =02P,$% @ &#@*5WWB=9YI!0
M-1H !@ !X;"]W;W)K<VAE971S+W-H965T-"YX;6RM66USHS80_BL:]Z:3
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MV/7TL(<@;F+[AE 1X+ F9S1VC6BN+\3/6A%:L>HGWH1E3*/EX6DRX0AR9$*
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MU>&&4=4<E !U_X5S>3@I!VB_%,W^!5!+ P04 " 8. I7OO E]E\) ]
M4 & 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+V<76_;.!:&_XK@&<RV
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M9% V56=*^B, 245B22HBM$BP[C]0^@-58\-]4#TH$9 IPLO]_R)U=V@Z4)B
MDAN)C#VT%:A1!J6FQD1")8%)%PZ'PI8N1&&L/YA'S'2AOB"T2%&RB"-]_\U2
M;DI0,K]XUD3UBL0Z I\N'%PRNVUZ#U:3WFP VJ40:FI89%<2<#2A</1L*0+
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M4$L#!!0 ( !@X"E?H'PSJE@( ,@& 8 >&PO=V]R:W-H965T<R]S
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M% @ &#@*5X71JDU3!P TR !@ !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6RM6FUOXS82_BN$6Q2[P'HMDI8MIXF!K+>+YH"V07.]^\Q(=,Q;B71)
MRMGTU]]0LBU;I)@ Z_T0ZV4X>N:%\PS)O7Y6^JO9<&[1MZJ4YF:TL79[-9F8
M?,,K9CZJ+9?P9JUTQ2S<ZJ>)V6K.BF9054Y(DLPF%1-RM+QNGMWKY;6J;2DD
MO]?(U%7%],LG7JKGFQ$>'1[\*9XVUCV8+*^W[(D_</O7]E[#W>2HI1 5ET8H
MB31?WXQN\=6*+MR 1N(_@C^;DVOD3'E4ZJN[N2MN1HE#Q$N>6Z>"P<^.KWA9
M.DV X^^]TM'QFV[@Z?5!^Y?&>##FD1F^4N5_16$W-Z-LA J^9G5I_U3/O_*]
M0:G3EZO2-'_1\UXV&:&\-E95^\& H!*R_67?]HXX&0!ZP@/(?@#I#Y@.#*#[
M ;0QM$76F/696;:\UNH9:2<-VMQ%XYMF-%@CI OC@]7P5L XNUPI64!0>('@
MRJA2%,S"S8.%'XB6-4BMT8J9#?H"$3?H72U970B0>8_&Z*^'S^C=C^_1CTA(
M].^-J@V3A;F>6$#F]$_R/8I/+0HR@&*&?E/2;@SZ!= 4Y^,G8-'1+'(PZQ.)
M*OQ7+3\BFGQ )"$T@&?U]N$D H<>O4P;?71 WQ];KID5\JE-6V$%-U<A-[5J
MIF$U;DI?F2W+^<T(YJSA>L='RY]^P+/DYY"-%U)V9O'T:/$TIGWY.U0@(7-5
M<?2N5,:\#UG;JI@U*ER]V2W'>)YDR?5D=VI'0(PL%G1^%#M#F!X1IM&8W!;_
M@^G5YKA54))R)7-1<B0!NH/LGKKKW&5_[:8()+EZ:R332T;R0LK._#0[^FD6
MC>2#5?G7L2N5!8)X G\8UE1@_LU=\Y#QK<;T)&+3A&:]L/I"-'6S+134^1'L
M/ KV,P</Y.)5@'/OVUFZZ.'S94A&P_"R([PL/BN4'#?I)*3E$"H;PYAYWU^0
M'D1?) D#7!P!+MX&L.00\!BZA??IV3SMP?-E%C,<!HB3CK"2*,35ALDG[N;B
MF@F-=JRLN2,I4^<YAUF[92]N4J-2L$=1"OL2I*/$@S;&">U7GH 8F0VD*#ZA
M7!RUX+92VHI_VB0%Y 5_A&)I3,UDSF&.&1NF4.R[W /LRPQD!"8=7!(ME*W#
M3:_Z&<.A< +='QT]5 GWZB]4"B^E[=P9'9'C*&LN[S7?,E$<9D;K 64W7$.W
MIK5+O-8U04]0O^S,:#^$OM"8S,EL((P=(>,X(__1@(3JR,6./98\C'#J?1SW
M\?DB8T+(4)IU=(RC++;')UT!>MV1:23-]S!]D3$FR9 ;.S;$<3J\S7-5NYX!
MZHQS8Q!>@-JF_>(8$,)TJ+9T_(?C! CP=,VC^7DR7X/@?=X;4SSWTL 7 _K.
M!O!W!(GC#/F9KSG +"!1=US68??ZM#=.B8_0%\,TF0\14$>1.,Z173/?DF2<
M:'P.!*))^KU&4 RG8:BDXTH2Y\IV3KT2<!+BPD7?FP&I4Z%S@!T5DC@5_OZ6
M_CH(VB>Z,4DRW'=L2 Y/23H=0-ZQ(HFSXIW<0?_VAH4 N2C]74K;N=4=_9%7
MZ*_6^8:YN@)]RU:[:-F7IL;POVNQ=8U7T <!3J-IOV2'I#"FBX%0=<Q'7E^+
MGB69",0N"#M =0'8 :D([(X027R!^D5(: C?DF$776M>2MNYU1V_DCB_WFN5
M<UX8M-:J0LPB*&&H8OHK!%&M@1R<0R#Y8"E:0?MLW.HTZ!2?7A<TZZ]! U)T
ME@ZL\DC'PB3.PN=&%)H]%^JYZ?5AV5>A4C$93CB?5*<)_.NC]L4&VB_2$2^)
M$^_]?MD$&-U4AEG]^HJ$!(@8DWY#&Y(B@].CHV$2I^%S'Q_ &E3+ CCOEVI;
MJA?.4;-]@0YU"]V73 9-\0G8Z]@",@-NIQU#TSA#GUO19#-PX'[[@NM<F'!I
MHCX=]^$&1/!L"'#'V/2-C W5?R<***B/+V@=*%5!U#X;3Q<4>\A],9K.!RB;
M=I1-H^1XV)/43=?VKN#MU7O'",ZB#ZU=+OMWK&SV!1VQN6T:+7*W*]Z\=\_Z
M@D%;26#_"$]G?5M],6"/TT;FW-J3+><X5:^^SZ2??L@()C\_\B<AY;[F ML+
M502-]:D;>NV4]-NQD%R:970H+3N.IW&.OXRUW"V6HG8&UL=IYN]\A>2F\P0/
M-,RT:PIHO"DXV4$\]C .C0!PP<,%^T5+J7MW!E=KT!?Z15>[T;=Y&:])7LC
MP7H+Y:"S0DOT?J0#,EDV%.>N@Z#Q#N+NC'R_SPJ_6_ KKB\S'UA]TJZEH/&6
MXNZPR7W/1/$!W<F\K N7HRNV%9:5XA] ?A#Z@$X.R:1[?LCOVSBE^-W%?-K?
M)P\(#56<KO^@\?[C(<35I_MK+FC;[]DNW .8!5'O#?-%QEXQG9P<#U=</S6G
MY@8UZ=0>J1Z?'D_F;YOSZ-[S3_AJU9ZO=VK:X_[?F :>,*CD:U"9?)R#JW5[
M@M[>6+5M#J$?E;6J:BXWG$&GY@3@_5HI>[AQ'SC^/X;E_P%02P,$% @
M&#@*5P@NHO'H!0 /PT !@ !X;"]W;W)K<VAE971S+W-H965T."YX;6R5
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M6ZTJ.<C"5.+2D2<3A@E0\8LRTI1*:G&%28(&@Q=_O2I\<%#1W_<Q- XNA\
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M*_"'\2CH%P%14CO5P,P35O3DN*\S/2Q+Z<HV;=GG*?5-%10A]TXJSYM+V:L
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M/9$+&_#@3I]\39/C#5BO+;IH'O !XV^FU7]02P,$% @ &#@*5YSK')41
M!P 210 !@ !X;"]W;W)K<VAE971S+W-H965T.2YX;6RM6%EO&S<0_BN$
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M3_99_\E4_5^VQ:7TRI/@#;EH@HSL,KFXLL:C5!Z??%H"<BZS12G-FBQD%LO
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M#-_41NS/21;NFQK<:+;LO,UH1^TT.9XR[3C?W X!N@RO8G79&-GV:^H?\0D
M8:US*E#!"-X;-COA88OG!DFPT/*X/Z!Z4/,U3\UO \!85UR:G+)FB6BW<_(-
MJZ9=/O:Q>K#M.\&P\WD'_\U;\$<L9H0)\4M/\[3Y3C:)GX=:\?B1[8-T"X5Y
MTC!'U='@U8N></'#5;P)MN2/13,;@BWX<HEK.#@2P/?T#U)]0P<T7P\O_@50
M2P,$% @ &#@*5Y$JC*Z#"@ YQL !D !X;"]W;W)K<VAE971S+W-H
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M[/69V"7(5C9_$G]\_>?>R<'AJZ&03CP >G_)I,:I[0SN217K4I#<R FE<F?
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MTDZ81=_A$*EW*?8 ,HA,_6HJG9+!0_$9)536:"%KBM;0B*-OHQXGD@V>(9
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M4$L#!!0 ( !@X"E<H&=:[.0< "44 9 >&PO=V]R:W-H965T<R]S
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M <_G%O&O;TA!^V7P[&]02P,$% @ &#@*5_BV",D1! H !D !X
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M]'>+5RB$ R(9WWO,8*!T@8?V'OU7GSOELF$&KY3XR@M;+8)9 66K!7V6NU^
MPSZ?B</+E3#^%W:=;S8-(&^-574?3 IJ+KM_=M?7X2!@%K\0D/8!J=?=$7F5
M'YAER[E6.]#.F]"<X5/UT22.2]>4&ZOI*:<XN[Q&8S7/+19PQ4P%3/;&Q^\M
MOV4"I37SR!*3\X_R'G75H:8OH)["9R5M9>"C++!X'!^1PD%FNI>Y2H\"_M'*
M$61Q"&F<9D?PLB'MS.-E+^"]F"O\<[FABM!B^?>YM#O4\?.H;@.=FX;EN AH
MAQC4MQ@LW[Y)3N.+(YK'@^;Q,?3_W:JCJ,]K?@T5?*D0KE3=,'D/;OM;^E*
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MJQK_CM\H2S<&;U9T14/M'.AYJ6A_]P-',%SZEC\ 4$L#!!0 ( !@X"E<C
M'3%#W@( ) & 9 >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*U5;6_3
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M] @@Z0&)U]T%\BK?,LL6,ZUVH)TWL;F-3]6C21R7KBFW5M,M)YQ=+/-<MUC
MU1VUV: !)@OX;"O4<-EJC=+")\XV7'#+T<Q"2S$=,LQ[_E7'GSS"/X%K)6UE
MX$H66-S'AZ1U$)P<!*^2)PD_MO(4TF@$292D3_"E0P%2SY<^PK=F>[81?>*^
M&DP8^+'<&*OIE?GY4,H=8_8PH_N,+DS#<IP'])T8U'\P6+Q\$4^B-T_HS0:]
MV5/LS]"PY^2'@SL>NROOGO?NXLB=&5 E4 ]QZ*%'O,4<ZPV!TMB?)K!#C9"K
MNM'<$#\!2R5HA!AXQ2782K6&@.;UQ3^V>R373+8E-;#57&[A!++1.(IIG8PF
MTPPNZ:5T[077(*;S"I)1$B?T/#^/X*INA-IC%Y_28MT (9T;E%AR:YP[B4Q'
M<3J&M58E&C>FF( 2*<UL? :3.(7;-L_I!AJVKX]+L8>7+\XHWAL83Z.^NN-L
M"C%97Y0E&O9_=3V!\]%Y%M$:9Z-XG#STHH5'4Z)&O?6ST%".K;3=P!A.AW&[
M[*;,/_=N5E\SO>72@,"2H-'I=!R [N9?9UC5^)FS498FF-]6],M [1SHOE3*
M'@P78/@)+?X"4$L#!!0 ( !@X"E=^'4]A#0H "(: 9 >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;*U9;6_;.!+^*X0WNT@ UW8<)\VV28"DV>)Z
MN-TKFO;VP^$^T!(E<RN)*DG9\?WZ>V9(R9+CY+JX XK4EC@OG'GFF2%]M3'V
MJULIY<5C653N>K3ROGXSG;IDI4KI)J96%=YDQI;2XZO-IZZV2J8L5!;3^6QV
M,2VEKD8W5_SLH[VY,HTO=*4^6N&:LI1V>Z<*L[D>G8[:!Y]TOO+T8'IS5<M<
M/2C_I?YH\6W::4EUJ2JG326LRJY'MZ=O[A:TGA?\0ZN-ZWT6M).E,5_IRX?T
M>C0CAU2A$D\:)/Y;JW>J*$@1W/@6=8XZDR38_]QJ?\][QUZ6TJEWIOA=IWYU
M/;H<B51ELBG\)[/YBXK[.2=]B2D<_Q6;L';^>B22QGE31F%X4.HJ_"\?8QQZ
M I>S9P3F46#.?@=#[.6]]/+FRIJ-L+0:VN@#;Y6EX9RN*"D/WN*MAIR_^:QL
M*?YF9'4U]5!'#Z=)%+T+HO-G1"_$KZ;R*R=^J5*5#N6G<*/S9=[Z<C=_4>%?
MFVHBSF9C,9_-SU[0=];M[8SUG3VC[UXMO;C7+BF,:ZP2_[Q=.F^!@W\=VFS0
MM3BLBVKCC:MEHJY' +]3=JU&-S_]<'HQ>_N"IXO.T\5+VE_.PG>*B@^5N*VM
M+BA\\['P*R7>F;*6U5:HRBNK4J$K;_@%"]SF5BD4F ?F_$I\_/UN(KX@EY:7
M0*)TPF0'UH]I+5"8*B'74A=R6> 32XB"5FJ4&_[E$,BE5P)N58FN92%D:1H8
MA-JF%G#F:#Z;S #LHJ :/?[IA\OY?/;VLY45Z$=\8,/\\/3M2=^8%[0O#WX0
M,O/194JTKG*1DDV802S>JZ5MP#9B?LFX6@CIA'KTBC!+#MPV.:I,G)W&UTT-
M/TB9DUZ[3 ;R@+^)LAXD)Q)3I9H>.N% FN!%Q$Y7A\)Z[)IDQ=Z$=,3=W9:0
MT?^6K!E5J]H-3L0=""85W^\!^ =X2 _;#VG:8,.R<$:89:$I&[SM4GX=) _9
M2H-2)&F02-+[?\CD()5C82RV43 WKU6Q#0@D4\/4#^+60=W]+XB@QT\RL$N[
M3!)5>_B@Q'++3[Y,'B;BO3$I#*3BWC:YN$U!Q9K(A#4<]YQ\?W_;>4?%LS$(
MXEHY3[$/X:W0JU)2TP;IPV_WG8QKEJ5VCK-+:4?34<"8$K]*"S!%G)Y-Q"T7
M)SA3=9PY+/H5$I]:N:E$:O#G:-'/3ZSK74@GXC.^HVT[;#ZEF%7&*R=JN>7X
M+F7!06DZ@MC)4DWM^T(H=0A11R$9TFTVI/B8464:!T/NY,V>W,<.84=B,1O/
M9C.0D@P) W93(O44I,[HHXP@6@V[EA@R=WQY?GDB?D-I)M+:+1F,4#T29S^/
M3Q=S\= LG?K64(E&/M1,D,Z_,A7 6"NK33H6FY5&R$$5G(H]IA@&6SN,*-\:
M;7OEA>_814E-DI1V^T)(J3P1VZ)QG>D>/'N1Q=Q!K>N)^8N0K][*#3(+K$B[
MTQ@AW4]JBGK9=LFDHA$9*MUSF*J*'+94#\%W[ 2%+ZF:3/8&B3L1L\GYCT(N
MS5JQ;NP*!<<B^,J$H;(,94W(/=806$!@(CYD^\N3E:QR ,ROK&ERP,%W;6<\
MR$E8'K<'FOH#84"4@QFP1[M-KG'SC!W4"^0[E7AH<\7 W@%ZC[V1T@39;7Q@
M9"G.+F:O4KD56PHR:C+RA:=(54VYY"C!C2TZ3"%K,/DX\%IGMBVFB(F0PQ9"
M5B4FKQCDG8!ZQ/3ML!,HC,Q]P%-8/9I-?NZ*FZKBZ+17[6EC*<$<WQ6D>(73
MC\$1)T(WW.,2.%"W_#ST--4IL0/<3!K[U-D_;VT^U$\M:]"M$#?N91*)4*^8
MXS.EVNZDUC$(NP9I:Q,PB6[B0@=U.TPK)$59AC/)[R NCN4)A7(^".7Q\D3,
M)[,?6W!%.@G<>H@/QXP.V;<N3()8<5Q>8/5Q5S6L@/K9017DON(N-WYF!XLG
M.UC\F1T,6MI#@Y[H'&:IWJ1"^>J]$+^$)+"+1-,[##A% XM \&WTL<,7CDZT
M*N91EZ5*-4\9@2'I1=:@;J/;P/1%MZ^.;GM>C'FW \7(@O&RB#6R*PF:BM!L
M@RB!J=!RJ0OMMX>Z6:"//I%&?#*PGJ40:7G[#;D9IXF(<0KDZ>NWCGJ-XZF@
MMCAI6Y@_5H\)&@,S6\8@H KC6:GIK3OAO;*%9OD',2Z03=-+H>)8LE\>\; Z
MH9/"X(4413_J@%Y<^J3'/:E*R;'K*NL\@HP'WZ:J)9@B@,VQ62"ABN?Q;N+;
M'UI?:*O$Q^VPV!9[18,I!2M!3ZHD++6-&X8I45SK?H6D.0:=MSKQ RN9-26S
M 1,: S=KN._RM(%XY"A#1E2A%=4WUVCH0$ULGJ)4:"DV3+:5,X5.Y6ZCQH;#
M%YD+'BV1XHK 9VPNJSB,LF:H1FBY6^NU3L/\86FFH&?MOH.6E*90O6P8B"2]
MQ@@)L#!$;5BTT2XR8:;"[K2GF0W'%Q*!1%0=!M4PF_ 1CD^..!4H%S8 6TUX
MW485J6L=ZDM3Y]"9?NYD$DAIK3O+B:PUJI2;'[<1G$40?W8#Y<!ARL3I_'R?
MPE -%**4";,]K80Y9MFD.:9 6=.:70$NC;0IEP-0E7ACX^B[[R$=F9!(VAKV
M0V5/<C++-%T&[0$.P"D:Y@7.=FR=W7393JA4:UA&];/#"#FOH2?1<!J&/#O
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M^5< [,&;DC^NE$1B: '>9\;X]@L9Z'X6NOD/4$L#!!0 ( !@X"E>#>3AW
MKP0 (T+ 9 >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;)U684_C.!#]
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M#+1.7) .!@N64Q+F:X5(=Y2!8VMK&4?A^<X[M]L__T*M;3)8/%S I-*<</)
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M<X\9S<NHK &]7TEIZH4-T$S@LW\ 4$L#!!0 ( !@X"E<M+B#<7@T -PM
M 9 >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;,U::6_C-AK^*T0Z*1)
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M3JJZ*<R*O]^%C10FX<NEDFB,: .>SXTIJAM"4'_0_?Z_4$L#!!0 ( !@X
M"E=IXF)A$ 0 /0( 9 >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;)56
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M+/X%4$L#!!0 ( !@X"E<YRB'U+@, (H' 9 >&PO=V]R:W-H965T
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MB=H9T'ZFZ*=93QQ!>_W.?@%02P,$% @ &#@*5R@:":T#!@ 41 !D
M !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK5AM;]LV$/XKA <4+9#Z+6]%
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MNV28]'$.6>U44(W$S5-62+,"C$E9*L_]Z37)O?KAW7@\O)C?7//3Z.(-RZ_
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MXP!Q\0(;7X*M^-*XL &OH/Q8X,0&1P+XG<Y2VQ=RD/Z+,/D;4$L#!!0 (
M !@X"E=?31,(Y@( &4& 9 >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;(U546_:,!#^*Z=TJEH)-2%08!20@&[:JE:JVFY[F/;@)!=BU;&I[4#;7[^S
M RF=*-H+N3O??7??^7R,UDH_F@+1PG,II!D'A;7+81B:M,"2F3.U1$DGN=(E
MLZ3J16B6&EGF@TH1QE'4"TO&93 9>=NMGHQ49067>*O!5&7)],L,A5J/@W:P
M-=SQ16&=(9R,EFR!]VA_+&\U:6&#DO$2I>%*@L9\'$S;PUG7^7N'GQS79D<&
MQR11ZM$IW[-Q$+F"4&!J'0*CSPKG*(0#HC*>-IA!D](%[LI;]*^>.W%)F,&Y
M$K]X9HMQ, @@PYQ5PMZI]3?<\#EW>*D2QO_"NO;MGP>05L:J<A-,%91<UE_V
MO.G#3L @^B @W@3$ONXZD:_RDEDV&6FU!NV\"<T)GJJ/IN*X=)=R;S6=<HJS
MDROV^@I$2;!$:58W2F9PS5-J/,)TH1'I#BR</+!$H#D=A9;2NN PW:28U2GB
M#U+TX$9)6QCX(C/,WL>'5&Y3<[RM>18?!+RJY!ETHA;$4=PY@-=I>M#Q>)T/
M\&:5(8LQU(<RX?*M"U-CZ%E,TZ>*&^ZMOZ>)L9I&Z<^^/M1INOO3N.<U-$N6
MXCB@]V-0KS"8'!^U>]'% 1+=AD3W$/ID3CUVA='\V +F?G)0MZ"Q>S([^C5G
M"1?<OK0\USM,D:_<'>]C=C#W?F8/!4).@Z767"[ .F3PI](:2 LF%VB 2[#D
M1XU?,OER?#2(V_T+.MX6*39%<O+-*NV1R-_P9RCKH4(W5$ C@<U(P(F'594A
M8N9T"#,FF$P1F &5_Z-=$N\R00V=MH^.89IE_K(-]22KTEI\GV"^I[XA0>6H
M-56C<86R0O@$_5:O%]'7,XLO2#HY;\7]]BE)<:LS^ P/RC)A_LMUWY2$.T^?
M[GOA%YQK8"5MO04::[-#I_7J>'.O%_ -TPM.5 7F%!J=N96EZZ56*U8M_2))
ME*7A\F)!_P.HG0.=YTK9K>(2-/\LD[]02P,$% @ &#@*5_5#K\JM P
M00H !D !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULU59M;]LV$/XK!W4H
M:L"(9#E. ]<V8"<-UJ)!O3CM/@S[0$LGBPA%>B1E)_]^1TJ6%<_V@GW;%XDO
M=_?<RW,D1UNEGTR.:.&Y$-*,@]S:]3 ,39)CP<R%6J.DG4SI@EF:ZE5HUAI9
MZI4*$<91=!46C,M@,O)K<ST9J=(*+G&NP91%P?3+#(7:CH->L%MXX*O<NH5P
M,EJS%2[0_EC/-<W"QDK*"Y2&*PD:LW$P[0UG R?O!7YRW)K6&%PD2Z6>W.1+
M.@XBYQ *3*RSP.BWP1L4PADB-_ZJ;08-I%-LCW?6[WSL%,N2&;Q1XG>>VGP<
M7 >08L9*81_4]E>LX_$.)DH8_X5M+1L%D)3&JJ)6)@\*+JL_>Z[S\!:%N%:(
MO=\5D/?REEDV&6FU!>VDR9H;^%"]-CG'I2O*PFK:Y:1G)W=<,IEP)N"+-%:7
ME&]K@,D4[AC7\).)$N$>F2DU5GL?'ME2H.F,0DOXSDJ8U%BS"BL^@74%]TK:
MW,!GF6+Z6C\DOQOGXYWSL_BLP:^EO(!^U(4XBOMG[/6;9/2]O?ZI9.Q#ON4F
M$<I%;>"/Z9)20_SY\UC,E<G+XR9=3PW-FB4X#JAI#.H-!I/W[WI7T:<S#E\V
M#E^>LSZ9&H-4DKH^*3#;+ILC/3Q@4FK-Y0IFS'!S+(*S&,<CJ(&+%G#F@#=[
M8-T +QTP, ,J RH9-B6#+6IT&YD2=#H0M[@$FZO2$ %-9PB_E<J2];GF"0+M
M+?A*\HPG3%KX;G/4\'WI/'*,) *O2\?/;[A! 7'GE?0/J4Y)]COPJ"QU0!74
MT+$47ZC)]!,=BEE)KL OT!O$W5X_IM'[=]=Q+_[T:K3;K0RQ*CMO5:J3Z9I.
M<+;D@EN._R6YMYA@L:2L]'L^P?'_*L'Q=?>Z=S)7]>YA@M^D]*V5U469)&@,
MK-F+.\^:C+^<L#'X&-7?"KI=H7_3.-/A@Z;#!V<[?-_.73CL=F+"07=WCY3!
MR2@ZXLEQ=P\>.P#.NG#\ 'C,L2:5 [<>3M= E!FB#B0YDRO/JC9[,[]G3E8A
M+7TX7H@_0U'=&.ANC(/#PUW&/@DURPBI8MT!QQ=DIGWQ4*H$W7GH^NJ?'5-5
M;IJFW&7+-'6].19-KQOU(YC709"]';L^;]S"AU[W*HHZ;<#7(>QI<XPJ8>M:
M+U"O_./%0*)*::L;OEEMWD?3ZEFP%Z\>5_=,KSA%(S CU>CB(Y5<5P^6:F+5
MVC\2ELK2D\,/<WKCH78"M)\I.BCJB0-H7HV3OP%02P,$% @ &#@*5S]$
M-$,E P > < !D !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULC55MC]LV
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MIKOGNX'3NW"WKK6CFSJ8-3V-:+P#K6^T=L>!3] _MHN_ 5!+ P04 " 8
M. I7JR%UU.," !,!@ &0 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R5
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MU.Y1NPMT7BEE'Q?.P/ #F?T!4$L#!!0 ( !@X"E=&+CM9H@( )\% 9
M >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U4VT[;0!#]E9&+*I H=IQ
M0YI8(E!4JE)%7-J'J@\;>Q*O6.^Z.VL"_?K.KH.;5B$OR5[FG#GCV3/CE;$/
M5"(Z>*J4IDE4.E>/XICR$BM!1Z9&S3<+8ROA>&N7,=4611% E8K3)#F)*R%U
ME(W#V<QF8],X)37.+%!35<(^3U&9U23J12\'-W)9.G\09^-:+/$6W7T]L[R+
M.Y9"5JA)&@T6%Y/HK#>:#GQ\"/@F<44;:_"5S(UY\)NK8A(E7A JS)UG$/SW
MB.>HE"=B&;_6G%&7T@,WUR_LEZ%VKF4N",^-^BX+5TZB800%+D2CW(U9?<)U
M/<>>+S>*PB^LVMC^:01Y0\Y4:S KJ*1N_\73^CML (;)*X!T#4B#[C914'DA
MG,C&UJS ^FAF\XM0:D"S.*E]4VZ=Y5O).)?=H:W@BQ$:]N_$7"$=C&/'O/XV
MSM<<TY8C?87C!*Z-=B7!1UU@\2\^9CV=J/1%U#3=2?BYT4?03PXA3=+^#KY^
M5V0_\/5?X;O N8,+2;DRU%B$'V=S<I8?Q,]MQ;9<@^U<WB0CJD6.DXA=0&@?
M,<K>ONF=)!]V*!UT2@>[V+-;-EW1* 2SX*[HY;O0GZ#_2K/FAOW@:)OJG;S;
M5=^5G*=QY(0NI%Z"-@X):O'L'P*_=25TCM!P4RTXCNW>"H$@KY#[A%V?(#=L
M57+AQH<OC&++>^)]J?G$-,2)Z&#T'VYFI<YE+13LP2 Y3)($[K6HC'7R-Q9L
M,2Z^X.:91CM@!I!$39"6&Y]N?W@\/("O/,!R8>VS3\AH'[P'_=/#WB"%;9V)
M-TQ3H5V&T4 0TK3^Z4Z[Z7/6FNYO>#NZKH5=2OXJ"A<,38[>'T=@VW'0;IRI
M@P7GQK&AP[+D"8K6!_#]PO"G7V]\@FXF9W\ 4$L#!!0 ( !@X"E<?$#7K
M^P( ,@& 9 >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(65;6_:,!#'
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MCT"'OADF5M6^5RV4I<[GAR5]:E [ WJ_5,IN)R[ [N,U^0=02P,$% @
M&#@*5R<XLG<#!0 :PT !D !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
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M-_:?&V+3U+=)FCVG^@L<)O3#\9QT!::&:#*@*)3 2> 1]>.(QP].]+'P#(!
M"A>VN9Z0 _41A$Z,_PE$J$+_7[!1D:0S>!(\?X;0P3NKUOY:XOF(G)H]\9T(
M7\6Q$^+4/$5. <=:(I;-,7=W[WZRDB'7[/;U:I&4@>[=5M\A\AV,?7_,MK5
M%K=7E<%O8YF1@[\JRP.8;?/V%7%</G*5"OSR7B/K\]?OIYQNY&1LU_!>E@G[
M_G"(K1\[202)$PQ;LL%O841$YCO>L/6(=.(?V4TWA M6IGBCILW0DLS(P:_I
M3RY?'DW4CX?TP8V<,"!W<6/9UN"5N-\?AK&-+DQP&$7[X#38N0 77"WL-1];
MF ZYO@NWN^TOB4E]@7X6KW^&?&-J(?#$<SY'5=>)\2NIZJM]_6#DREZG9]+@
MY=PNE_AKB"L2P/=S*4WS0 [:WU?C_P!02P,$% @ &#@*5Z/1+SM5 P
M?@< !D !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULI55M;],P$/XKIR"A
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MWRZLJL.$72E+\SJ\EG1!HO8&M%\H.C2;A0_07;GS7U!+ P04 " 8. I7
M_.M0RX0" !P &0 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RME6UO
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MTCQ,;(_J?WKI/U!+ P04 " 8. I7JWDGYC0% "Q( &0 'AL+W=O
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M\A]02P,$% @ &#@*5\ETY;RF @ > 8 !D !X;"]W;W)K<VAE971S
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M4#8 ]Y=2FNW$$G0_F^0W4$L#!!0 ( !@X"E=+KKS(( 4 ,XB 9
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ML>3J5ZKB9'1+4YS&%"?@+A629VJ&I XG8);3#GXBI.,@'N"1<9)^=LOX%((
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M9*OB^X,)DY(MB\,%P5/"\P'J]QEC\NTD_Z2A_H0E^@]02P,$% @ &#@*
M5]D3JQH?! O1@ !D !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULQ5EM
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MP+6!NK]B3+X.] +5?RS\?P!02P,$% @ &#@*5W;"89$I P SPD !D
M !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULS59M;]HP$/XK5E9-K42;$$J@
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MV MIL/_GPP1?7*#L =Q?2FEV$^N@>L.%OP!02P,$% @ &#@*5QH"[TH#
M P #0T !D !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULO5==;YLP%/TK
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M!!0 ( !@X"E=\(]X#Z ( "<* 9 >&PO=V]R:W-H965T<R]S:&5E
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M(]G"G+L3)M4I;IJYNLD!UP#U?<:8?.WHH[RY&Z;_ 5!+ P04 " 8. I7
M[Y?Z[ X# #L" &0 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RMEEUO
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M'P=[[.[.662^ VZP6!,F$85<Z[RSD;8NFK.U&2A>V>-IR94^[.QMH3]'0)@
M/9]SKIX'YL3K/G#2/U!+ P04 " 8. I7U%#Y880' "H2@ &0 'AL
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MLTP^;Y0)FH=33?\!4$L#!!0 ( !@X"E? &]J%9P( %<% 9 >&PO
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MN&YLW]+T+U!+ P04 " 8. I7[@\VC,8$ "-' &0 'AL+W=O<FMS
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MSW3_*RH&U%5X$4UX]A_LBV<="T1;+FA:&,L(4DSR7_A>$%$QZ%PR\ H#[\3
M\RX8^(6!?VK@7C#H% :=CQIT"X-LZ'8^]HRX HX&3&Z!TP]+='40<9^9BWY
MPD2]* O!Y%TL[<1D2M-4Z45B,)<2(<90#!:"1F_@)_ [9 PJ(<%M@ 3$";\;
MV4)Z5;9V5'AXSCUX%SSTP(P2L>8@)#&*Z_:VC+8,V3N$_.QI 7_;D@?@._?
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MHS):O-;*F$0+C**%!9KK5;/;@^.7":Y.^;$G=+4-SN1%+H601.BL9M/4=_>
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M5 B:9H=K!&/$U /R_I)2<3A1#LH=R,G_4$L#!!0 ( !@X"E?W_?P7U ,
M %@3 9 >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+5888^C-A#]*Q:5
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M*\6S\C(!HO5L O3ZEG-UO#&'*\UAVO)_4$L#!!0 ( !@X"E>:=!\V3!$
M CS 9 >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;,7=?V^;6+['\:>"
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MYJ*:0#4/U7Q4"U MI#2Y0IL @CY]Z9/H: !U6Q4<U#-136!:AZJ^:@6H%I(
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MOFV?SL6_ 5!+ P04 " 8. I7XKT<!Y0# "K$ &0 'AL+W=O<FMS
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M)N-FPTFM1K\[PL4@J989X!2H%!#/5X3P_48:Z/X_$?X+4$L#!!0 ( !@X
M"E=D0^QIG 0 , ; 9 >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;+V9
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MP6XVQD$03/S=&7?#PMT0=/>GI-R:@UR "FU=#$]<U#@8%0Y&H(/'K'<@ Z!
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MB7U L6DW^Q=02P,$% @ &#@*5]W]$TY/ P /0L !D !X;"]W;W)K
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M[6ED\<B1C5X/25X/F7>&'(@;M.(&Y[EGPW/\.\R9VMD4#BS.'0;1D4A;U�
M/])Y%M?<RA6%1VK=O7Z@ +$TC9@DJ2['=>5O5]M>;V):G*/UJ7\S\RWK"?:&
M=2OWF[YN++]2L638'^2PP*/P<NA'43=K]43QRG0CCUQA;V.&*^QO0>@ W%]P
MKEXF^H"V8XY_ 5!+ P04 " 8. I7A(]T#E0$ #<% &0 'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6RU6&MSHS84_2L:MK.SF6D, H/MK.V9Q-F^
MIMO-)&WWLPS7-A- KB3L9*8_OA)@P!@K-G6^V$CH/L[1XQXTWE+VS%< KW$
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M3O\#4$L#!!0 ( !@X"E>N<[67< ( '\& 9 >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;*U546_3,!#^*U:8T"9!G29MF48:J>M #&E2M3)X0#RX
MR;6QYMC!=MKMWW-VTM"AK!J(E\1GW_?=?>?<)=DI?6\* $L>2B'--"BLK2XH
M-5D!)3,#58'$D[72);-HZ@TUE0:6>U I:!2&$UHR+H,T\7L+G2:JMH)+6&AB
MZK)D^O$2A-I-@V&PW[CEF\*Z#9HF%=O $NQ=M=!HT8XEYR5(PY4D&M;38#:\
MF(^=OW?XRF%G#M;$*5DI=>^,ZWP:A"XA$)!9Q\#PM84Y".&(,(V?+6?0A73
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M%Z#[YZ2_ %!+ P04 " 8. I75BHEFJX# !@$@ &0 'AL+W=O<FMS
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M /5\R9C<WN@75(=*D[]02P,$% @ &#@*5Q.5RYQ) P T!0 T !X
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M P04 " 8. I7EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P
M#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX
MI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606
MIW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E
M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU
M@LD/['X 4$L#!!0 ( !@X"E>"S&:-V@, +\? / >&PO=V]R:V)O
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M?P%02P,$% @ &#@*5[DCVC>R 0 5!P !H !X;"]?<F5L<R]W;W)K
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M!!0 ( !@X"E=EX9FUMP$ &4< 3 6T-O;G1E;G1?5'EP97-=+GAM
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MJT*15:'(JE!D52BRJO^4]=V8Y5__^&KO::W+YI#/NK^+TT]02P$"% ,4
M" 8. I7!T%-8H$ "Q $ @ $ 9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0 ( !@X"E<\LOI=[0 "L" 1
M " :\ !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0 ( !@X"E>97)PC
M$ 8 )PG 3 " <L! !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#% @ &#@*5Y7I+JP.!@ HR !@ ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0 ( !@X"E=)H?+#
M& 8 !<: 8 " @5 . !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4 " 8. I7"6V50_X" ="@ &
M@(&>% >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#% @ &#@*
M5WWB=9YI!0 -1H !@ ("!TA< 'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0 ( !@X"E>^\"7V7PD #U0 8
M " @7$= !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" 8. I7Z!\,ZI8" #(!@ & @($&)P >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#% @ &#@*5X71JDU3!P TR !@
M ("!TBD 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0 ( !@X"E<(+J+QZ 4 #\- 8 " @5LQ !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4 " 8. I7G.L<E1$' !)
M% & @(%Y-P >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#% @ &#@*5Y$JC*Z#"@ YQL !D ("!P#X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4 " 8. I7*!G6
MNSD' E% &0 @(%Z20 >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0 ( !@X"E?XM@C)$00 * 9
M " @>I0 !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#% @
M&#@*5R,=,4/> @ D 8 !D ("!,E4 'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4 " 8. I7?AU/80T* B&@ &0
M @(%'6 >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0 ( !@X"E>#>3AWKP0 (T+ 9 " @8MB !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#% @ &#@*5RTN(-Q>#0
MW"T !D ("!<6< 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4 " 8. I7:>)B81 $ #T" &0 @($&
M=0 >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0 ( !@X"E<Y
MRB'U+@, (H' 9 " @4UY !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#% @ &#@*5R@:":T#!@ 41 !D
M ("!LGP 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M" 8. I77TT3".8" !E!@ &0 @('L@@ >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0 ( !@X"E?U0Z_*K0, $$* 9
M " @0F& !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#% @ &#@*5S]$-$,E P > < !D ("![8D 'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4 " 8. I7JR%UU.,"
M !,!@ &0 @(%)C0 >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0 ( !@X"E=&+CM9H@( )\% 9 "
M@6.0 !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#% @ &#@*
M5Q\0->O[ @ R 8 !D ("!/), 'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4 " 8. I7)SBR=P,% !K#0 &0
M @(%NE@ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M ( !@X"E>CT2\[50, 'X' 9 " @:B; !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#% @ &#@*5_SK4,N$ @ <
M !D ("!-)\ 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4 " 8. I7JWDGYC0% "Q( &0 @('OH0
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0 ( !@X"E?)=.6\
MI@( '@& 9 " @5JG !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#% @ &#@*5TNNO,@@!0 SB( !D
M ("!-ZH 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4 " 8
M. I7V1.K&A\$ "]& &0 @(&.KP >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0 ( !@X"E=VPF&1*0, ,\) 9
M " @>2S !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#
M% @ &#@*5QH"[TH# P #0T !D ("!1+< 'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4 " 8. I7?"/> ^@" G
M"@ &0 @(%^N@ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;%!+ 0(4 Q0 ( !@X"E?OE_KL#@, .P( 9 " @9V]
M !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#% @ &#@*5]10
M^6&$!P J$H !D ("!XL 'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6Q02P$"% ,4 " 8. I7P!O:A6<" !7!0 &0
M @(&=R >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0 (
M !@X"E?N#S:,Q@0 (T< 9 " @3O+ !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#% @ &#@*5_?]_!?4 P 6!, !D
M ("!.- 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4 " 8. I7FG0?-DP1 (\P &0 @(%#U >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0 ( !@X"E?BO1P'E ,
M *L0 9 " @<;E !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#% @ &#@*5V1#[&F<! P!L !D ("!
MD>D 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4 " 8. I7
MW?T33D\# ]"P &0 @(%D[@ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0 ( !@X"E>$CW0.5 0 -P4 9
M " @>KQ !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M @ &#@*5ZYSM9=P @ ?P8 !D ("!=?8 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4 " 8. I75BHEFJX# !@$@
M&0 @($<^0 >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0 ( !@X"E<3E<N<20, - 4 - " 0'] !X
M;"]S='EL97,N>&UL4$L! A0#% @ &#@*5Y>*NQS $P( L
M ( !=0 ! %]R96QS+RYR96QS4$L! A0#% @ &#@*5X+,9HW:
M P OQ\ \ ( !7@$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0 ( !@X"E>Y(]HWL@$ %0< : " 64% 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0 ( !@X"E=EX9FUMP$
M &4< 3 " 4\' 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@ W #< ^ X #<) 0 $!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
<Version>3.23.2</Version>
<ProcessingTime/>
<ReportFormat>html</ReportFormat>
<ContextCount>145</ContextCount>
<ElementCount>225</ElementCount>
<EntityCount>1</EntityCount>
<FootnotesReported>false</FootnotesReported>
<SegmentCount>40</SegmentCount>
<ScenarioCount>0</ScenarioCount>
<TuplesReported>false</TuplesReported>
<UnitCount>4</UnitCount>
<MyReports>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R1.htm</HtmlFileName>
<LongName>0000001 - Document - Cover</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/Cover</Role>
<ShortName>Cover</ShortName>
<MenuCategory>Cover</MenuCategory>
<Position>1</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R2.htm</HtmlFileName>
<LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
<ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>2</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R3.htm</HtmlFileName>
<LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
<ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>3</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R4.htm</HtmlFileName>
<LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited</Role>
<ShortName>Condensed Consolidated Statements of Operations (unaudited)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>4</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R5.htm</HtmlFileName>
<LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (unaudited)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited</Role>
<ShortName>Condensed Consolidated Statements of Stockholders??? Equity (unaudited)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>5</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R6.htm</HtmlFileName>
<LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (unaudited) (Parentheticals)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals</Role>
<ShortName>Condensed Consolidated Statements of Stockholders??? Equity (unaudited) (Parentheticals)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>6</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R7.htm</HtmlFileName>
<LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
<ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>7</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R8.htm</HtmlFileName>
<LongName>0000008 - Disclosure - Nature of Business</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/NatureofBusiness</Role>
<ShortName>Nature of Business</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>8</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R9.htm</HtmlFileName>
<LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/SummaryofSignificantAccountingPolicies</Role>
<ShortName>Summary of Significant Accounting Policies</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>9</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R10.htm</HtmlFileName>
<LongName>0000010 - Disclosure - Jazz Collaboration and License Agreement</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/JazzCollaborationandLicenseAgreement</Role>
<ShortName>Jazz Collaboration and License Agreement</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>10</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R11.htm</HtmlFileName>
<LongName>0000011 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements</Role>
<ShortName>Financial Instruments and Fair Value Measurements</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>11</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R12.htm</HtmlFileName>
<LongName>0000012 - Disclosure - Restricted Cash and Cash Equivalents</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/RestrictedCashandCashEquivalents</Role>
<ShortName>Restricted Cash and Cash Equivalents</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>12</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R13.htm</HtmlFileName>
<LongName>0000013 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
<ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>13</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R14.htm</HtmlFileName>
<LongName>0000014 - Disclosure - Term Loan</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/TermLoan</Role>
<ShortName>Term Loan</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>14</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R15.htm</HtmlFileName>
<LongName>0000015 - Disclosure - Common and Preferred Stock</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CommonandPreferredStock</Role>
<ShortName>Common and Preferred Stock</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>15</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R16.htm</HtmlFileName>
<LongName>0000016 - Disclosure - Stock-based Compensation</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensation</Role>
<ShortName>Stock-based Compensation</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>16</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R17.htm</HtmlFileName>
<LongName>0000017 - Disclosure - Related Parties</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/RelatedParties</Role>
<ShortName>Related Parties</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>17</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R18.htm</HtmlFileName>
<LongName>0000018 - Disclosure - Net Loss Attributable to Common Stockholders per Share</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare</Role>
<ShortName>Net Loss Attributable to Common Stockholders per Share</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>18</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R19.htm</HtmlFileName>
<LongName>9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
<ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
<MenuCategory>Policies</MenuCategory>
<ParentRole>http://werewolftx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
<Position>19</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R20.htm</HtmlFileName>
<LongName>9954702 - Disclosure - Jazz Collaboration and License Agreement (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/JazzCollaborationandLicenseAgreementTables</Role>
<ShortName>Jazz Collaboration and License Agreement (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/JazzCollaborationandLicenseAgreement</ParentRole>
<Position>20</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R21.htm</HtmlFileName>
<LongName>9954703 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables</Role>
<ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements</ParentRole>
<Position>21</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R22.htm</HtmlFileName>
<LongName>9954704 - Disclosure - Restricted Cash and Cash Equivalents (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/RestrictedCashandCashEquivalentsTables</Role>
<ShortName>Restricted Cash and Cash Equivalents (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/RestrictedCashandCashEquivalents</ParentRole>
<Position>22</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R23.htm</HtmlFileName>
<LongName>9954705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
<ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
<Position>23</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R24.htm</HtmlFileName>
<LongName>9954706 - Disclosure - Term Loan (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/TermLoanTables</Role>
<ShortName>Term Loan (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/TermLoan</ParentRole>
<Position>24</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R25.htm</HtmlFileName>
<LongName>9954707 - Disclosure - Common and Preferred Stock (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CommonandPreferredStockTables</Role>
<ShortName>Common and Preferred Stock (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/CommonandPreferredStock</ParentRole>
<Position>25</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R26.htm</HtmlFileName>
<LongName>9954708 - Disclosure - Stock-based Compensation (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensationTables</Role>
<ShortName>Stock-based Compensation (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/StockbasedCompensation</ParentRole>
<Position>26</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R27.htm</HtmlFileName>
<LongName>9954709 - Disclosure - Net Loss Attributable to Common Stockholders per Share (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareTables</Role>
<ShortName>Net Loss Attributable to Common Stockholders per Share (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare</ParentRole>
<Position>27</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R28.htm</HtmlFileName>
<LongName>9954710 - Disclosure - Nature of Business (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/NatureofBusinessDetails</Role>
<ShortName>Nature of Business (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://werewolftx.com/role/NatureofBusiness</ParentRole>
<Position>28</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R29.htm</HtmlFileName>
<LongName>9954711 - Disclosure - Jazz Collaboration and License Agreement - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails</Role>
<ShortName>Jazz Collaboration and License Agreement - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>29</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R30.htm</HtmlFileName>
<LongName>9954712 - Disclosure - Jazz Collaboration and License Agreement - Contract with Customer, Contract Asset, Contract Liability, and Receivable (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails</Role>
<ShortName>Jazz Collaboration and License Agreement - Contract with Customer, Contract Asset, Contract Liability, and Receivable (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>30</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R31.htm</HtmlFileName>
<LongName>9954713 - Disclosure - Financial Instruments and Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
<ShortName>Financial Instruments and Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>31</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R32.htm</HtmlFileName>
<LongName>9954714 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails</Role>
<ShortName>Financial Instruments and Fair Value Measurements - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
<Position>32</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R33.htm</HtmlFileName>
<LongName>9954715 - Disclosure - Financial Instruments and Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails</Role>
<ShortName>Financial Instruments and Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>33</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R34.htm</HtmlFileName>
<LongName>9954716 - Disclosure - Restricted Cash and Cash Equivalents - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails</Role>
<ShortName>Restricted Cash and Cash Equivalents - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>34</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R35.htm</HtmlFileName>
<LongName>9954717 - Disclosure - Restricted Cash and Cash Equivalents - Summary of Restricted Cash (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails</Role>
<ShortName>Restricted Cash and Cash Equivalents - Summary of Restricted Cash (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>35</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R36.htm</HtmlFileName>
<LongName>9954718 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
<ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
<Position>36</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R37.htm</HtmlFileName>
<LongName>9954719 - Disclosure - Term Loan - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/TermLoanNarrativeDetails</Role>
<ShortName>Term Loan - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>37</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R38.htm</HtmlFileName>
<LongName>9954720 - Disclosure - Term Loan - Schedule of Long-Term Debt Instruments (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails</Role>
<ShortName>Term Loan - Schedule of Long-Term Debt Instruments (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>38</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R39.htm</HtmlFileName>
<LongName>9954721 - Disclosure - Common and Preferred Stock - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails</Role>
<ShortName>Common and Preferred Stock - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>39</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R40.htm</HtmlFileName>
<LongName>9954722 - Disclosure - Common and Preferred Stock - Schedule of Common Stock Reserved for Issuance (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails</Role>
<ShortName>Common and Preferred Stock - Schedule of Common Stock Reserved for Issuance (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>40</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R41.htm</HtmlFileName>
<LongName>9954723 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensationNarrativeDetails</Role>
<ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>41</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R42.htm</HtmlFileName>
<LongName>9954724 - Disclosure - Stock-based Compensation - Expense Recognized (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails</Role>
<ShortName>Stock-based Compensation - Expense Recognized (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>42</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R43.htm</HtmlFileName>
<LongName>9954725 - Disclosure - Stock-based Compensation - Restricted Stock Award Activity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails</Role>
<ShortName>Stock-based Compensation - Restricted Stock Award Activity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>43</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R44.htm</HtmlFileName>
<LongName>9954726 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails</Role>
<ShortName>Stock-based Compensation - Weighted Average Assumptions (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>44</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R45.htm</HtmlFileName>
<LongName>9954727 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
<ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>45</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R46.htm</HtmlFileName>
<LongName>9954728 - Disclosure - Related Parties (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/RelatedPartiesDetails</Role>
<ShortName>Related Parties (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://werewolftx.com/role/RelatedParties</ParentRole>
<Position>46</Position>
</Report>
<Report instance="howl-20230630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R47.htm</HtmlFileName>
<LongName>9954729 - Disclosure - Net Loss Attributable to Common Stockholders per Share - Antidilutive Shares (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails</Role>
<ShortName>Net Loss Attributable to Common Stockholders per Share - Antidilutive Shares (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>47</Position>
</Report>
<Report>
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<LongName>All Reports</LongName>
<ReportType>Book</ReportType>
<ShortName>All Reports</ShortName>
</Report>
</MyReports>
<InputFiles>
<File doctype="10-Q" original="howl-20230630.htm">howl-20230630.htm</File>
<File>a06302023ex311.htm</File>
<File>a06302023ex312.htm</File>
<File>a06302023ex321.htm</File>
<File>howl-20230630.xsd</File>
<File>howl-20230630_cal.xml</File>
<File>howl-20230630_def.xml</File>
<File>howl-20230630_lab.xml</File>
<File>howl-20230630_pre.xml</File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy items="491">http://fasb.org/us-gaap/2023</BaseTaxonomy>
<BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase>true</HasPresentationLinkbase>
<HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
"instance": {
"howl-20230630.htm": {
"axisCustom": 1,
"axisStandard": 16,
"baseTaxonomies": {
"http://fasb.org/us-gaap/2023": 491,
"http://xbrl.sec.gov/dei/2023": 31
},
"contextCount": 145,
"dts": {
"calculationLink": {
"local": [
"howl-20230630_cal.xml"
]
},
"definitionLink": {
"local": [
"howl-20230630_def.xml"
]
},
"inline": {
"local": [
"howl-20230630.htm"
]
},
"labelLink": {
"local": [
"howl-20230630_lab.xml"
]
},
"presentationLink": {
"local": [
"howl-20230630_pre.xml"
]
},
"schema": {
"local": [
"howl-20230630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
"https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
]
}
},
"elementCount": 346,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2023": 5,
"total": 5
},
"keyCustom": 26,
"keyStandard": 199,
"memberCustom": 10,
"memberStandard": 21,
"nsprefix": "howl",
"nsuri": "http://werewolftx.com/20230630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0000001 - Document - Cover",
"menuCat": "Cover",
"order": "1",
"role": "http://werewolftx.com/role/Cover",
"shortName": "Cover",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000010 - Disclosure - Jazz Collaboration and License Agreement",
"menuCat": "Notes",
"order": "10",
"role": "http://werewolftx.com/role/JazzCollaborationandLicenseAgreement",
"shortName": "Jazz Collaboration and License Agreement",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000011 - Disclosure - Financial Instruments and Fair Value Measurements",
"menuCat": "Notes",
"order": "11",
"role": "http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements",
"shortName": "Financial Instruments and Fair Value Measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000012 - Disclosure - Restricted Cash and Cash Equivalents",
"menuCat": "Notes",
"order": "12",
"role": "http://werewolftx.com/role/RestrictedCashandCashEquivalents",
"shortName": "Restricted Cash and Cash Equivalents",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "howl:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000013 - Disclosure - Accrued Expenses and Other Current Liabilities",
"menuCat": "Notes",
"order": "13",
"role": "http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities",
"shortName": "Accrued Expenses and Other Current Liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "howl:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000014 - Disclosure - Term Loan",
"menuCat": "Notes",
"order": "14",
"role": "http://werewolftx.com/role/TermLoan",
"shortName": "Term Loan",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000015 - Disclosure - Common and Preferred Stock",
"menuCat": "Notes",
"order": "15",
"role": "http://werewolftx.com/role/CommonandPreferredStock",
"shortName": "Common and Preferred Stock",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000016 - Disclosure - Stock-based Compensation",
"menuCat": "Notes",
"order": "16",
"role": "http://werewolftx.com/role/StockbasedCompensation",
"shortName": "Stock-based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000017 - Disclosure - Related Parties",
"menuCat": "Notes",
"order": "17",
"role": "http://werewolftx.com/role/RelatedParties",
"shortName": "Related Parties",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000018 - Disclosure - Net Loss Attributable to Common Stockholders per Share",
"menuCat": "Notes",
"order": "18",
"role": "http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare",
"shortName": "Net Loss Attributable to Common Stockholders per Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)",
"menuCat": "Policies",
"order": "19",
"role": "http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
"shortName": "Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
"menuCat": "Statements",
"order": "2",
"role": "http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"shortName": "Condensed Consolidated Balance Sheets (unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954702 - Disclosure - Jazz Collaboration and License Agreement (Tables)",
"menuCat": "Tables",
"order": "20",
"role": "http://werewolftx.com/role/JazzCollaborationandLicenseAgreementTables",
"shortName": "Jazz Collaboration and License Agreement (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954703 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
"menuCat": "Tables",
"order": "21",
"role": "http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables",
"shortName": "Financial Instruments and Fair Value Measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954704 - Disclosure - Restricted Cash and Cash Equivalents (Tables)",
"menuCat": "Tables",
"order": "22",
"role": "http://werewolftx.com/role/RestrictedCashandCashEquivalentsTables",
"shortName": "Restricted Cash and Cash Equivalents (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954705 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
"menuCat": "Tables",
"order": "23",
"role": "http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
"shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954706 - Disclosure - Term Loan (Tables)",
"menuCat": "Tables",
"order": "24",
"role": "http://werewolftx.com/role/TermLoanTables",
"shortName": "Term Loan (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954707 - Disclosure - Common and Preferred Stock (Tables)",
"menuCat": "Tables",
"order": "25",
"role": "http://werewolftx.com/role/CommonandPreferredStockTables",
"shortName": "Common and Preferred Stock (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954708 - Disclosure - Stock-based Compensation (Tables)",
"menuCat": "Tables",
"order": "26",
"role": "http://werewolftx.com/role/StockbasedCompensationTables",
"shortName": "Stock-based Compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954709 - Disclosure - Net Loss Attributable to Common Stockholders per Share (Tables)",
"menuCat": "Tables",
"order": "27",
"role": "http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareTables",
"shortName": "Net Loss Attributable to Common Stockholders per Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954710 - Disclosure - Nature of Business (Details)",
"menuCat": "Details",
"order": "28",
"role": "http://werewolftx.com/role/NatureofBusinessDetails",
"shortName": "Nature of Business (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R29": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954711 - Disclosure - Jazz Collaboration and License Agreement - Narrative (Details)",
"menuCat": "Details",
"order": "29",
"role": "http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails",
"shortName": "Jazz Collaboration and License Agreement - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-4",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:UnbilledReceivablesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"us-gaap:PreferredStockParOrStatedValuePerShare",
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
"menuCat": "Statements",
"order": "3",
"role": "http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
"shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"us-gaap:PreferredStockParOrStatedValuePerShare",
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-4",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiability",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954712 - Disclosure - Jazz Collaboration and License Agreement - Contract with Customer, Contract Asset, Contract Liability, and Receivable (Details)",
"menuCat": "Details",
"order": "30",
"role": "http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails",
"shortName": "Jazz Collaboration and License Agreement - Contract with Customer, Contract Asset, Contract Liability, and Receivable (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-4",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiability",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "howl:SuccessPaymentLiability",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954713 - Disclosure - Financial Instruments and Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details)",
"menuCat": "Details",
"order": "31",
"role": "http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"shortName": "Financial Instruments and Fair Value Measurements - Assets Measured at Fair Value on a Recurring Basis (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-52",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:AssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "howl:SuccessPaymentLiability",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954714 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)",
"menuCat": "Details",
"order": "32",
"role": "http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails",
"shortName": "Financial Instruments and Fair Value Measurements - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R33": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-60",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLiabilitiesFairValueDisclosure",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954715 - Disclosure - Financial Instruments and Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
"menuCat": "Details",
"order": "33",
"role": "http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"shortName": "Financial Instruments and Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-62",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RestrictedCash",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954716 - Disclosure - Restricted Cash and Cash Equivalents - Narrative (Details)",
"menuCat": "Details",
"order": "34",
"role": "http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"shortName": "Restricted Cash and Cash Equivalents - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RestrictedCash",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954717 - Disclosure - Restricted Cash and Cash Equivalents - Summary of Restricted Cash (Details)",
"menuCat": "Details",
"order": "35",
"role": "http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails",
"shortName": "Restricted Cash and Cash Equivalents - Summary of Restricted Cash (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-43",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:RestrictedCashNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "howl:AccruedManufacturingCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954718 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
"menuCat": "Details",
"order": "36",
"role": "http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
"shortName": "Accrued Expenses and Other Current Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "howl:AccruedManufacturingCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-68",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954719 - Disclosure - Term Loan - Narrative (Details)",
"menuCat": "Details",
"order": "37",
"role": "http://werewolftx.com/role/TermLoanNarrativeDetails",
"shortName": "Term Loan - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-68",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-63",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentCarryingAmount",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954720 - Disclosure - Term Loan - Schedule of Long-Term Debt Instruments (Details)",
"menuCat": "Details",
"order": "38",
"role": "http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails",
"shortName": "Term Loan - Schedule of Long-Term Debt Instruments (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-63",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockSharesAuthorized",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954721 - Disclosure - Common and Preferred Stock - Narrative (Details)",
"menuCat": "Details",
"order": "39",
"role": "http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"shortName": "Common and Preferred Stock - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (unaudited)",
"menuCat": "Statements",
"order": "4",
"role": "http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
"shortName": "Condensed Consolidated Statements of Operations (unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954722 - Disclosure - Common and Preferred Stock - Schedule of Common Stock Reserved for Issuance (Details)",
"menuCat": "Details",
"order": "40",
"role": "http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails",
"shortName": "Common and Preferred Stock - Schedule of Common Stock Reserved for Issuance (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-84",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-3",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954723 - Disclosure - Stock-based Compensation - Narrative (Details)",
"menuCat": "Details",
"order": "41",
"role": "http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"shortName": "Stock-based Compensation - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "2",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954724 - Disclosure - Stock-based Compensation - Expense Recognized (Details)",
"menuCat": "Details",
"order": "42",
"role": "http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails",
"shortName": "Stock-based Compensation - Expense Recognized (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-111",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-119",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954725 - Disclosure - Stock-based Compensation - Restricted Stock Award Activity (Details)",
"menuCat": "Details",
"order": "43",
"role": "http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails",
"shortName": "Stock-based Compensation - Restricted Stock Award Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-119",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-131",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954726 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)",
"menuCat": "Details",
"order": "44",
"role": "http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails",
"shortName": "Stock-based Compensation - Weighted Average Assumptions (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R45": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-135",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954727 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)",
"menuCat": "Details",
"order": "45",
"role": "http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails",
"shortName": "Stock-based Compensation - Stock Option Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-133",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:SubleaseIncome",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954728 - Disclosure - Related Parties (Details)",
"menuCat": "Details",
"order": "46",
"role": "http://werewolftx.com/role/RelatedPartiesDetails",
"shortName": "Related Parties (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:SubleaseIncome",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "9954729 - Disclosure - Net Loss Attributable to Common Stockholders per Share - Antidilutive Shares (Details)",
"menuCat": "Details",
"order": "47",
"role": "http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails",
"shortName": "Net Loss Attributable to Common Stockholders per Share - Antidilutive Shares (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-25",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited)",
"menuCat": "Statements",
"order": "5",
"role": "http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-30",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited) (Parentheticals)",
"menuCat": "Statements",
"order": "6",
"role": "http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals",
"shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (unaudited) (Parentheticals)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-5",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
"menuCat": "Statements",
"order": "7",
"role": "http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000008 - Disclosure - Nature of Business",
"menuCat": "Notes",
"order": "8",
"role": "http://werewolftx.com/role/NatureofBusiness",
"shortName": "Nature of Business",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
"menuCat": "Notes",
"order": "9",
"role": "http://werewolftx.com/role/SummaryofSignificantAccountingPolicies",
"shortName": "Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "howl-20230630.htm",
"contextRef": "c-1",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 40,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r494"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r495"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two",
"terseLabel": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityExTransitionPeriod": {
"auth_ref": [
"r497"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
"label": "Entity Ex Transition Period",
"terseLabel": "Entity Ex Transition Period"
}
}
},
"localname": "EntityExTransitionPeriod",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r496"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r491"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://werewolftx.com/role/Cover"
],
"xbrltype": "tradingSymbolItemType"
},
"howl_A2017StockIncentivePlanMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "2017 Stock Incentive Plan",
"label": "2017 Stock Incentive Plan [Member]",
"terseLabel": "2017 Stock Incentive Plan"
}
}
},
"localname": "A2017StockIncentivePlanMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "domainItemType"
},
"howl_A2021StockEmployeeStockPurchasePlanMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "2021 Stock Employee Stock Purchase Plan",
"label": "2021 Stock Employee Stock Purchase Plan [Member]",
"terseLabel": "2021 Stock Employee Stock Purchase Plan",
"verboseLabel": "Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan"
}
}
},
"localname": "A2021StockEmployeeStockPurchasePlanMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_A2021StockIncentivePlanMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "2021 Stock Incentive Plan",
"label": "2021 Stock Incentive Plan [Member]",
"terseLabel": "2021 Stock Incentive Plan"
}
}
},
"localname": "A2021StockIncentivePlanMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "domainItemType"
},
"howl_ATMOfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "ATM Offering",
"label": "ATM Offering [Member]",
"terseLabel": "ATM Offering"
}
}
},
"localname": "ATMOfferingMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_AccruedContractResearchCurrent": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": 4.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued Contract Research, Current",
"label": "Accrued Contract Research, Current",
"terseLabel": "Contract research"
}
}
},
"localname": "AccruedContractResearchCurrent",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Accrued Expenses and Other Current Liabilities",
"label": "Accrued Expenses and Other Current Liabilities Disclosure [Text Block]",
"terseLabel": "Accrued Expenses and Other Current Liabilities"
}
}
},
"localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilities"
],
"xbrltype": "textBlockItemType"
},
"howl_AccruedManufacturingCurrent": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued Manufacturing, Current",
"label": "Accrued Manufacturing, Current",
"terseLabel": "Manufacturing"
}
}
},
"localname": "AccruedManufacturingCurrent",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_CollaborationAgreementEstimatedFutureReimbursableCosts": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Collaboration Agreement, Estimated Future Reimbursable Costs",
"label": "Collaboration Agreement, Estimated Future Reimbursable Costs",
"terseLabel": "Estimated future reimbursable costs"
}
}
},
"localname": "CollaborationAgreementEstimatedFutureReimbursableCosts",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_CollaborationAgreementTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Collaboration Agreement, Term",
"label": "Collaboration Agreement, Term",
"terseLabel": "Collaboration agreement, term"
}
}
},
"localname": "CollaborationAgreementTerm",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"howl_CollaborativeAgreementTransactionPrice": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative Agreement, Transaction Price",
"label": "Collaborative Agreement, Transaction Price",
"terseLabel": "Transaction price"
}
}
},
"localname": "CollaborativeAgreementTransactionPrice",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_CommonStockAmountAuthorized": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Common Stock, Amount Authorized",
"label": "Common Stock, Amount Authorized",
"terseLabel": "Common stock, amount authorized"
}
}
},
"localname": "CommonStockAmountAuthorized",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_DebtInstrumentConditionalFeeLiability": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Conditional Fee, Liability",
"label": "Debt Instrument, Conditional Fee, Liability",
"terseLabel": "Debt instrument, conditional fee, liability"
}
}
},
"localname": "DebtInstrumentConditionalFeeLiability",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_DebtInstrumentConditionalFeePercentageOfAmountDrawn": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Conditional Fee, Percentage Of Amount Drawn",
"label": "Debt Instrument, Conditional Fee, Percentage Of Amount Drawn",
"terseLabel": "Success Fee (percent)"
}
}
},
"localname": "DebtInstrumentConditionalFeePercentageOfAmountDrawn",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"howl_DebtInstrumentCovenantMaximumAnnualCapitalExpenditure": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Maximum Annual Capital Expenditure",
"label": "Debt Instrument, Covenant, Maximum Annual Capital Expenditure",
"terseLabel": "Maximum annual capital expenditures"
}
}
},
"localname": "DebtInstrumentCovenantMaximumAnnualCapitalExpenditure",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"howl_DebtInstrumentCovenantPeriodAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Period",
"label": "Debt Instrument, Covenant, Period [Axis]",
"terseLabel": "Debt Instrument, Covenant, Period [Axis]"
}
}
},
"localname": "DebtInstrumentCovenantPeriodAxis",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"howl_DebtInstrumentCovenantPeriodDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Period",
"label": "Debt Instrument, Covenant, Period [Domain]",
"terseLabel": "Debt Instrument, Covenant, Period [Domain]"
}
}
},
"localname": "DebtInstrumentCovenantPeriodDomain",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_DebtInstrumentCovenantPeriodOneMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Period One",
"label": "Debt Instrument, Covenant, Period One [Member]",
"terseLabel": "Period One"
}
}
},
"localname": "DebtInstrumentCovenantPeriodOneMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_DebtInstrumentCovenantPeriodTwoMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Period Two",
"label": "Debt Instrument, Covenant, Period Two [Member]",
"terseLabel": "Period Two"
}
}
},
"localname": "DebtInstrumentCovenantPeriodTwoMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Default or Late Payment Fee, Percent of Unpaid Amount",
"label": "Debt Instrument, Default or Late Payment Fee, Percent of Unpaid Amount",
"terseLabel": "Default payment fee (percent)"
}
}
},
"localname": "DebtInstrumentDefaultOrLatePaymentFeePercentOfUnpaidAmount",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"howl_DebtInstrumentMaximumBorrowingCapacity": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Maximum Borrowing Capacity",
"label": "Debt Instrument, Maximum Borrowing Capacity",
"terseLabel": "Term loan available"
}
}
},
"localname": "DebtInstrumentMaximumBorrowingCapacity",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_DecreaseInContractWithCustomerLiability": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Decrease In Contract With Customer, Liability",
"label": "Decrease In Contract With Customer, Liability",
"negatedTerseLabel": "Reductions"
}
}
},
"localname": "DecreaseInContractWithCustomerLiability",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_DevelopmentAndRegulatoryMilestones": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Development and Regulatory Milestones",
"label": "Development and Regulatory Milestones",
"terseLabel": "Development and regulatory milestones (up to)"
}
}
},
"localname": "DevelopmentAndRegulatoryMilestones",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Earnings Per Share Basic And Diluted Other Disclosures1",
"label": "Earnings Per Share Basic And Diluted Other Disclosures1 [Abstract]",
"terseLabel": "Weighted-average common shares outstanding, basic and diluted"
}
}
},
"localname": "EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "stringItemType"
},
"howl_EmployeeStockOwnershipPlanOfferingPeriod": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Employee Stock Ownership Plan, Offering Period",
"label": "Employee Stock Ownership Plan, Offering Period",
"terseLabel": "Offering period"
}
}
},
"localname": "EmployeeStockOwnershipPlanOfferingPeriod",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"howl_EmployeeStockOwnershipPlanPurchasePricePercent": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Employee Stock Ownership Plan, Purchase Price, Percent",
"label": "Employee Stock Ownership Plan, Purchase Price, Percent",
"terseLabel": "Employee stock ownership plan, purchase price, percent"
}
}
},
"localname": "EmployeeStockOwnershipPlanPurchasePricePercent",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"howl_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 13.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase (Decrease) In Operating Lease Liability and Right of Use Asset",
"label": "Increase (Decrease) In Operating Lease Liability and Right of Use Asset",
"terseLabel": "Operating lease liability"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"howl_IncreaseInContractWithCustomerLiability": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase In Contract With Customer, Liability",
"label": "Increase In Contract With Customer, Liability",
"terseLabel": "Additions"
}
}
},
"localname": "IncreaseInContractWithCustomerLiability",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_JazzCollaborationAgreementMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Jazz Collaboration Agreement",
"label": "Jazz Collaboration Agreement [Member]",
"terseLabel": "Jazz Collaboration Agreement"
}
}
},
"localname": "JazzCollaborationAgreementMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_NonCashInterestExpense": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 15.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Non-Cash Interest Expense",
"label": "Non-Cash Interest Expense",
"terseLabel": "Non-cash interest expense"
}
}
},
"localname": "NonCashInterestExpense",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"howl_NonRefundableUpfrontCashPaymentReceived": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Non-Refundable Upfront Cash Payment Received",
"label": "Non-Refundable Upfront Cash Payment Received",
"terseLabel": "Non-refundable upfront cash payment received"
}
}
},
"localname": "NonRefundableUpfrontCashPaymentReceived",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_SalesBasedMilestonesUpTo": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sales-Based Milestones (up to)",
"label": "Sales-Based Milestones (up to)",
"terseLabel": "Sales-based milestones (up to)"
}
}
},
"localname": "SalesBasedMilestonesUpTo",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_SalesCommissionsPercentage": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sales Commissions, Percentage",
"label": "Sales Commissions, Percentage",
"terseLabel": "Sales commissions, percentage"
}
}
},
"localname": "SalesCommissionsPercentage",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"howl_StockIssuanceCostsIncurredButNotYetPaid": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Stock Issuance Costs Incurred But Not yet Paid",
"label": "Stock Issuance Costs Incurred But Not yet Paid",
"terseLabel": "Issuance costs in accounts payable and accrued expenses"
}
}
},
"localname": "StockIssuanceCostsIncurredButNotYetPaid",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"howl_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets",
"label": "Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets",
"terseLabel": "Stock option exercise receivables in prepaid expenses and other current assets"
}
}
},
"localname": "StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"howl_SuccessFeeLiabilityPaid": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Success Fee Liability Paid",
"label": "Success Fee Liability Paid",
"terseLabel": "Success fee liability paid"
}
}
},
"localname": "SuccessFeeLiabilityPaid",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_SuccessPaymentLiability": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": 6.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
},
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherLiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Success Payment Liability",
"label": "Success Payment Liability",
"terseLabel": "Success payment liability"
}
}
},
"localname": "SuccessPaymentLiability",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"howl_TermLoansMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Term Loans",
"label": "Term Loans [Member]",
"terseLabel": "Term Loans"
}
}
},
"localname": "TermLoansMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"howl_TrancheIILoanMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tranche II Loan",
"label": "Tranche II Loan [Member]",
"terseLabel": "Tranche II Loan"
}
}
},
"localname": "TrancheIILoanMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"howl_TrancheILoanMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tranche I Loan",
"label": "Tranche I Loan [Member]",
"terseLabel": "Tranche I Loan"
}
}
},
"localname": "TrancheILoanMember",
"nsuri": "http://werewolftx.com/20230630",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r184",
"r185",
"r186",
"r187",
"r254",
"r341",
"r356",
"r386",
"r387",
"r446",
"r447",
"r448",
"r449",
"r450",
"r457",
"r458",
"r463",
"r469",
"r473",
"r478",
"r517",
"r553",
"r554",
"r555",
"r556",
"r557",
"r558"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r184",
"r185",
"r186",
"r187",
"r254",
"r341",
"r356",
"r386",
"r387",
"r446",
"r447",
"r448",
"r449",
"r450",
"r457",
"r458",
"r463",
"r469",
"r473",
"r478",
"r517",
"r553",
"r554",
"r555",
"r556",
"r557",
"r558"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r184",
"r185",
"r186",
"r187",
"r247",
"r254",
"r280",
"r281",
"r282",
"r340",
"r341",
"r356",
"r386",
"r387",
"r446",
"r447",
"r448",
"r449",
"r450",
"r457",
"r458",
"r463",
"r469",
"r473",
"r478",
"r481",
"r514",
"r517",
"r554",
"r555",
"r556",
"r557",
"r558"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]",
"terseLabel": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r184",
"r185",
"r186",
"r187",
"r247",
"r254",
"r280",
"r281",
"r282",
"r340",
"r341",
"r356",
"r386",
"r387",
"r446",
"r447",
"r448",
"r449",
"r450",
"r457",
"r458",
"r463",
"r469",
"r473",
"r478",
"r481",
"r514",
"r517",
"r554",
"r555",
"r556",
"r557",
"r558"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]",
"terseLabel": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r14",
"r477"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r16"
],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"terseLabel": "Accrued expenses and other current liabilities",
"totalLabel": "Accrued expenses and other current liabilities"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedProfessionalFeesCurrent": {
"auth_ref": [
"r16"
],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Professional Fees, Current",
"terseLabel": "Professional fees"
}
}
},
"localname": "AccruedProfessionalFeesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
"terseLabel": "Non-cash investing and financing activities:"
}
}
},
"localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r68",
"r477",
"r565"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional Paid in Capital",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r289",
"r290",
"r291",
"r373",
"r509",
"r510",
"r511",
"r549",
"r567"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional Paid-in Capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r46",
"r47",
"r256"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
"auth_ref": [
"r5",
"r91"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
"label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
"terseLabel": "Issuance costs"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedParentheticals"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r284",
"r292"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Share-Based Payment Arrangement, Expense",
"terseLabel": "Total stock-based compensation",
"verboseLabel": "Total stock-based compensation (less than)"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfFinancingCosts": {
"auth_ref": [
"r75",
"r219",
"r326",
"r503"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 14.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense attributable to debt issuance costs.",
"label": "Amortization of Debt Issuance Costs",
"terseLabel": "Amortization of debt issuance costs"
}
}
},
"localname": "AmortizationOfFinancingCosts",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r165"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Antidilutive securities excluded from computation of earnings per share (shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r30"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]",
"terseLabel": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r30"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]",
"terseLabel": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
"auth_ref": [
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
}
}
},
"localname": "ArrangementsAndNonarrangementTransactionsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r97",
"r121",
"r141",
"r172",
"r175",
"r177",
"r179",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r298",
"r300",
"r318",
"r346",
"r409",
"r477",
"r490",
"r515",
"r516",
"r551"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r117",
"r125",
"r141",
"r179",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r298",
"r300",
"r318",
"r477",
"r515",
"r516",
"r551"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r50"
],
"calculation": {
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Fair Value Disclosure",
"totalLabel": "Total assets"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r258",
"r259",
"r260",
"r261",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation and Consolidation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Business Combination and Asset Acquisition [Abstract]"
}
}
},
"localname": "BusinessCombinationAndAssetAcquisitionAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
"auth_ref": [
"r27",
"r28",
"r29"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
"label": "Capital Expenditures Incurred but Not yet Paid",
"terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
}
}
},
"localname": "CapitalExpendituresIncurredButNotYetPaid",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Cash": {
"auth_ref": [
"r104",
"r348",
"r384",
"r404",
"r477",
"r490",
"r499"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash",
"terseLabel": "Unrestricted cash"
}
}
},
"localname": "Cash",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Cash and Cash Equivalents [Abstract]"
}
}
},
"localname": "CashAndCashEquivalentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r26",
"r119",
"r459"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://werewolftx.com/role/NatureofBusinessDetails",
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAxis": {
"auth_ref": [
"r119"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of cash and cash equivalent balance.",
"label": "Cash and Cash Equivalents [Axis]",
"terseLabel": "Cash and Cash Equivalents [Axis]"
}
}
},
"localname": "CashAndCashEquivalentsAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
"auth_ref": [
"r119",
"r348"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
"label": "Cash and Cash Equivalents Disclosure [Text Block]",
"terseLabel": "Restricted Cash and Cash Equivalents"
}
}
},
"localname": "CashAndCashEquivalentsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalents"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails": {
"order": 1.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents, Fair Value Disclosure",
"terseLabel": "Money market funds"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r26",
"r82",
"r137"
],
"calculation": {
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"periodEndLabel": "Cash, cash equivalents and restricted cash and cash equivalents\u2014end of period",
"periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents\u2014beginning of period",
"totalLabel": "Cash, cash equivalents and restricted cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r0",
"r82"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r114",
"r122",
"r123",
"r124",
"r141",
"r159",
"r160",
"r162",
"r164",
"r170",
"r171",
"r179",
"r188",
"r190",
"r191",
"r192",
"r195",
"r196",
"r228",
"r229",
"r232",
"r235",
"r242",
"r318",
"r365",
"r366",
"r367",
"r368",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r385",
"r396",
"r418",
"r439",
"r451",
"r452",
"r453",
"r454",
"r455",
"r498",
"r505",
"r512"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class of Stock [Domain]",
"terseLabel": "Class of Stock [Domain]"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [
"r122",
"r123",
"r124",
"r170",
"r228",
"r229",
"r230",
"r232",
"r235",
"r240",
"r242",
"r365",
"r366",
"r367",
"r368",
"r469",
"r498",
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class of Stock [Line Items]",
"terseLabel": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CollaborativeArrangementDisclosureTextBlock": {
"auth_ref": [
"r107",
"r109",
"r113"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
"label": "Collaborative Arrangement Disclosure [Text Block]",
"terseLabel": "Jazz Collaboration and License Agreement"
}
}
},
"localname": "CollaborativeArrangementDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreement"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r21",
"r59",
"r347",
"r395"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
"auth_ref": [
"r22"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate number of common shares reserved for future issuance.",
"label": "Common Stock, Capital Shares Reserved for Future Issuance",
"terseLabel": "Common stock available for issuance (shares)"
}
}
},
"localname": "CommonStockCapitalSharesReservedForFutureIssuance",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r479",
"r480",
"r481",
"r483",
"r484",
"r485",
"r486",
"r509",
"r510",
"r549",
"r564",
"r567"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r67"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock par value (usd per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r67",
"r396"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock authorized (shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r67"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock issued (shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r5",
"r67",
"r396",
"r415",
"r567",
"r568"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"terseLabel": "Common stock outstanding (shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r67",
"r350",
"r477"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"terseLabel": "Common stock, $0.0001 par value, 200,000 shares authorized as of June\u00a030, 2023 and December\u00a031, 2022; 35,642 and 31,515 shares issued as of June\u00a030, 2023 and December\u00a031, 2022, respectively; 35,642 and 31,434 shares outstanding as of June\u00a030, 2023 and December\u00a031, 2022, respectively"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
"auth_ref": [
"r518"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
"label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
"terseLabel": "Contract with Customer, Contract Asset, Contract Liability, and Receivable"
}
}
},
"localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r244",
"r245",
"r246"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"periodEndLabel": "Deferred revenue, ending balance",
"periodStartLabel": "Deferred revenue, beginning balance"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Contract with Customer, Liability [Abstract]",
"terseLabel": "Contract liabilities:"
}
}
},
"localname": "ContractWithCustomerLiabilityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ContractWithCustomerLiabilityNoncurrent": {
"auth_ref": [
"r244",
"r245",
"r246"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
"label": "Contract with Customer, Liability, Noncurrent",
"terseLabel": "Deferred revenue, net of current portion"
}
}
},
"localname": "ContractWithCustomerLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r87",
"r139",
"r197",
"r203",
"r204",
"r205",
"r206",
"r207",
"r208",
"r213",
"r220",
"r221",
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"terseLabel": "Term Loan"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoan"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r13",
"r63",
"r64",
"r98",
"r100",
"r142",
"r198",
"r199",
"r200",
"r201",
"r202",
"r204",
"r209",
"r210",
"r211",
"r212",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r327",
"r464",
"r465",
"r466",
"r467",
"r468",
"r506"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument, Basis Spread on Variable Rate",
"terseLabel": "Floating rate spread in effect (greater than) (percent)"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r13",
"r100",
"r224"
],
"calculation": {
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails": {
"order": 1.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Long-Term Debt, Gross",
"terseLabel": "Principal"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [
"r142",
"r198",
"r199",
"r200",
"r201",
"r202",
"r204",
"r209",
"r210",
"r211",
"r212",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r222",
"r327",
"r464",
"r465",
"r466",
"r467",
"r468",
"r506"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r19",
"r142",
"r198",
"r199",
"r200",
"r201",
"r202",
"r204",
"r209",
"r210",
"r211",
"r212",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r327",
"r464",
"r465",
"r466",
"r467",
"r468",
"r506"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]",
"terseLabel": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r19",
"r39",
"r42",
"r55",
"r56",
"r58",
"r60",
"r89",
"r90",
"r142",
"r198",
"r199",
"r200",
"r201",
"r202",
"r204",
"r209",
"r210",
"r211",
"r212",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r222",
"r327",
"r464",
"r465",
"r466",
"r467",
"r468",
"r506"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-Term Debt Instruments [Table]",
"terseLabel": "Schedule of Long-term Debt Instruments [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
"auth_ref": [
"r57",
"r209",
"r225",
"r465",
"r466"
],
"calculation": {
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails": {
"order": 2.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
"label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
"negatedTerseLabel": "Unamortized debt discount and issuance costs"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentUnusedBorrowingCapacityFee": {
"auth_ref": [
"r18"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of commitment fees for the unused borrowing capacity under the long-term financing arrangement that is available to the entity.",
"label": "Debt Instrument, Unused Borrowing Capacity, Fee",
"terseLabel": "Delayed draw fee"
}
}
},
"localname": "DebtInstrumentUnusedBorrowingCapacityFee",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
"label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
"terseLabel": "Defined contribution plan, maximum annual contributions per employee, percent"
}
}
},
"localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r3",
"r34"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation expense"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r255",
"r257",
"r285",
"r286",
"r288",
"r474"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement [Text Block]",
"terseLabel": "Stock-based Compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Payment Arrangement [Abstract]"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_DividendsPayableCurrentAndNoncurrent": {
"auth_ref": [
"r64",
"r65",
"r99",
"r487",
"r561"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
"label": "Dividends Payable",
"terseLabel": "Dividends declared"
}
}
},
"localname": "DividendsPayableCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]",
"terseLabel": "Net loss per share attributable to common stockholders, basic and diluted"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r132",
"r148",
"r149",
"r150",
"r151",
"r152",
"r157",
"r159",
"r162",
"r163",
"r164",
"r168",
"r310",
"r311",
"r344",
"r355",
"r460"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"verboseLabel": "Net loss per share, basic (usd per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r132",
"r148",
"r149",
"r150",
"r151",
"r152",
"r159",
"r162",
"r163",
"r164",
"r168",
"r310",
"r311",
"r344",
"r355",
"r460"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"verboseLabel": "Net loss per share, diluted (usd per share)"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r156",
"r165",
"r166",
"r167"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Net Loss Attributable to Common Stockholders per Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r16"
],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": 5.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Employee-related Liabilities, Current",
"terseLabel": "Employee compensation and benefits"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
"terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r287"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Share-based compensation not yet recognized, recognition period"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
"auth_ref": [
"r546"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
"terseLabel": "Share-based compensation expense not yet recognized, excluding option"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
"auth_ref": [
"r546"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
"terseLabel": "Share-based compensation expense not yet recognized (less than)"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
"label": "Employee Stock [Member]",
"terseLabel": "Employee stock"
}
}
},
"localname": "EmployeeStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Employee Stock Option [Member]",
"terseLabel": "Shares reserved for future issuance under the 2021 Stock Incentive Plan",
"verboseLabel": "Stock options"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails",
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
"auth_ref": [
"r48"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of employee stock ownership plan.",
"label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
"terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
}
}
},
"localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
"auth_ref": [
"r49"
],
"lang": {
"en-us": {
"role": {
"documentation": "Entities identify multiple employee stock ownership plans by unique name.",
"label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
"terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
}
}
},
"localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r5",
"r115",
"r128",
"r129",
"r130",
"r143",
"r144",
"r145",
"r147",
"r153",
"r155",
"r169",
"r180",
"r181",
"r243",
"r289",
"r290",
"r291",
"r295",
"r296",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r309",
"r319",
"r320",
"r321",
"r322",
"r323",
"r324",
"r331",
"r357",
"r358",
"r359",
"r373",
"r439"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
"auth_ref": [
"r10",
"r50",
"r52",
"r95"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
"label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
"terseLabel": "Assets Measured at Fair Value on a Recurring Basis"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
"terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
"auth_ref": [
"r6",
"r52"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
"label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
"terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
"terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
}
}
},
"localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByBalanceSheetGroupingTable": {
"auth_ref": [
"r50",
"r53",
"r54"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
"label": "Fair Value, by Balance Sheet Grouping [Table]",
"terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
}
}
},
"localname": "FairValueByBalanceSheetGroupingTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r211",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r314",
"r337",
"r338",
"r339",
"r465",
"r466",
"r470",
"r471",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r313",
"r314",
"r315",
"r316",
"r317"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Measurement Frequency [Axis]",
"terseLabel": "Measurement Frequency [Axis]"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r312"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Financial Instruments and Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r211",
"r248",
"r253",
"r314",
"r337",
"r470",
"r471",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Quoted Price in Active Markets (Level 1)"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r211",
"r248",
"r253",
"r314",
"r338",
"r465",
"r466",
"r470",
"r471",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Significant Other Observable Inputs (Level 2)"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r211",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r314",
"r339",
"r465",
"r466",
"r470",
"r471",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Significant Unobservable Inputs\u00a0(Level\u00a03)"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Measurement Frequency [Domain]",
"terseLabel": "Measurement Frequency [Domain]"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
"terseLabel": "Change in fair value"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
"auth_ref": [
"r51"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
"terseLabel": "Additions"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
"auth_ref": [
"r51"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
"negatedTerseLabel": "Payment at Success Event"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r211",
"r248",
"r249",
"r250",
"r251",
"r252",
"r253",
"r337",
"r338",
"r339",
"r465",
"r466",
"r470",
"r471",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r312",
"r317"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value, Recurring [Member]",
"terseLabel": "Recurring"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r76",
"r420"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"terseLabel": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"auth_ref": [
"r74"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing general and administrative expense.",
"label": "General and Administrative Expense [Member]",
"terseLabel": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r182",
"r183",
"r423"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r183",
"r423"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
"auth_ref": [
"r2"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
"label": "Increase (Decrease) in Accounts Payable, Trade",
"terseLabel": "Accounts payable"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableTrade",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccruedLiabilities": {
"auth_ref": [
"r2"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
"label": "Increase (Decrease) in Accrued Liabilities",
"terseLabel": "Accrued expenses and other current liabilities"
}
}
},
"localname": "IncreaseDecreaseInAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
"auth_ref": [
"r342",
"r502"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Increase (Decrease) in Contract with Customer, Liability",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "IncreaseDecreaseInContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
"auth_ref": [
"r502"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
"label": "Increase (Decrease) in Derivative Liabilities",
"terseLabel": "Change in fair value of success payment liability"
}
}
},
"localname": "IncreaseDecreaseInDerivativeLiabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
"auth_ref": [
"r502"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
"label": "Increase (Decrease) in Other Noncurrent Assets",
"negatedTerseLabel": "Other non-current assets"
}
}
},
"localname": "IncreaseDecreaseInOtherNoncurrentAssets",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
"auth_ref": [
"r2"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
"label": "Increase (Decrease) in Other Operating Liabilities",
"terseLabel": "Other liabilities"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingLiabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherReceivables": {
"auth_ref": [
"r2"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in receivables classified as other.",
"label": "Increase (Decrease) in Other Receivables",
"negatedTerseLabel": "Other receivables"
}
}
},
"localname": "IncreaseDecreaseInOtherReceivables",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r2"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedTerseLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r57",
"r103",
"r131",
"r173",
"r325",
"r424",
"r488",
"r566"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"terseLabel": "Non-cash interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r133",
"r135",
"r136"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeNet": {
"auth_ref": [
"r77",
"r79"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
"label": "Investment Income, Net",
"terseLabel": "Interest income, net"
}
}
},
"localname": "InvestmentIncomeNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r15",
"r141",
"r179",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r299",
"r300",
"r301",
"r318",
"r394",
"r461",
"r490",
"r515",
"r551",
"r552"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r72",
"r101",
"r352",
"r477",
"r507",
"r513",
"r550"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and stockholders\u2019 equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and Stockholders\u2019 Equity:"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r17",
"r118",
"r141",
"r179",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r299",
"r300",
"r301",
"r318",
"r477",
"r515",
"r551",
"r552"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LoansPayableMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Borrowing supported by a written promise to pay an obligation.",
"label": "Loans Payable [Member]",
"terseLabel": "Term loan"
}
}
},
"localname": "LoansPayableMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r13",
"r100",
"r210",
"r226",
"r465",
"r466",
"r562"
],
"calculation": {
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
"label": "Long-Term Debt",
"totalLabel": "Net carrying amount"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermNotesPayable": {
"auth_ref": [
"r19"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 4.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
"label": "Notes Payable, Noncurrent",
"terseLabel": "Notes payable, net of discount and issuance costs"
}
}
},
"localname": "LongTermNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-Term Debt, Type [Axis]",
"terseLabel": "Long-term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r19",
"r35"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-Term Debt, Type [Domain]",
"terseLabel": "Long-term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/TermLoanNarrativeDetails",
"http://werewolftx.com/role/TermLoanScheduleofLongTermDebtInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r519"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money market funds"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MovementInDeferredRevenueRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Movement in Deferred Revenue [Roll Forward]",
"terseLabel": "Movement in Deferred Revenue [Roll Forward]"
}
}
},
"localname": "MovementInDeferredRevenueRollForward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementContractwithCustomerContractAssetContractLiabilityandReceivableDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r134"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Financing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r134"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Investing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r82",
"r83",
"r84"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r73",
"r84",
"r102",
"r116",
"r126",
"r127",
"r130",
"r141",
"r146",
"r148",
"r149",
"r150",
"r151",
"r154",
"r155",
"r161",
"r172",
"r174",
"r176",
"r178",
"r179",
"r188",
"r189",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r311",
"r318",
"r354",
"r417",
"r437",
"r438",
"r462",
"r488",
"r515"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss)",
"terseLabel": "Net income (loss)",
"totalLabel": "Net loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Recent Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r78"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income (Expense)",
"totalLabel": "Total other income"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NonoperatingIncomeExpenseAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Nonoperating Income (Expense) [Abstract]",
"terseLabel": "Other income:"
}
}
},
"localname": "NonoperatingIncomeExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
"auth_ref": [
"r12"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
"label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
"terseLabel": "Restricted Stock Awards Activity"
}
}
},
"localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OperatingExpenses": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
"label": "Operating Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "OperatingExpenses",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Expenses [Abstract]",
"terseLabel": "Operating expenses:"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r172",
"r174",
"r176",
"r178",
"r462"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Operating loss"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r329"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"terseLabel": "Operating lease liability, current"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r329"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 5.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Operating lease liability, net of current portion"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r328"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating lease right of use asset"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
"auth_ref": [
"r503"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 12.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
"label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
"terseLabel": "Non-cash lease expense"
}
}
},
"localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"auth_ref": [
"r62",
"r94",
"r362",
"r363"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
"terseLabel": "Nature of Business"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NatureofBusiness"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r16"
],
"calculation": {
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Accrued Liabilities, Current",
"terseLabel": "Other"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r120"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other non-current assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesCurrent": {
"auth_ref": [
"r16",
"r477"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Current",
"terseLabel": "Deferred revenue, current"
}
}
},
"localname": "OtherLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesFairValueDisclosure": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of other liabilities.",
"label": "Other Liabilities, Fair Value Disclosure",
"periodEndLabel": "Contract liabilities, ending balance",
"periodStartLabel": "Contract liabilities, beginning balance",
"totalLabel": "Total liabilities"
}
}
},
"localname": "OtherLiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails",
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsFairValueAssetsMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r20"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other liabilities"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r80"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"terseLabel": "Other expense, net"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherReceivablesNetCurrent": {
"auth_ref": [],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
"label": "Other Receivables, Net, Current",
"terseLabel": "Other receivables"
}
}
},
"localname": "OtherReceivablesNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PayablesAndAccrualsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Payables and Accruals [Abstract]"
}
}
},
"localname": "PayablesAndAccrualsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_PaymentsOfStockIssuanceCosts": {
"auth_ref": [
"r25"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
"label": "Payments of Stock Issuance Costs",
"negatedTerseLabel": "Payment of equity issuance costs"
}
}
},
"localname": "PaymentsOfStockIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r81"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedTerseLabel": "Purchases of property and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PerformanceSharesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement awarded for meeting performance target.",
"label": "Performance Shares [Member]",
"terseLabel": "Performance Shares"
}
}
},
"localname": "PerformanceSharesMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PlanNameAxis": {
"auth_ref": [
"r520",
"r521",
"r522",
"r523",
"r524",
"r525",
"r526",
"r527",
"r528",
"r529",
"r530",
"r531",
"r532",
"r533",
"r534",
"r535",
"r536",
"r537",
"r538",
"r539",
"r540",
"r541",
"r542",
"r543",
"r544",
"r545"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by plan name for share-based payment arrangement.",
"label": "Plan Name [Axis]",
"terseLabel": "Plan Name [Axis]"
}
}
},
"localname": "PlanNameAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PlanNameDomain": {
"auth_ref": [
"r520",
"r521",
"r522",
"r523",
"r524",
"r525",
"r526",
"r527",
"r528",
"r529",
"r530",
"r531",
"r532",
"r533",
"r534",
"r535",
"r536",
"r537",
"r538",
"r539",
"r540",
"r541",
"r542",
"r543",
"r544",
"r545"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan name for share-based payment arrangement.",
"label": "Plan Name [Domain]",
"terseLabel": "Plan Name [Domain]"
}
}
},
"localname": "PlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r66",
"r228"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock, Par or Stated Value Per Share",
"terseLabel": "Preferred stock par value (usd per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r66",
"r396"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred stock authorized (shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r66",
"r228"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred stock issued (shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r66",
"r396",
"r415",
"r567",
"r568"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred stock outstanding (shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r66",
"r349",
"r477"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock, Value, Issued",
"terseLabel": "Preferred stock, $0.0001 par value, 5,000 shares authorized at June\u00a030, 2023 and December\u00a031, 2022; no shares issued or outstanding as of June\u00a030, 2023 and December\u00a031, 2022, respectively"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r501"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrimeRateMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
"label": "Prime Rate [Member]",
"terseLabel": "Prime Rate"
}
}
},
"localname": "PrimeRateMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
"auth_ref": [
"r1"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
"label": "Proceeds from Issuance Initial Public Offering",
"terseLabel": "Proceeds from drawdown of term loans"
}
}
},
"localname": "ProceedsFromIssuanceInitialPublicOffering",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r1"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Proceeds from at the market offering of common stock"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
"auth_ref": [
"r24",
"r365"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
"label": "Proceeds from Issuance of Long-Term Debt",
"terseLabel": "Drawings on term loans"
}
}
},
"localname": "ProceedsFromIssuanceOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r1",
"r9"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds from Stock Options Exercised",
"terseLabel": "Proceeds from stock option exercises"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockPlans": {
"auth_ref": [
"r1"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
"label": "Proceeds from Stock Plans",
"terseLabel": "Proceeds from issuances under Employee Stock Purchase Plan"
}
}
},
"localname": "ProceedsFromStockPlans",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r4",
"r345",
"r353",
"r477"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyTransactionsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Related Party Transactions [Abstract]"
}
}
},
"localname": "RelatedPartyTransactionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"auth_ref": [
"r332",
"r333",
"r334",
"r335",
"r336",
"r370",
"r371",
"r372",
"r421",
"r422",
"r423",
"r443",
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Related Party Transactions Disclosure [Text Block]",
"terseLabel": "Related Parties"
}
}
},
"localname": "RelatedPartyTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RelatedParties"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
"auth_ref": [
"r294",
"r547"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
"terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
}
}
},
"localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r61",
"r293",
"r559"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research and Development Expense [Member]",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCash": {
"auth_ref": [
"r499",
"r504",
"r560",
"r563"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
"label": "Restricted Cash",
"verboseLabel": "Non-current restricted cash"
}
}
},
"localname": "RestrictedCash",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
"auth_ref": [
"r119"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents [Domain]",
"terseLabel": "Cash and Cash Equivalents [Domain]"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/FinancialInstrumentsandFairValueMeasurementsAssetsMeasuredatFairValueonaRecurringBasisDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
"auth_ref": [
"r563"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Restricted Cash and Cash Equivalents Items [Line Items]",
"terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestrictedCashCurrent": {
"auth_ref": [
"r499",
"r504"
],
"calculation": {
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
"label": "Restricted Cash, Current",
"terseLabel": "Restricted cash included in \"Prepaid expenses and other current assets\"",
"verboseLabel": "Restricted cash and cash equivalents, current"
}
}
},
"localname": "RestrictedCashCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails",
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedCashNoncurrent": {
"auth_ref": [
"r106",
"r500",
"r504"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
},
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
"label": "Restricted Cash, Noncurrent",
"terseLabel": "Restricted cash and cash equivalents",
"verboseLabel": "Restricted cash and cash equivalents, non-current"
}
}
},
"localname": "RestrictedCashNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsSummaryofRestrictedCashDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedStockMember": {
"auth_ref": [
"r30"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
"label": "Restricted Stock [Member]",
"terseLabel": "Unvested RSAs"
}
}
},
"localname": "RestrictedStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
"label": "Restricted Stock Units (RSUs) [Member]",
"terseLabel": "Shares reserved for vesting of restricted stock units",
"verboseLabel": "Unvested RSUs"
}
}
},
"localname": "RestrictedStockUnitsRSUMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails",
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r69",
"r91",
"r351",
"r360",
"r361",
"r369",
"r397",
"r477"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated undistributed earnings (deficit).",
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r115",
"r143",
"r144",
"r145",
"r147",
"r153",
"r155",
"r180",
"r181",
"r289",
"r290",
"r291",
"r295",
"r296",
"r302",
"r304",
"r305",
"r307",
"r309",
"r357",
"r359",
"r373",
"r567"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated undistributed earnings (deficit).",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
"auth_ref": [
"r105",
"r548"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
"label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
"terseLabel": "Collaboration revenue"
}
}
},
"localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenuesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Revenues [Abstract]",
"terseLabel": "Revenue:"
}
}
},
"localname": "RevenuesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale of Stock [Domain]",
"terseLabel": "Sale of Stock [Domain]"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SaleOfStockPricePerShare": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
"label": "Sale of Stock, Price Per Share",
"terseLabel": "Price per share (in usd per share)"
}
}
},
"localname": "SaleOfStockPricePerShare",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accrued liabilities.",
"label": "Schedule of Accrued Liabilities [Table Text Block]",
"terseLabel": "Accrued Expenses"
}
}
},
"localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r30"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
"terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r30"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of (Loss) Income per Share"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
"auth_ref": [
"r19",
"r39",
"r42",
"r55",
"r56",
"r58",
"r60",
"r89",
"r90",
"r465",
"r467",
"r508"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
"label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
"terseLabel": "Schedule of Long-Term Debt Instruments"
}
}
},
"localname": "ScheduleOfDebtInstrumentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"auth_ref": [
"r45"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
"terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationExpenseRecognizedDetails",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r45"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
"terseLabel": "Stock-based Compensation Expense Recognized"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
"auth_ref": [
"r294",
"r547"
],
"lang": {
"en-us": {
"role": {
"documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
"label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
"terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
}
}
},
"localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
"auth_ref": [
"r11",
"r96",
"r563"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
"label": "Restrictions on Cash and Cash Equivalents [Table]",
"terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
}
}
},
"localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
"auth_ref": [
"r11",
"r96",
"r563"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
"label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
"terseLabel": "Restrictions on Cash and Cash Equivalents"
}
}
},
"localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RestrictedCashandCashEquivalentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r7",
"r8",
"r44"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
"terseLabel": "Summary of Stock Option Activity"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r93"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
"terseLabel": "Weighted -average Valuation Assumptions"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r36",
"r37",
"r38",
"r39",
"r40",
"r41",
"r42",
"r89",
"r90",
"r91",
"r122",
"r123",
"r124",
"r170",
"r228",
"r229",
"r230",
"r232",
"r235",
"r240",
"r242",
"r365",
"r366",
"r367",
"r368",
"r469",
"r498",
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule of Stock by Class [Table]",
"terseLabel": "Schedule of Stock by Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
"auth_ref": [
"r5"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
"label": "Schedule of Stockholders Equity [Table Text Block]",
"terseLabel": "Schedule of Common Stock Reserved for Issuance"
}
}
},
"localname": "ScheduleOfStockholdersEquityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SecurityDepositLiability": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.",
"label": "Security Deposit Liability",
"terseLabel": "Security deposit liability"
}
}
},
"localname": "SecurityDepositLiability",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RelatedPartiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r2"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Noncash Expense",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
"auth_ref": [
"r274"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
"negatedTerseLabel": "Forfeited (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r274"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted Average Grant Date Fair Value - Forfeited (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"auth_ref": [
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
"terseLabel": "Granted (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted Average Grant Date Fair Value - Granted (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"auth_ref": [
"r269",
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
"periodEndLabel": "Unvested at end of period (shares)",
"periodStartLabel": "Unvested at beginning of period (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
"terseLabel": "Shares/Units"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r269",
"r270"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
"periodEndLabel": "Weighted Average Grant Date Fair Value - Unvested at end of period (in usd per share)",
"periodStartLabel": "Weighted Average Grant Date Fair Value - Unvested at beginning of period (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
"terseLabel": "Weighted-Average Grant Date Fair Value Per Share"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"auth_ref": [
"r273"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
"negatedTerseLabel": "Vested (shares)",
"terseLabel": "Vested (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
"auth_ref": [
"r276"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
"terseLabel": "Aggregate fair value of awards that vested"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r273"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted Average Grant Date Fair Value - Vested (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
"auth_ref": [
"r281"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
"terseLabel": "Dividend yield"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r280"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
"terseLabel": "Expected volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
"terseLabel": "Risk-free interest rate"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
"terseLabel": "Maximum number of shares to be added annually, as a percentage of outstanding shares (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
"auth_ref": [
"r475"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
"terseLabel": "Common stock authorized to be issued (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
"terseLabel": "Weighted-Average Remaining\u2028Contractual Life\u2028(in years)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"auth_ref": [
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
"terseLabel": "Exercisable at end of period (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"auth_ref": [
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"terseLabel": "Weighted-Average Exercise Price - Exercisable at end of period (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
"auth_ref": [
"r276"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
"terseLabel": "Aggregate intrinsic fair value of options exercised"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
"negatedTerseLabel": "Cancelled (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r265"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
"verboseLabel": "Granted (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r275"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted-average grant date fair value of awards (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r261",
"r262"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
"periodEndLabel": "Outstanding at end of period (shares)",
"periodStartLabel": "Outstanding at beginning of period (shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
"terseLabel": "Number of Options"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r261",
"r262"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"periodEndLabel": "Weighted-Average Exercise Price - Outstanding at end of period (in usd per share)",
"periodStartLabel": "Weighted-Average Exercise Price - Outstanding at beginning of period (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
"terseLabel": "Weighted-Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
"terseLabel": "Maximum number of shares to be added annually, as a percentage of outstanding shares (percent)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r258",
"r259",
"r260",
"r261",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]",
"terseLabel": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationRestrictedStockAwardActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
"terseLabel": "Weighted-Average Exercise Price - Exercised (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"terseLabel": "Weighted-Average Exercise Price - Cancelled (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r265"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"terseLabel": "Weighted-Average Exercise Price - Granted (in usd per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r279"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
"terseLabel": "Expected term (in years)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationWeightedAverageAssumptionsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r43"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
"terseLabel": "Weighted Average Remaining Contractual Life - Exercisable"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"auth_ref": [
"r92"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
"terseLabel": "Weighted Average Remaining Contractual Life - Outstanding"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares, Outstanding",
"periodEndLabel": "Stockholders' equity, ending balance (shares)",
"periodStartLabel": "Stockholders' equity, beginning balance (shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r85",
"r138"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Summary of Significant Accounting Policies"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/SummaryofSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r114",
"r122",
"r123",
"r124",
"r141",
"r159",
"r160",
"r162",
"r164",
"r170",
"r171",
"r179",
"r188",
"r190",
"r191",
"r192",
"r195",
"r196",
"r228",
"r229",
"r232",
"r235",
"r242",
"r318",
"r365",
"r366",
"r367",
"r368",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r385",
"r396",
"r418",
"r439",
"r451",
"r452",
"r453",
"r454",
"r455",
"r498",
"r505",
"r512"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Class of Stock [Axis]",
"terseLabel": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r5",
"r23",
"r115",
"r128",
"r129",
"r130",
"r143",
"r144",
"r145",
"r147",
"r153",
"r155",
"r169",
"r180",
"r181",
"r243",
"r289",
"r290",
"r291",
"r295",
"r296",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r309",
"r319",
"r320",
"r321",
"r322",
"r323",
"r324",
"r331",
"r357",
"r358",
"r359",
"r373",
"r439"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
"r143",
"r144",
"r145",
"r169",
"r343",
"r364",
"r385",
"r388",
"r389",
"r390",
"r391",
"r392",
"r393",
"r396",
"r399",
"r400",
"r401",
"r402",
"r403",
"r405",
"r406",
"r407",
"r408",
"r410",
"r411",
"r412",
"r413",
"r414",
"r416",
"r419",
"r420",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r435",
"r436",
"r439",
"r482"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r143",
"r144",
"r145",
"r169",
"r343",
"r364",
"r385",
"r388",
"r389",
"r390",
"r391",
"r392",
"r393",
"r396",
"r399",
"r400",
"r401",
"r402",
"r403",
"r405",
"r406",
"r407",
"r408",
"r410",
"r411",
"r412",
"r413",
"r414",
"r416",
"r419",
"r420",
"r425",
"r426",
"r427",
"r428",
"r429",
"r430",
"r431",
"r432",
"r433",
"r434",
"r435",
"r436",
"r439",
"r482"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
"auth_ref": [
"r5",
"r66",
"r67",
"r91"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
"label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
"terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r5",
"r66",
"r67",
"r91",
"r365",
"r439",
"r452"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Stock Issued During Period, Shares, New Issues",
"terseLabel": "Issuance of common stock from at the market offering, net of issuance costs (shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails",
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r5",
"r66",
"r67",
"r91",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
"negatedTerseLabel": "Exercised (shares)",
"terseLabel": "Stock option exercises (shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
"http://werewolftx.com/role/StockbasedCompensationNarrativeDetails",
"http://werewolftx.com/role/StockbasedCompensationStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
"auth_ref": [
"r5",
"r66",
"r67",
"r91"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
"label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
"terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
}
}
},
"localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r5",
"r66",
"r67",
"r91",
"r373",
"r439",
"r452",
"r489"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Stock Issued During Period, Value, New Issues",
"terseLabel": "Issuance of common stock from at the market offering, net of issuance costs"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
"auth_ref": [
"r5",
"r23",
"r91"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued as a result of the exercise of stock options.",
"label": "Stock Issued During Period, Value, Stock Options Exercised",
"terseLabel": "Stock option exercises"
}
}
},
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockOptionMember": {
"auth_ref": [
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
"label": "Equity Option [Member]",
"terseLabel": "Shares reserved for exercises of outstanding stock options"
}
}
},
"localname": "StockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r67",
"r70",
"r71",
"r86",
"r398",
"r415",
"r440",
"r441",
"r477",
"r490",
"r507",
"r513",
"r550",
"r567"
],
"calculation": {
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
"label": "Equity, Attributable to Parent",
"periodEndLabel": "Stockholders' equity, ending balance",
"periodStartLabel": "Stockholders' equity, beginning balance",
"totalLabel": "Total stockholders\u2019 equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://werewolftx.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
"terseLabel": "Stockholders\u2019 equity:"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedBalanceSheetsunaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r88",
"r140",
"r227",
"r229",
"r231",
"r232",
"r233",
"r234",
"r235",
"r236",
"r237",
"r238",
"r239",
"r241",
"r243",
"r308",
"r442",
"r444",
"r456"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for equity.",
"label": "Equity [Text Block]",
"terseLabel": "Common and Preferred Stock"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStock"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubleaseIncome": {
"auth_ref": [
"r330",
"r476"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of sublease income excluding finance and operating lease expense.",
"label": "Sublease Income",
"terseLabel": "Sublease Income"
}
}
},
"localname": "SubleaseIncome",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/RelatedPartiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for reporting subsequent events.",
"label": "Subsequent Events, Policy [Policy Text Block]",
"terseLabel": "Subsequent Events"
}
}
},
"localname": "SubsequentEventsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Sale of Stock [Axis]",
"terseLabel": "Sale of Stock [Axis]"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_TypeOfArrangementAxis": {
"auth_ref": [
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
}
}
},
"localname": "TypeOfArrangementAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_UnbilledReceivablesCurrent": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
"label": "Unbilled Receivables, Current",
"terseLabel": "Unbilled receivables"
}
}
},
"localname": "UnbilledReceivablesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/JazzCollaborationandLicenseAgreementNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r31",
"r32",
"r33",
"r108",
"r110",
"r111",
"r112"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]",
"terseLabel": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_VariableRateAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of variable rate.",
"label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate [Axis]"
}
}
},
"localname": "VariableRateAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
"label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate [Domain]"
}
}
},
"localname": "VariableRateDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/TermLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WarrantMember": {
"auth_ref": [
"r479",
"r480",
"r483",
"r484",
"r485",
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
"label": "Warrant [Member]",
"terseLabel": "Warrants to purchase common stock"
}
}
},
"localname": "WarrantMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CommonandPreferredStockScheduleofCommonStockReservedforIssuanceDetails",
"http://werewolftx.com/role/NetLossAttributabletoCommonStockholdersperShareAntidilutiveSharesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r158",
"r164"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Weighted average common shares outstanding, diluted (shares)"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r157",
"r164"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Weighted average common shares outstanding, basic (shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://werewolftx.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 4
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "2C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "808",
"URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "954",
"URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "808",
"URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "808",
"URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r113": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "808",
"URI": "https://asc.fasb.org//808/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r114": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r156": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "https://asc.fasb.org//260/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "326",
"URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r255": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "https://asc.fasb.org//718/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(l)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "730",
"URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "808",
"URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)(i)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)(iii)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)(iv)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(i)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r332": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "850",
"URI": "https://asc.fasb.org//850/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "850",
"URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "850",
"URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "912",
"URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(19))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(21))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(22))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(2)(i))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "205",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "27",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(b)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(c)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(e)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(f)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(g)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(h)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(e)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(f)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(13)(a)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(13)(a)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(14))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(15))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(16)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(17))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(19))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(2)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(2)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(3)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(3)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(3)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(4))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(e))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(8))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(e))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-05(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-05(4))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Subparagraph": "(b)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "220",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(2)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(2)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(2)(e))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(2)(g)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(5))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(5))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(9))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(1)(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r443": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(c)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r444": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "235",
"Subparagraph": "(e)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r450": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(b)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(c)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "12A",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(b)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(a)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "310",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "405",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "830",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "830",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "830",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r491": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r492": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r493": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r494": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r495": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r496": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r497": {
"Name": "Securities Act",
"Number": "7A",
"Publisher": "SEC",
"Section": "B",
"Subsection": "2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r504": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r505": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r506": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r507": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r508": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r509": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r510": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r511": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r512": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r513": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r514": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r515": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r516": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r517": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r518": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r519": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r520": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r521": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r522": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r523": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r524": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r525": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r526": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r527": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r528": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r529": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r530": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r531": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r532": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r533": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r534": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r535": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r536": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r537": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r538": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r539": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r540": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r541": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r542": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r543": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r544": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r545": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r546": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r547": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "730",
"URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r548": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "808",
"URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r549": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r550": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r551": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r552": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r553": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r554": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r555": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r556": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r557": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r558": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r559": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r560": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(1)(a))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r561": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15)(a))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r562": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r563": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r564": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "205",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r565": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(18))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r566": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Subparagraph": "(i)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r567": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r568": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r62": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "https://asc.fasb.org//205/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(24))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(4))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(8))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(a),(b))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.8)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r85": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org//235/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r87": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org//470/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r88": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org//505/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r94": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "810",
"URI": "https://asc.fasb.org//810/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(1)(a))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15)(5))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
}
},
"version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001785530-23-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001785530-23-000025-xbrl.zip
M4$L#!!0 ( !@X"E>C2<$(R < ,XD 2 83 V,S R,#(S97@S,3$N
M:'1MY5IM<^(X$OY^OT*7J9M)J@S!O.2%,*EB K/#U522)>1F]M.6L-M8%]OR
M2C*$^_77+9E MEPE]V93#8?"+9:K7YY]'1;IA.;-#GMQ,##T[]U_EZIL)X,
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M.!3$4CE"@5!,Z$Z2)4Q+A.@'2^-." 4I]DBB2% L2D10'8Y;>T)N(Y9E,B9
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M[G_OK]EA=?'!B3H?@8FG?I,ZUT 9JHL9'>=S@SX#54FT N"<3V3/3%8/$3]
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M>>)'/.6G^SW1OOT=TW\!4$L#!!0 ( !@X"E>=1GP"P0< .,D 2
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M@4 H=#D02S$=EH2DV#060<QT;G\6\Z= 6:'$.C 6.D$[9#NKJ3 Q'-09!<Y
MJS>#:3*$FQ-,"]EPMAR&5XS*QO>#2F*12)%W"Z%%GDN ),0QK);&11J!<;@1
MT"/2(,E#Z 26EI): @Z%9:D,4+ HMNA.D@5,"X3H1TMC)X3"*BY9B3R! + I
M 2"WG';V!%S'+$KD5,^!JV@DM%$<"W%[T=L-*TM+^--S8U:L?<40;+XX" X>
MY.N=+N!5M!F60F04"9RZ''895^30@NR+84(VJXP T6$B=&S%K=@8]&DIU)Z'
M0@>)U#GF66)5,O&PR90,*,1ES7:!DI .P^%SI<@YNF(6!N<U<\32+@>]V"7
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M9^CC[R@IVOU'\J5G!.296'OIW='!=]\=N4<$X7Q?E!:D83EL&:<+_K!XVQH
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MV RYV3QETZ<-&[_L*7[]1T;[[N.F/P!02P,$% @ &#@*5U.3LBDQ!0
M+1L !( !A,#8S,#(P,C-E>#,R,2YH=&WM66UOVD@0_GZ_8H[HVD3"CNT0
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M8@G1A)G4844&5I 09FI()JDRWJ\;,DE3P&6X)Y(B-BI#.%3=KHH9)SPT_Z/
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M7&"F;]=AD# :XQR',YUF%Q3&Q6!OAXHASH2A%M*\:-D\E@P'CPPGCS7FK?N
MK&RJ%)?3P<L&]Y:,GXWV9Z-]G9"O-5J4+G2RA#,7IE(H_:HJ]ZOILZ\:I9?4
M7XNF>K!Z5K_95*>2$I5+>K>K7G,;KGX8H@^T>?/W<)/=MH_-]SS0WSP\R82R
MKPDZDJ;$=.VUXY3KAW7[W.U=+R$S3(9</[SDJ=?5W^I%S/IAR1-G1.6U.*[:
MML=D_P%02P,$% @ &#@*5PYR;N^+60( #G@4 !$ !H;W=L+3(P,C,P
M-C,P+FAT;>Q]ZW/B2++O]_-7Z+)[]W9' WB[9[Q#8_;O>L]T[;7=N^<O5\V
M"JDPVA82HX=MYJ^_F56E!R! @$2U(DXLVWTJLK\959F5F;63__W?6(JK]1Q
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M2L*E@(Z?6MB0F(1+ ?T7M;#QN)T8>/S"FK(UTVBJA8WR2204V9\I;*!1PN;
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M[YS$]VQQJ&LW<&"V,]M7^#X4^RQ\0:- MW'@*5IL".5[$VOJN/>=)PB.*Q7
ML?&#KUY)GJ0Y+4%X;E+XS+J=>R3A#\IH.2:O--@WTF.\'O%ZX^!M6I0?L;S?
MM&[S>THPP1-60_P1;GN OY7;VZH2U*,'&W7Q*F>Q72=V\F,!Z3C(R"IRKH/:
M6KH$7^/$09E"Q(>D6 8^ A&>=5ZH>#\((\N:@?^MBEP<!<C"4&.[KH$)9^B-
MQ[;=X7:Q(\KV!]=_L0JO<M#$Q&$2U\5]HWESA.TQBL<%)H>^"Z+NNL'N)V@;
M\6$>\,<EC#_"\BE JPT-B\$*7RA>5F633:3\)M&>RY%@'TL!S?NUPJ3H-B.J
M0T?H+BT$06+4P*_Q !;1?O<-;@S@9)!I."L\TMP.?];PI/.A':9>_,<&NBL(
M*]9GS4;]#@:WMXB7&1LUPR"FGJ*DVF5< ?X5:3J'$GU% EZP=Z3;FC]/":9-
M1H8)O&:TTFQGBM3D:CU,?</4'RH*&'B667(2TF1J4O"(>4"2^4#X69;NB3D]
M(OX%GXXM.&%*# <G\F9(X\CD6$4)8!A]$T/GVI1MLJ?8I%^C\]@".B$Z%>?K
M,4K!\_S?B4J238\&H :Y]M%<!.S:0\ $%T6,V4[9>]:+4!73"=G&/^97"3K@
MMRU B!'5WX7)0T)K!KD//-E09"82-]B28PP4&P>HQ<#7*2/ ;ZW0>Z\NJ?XP
MNS-8;Y+R-^=RN+CV84H6GQ@).W!J6-SRX(LG& D4@_2X__*? &2@&.,9&<"(
M(<'EVY_:5IQ/D=O P_89434&88ROH*X/&C_^>OP7!PIQ88''[\! #!XU9G?'
ML;7TN) O$ZCC15+/!9=K\=@L8T;4D H-8X>FW[P6 4'#> I%%PN5!4'8,%L%
M\3AC*I:M5PY]-0 ;]JC*%K]P&4"U$9(N9$%L["O88%ACIA[@^7#MC>Q %ICA
MQA#E,T&NP%!-U&_P'SM(X,DY/RZICJ'8E1>YB7:JJH#*97-UD8>LUY#U&@7+
M.']VP$3 G1^^9K _%8M,L--DZ995<"3M-PNU,=/=#E[BEETX2U@[J/-J:%2)
M)NU%DPZ5O\^" :C^+9$/'AI^85)TL-,=>#;Q3#8>F!%F)WMW53'M%]L55M80
M%)WX)C?V5@R+_QF,"F<GO%V>\<ZN!COM8">T^RJW$V[OOGS_[]N[&_$;K($\
M"S,U(<#(HH3M_:VU,)G+$VP1<8/ 8!F#4[XK@$,&,[FN/-DFKDLCYMJ!]V(9
M:(+#*# F*2R)]*-C-KPC,F#7C<_$K0MNM?-2'JS(:?;:GX,2%$8Q=S89VIB*
M./09G5DJ&3JVK(J'UY^,?-,$GROP6YGV6#!%JSQ=,H0=_I5Z3L6V8U=4>T71
M$N7)G\! 9X6>1;+:N(]')P!(PCY&#EK@ CDVF+L\Z(ARR#+18.7&9#.]*F)!
M,<>.A>/U5P ]<QG!RPML\U!-1#446G!T174NZ38Z3AC?)CPD7@41U5($AJ.(
MA\(=.C\M PLG;(<C-G.T:Z4XS7\NS/%&B<%OHPT:F-]H$O,@EVG:;UB\6[IM
MAG[]^!L-Z<:PO-4P0'($0542.45A BRO'YI5P["KSW1I?$\XNMFT,< '%UE\
MF>TMH%,^OYO%];"&?E;L)>+1X&A%^%\ $&7:DF,ZB\Z3N,@5%Y8=9@V$>;5B
M=0[W]EUB\A,?Q!.>\D(MR@-I&/X1!5\\@A5D'N!#L0T2BBG=P6,;GHKM4L+O
M(\/CIK;#5"Z&FL4&2W"1Y414@]BG\.>#&(4+D	+)Y$V3%0QFPHEOT?I1G%
MJR#C]0"^"*+:8FFD\8S]8!D,XCD\Z!0K0XEM@,_GM+$"X>?_J375=I7]H]5J
MA'>OS"B5<#D&7-"&H,'V''(_SF$Z LWD1=O;;,'B!4B+V4X,=B):C'%"#2PN
M,(0"] A4Q.N5&+:"/^)?'5)<L5"]X%87K%P_DM+1>7&+-9-(*@*2%FWY,3R
MNRT4JWN0J2(8+I 1N/"\),X,W68PH$VJ^29E&QEL>Y+%9/G.)8.I&V:[+^JB
M>0C&[*&YC+V\ :B#!^I;.-((B:%"-#-E@D@LYH9%QB2P6X(H KIHF*HW5]W
MF,VTTI(ZX[LQ8@M]N:0"$.Y;S'BS%O?O?ECV6[@)%\0T8O915%PUBRQ!&$3,
M_@-P^=)&/SQPOLWEWB_KI(4@!4O6X/X9,'L6I$X!*	,PG7<A/?](R:;F.6
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MIH[/^N*(?5"NJU!7 @.YQ0YOB,$KM/.90<^LL5C:DV6SW$ ,6^FP>PH,J(8
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M)AD*62C54+(>$GW8^;.UX\^+ZV:F&<9GQK9WBC2UGXSW"\NVOF(& 89]\?2
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M."^&%8RL"YP3O[#1-.:E2J/ %&=O<&$OO, KJ&EL3;&5"&:9D]@,#/<&+=8
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MCQ&)3C>O6IX"E==)2*4T(O.&U /J%!;1>K@)R%U6"LR9T@U&\S5;>=U/J*$
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M.714, >*$Y[?#O6&U-',1A'=TF*3NM)RG<4YQTY^6I*6#!>Y,(9#G2QNU!5
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MTE:KA8(,_3I4<==Q%?<4*C;&(>*.E:^F_>8J'WR+^+H!]WQ<.;4C**)TD_U
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M'TE:EIA6Y3(A0:V(G=$+V@7UDX<<"!:[6"'GA#@OAE7C<[SH F[$+VS'?N$
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M@]TADB)8GQ:,ZTRN4J]<KI*:U55ZBO3@%<\(!6H^@,.D >\3'*!N@@/477:
MGOS)!!$(#(]]08D^H03?V-(Q8M],&(D:[H^E), OQ#7<^]'"Y&?\OPD$Z"U.
MM3# 6!E'3H8*FS@R*.X1,ZF:<YE+N@#.1<@S1+_!#$::+*\GC#)?0+5.P,L4
MEYKLDEKEUE[@V8U!;[%?7.,]4/-HONKLK<K<"_GC8X)>*:5B&]_AWAU.P=$C
MDQ5?[O@F=>.&';-:N6^J/*&ERI0VNR/HF(/*>V*X+K+W0\S=?KJY#EUMO/^%
M6K"\,9]*0R>,ZD&2.-(0C$:@U=2,W([O%O,E6.2$C>&*"1P)O?V_7ET]1%_
M99 MI/SIF"J -U@Z<6#5N+9UIBH8%(/77#W-CS/QR>]3YFC$'OH>/B3($P4
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MQY$7+-2T3 VUC=FU+'5+@P81EL+.#=,%P@#C>OLX:W6LG2Y .U&N7(!6EES
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M]Q*9SR9\IQ^6_58#PR"H< ^V]30R#;81AI05>AE8I EB'$9UN7LY#;@3$^=
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M2@EF,038(=S?"X[$$CDWN-"@:&).(;9;6EK9/=L+GXIG:PYI]!)&%^YR!C?
MI'A&=,@/4=,USQ/40$E!CY6M] \D?Y%6'%(3EV&7+]7S] VLBDAI!D@9 @&#
M8F(WTN<CKCUY-CAN%I,__LA5/1V ;ME3JI$V@=\DPF E5,E?Q8[Z^J*9JI#%
M8.^]YMDUM@?/D",P$SA5#"4ZG1H!2)9UEE@U8R6/001T:6\V4%B9%HGF^B9'
M@EU?P2I9E2]U\R[,GKE[N6?\&^CN(+B9<2EI-1JPE*@)G9#FEQ*FZ;G0+:T-
MB4H>K-R5=<VAIY)GHRB6=?BKJ/$ XTLT3<M,CR;V!NVF<%5S[7*5P,E@+C,P
M(K0M)Z-6+AOU_F;>:K$.<V@.U-C*LF@O5(,,'( FNBZID6 &2UM2/\"5VQ8.
MC:P7<"I6-[3C?;,V5./'LE5APK'V>FD:.\G"A$ _]V5A@BQ,6)\V6YH$6;%W
M\=T"/6ORI,K@?(VPF7"^W0R#3\5.\MAVG<)$EOJJ@^2V7J=6.+-[&'^[<MFN
MKSJV.>[!AN%*L7DEN'8O]I.66":6@33-&^9J'K9LTQ5?$G>IY4XR =@I+E>6
M'IH"3#J7$N9;C4YA:W4VQE]&L/S;;\R89ZHGS$K84( ?;@N9D<V7ONI>^<!>
M:_LP>MW]>+&KI\3''B[X8+,X-99#/W7I1?"/S\&9,H;%:,$>^CS_!5P(%P[-
M81_DEZ,ULM[@ZZ0X/D=\65RNLTL+1_GP:ZU^O=OMKKS<J#=77EOWVF:KWFD.
MMGKM^FNM?EL.ME2#53NI7KOA\*=5AZ*MN37A!#1N*A_GH+"E0$V#=\CD2PY;
M:Q8/W<J'#F6ZM>0\.U,0![:0$IA!^P%R*6AQ)7*@W3.FP6.0-GW.1)BS+[-H
MB=P/%=[KY)//O[Q.L,8O4H!AY=R%#<W.,IMZ"O/9%)S&RN-2\SAR58ZPT"/,
M+$C))X,O"1+[V\ 0 >"[GN""'5.TOBQ$X7<ZE_ZTC@E.FF&ACPG>/A37RK1E
ME"X:UXH"2-W*9:_:[:[**-F%(_L^17OADZE/T9;B46KQ6'<*_:VE.92X]-;*
M("7K#IIO-7JY'30O142*R($.FE\G(^##9Y>1%"M)OW+9J:J]Y9V=]$?,2PF1
M$G*81:1U2!MK4+E4JZW^H$ +R+XB$W&':E L=^H9,VV7XE0I'56Q2=>:8A]6
M'[?\F+.ZV8T]0<60)V5.1J$<TFEK-G)RVG+DY+[7Z0VQ)RG&4HS+YUPVF[DY
MEU*4I2B?OB@7W0ENJKL[P5*2I22?OB07U5EOMG)RU@L@QLS)_\2235>U,"]%
MMO#:@K)8TR)=') 2M%&UXHTAL'>&J'</JYTW5BSG>/A[NU6NAN_MK W?OQ+#
M^2=6WD8=WI?/?&\UVTN]U>&WY1;OT?G*MY8+/T7G4^%W%/8AY5M4@KW=T>_B
MTPD#*DTMR]?H_"OL=8(MW0TO:&D1-M(*DN/_/WM?VMPVDJ3]5Q :SQMR!,0F
M>-.>481\37C6;6LM]_3N?MD @:*(-0BP<4BM^?5O9E;A(@ 2X F2M3';EBBP
M4)57965E/BG055*-$G@U/LNV<T6H"8$6C4B# ?4NTBU>\1=56NM)9RWJ,.XH
M9,WL3--)&#]X1B )H.!/%G $"<,".B&4:';R*8RG&-?#G6"M+B79$^"JD_J
M:GZQ.]GR1W&?:6RXC.U/W0G"F- 3IA[H?*$8IEPPBE6"Y0T] M-YGED(MI1_
M33QFA(DB%I3JO4:EKSIOCQ:U^2;P&P[#C16,R<,J;_(&U@E>8ODS1$#C/5YO
M$#!54&4&/V+MXTM4TPR,=;'CY[]YW\-H<AR>)P&\)UZGNL)%_14Y: '.)]4W
MC;JI8S&&_T:Y_D(@*MIK)4\!L03EC]#%(AJ2,9\WEZ?.LIPB?.F\4P<"NY,
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MDZ3DSA1'O=):HDX](A0:A)-6CL&:/C:Q,@CG%!VKWZU@EO-)_:Q3FO5@XT#
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MW!D<-@= *HU4FOU%;G:@- @?T%.U MCK?%!GDW[BU;+EL=GE*67+#^OV+/S
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MGDX9D-[5;7>L:KT=MPQK !0C0L-L2C!H1Z:GH7K4X#NC8>E -832XY_?\V>
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MM &OF@B_NA999A%+\X@)]!WQ>[-XP\;5*Z/2K)9Z%"2,@#<%=G" (Q*CI9)
MN7H:4N#'K\HWL;REV[XEGHEH(+KX>D",B3*TTJ9!IW -IRBO[-[X9F"DE=\,
MT.3>Q^_PD]O2HH"G-KZZ[:ZZ(.7Q-#YSSF-P@[F,T+DA$1@?3&+*[4Z3KX[#
M2\,LR5C=/664R<=I%[HZ&*Q@Y@>ZG;VG%%&^OX )H#]5;+.;V+Y.^^IVJ(YA
M3:->OE8GHE(Q@3AL@:+#R0L8E2C32C6"6=.4<ZO/&/U.;O4Z%KD3#>[Q/<DP
M^25I*!W=/&QT2@@P NZP((X"U@Y)9)EU@ A3!R,Q1===L1G@@4Z3F:%!%T++
MBBO ^B+F11!^#=VK:GJH.1^]B6MJEI,:DVPG?FJG6WP;6^:EHDGQ@>@415O$
MW.-;-MXN.G1),'?IOMT#;V$C[[("90H<S"+2<--;PZWL]%;D8^YN7M^2:$2=
MR?4+?=[2'0#HOLPD:J%,@FG236\RC_,P*9R\"K:6\I[$K>DG?BL?6?2=(+?D
M8QC%[;Q[G<'I(KBDG24OHFCQF95?3T>7@[(SM^S,+3MS5T&2279'ZL]]N6VY
M.2$RS;EKX.K4Z?53M62XV?3:?1?W\R&,;.>^&5R\<)Z\M//$_F2>8?E\QT]?
MHO%MWUW0)>CVC2&K2=_)-^ JB2*M@7).A2!$=B%G5>3F?G(][N1&/FY-V(9>
M9X@]HH>]?"K%L7M(7K9<](\M%QC'5CL]V3M\CR:6L%HQ'6<:)YK'YW44D!VW
MI#Q771GL7%?RZH!W&%J^35*3VE2>*WN'^V=OMPWL[32C=>69VKJ,._FL>U@A
ML^.VXN>J *,#* !F1.<A)([M UX"=\<'X&YG/7>E)[>-=1/U?W$</+F"[[0[
MFA)U@^?7G<I]Z!DSW6?*O:T[TL>KH"7C]@&T!.]$NSMJ$);S\9 QTM-;S63M
M $SN7=WN_E2[WM.+S%BA.3P-(\9MUV<'([]8))HQ7G)S+Y3HSI'#.%T$S5#;
MNSJY2M>N%O?7P.WNQ)X-KF['W8;Z=DWOC^NO-X+;>V>[P#$^4P79O7[4M([#
MJ]N1.ACLZ."[P[B>%)I2H3GVC5EWA#=FHW85FRLAQ+>"$-?*(<1K5%6.XJK*
M!N".%U6(-BOO<F66Y;AV:]NXN)/RZ3&)G63].T?8I8XDI*#40E/@2N7[X?6Z
MXWPA:'><+P0EQ;^94#_.]/LVZH@KWE#PWB8AE]=,E.W :6#U6:Z)XEC:[S=.
M',-U+2&2F.XB$( DI:O.U&/14_AI4MN&\'IS#F K0 017LA4Q>E8X*X@+E%H
MFQSX"S%8Q!LRN3))$\Z';W[R!A#*&RS2X@!8F6^H^7MA_5GWS&2H[P]WJ:&*
M;Y%3#_^6>EB,MUAXL-=QL2??0%2>$-R!GU(G\68$IP7.6^B-,!'7A(FZTZEE
M, ]^B@M,.<@,+".T YT@W7ZDFRIG:8//XF+2B%/1_;@ ^1'@43H!K7$LBE7@
M5VH:EX^CE+M/EI\&O8CYW51$Q-JZO2Y.TZC55>[EK:DE/(YU/$)ZR8.!I2NI
M(\"TE3&M)8L 3V4M E?Y"3/ +J1@\6- 5=ZZ 7$]N-C%CS@"*:P8$P3<-027
M!"\?=M6X[BLV&???D@+1.X3\Y'"F,6B<R14ID6PQ;[0O<*CU2)V%"D>EH]2^
M/!WEB[3A!,7E1WK12;ELU#> &V8@#MK>-3:7FR$TEIL:R0SJ? *1MM):JFE3
MR:%%33!7;H0 $-E< K$Q&(J<8.=2G);;LXRIY0\>V+1&4SE188JK^[AFV@AX
M]&CYO+*^;B2PMZ94+'&!TT[K'69)/!)SWKWDO.0[9.I7*M[^-MVL(#"I,.MA
M!HS:[7?480$V95GM3X'D9=$ =.4[$4T XCY$&)"(T? ) 98>;D;*U+(%7AW'
M'OOXGMK7D/$718-:9'81FQ$A(#T+M0UQSE>U9"GA1K_QW-!@+U='O:ZJ:?G,
MW#)N9.*89;<XG$>K.]F4D&W0>+)U,$M/'8WR]WME-(,7@0T2ZKV.?&)[Y!@,
MP@'0GW3+IM*T=517PH4;P73!3L#2VS5L[VG4L+J<*4.N;0YGNE>WO>%PG7$)
M"1.8F?F#3&J_\=@BRI_(XKAPOB#<"/#&G8L@?K;I4,*-I(L\H4\GH_*],WF0
M\'*S^!OXJ1FANZ>:$8F5),V3^+$107OMEVBO% ^E2L;72HZ0FZGE^0%V/,)W
M,1UF/;60U-0B284W@B@[,50O_T;\=]&%)5UH1= QT2D-0QSX7>HJQH4Q=A?4
MHL'PX:71NAHG7HXBG!(T9?IZ#%X2H9/@^#;XQZ)Y1?T^6^/1:D2*334@W0DB
M5;Q-!P>!_EP$>M+K7=VNP'A.")2NK,E:)H<+ILGQ%DUNL^DC@1 -6V$59ZVE
M?(P/*?_401:]%R7-^XUJ\L?CQIL<NOKNCMIJ=YR__J:5UURSUFXW?M$#7'1_
MV%>'_0)(E931XDO,-LM2.4H 6"87@;,-LEI<=;.VJ[*GD7$&@YGE(QRHAZA&
M3G)F.,43PDJP(: A$;*V?*UK-[:GRZV4_ Q%OHC:'N0[-\76/./SK$D;:O 9
M<)/H6O54SJ:L\OA1ME4TRT?;/C[<W^\XV@;N=;818/I0+TQ9;65=UY#O^)O!
MB'(=51"@RN>A*LG,P)^4CXR_;N >9S>9V%FNLL_LRALN<&#S[C#5KBP-7L]'
M=IV<F]S9RDUVGZE7[T:Q#ZV]#K5H:[&]BUF_M0"/X=0X&M41X'6AC>+#@];N
M->KTT&_#-ESE]) 0H=(Y(AUCV.E)HOX!0FLW/@K71VA"K:]J_0+QR[G2._6=
MN5'-^,ZLT'4NV-5PH\9;7VX?$_14 J L?)&5N48_W>:L9?M1_KZ:HD0HD-0,
MBPE$V=I68UU$] .;HD:]CUX$@Z+/D^T:E?HC(JE&SI(P'87FH0/FH3RZ8'FI
M%>L>[H%X;8^J(7I$SJT;T4HJ#J65W$MFX:FS1(;37'*'QN7J030OZ'6ZL>^%
M&62H)M^Q$T2(KS!%C"UB1]*++YH-1R>UT"QY%BD+-0<B!0YM7>&7;5$XU7;]
M##ZPB+%F;&#.8Z!N$TO*@5TI0K]H4#Z K=/W.6!L/-EK%]P-:ZHX;L";O9(1
MAM>HT?>RWBJH&CV1>E*@_E91UADU?#1#<:62(->69&2AD*:P>R/QHBWHV[/H
MS(12&0'%<J3:C+$$G33>P"N?7<_TF9,(8O?J-NGSO)QBE?1?6>+K<B<Q<GB6
MUY[X;[P9!@=,34)BEJ]R/RS5+4EDZJ@;HQYK[95-X,J)%YUI(KC;4M7M7=V.
M5@0&LS%0$EK=PF9^WD\6\"XA5505P7XC+6"POZ1[^\#Y#,Z[='P_HN3T27)N
M2'*6!2<G"U$WY,WI(10Q%D04H>SFB1?BV*#&3]Z2&7[5Q2<I9NCSQH[O;-WX
M>?-@P'D8!L,QN*;.P>[9_)VIT?%",WIU;-$B$\.S%OC ^'EV:)'QL?2&6.GP
MUA4WR!O<+$$@XEV&G]!1YY*347P9HH-',N>9$&\4S_)_WDP]ZF,N.LU0/Z'K
M[7;*7-+VQJ[>)R#DOY".=\FTO\.D/\&</XLI?X<9%ZKB )&G\S#:?WW]EN"6
MZ?8)G>)XN6OU)+.>R?KU3*JLYZ.8"_;FT0J5"\^*R;*&V#6XG],I?,A/+^W)
MQ61R:HS4:'Y&Z_]7/-]2CHZN;L>=5C[:CRREC!HG67[4+T)YL9AMG@8)HE8:
MI02 W,!T/[KK*4#!P0+2$S:;!1JREH+35UKKVG8=P?&Q$![5DR$CQS+O"YF
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M96.E[1LK=99B"JG_-J!'4@$YIM.]D8//P\2:6!*6-U1RB4_!=/3&S$69>6A
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M#Q%'6N/!>B?G# ZL*)3?WSTV"-"%UA *\OQ@76K0 Q8= F].=B&S7R?:W$P
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M#XFI+Q:>^R=,) A5.H>)?9&/JZ%GUQ/?(3/53A%]'N93I#1J8 70%>"<\*!
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M6>M#B]/.F*%O#H.G"$G]"(9O??#NP<3@'TV8@P%O@@D:[LT40SRPZ/1Z<4+
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M=YR"22GE(FD3!PP= _81W7*H8@8>H.*&*2S4YVF<J=?@\_RS,,!T4IP-O-?
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M5I-LTX'?84OJDJ+9-.1X*"E/5CB9*'$4"\IFEY#UY^('&_\SV'&Z*6"/+QA
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M& $<ZW90K>H($X7/3]7YZ!AOMV)"GWPLA!%RW1A"<1BHCVZ.)I-/=T/O- 0
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MX,! LE?=UC@U9@+C73*XKY@>T,C!^>G9;T23)^1 9*_X+T:+ XFSSNTTM_C
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M?27TN:'T2FJY%=T @P2FAODKL'\O <@Z4^W^(46ACTLE,P>>;3$R;T/QA7>
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MM+,K2,,FX@K H;@T*)M@Z? .78=YO/%B2&&O:4A?!V>$S&,Y#NT.-VV87LQ
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MW@#<^!B<%]Y=++Q@(QQ!' 4-1RQ@G6*N\UTAT\:.@Z25969M]FN>Q3N91<F
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MY$=<C:>/'_V[CP@H$N<4L'7O?2-9($X^3/$XL-V!2E*K7A;]^_>H$7_0G!
M7/PCS)FQ&NO+4 WL+E"J&)_S.M191^1P5XZ6=1 "]HD649H[-&UF)<-!<(D;
M'-%4;#7=^GXMU2/=E[^\^>$];E\[_Z^(%5.6S_LM')FP/GFB\>,7;-07K[<[
M&)C[7#,\N$M_D5BD8L4-?+/SIKZ"]2>G%I&?HEYPQ?X$KK>_@)4"HPPK'C?Y
M#\K^^A[_U.]:&DG"S)P^H9_G6UJ,E"O0H6:D)'Q(6<FQV._R\$,)F6*'+@+I
M G=@)/"F[I-3$THK5<^@QL_<0"I5K'R^HWE4N3HFS;5TPZ,S(?UL11R4,XVD
MN>W:<_CNPS[/X<L=#D?742: 09SF,>'%WLMR?/;XF<:2[_-FF</0/WKSJ73[
M,.R/Q\,^_NH)N'9J<G52LNF7(O9;(IE=@^<&)^&ZWG7,57N%-T!3T,;.))[;
MZ[Q9MY+T]LRZ^'!L0<)7</R)%Q5<T$M*RNJ=C9QU W>I<9+V"R*MA?OA &/R
MZA(9+:E*7%[RN<Y2MCYCW\ FX?- P1,D54B\TGQD!Q9D>KFCWDP2R^#-.ER$
MB[6Z2VS3>9383Z;7#[\LVK D-D$U8K#D[I<YO=:FG"(KURN$V5'\C ,*YPQN
M<?@'U@S@H6C(K]_:\ (P$_8WZA&T8HS#EM;?ZNDL!RHY8#FR]$E$80W,V'00
M#VL4DD2;\"ZWM1'47$R^/M^X1%-,Z<L_$LW<PN0]?3*38,Z)M75<[N2[TS_<
MDP5YY/G^&@*R!?A,_X'*0D5'R3(ZU_\#EY?\^Z6)1#E@^(D5I=X5[<<'M@^C
ML_W BC%G^W*_>-?#Z7?Z9/GHB5^*R&O,\="K3]()(<?,Z7=/G]'1@M^S'V8>
MAL*14]@?RJK-I;M DJF^/S9RP$Q]_KI\]A#7Y;,3HGAM:E;/7;Q%<-X:E^$]
M770W!-B]XJ0&GX*W D)(/\?O#("XX:@$:S,U^S=\W!=PXV533"W(XWHX[BGF
MZ ;IV2P<OX3FLRJ54C457 1$"H*>X%)1X]5.PW="5D^^D_D<'6<+/<2@,O*Y
MQH%8V;G=^;FE&NXFCLXYN4JU(G%TKK^.]WCB( T->;LX?9H_.OWJ"_<E_>CT
MJ[7\*Z1:KC7O@RAB;.JW+B>*>/-T7G!$WQ5S;/[$\2'4VK6P=/A@<!6])'T6
MLR>'PV/I0I(!#RO?\E7M-2[E\TW"M**C; I+7/3++0HVA3>/7I=<<>[XROC!
M6T)FM/T6D>__@\X_I:PYP<Q+3.Y)\8SVFR%Q?;$I0J3\_M4+G[5J>I4;Q1>$
ML.;E]<O$YWSQCNB24+XW[Z1-(/VC7SNR^6\XKA T]=N>4_TJ'-(C?M:4M>5N
M?J#L9@XN-]XGM7GYY2<W;$L+%R:HQ90 _#^. <5P,))E3IHV*ZF6YRT79>%R
M5(VO)7C .<8<%TQN2YF%P.KMQS'LU9-%;)%H;9U7L(PT@5#M)_>SI.4P=KJ
M.U^YL@SS2;N+LI>X"#$@5X^*(&(FA8Z9Y"87R12&QDFRL&B,2D\0>#:/6SE<
M_](P2SH3+0V^IM,)P"5GNB0@L9SR: DV<%-T7-G!8;HH=H1$$RF*J7<^6?R@
ME2^RJ-9=^!7F-#O*W!]8.7@SZ:O :<OD)BP5 U.0'?MPDF[M#!Y-NGKSD(*]
M<OG'2EIZ\;H$"*NX>HA795Q!>,C@R^>^%(G;U\&"O:=^XV&(:&HH6D+5LOC5
M:L]*T&@NEC ,ND+\YY)Y.W[D,LE(77";,DQ2P<D@OXUXZ8ID#VW=\)3;HO65
MOM#7'%LRB;=KF<YBFRX36K&O'07G'4/IUZ[C+!>!"\4,49W+;!K2%8+);UON
MN4YM!;.]XU5]P[6&-8JC5S(; I8+8QMF+!@U-)FITW4O?0V^2PD[/>1875'9
M>H")DKRMK@84]:2.! PWM46"N"S,ML3!$G59JNJ$?OJ:" ZJY$\1(H2J?9B.
M@J&!@XVAL%)*->5:]@X&UWB(F_)O=8<O0TE+MO5%.Y[H;'""V%.;RDEP_&PF
M["]_EG"S8>122S6Y?\A-@2?[#\9!PB*1@MP.F1"P6IL7#:K<80H,MII_ _B8
MI(:RP;45)C6A611(K6(M#W4#Y;9I $8:;9& 9:0 &/@<9UN'9?B3!<4+XVVW
M+M:2>?%R:Q6)KX4!8V##-2@-4]WST H"/Z*3TO"IQF:3')I00HQ^*(!%:TQH
M1'^3[9""3<U@N0@L]VR6B?+#,<M$W8,#YX9YLG=@C=8%G^]O2WB@!WB,^OHE
M*K=NZ60(27*I28F?Y+]"J95V%,\+V\0-7#;25^0Q=)Y&"'\1>5]TP);!K1H?
M*\M]K$&)/LYY:]30Q0.@7^'3M#@"L#+E58DU3/VO$"LA<&W*[PMN!(7EEXA(
M00=2<'/&J<4P,^&RJ:^H7F&F($)UEIG'@'T_ J]Y9+>"Z$+U&9R7TN>"R&6W
MY43Y-(9]XDG'"J$UWA7[:'UVTL2Y>,%UO2)54N_)#D>*'B1(R7H98(&:^TTB
MH4@RL*2.:FI-8@5-XD(A&)$5K*0W<)(SJ5SIH9&!@,K6M8D^2?5%C0O%>*$L
MRFXPWC!>NO?5,[XICX X0##,K_4-7]C-&:!I 45T/]_\NBZ+QAFP<55[W^_&
MJ8LO#J2M-U':>O/E1)+Q2XD-5MQK;DDRMM@0T[@510#^[DKJ@_*]C::24\$#
M71?#$"M]2G&O9,,I;2RY@OVB+#XZ1K",OI_=;%A.%N_[9>O^T8OB-Y5+.?(T
MD6YZDP= )35@1I$_O@NB'BHO[3HZ&T*RA5^?G74-1D@:=W#'W]6//[+L^\UQ
M95_Y"W%:/I[#BE\55GPUAQ5S6/';[;C;!EZ\/7OW8?'ZM>"_WWSX\ZMWB]=_
M^_'-NY_./KQ^\[?/M42P:.\+ N4X3 0!4$[/3@CCA(P:V*'QT/RQ:5B D@7A
M4=WV5/;",Z\"3[LA4#"\-3C6_UWWB_:"T(*K'#E-2R4[4X^#OF@.5RJS9 Q;
M1KQH2]_BP,B66:<RDZ,4Z0V[IP1SF@L"5NK*-)M/3A:_8\L$@Q3$V]+ZHE>-
MU^8?*EU<PACMA%HH'KC?65*>:^P<X0BXU(C*GX5(AV<5O]W#JS3(KT18",R>
M2@X7GD8ZG&K$D%*BE]N7> 0ZJ@O#L!=;[QH12AHAK!"LYT43O8=Y3.&H'/F=
M]'.A>Z+<\E7>K!^5=?U1H,>=Q:YC:%M>NJEWX6)T?J SR<R":>U G"1!9T(B
M^L"3&! UHST"UX5T?=D%/[FA/AOX=_KXZ<.RN^_H]=^%4A;.TE^EER]PBO^9
M>N[VF=FC;\5['' H!5#Q S/>Z?'1G$ON&QQ#U?!"!X5S:D(RML <&05(F-;Q
M7T:&:'C.MB!;15&8<E%K]R>?"72=Z"+R4RWNP/^#16!"N]_2</+;?)P>;
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M)7CTN8'[ <WA"W742CF502VY4PN&>D_/GWR-&BNC.I(H8;%/M"U?H^WVR%(
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MGPJV;M,78FV<2$]EXG@,AV <[/V'6SXW+;?H2H/_@MWX[:N:DZ+[GWU(G"]
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M42&9V([^F_2FD2'HA@ K\F'&+SV!J^('OR&NZA *@*O,*?[$/SDZ^F4ZV[[
ME@$/1[9'B$R"XJ*R4>'C"*#40^JDN&'GS3L14YA8M0Q46L-JHO$0K]8V*I&0
M#PSE:H32I[8&/CUZT2N$^\,?('277F_UDL<2#9:2U/;:W,]!/VC&?JY*5=5
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M<7= N !N4:W7XR]E+2]@&4>#IKQYZ)?2%,;1S @OK=S"O]_$TW&M^WT86\5
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MR($I/RAY:3I[R&30N1M.=K'%<)Y3[[N $\BV6/-LSOH MVI$_KRK83R0M*E
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M=.0%($4,SQ7QM"[.UG JHWU^(;2W3/("3D6QY!2IQGE$=[OR_"%R3-.TH&^
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MDELM=OR#HNLBI+MD"G9- 6-2>¸A@EL06#?,&WN3</'TP"1W\MP)1'01:
M#:"T 2:->D<U):O=\@HL(^BHQPMNZXJEB2;S:)37IEPJE=7:'C\H5$6-O*(N
MWAVC(;@&M%@OVEH5"/#I L)?WBDSS(03<#C\"F\8^B,FW:/4S@C2Y2':UVVB
M*5XMO[+,B.@"8UT)ZI4>"$O<SPWY.7VV.,Y8GI+*W%I;""P46JEI$[&N3V^F
M\=34^4PS&5:/Y _5O659U:X<GZA#T&PQDBW(J&NKC?U0M[7R?A<ZRB&JS6F
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MI@[] 0J3)[I6VW%;LK@&HE1N'^ PL\Y]SZ==F\(9U'X=Q&WX1=/X553!-^8
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M2I'$SWIX,L!^LYS7*IP4'I>W%&-CB&*;T3)YJ=WOF*^B'VI[!$+AX7[^[+B
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M3?!D14U".GO4;A-\D^%O!)@7D=?*SVW_1V3)Z7-N3;JZJ G[:71UA">S:;/
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MT@2N^/:B@.NX"IY_!V^0+=[ R[]W*]X#\!-X+K@!NH4X#>^Q9M7AW5.O-;7
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MP^WR4)-Z2G-R)>#@EB9 ^CI8DFH)FZIT':F-X9/=J2QTP<VE8ZK(I M*/TP
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M4!+Z?O'YE_B3BGYGUZ7S_@_?OUU0T(<<@Z<AB:Z#N!6S*Y.#';IEXM=9<,
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M^$7H5(X'2KJXU#Z,B\O?<ZW9[ EJ%SA;A>]=^W!=F4ZMBU5O&6A#+A"X2ZO
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M!:7-EL0S3N0)STOQ4R]%ZDBDE> !K4@N)&0CT4^8)FW/<_: 2B5.:ZE%Y@%
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M7H="-+710/5[<]P3P\*J$0ZTEDJ@"WLT 5_381*S;"&NP?D 6@X[%$XNN?!
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M!T^-UTOV&X5GN*8#[#HX;NYT0EVP81\]RC6VTGU_W@</OP]F^/PTUFMWKF7
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MO /SA/_\!,OIBF!:$@;(+@GH1 );I"XJ8/C7_=\S/O#V,4#Q5.5Q&,/2LS)
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M=_;(+>L]*4R?%Q1#]66ZM.3JCSXXS'%N$XZ($R>PZ1-1, "WOO1Z"F8MG+U
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MT_X0^UCAOIIU3[$3U5P=2'K7 UC&G;2FABR]J>([+QNNXW2#LUXQ.O4W=<L
M/G<()\>&RU"J;3DOG@<Y!+2Z(1V=6HDW.R_[_<2A<)ZXAS#VJV#3+YDFMAA
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M2A:>2:_)QM"9]8$8PB5R2)8M5YR'0@<ATX)Q?5)Z .K1VR9:G[PBX+1TFQP
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ML=LI.F%3[X>$"[O<@>A3&0ZZ6[DDJZX) ^+N-[0F-AU[K"FD4GJN+)3VO&O
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MYXN7&SH +HE:1*ZKC[&/B<G8XBE2ANW%@44:./_)?U5N]N*=A'.#1'V"G5E
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M0/H%�(U_1HE_<298-,7>$B.)IS'%P4[0 V+QD_+Z1'M&UA?^3)D1_)5F[#
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M8B:=A*-R]4YH*6+.TSG6=]"5=DLN1G_$/' P2I]D%39;I0O%!%)7SO=@CDG
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M[S E0%2K=TH2D6N*F:J4 "CNOTG4\P1]N)=-5WK,P0-T0?4"GL=ME+?MXTT
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M101 6D]4MYLH;D7!K?-T/KRS)5V5E#ZW[@:KI[6[$UN2J3C6B9(9'.J5=DY
M<:1OF,WX(&4,R2#1=H_=))KQ$\R/]D&.PG;*6:MZAAGBO(P>AU4P.R!<UTEO
MU)R*G&EN6!^UPX^?9_8!9]:U \<XV@IZLO]TTI*3G6G#>G7F.&%#T=EY-C^U
MN4]5IJ/;=C?@ZI.L0?T8\SO6?B*4D-UR>6 8E"IDN-YYP>5,>X-+,)\S+_7)
M-H+/Y]L(Z 7:U?_YQ>UP]1<O?OV+<_/!N?G@P>U,&0OPKAT^#(MW*H+<A7\:
M1O2E A#)?GSOB64(P_56P+>O(@,<?>X-7*$_@\/G5526^IYX7(+9?IRF^)X
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M0M+H'PX&+,P>'0.DZB4]Y.B%7G,# OQ[94XTB'\.7>>-"5?E@T%&UBZ%X^E
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MPTJH7:/)T/?/GL4?Z?GND)X<?]>'03/7*Y@VT-GQPL'ECWU]1\'@=5A+M
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MXES87UW/ HLR"G2:A/& 777>,D2(C?<>%_FG8!+.$-RNGCI=K#+Y4WUX%S_
M>BU*T, 1 1V1LW 0GZ"ET+_,R<'__,4+D\,_$RLW;)9]UFA1CC&D^23^YB
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MLF 0DS8+=;M-<37":E2UYG"0^(4"GS766[63,=KJKZRDM59('B0CNG-/'XV
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M7Z"J.#Q2>,>[F$L $2D"=T9MC,\HQE#0WKA074G%6W.7*@P\HAS2P1I0?CG
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M3I/)9?<JBT07#KX]Q=5#4QM0,7TDCVFG@0& 8[1PV-:+&11^-\5*^9=/S R
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MP\*"$^OP0P#=\&EB0$$>BZ%^O]@.P?9CU$>>>AA<MLF^!CUNQW&,'"% 2/J
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MK70OQ JJW^@Y%53PHLT/*@>Y),F/6EV%4:_+#:;<")6&?^D%MK/A.'4Y&CE
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M<S;G=!! +#ZE,F$G/FLLPOFKF_HX<O3+TH(D(W*+T !.FL>;2J! WLA_.\;
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MOTL! !F$R8D&V7VN\U<62#)7#S"+?I63@L5K*5)GI-K]JEZ/YR'US,NQ9W7
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M!^%[H-G8$<9EHZGJ< %B\;5]77^K[PKZ%'53H@ :=XS0Q<J>Q5+,K!V83.1
MW!SEQE#9$LXG ?FGMX(1K//-1BA?Y<9)86M=;EB\D;[LI&S=M[6:P&@F;I!S
M=\$KQ.*61UOJR3?#A64NGQ\E]NMF1LB)HD8!:"[ [\@0ES7.B5UIF%1!E.YR
M?"[]!G1N=VJV#;HSNJL*4W).^6[760A1E7\IFK69Z4]V]\09YDX_O7Q"M(2Z
MJ24S%<2]I!9BQH7*$0)?6U!6$+"&;9B6XL9ED^GA.Y>)IX>\B?5FGIGK<5H=
M @S@_"3NDW":R^&=8L,JX[7&<% -<U M9Y^@ -395]2+SPE!1,D8U%)C):$
M+P?7V:Q9R0AP!- =$ #QL92L39LX#8$1O4>IKL2.;4>7A.4D?IL-2+SZ"CQ<
MS@J[-8KH\>=J&?Y_RDTS$TK"?=&'N4&/BZOO/,*U,I=>DVTWYN1+FO!OYL_[
M18<;Y>=OO-!\"*=HB:I38X*T0.:+B))B+02D:DTKR=L?L V[PPP[7+!6QW$"
M7,U23V<49SS4Y7)'#_*G-&V1.MPN8_'BS4^<Q%!H0)8 322?D5%6O5")T1!1
M-B3F6KN 3V6))0=,'+ZD/2^X&$O":+)\'APS5Y_SA%/A 8M@I73&'>' YVT
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MVB864[WBS;:4CG%I %3TP>%LVCP,OT7 9<T5XJE*M7ILP^- UDC?*6NF[RQ
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M_R*;D?YPSH2'*$> N23FK)I%/Q8LP&C74B[5>2YR#+BZ&YT\$].Z:*D1@;*
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MX E^)Z4Q !Z91X6E)+"W^1?#%4_3OI]3WI"#10\J/ O:7NR&5>;$5/"QVFZ
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MY1J_TI:A#,IA.V*(#NZT#FP[[$["+!/XF3/Z86#<OU<W\)M!Y!Q% &5/ GL
MN:.CM&!KN@[&[Y7HQUO_4^[!'K-BA0D!^38\?8M*9!PF!?)0[U"V^$<;7HAZ
MDW8,5 > <! WCF@O*O2DR%_MCF$4+T147>F(Z'LBETA61!X\>=&9#H>F%+M9
MM\%& Q+E^4$SE_VUT0,NOV:]DZKO!RKA1-F7,-T[:Y8<R=T*X0;E( YS%3?
M%(U-!HTNRHM=)OT$E[3-G)9V1I0/W4XYNFQ7HJ-0I$O"J&OS^4'@8$1XSK$L
M1%C-+%XR18T=L*7?\PPD&X"6&-J2E*"5^[H$*^(P)X8N]:0=RC_*9'DUJ((B
M EK$I< M$B9)-3^3%< \S=1!E7"S& WL'&\L]C_0<3LG ^4MVX3:BMG[(H-6
MXT@'_6Z3&1MM-N:CC6P9Y<]$R.6K!/JX-!C2F?9S!IS.7EIY>H*Y$;DC#4_:
MWQ#'@#IQ2:*&[PT(4%.NJIUI&KFY"[O*8XAR50%CR%\8*'J8*6&!@HO@L4+B
MI^U271UMK,,HN160S)L\#]H.J)FG7W;5!;757K1797;C3QU?H]WJEY)*S*SS
MPW3\QMC_*R05GYX]=DG%:['U-&K4_/2"S=];(*YIF.A#2L(,/1.4O0:#$7T/
MY-L/TVNX*T:R62@FO<N+J%-FVF3^4#!3YTG2Q70;J+@7:5SMGL8OJ;SL(;*.
MJYG. :HVH^^L#[YT/+'\O1\H)/5&)^VG\?A=E)<$I921%L7%O^9]D?]S\2=N
MI7@+\D\BR'M?<FLK_SVCKY]ONZI>B#["V>GB=5>UH'5-_Z!PY^L<3"W,O'73
MQ*(U-UA*FAIJ)ZN$.DGRDN$&;*-S6RTWK1*8U5LL$;S=NKV>HRIG)U5OLZ%!
MU;.?52KQ.:/&YM_(,1F"'6 B[Z8_2Q8H8*ZW6(ZLX>A[.OA9W"'_,!?L'>W#
MN[6]V<P@S+4EQ*8K ^9*N2OA\7[XL>T'M[;OS:D(Z_2>@-]A-&0(RE$W/S+'
MXYV*/B%;AM3?VN^F=D)L!*F[UXOSX3*\.N=;/E>IE';T0$2QBM@G9I;],)%,
M_26(44]DQ%;X?\_O:?PP%K\_.WWV35@0'RT%]KL_+G[_]-GI-]]P&Z@><K M
MP?,5BEJ3ZW!&[Z)J'14@G*I#$FDIU''"FZIMRV[?P#%<0V4FV%]F%$TVD.N2
M95E04'%(C.9N9@\Q0^P:5FS:'TEA:CM_1CN3>$<C^.XVQEIM,P%'!^,(V;!4
M@="!'$'Y'RTCK-&'1AG8N\%-B-W>NS SQU+E_<\,DSML-K1G&)E;-H3=W$B/
MIHL+:3.-66%B9HTR='#'/%9_Y)7U' H=;/8Y3O]#V)B9X_:I2-0H5VE"R3$@
M<]7&!E_)!(W6QG$R[[]AQFMX";<$F#.9J&-9=BE;%9C<HC3&<4-^_#D<<72E
M^[*=)]IJ5YFD2EFHEE[M[*OG_71"C_/Y\0RLS5M1+JM^7.)602WF08-ZXYWZ
M9(\S>^\SV^PCY\&( V]549]2;Z'*3%^S*JGI DFR5XY =/8+0.LK7E ,>62\
M3%8.TW3N]F84NO*J"J.B&3)YU'$W3\J6PX#5E^=V$2T-LIH,9NC)\ZY<#3V9
MKI:N6N+3L^>+X#$(BU*.&A2!ED$Y'8L:C@GRN)#O>R'78%M+1!4UX";VC>TN
M=ZJB,RN9"3&]RBRF%U%%1[4CJ><>9_9C'3[.=/3J"&K)/N$D.4[1?4]1.]:X
M-;A L)3$G:0;3M# RM6O#"+V]W9T'9;PRVT/T[F _-EQDN]]DDE/S!#AP9 V
MX58>U"140;W2&4=7_CA9'Z/_0_-7$?U .*T-3CM//9TW'@P5_IG7>V*9NUZW
M4G 41F.MK!QG\_[[78TH#10"95,X[6^F[S_.RL<X]<#:IZTEQRFX[RD(@=H!
M7()9N FT(8'R':?L_MWY=NM=".&E!!HY!&D%J2,=9^7^G;M9N1:3 %42JN/,
M?$1/SF$OKO)ZB-S@*JAB.(<;ING81OG'+[\XME$>VRB/YNM>/#2/)8OLAE?!
M=FQ2MGGKO>)FD0@<0X-@@A[+A(J V8M%E5H,Y <1:<> Z:,Q"@" ;5 +ZWSJ
MRBUK+%U0P2:Z[3I33)\8]4E-2[DK&?531$$D*OL477[-94:[!5(8U&QY,9OL
M.*Z%^R\\-NT@<*T^C=9<XI"=&\<<[UK5#K4LLKAM;$H\SNW'G5NTQ(YURV:4
M'C7F2!4;B4QSH(8W*L86B_PR)_K4L%J.TWK_,:) HZ6 ;KAPE/D35<FE](:-
MI2./DW;_3.)A>U4[1604)9E*$?U^7^Y%UK(IZ^/4W'O^F%R2NA[W+:#AC'O4
MC\S/'PM0+BU'$J;,))B/<W+__)_]=MB53I\P081P"HMDP:#:MR42#!*T4"J[
MB PC9#%X,)Q8ZH:H U3.9E;3CW^EG';T&\7%>38/[2L_ AL_=M[!10WJ0TX7
M 7 +L3CD5L1QQCX"WR"K(&O&.^P]UDU?YJ"+O69JYC2;0RDE%EN84=9IHZ3"
M/T+(WQ>5DO_0O&_+I1"44CB2=\R(0W!2>8+C&KAW&^\M^AP^>*(D>9RC^YXC
MB_I,T 1R-5-UTP_P>1ZGY]\35< U$E)6,H#:.;Q):*3(I%Z4^U;\':GO/DH.
M@H3<2<Z!;=[OLA3W@8YS:06D4Z;.B:>)73G+,FE^:73*T$)."PNQ/!&1X]3,
MWA;(>+DN]K1PR^C52*%HU]&DBM!VO*/&=$@TAO]U-,S!S2VOR*DA[W/HPQRR
MLG5XNH.=]Y->>^\<>;*$]*FIA2=\85_F77^Z> MA2_./H "HFJ!)8D[E /FY
MF#X,[&G$CD$0CQTS,:F2+>5JNYVCZ[+^C$CG)21FHDF+QNO'H"AX1Y*15RM?
MFVA= <1 F<*RC4I*OT8[*YCRY /0+VO- VE67UEQF3EX0*PSOD<?3)EH53,.
MF]3 J;+F"C7J)J6\6RQ92B8E5OA&(;3H>Z)9OGRH\W6CF2$*A]N00X4=*J2"
M*$MDRF^4$/WIQ*""^:%)U]D>U\?B\O][J2M#9:NU[ 6SO@" EPV.7A6<%#<1
MPQFI740$CPF-&!C,#X3? -"5?/VBO*P:_UV]+VG0$L_@],9HT:=OCVX>O$&1
MH76<@EK8.UV<*^$=B1+3*'#@3J9>O@.;-1*[1=.9WL/N.M!.NVXN29VO=YPR
M%'_P9(2/;[%AXKX;;19G=$$FJ/OBU=P#]OX12S"16CUSE'#'@4\"S+O6EHVN
MM; .AUXJ+QU1! 8'&L*W'B49-RHH.(W<D8'@,.GC%YC9[2"[>M!;_8ZF^2=T
MC9$LU!9$'\ZO, 4:%A8*RV8D%8_R2+-+9\N1QY NN<B[*M%,^3,=B?XBR4[6
M;)77UW99#.U@>ZAC_T%&J?#Z2V9O;8FE#,J8+ T-3U9'/HSF%_\U4:X>CRWS
M]4@<2=<DY:"ZXCX(T&F*:S4S<U'Q&Y7)80>(*O0+'CDGWX0'R7C>:!RXE)Z)
M\?'+/3.O(<?"NRQ9TQX6%\8T9DZ-QVC$-,U)TA ^+C5C2K<UDJ4X 5$_&DQ/
MPRZ,>LG<KKP!F V6L</3]6\4S^ 25(R16T@Y84>L2HTI[BZ#S_PO)2TOVN6P
MT4C*I)&51V93=I?T[H1"QV=$%^WRTYO\'V@A[;8MC@7'>BH./MG^+;3HN#I7
M]<'\PJX/38\!@F\=40\+SI+A(3K:'30*LVX(8Z/FB"=795ECQ#DRJ8B-L&>5
M%B)W?I168T3P6TF'*&G=V XVHE.A41QKE$\(%>?["H[$6_>?%:SS/?AZBC(L
M^$Z(?&3CP$N4E"UC".6D7!U1(A\#);+9E@7/B=I'HJP/QJR0Q &13'-'H1K*
M.=9X @VU]15[X\_IN\>9O/>"*Y]&/)M1FT!(T45M?I._YR_L2LC"X5"RN;VN
M*'H)I_5FJ]59*:@F^_2A'CIW#!/^+J$G]*QPG'?EJ,#DJ*K0/ @V>/H/<F6"
M=\&E:00%'!L. #J7&SJNJ0$AD5LKFW6N#E9DPC2^N^Y6A]I#'?P/Q@G.I22:
MT,FH2^I52&42@-JAH6<*:,3 Z5"_U7>_'V;E8,<W_EE5XJ N*9)9/+V54E2
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MR^)1.EFOAX[HJ&$4WK+W(=I63S[7>&;.MPGF:/QUC#E9&^_1KD+ A29G#7*
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M(@9N0 Q\<Q@Q<(>9>O;D=_]NG$%XP^5)HMOD#=_7OGS]R\$'R3N7/P'H]
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M]=*880BKU1L94UT \H91H!7K,0H\4*#IDQ[WHTGU\>RC"WZ""&"B7*G&F/#
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M[)K]-?TU6DXG/_X#4$L#!!0 ( !@X"E<VA![P" T %"% 1 :&]W
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M3UNNU\V*"M2<+"MGKQV_;"&LE*##2)%SC=49&>$HU"01^RW"(1U1$FA'" E
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M<E[EW-E9D>NO(I?P1BES YUACQ+^*".@01@^$#&]Y)BY031O;45@=Q4!($5
MVR#CGO+IU"SZMX*,B':SP&2DKAG4>F*KZ?=631]S,BX_YQ7GQ@W"PN@+FTHZ
M(YW")&#ZXQA_KZ>U(O$U%V\#(\]P0EE6#<+ACH0XKO^XKPPK-%:[[^<7;L,
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MW4:Z995:CK&D3)X$6,T;:>?19M3)'V7C$RQIM47E?;M@=;X-5)Z\V,ED^C1
M6&4;@_NB>?>0Z=^'MUF@KK?LO4F"U5=RM:TZOM+L=; *0/.'R\.>L^6A_LCX
M4!)A)O$+-HN4?LVUC) :7=_-?S;;/:OSY2IQ=9QO\>9+;M+2T]3*)/4%93N/
M3._1<O<;Z<2V6GF]N:LR5ZO+Y*J$3K7XID]1-ASF.]3+#3>*M46&%?DUAT^<
MD,]LCJ]2--$5G+=3*H%?F:L5[EQ]L^HN30.Q3;=<ZDW6A=16K'+%R\763=-G
MWM2H<(%9$(6$CRXY&\/3,S)4F2BG%E3.7&T0]G+ES"R$J1B80T&09UZ"J*4X
MK8GX%FRRU1N!KLRL:.:*FB5[=TT?H05&7PRMS.:.#B!TYD""$1<74D9P+<8F
M *XJRXI_KOQ8BG]V>&=WEU#:!:3[@-).--))UN_5UAOECKRL(.?*?(4[P$T?
MXNLMG@22D/R/&?V=!!M L9"G%<U<(:X$S40*6HCY@'5NGT629]X/GK$(!K[V
M?:I>-X"P"WLKV+G"5PG8F:0UGI6-2)3*_$!^;JR?"-Q?3(+!$Q%X##7,:#J#
M%]6"Z[K,K:@[_VQ)OTK%H40>R@C\@'QN*?/TQIAE@V.\A*L5Y%R9J@3D>#S'
M@IH]H)=_B5:Q[KB.U(I3KKZT\ENV1L)0\7#;@"D:T#""P-(\J'CV:E/2K&!O
MZG2=A[*=B!_^Z3WE6WOY6NCX^]+5T7!Q='(-O?$CN+/VEZ73+HO?11$Q;2$\
ME.;LRG%KA$.X\1;NO89<O)B$47@'U]TJ$<$=N7!3_Y'&AO+@P=QB&T0B^?&Q
MC#1_JB+X]B_!H]EQ*VY.%=&LXDMOXR<IT85^ VP6MV/G%+I@OB!Z'K]@Z=&;
MGS+'B.:G< JU<Z:OHFK\;AC?T7G<TA("JBI90/N[]E_QZF"!##Y/F9^Z":S7
M-!]$W>I(E;C 6TJ^M?K_F,Y"_DI('" \,ST[3.CL5LN^C80_T=@:#6Z)\,UE
M1@5VJ,K&;H_X:O]J>L_T5.B@\W)%&:Z&,W,(#L])VD,=G]Z,!E/XL>F9P,^L
M4/%:O#:M_>)/=@ 3D.E@A94-KD'Q!M=\F7D@+^HD-/=2%)CC;4PW/B%F#*-2
M,2Z# @M&V5C>)NLTG+/PM2YGL$R26*6% K([2(R1-4NL03(Z:O-[IR4"\F\V
MKC%4G@C3;GD;RW_F5V0ZA#O4UZOM2/R>J =\BJG+2KC<U[/XK\[<B$L=0-_B
M5_/7:.8#^F;TR&:8!O&8=IP:JK'<BAFB#+\;1NJ#GR'>"O '#U<WHQ&!,5&N
MU)J&6Z% F;'/#),Z,*646ZCB%7ZATVAZPH7@SQJ-4SS#?EFDZDI>8>"MQ&D!
M&;Y?F):LJVF4#=M86,=5R;IJ6XX+R>IK^[Y1Z3T.B83$E4KX^W!R$4D5JEI&
M\H=&F]><P=&L"Z:(7MM5$AH5ZE'4_ T9Q+MZYGWD^T1*O93-T[U;O9 5XU34
M?EL57)_!_]"2IE!=.X_@1W)WA$Z'D9"@P"F7</-DI8* G=W69I!GY(F$? 8/
M!_#+HC%4<KAXO:)Z0"K-I]@6+J1;K'=QYF>OG#A2;^L$/>AUNOLFV;]@,,W2
M)P+)OB5Z*B?:BC C]Y.[^1 MU\U.MQ7J:0AZ70/!4L5F7J1QP="5P58H7%R8
M2@/Y.-:M4=E:9?#'EW.3<.\*LVBD-8F@=XXAXGJ:;9U^TM.BLMQ9<\VVPB5-
MI'H"NZ>+=>YQ]L#+0]NU!%N[.*8; V<DW2!(_O(2&U_"]_D2!^L^G NX&3W*
M^#=:ULV&6CRW-;J$K0)_0BXNP$\MWKRNZ59X]/HB0I)D#QB+<*@S;*IP:-(9
M[7>1*,Z :G+;JBV%;!EE\$)EG?)+3+<!@ -U%%#-7R:K2,U:<.I_[IZZA8[Z
MMOU.9_IMG6Z2[#NI/]L5+FR_K9%!YK!%7$L?1&K"!9PH+4G)2VBV5=$XCTI.
ML)L:@5X?(6X+3B)US=5_B2JOP[C2;VV,<0U'5T<1"Z!WC[.1T$,22F>)L\:7
MAI3 [DR_M198)&/5LO RHJV8IS/'%7^\$.%3<P ]N0-&.^JM(+!;5K#-'/]F
MOMSSW\S\CW<*<VI)ZG5VBK]_^A]02P,$% @ &#@*5]:GC=W)$P M[,
M !4 !H;W=L+3(P,C,P-C,P7V-A;"YX;6SE7=ER&\>2??=7<#2ODV;MB\/V
M#5G+A")D2R'9<^\;HI8L"6$0S=L-:)FOGRQP$4B")$A44Y#FA0O8[#Z9>3HK
M,ZLJZ^=_?#J:'7S ?IAV\U\>\1_9HP.<IRY/Y^]^>?37G\_!/?K'KS_\\/-_
M /SKMS<O#YYV:7F$\\7!DQ[# O/!Q^GB_<'B/1[\L^O_GGX(!Z]G85&Z_@C@
MU]6_/>F./_?3=^\7!X()>7;9V5_[G[26*"4R$,@X*&8<>(\(2D8NO52V)/-?
M[W[*W#FT*H+VPH**VH*+0D!0/ 2FG(@LKFXZF\[__JE^B6' Q)O/JQ^_>71
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M 7_]X?\ 4$L#!!0 ( !@X"E>C)#O(33L $+3 @ 5 :&]W;"TR,#(S
M,#8S,%]D968N>&UL[7U9DQM'DN;[_ JN]G6]&??1-CUC%"7.<DT2:135/?L$
MB\.#Q#8*X HD9Q?OQZHNPI5A00B$ZC#9%:J \STXXL(=P\__O7?OQU-7OR)
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M;C1K#*?;J7F""&JDFAX26FL[HWP\P7=E!R&=) TAV9(BH ,MC23XDT\1@BF
M9&42_%F,O#7(VE$_5(+>WJ&X)X4?2CK@1_K<NW*)R55*BZ"#7W'RA+P-L98N
M%/#"<N"2S$?#!=>Y-737$K*W]+\]@6+66CD]Y A<(F=!4J'S/ES\YE+$[NQB
M>Q-R>THF[$CJ?M(,&RCY>HK) !HZ SBYCSAX4UOJJQ"WXG!A(GIWG# MK
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MJ'! IA0H@R2#U5P1Y$;$0 (2S]>%6RETF^O"+MKHU[BYJV8+8]2.D?GM+$E
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M\#7W,49)QA#)H?#6C4$WI>UQ8*473?3@2[Z=DME$7O3/W[Z0;8VCP+S5*3)
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M,^8?!FB!VZ$\F&<CA.02C(^$Q9P-Q!0CI%!8+D9XVSQEHS$+ TU.T(Y+DY@
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MR5CE 5X\KOH1X]!B&RTU\_=%'K!PYW=%+KHY:"N;^\: ;$!3\_=%#IU4^@$
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MZ*9P[H'NR,ZIZRD2SYIL*"S"TUGT KC0(3"=F%;-C=.F' P5E3H(!.]1
M^0<3A]J-\1^_KW_ RK_(7K/B/ <1:IIN)#O/ZZA(,M:28H)FNG4/LA[9V7^,
M;'B0MMWQFX&E!]]O/667_)5-Z.LI;'8?;7L*@1T*"Z8Z:W ?B,')E V:P
MC@E0 0L$7A*@3=8[RQA7K9,O]H.T^X)6#Q5H710X:#A+"J.TD 5<607^--E,
MEG-@5@4I=$%C>FL<N/]P5EN];1R:ZB+T_L>MGQ+E(W=*>%MGF2(HKAF1QR/P
MP%GPA;/H6U^FKR7DD:%@=V'WL!_</;\=5<G2*PDNUIW09T%^E$300JF4BDCM
MJ\SN).AQ(V('X?>0J/./4&/YRU-BC$<TGK8GID.F,]&:.N0X@R^J>'1,AM2Z
M8. * 8],\]L+]]9L^ELN*$Y_7;_4++)_^Y?_#U!+ P04 " 8. I7RUYH
MAG"; RL@8 %0 &AO=VPM,C R,S V,S!?;&%B+GAM;-R]>Y/;.)8O^/]\
M"F[UQHPK(M'%!T W=-S(\N/7M]PV;XNN_O.5FPH\'3JME+*$25797_Z!?C0
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M?!;;;G9$GME?O#,_U=W8AEK(M.RGINX=4=5O*S67JF++O::CJ?S+=^:GR;H
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MV@>:SJ=Z&'12MZAX.+7;'NTVP3^I0IF7'N[G\I7ZIF:+)]MZXZL;9W'.,R@
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MM#[W"C"4I%@*F&GA=>?0TM?8V&1'U#+AJ]@5UH]'VA!V(Y% N/7M>' V4LG
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MH$. [)O_V0NM"QF?W=H:,L>SEW8'69W]WNV:S/2P,L'[Q4J=J@S'E3 FK28
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MH<S62H=< AA:HA'8)#':2QCG!&2>^[ESO0T-L(IY=M44HQ^L3)V+6%QA*KK
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M1A*H.8$R$3X'W"=[&=M&[^5B9F1>V&O,;VHODX+=T.W^?2<-W/Y+70[$3X^
M&_M<C6O?!^&]0^I-2*V0!:*@TWT,2CJM:A[23/O#UU_?EP?P-FRZF"1*HCS)
M8\!%!@$D,@><( U2PJ$B.<H0]*LE>[*;L5'+_I7RM+ZL+*+UW :'20.^&AZ
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MV@OI7'P[5*K?29KF64;,WMALF96]BR* :J5 SB'.N98,Y= G(O6X"R_V&2P
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M<(ZP+OB%3"'FU?_P&<:ZP',R 5FGAOQH3ZJI#8ZQ5NK/SX]\,9OP.*-Y(C(
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MF=I!N5W7:I?'NZ7!^Z3T>B[MD=67)R/B?&433]4GCI^44--O2D[BE,5QGDN
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ME&ABKZ'!<DN<$G\WG<3)?^]:)^Q>2C.<Q<=%L6*S_W?Z5$T]D@B!;95JC7(
MD8@!42H#(H,IIKE$B"*_2F&GNAG;1*PDC6I1[Z)*V,A(ZSDS6Y"]/$_#X-7S
MK.T*58>Z86U(7%$Y[&2S ]<.:U/MN'I8Z],=ZX<=)![8WNN(.(58PP3$G*0
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M,ITG@$B<6VM" I3#!+K+"PDAU"Q00)0/(0>F]5Q__7KLDQP:&-0*CDC;6,3
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M0!'/0 )S@KF $@LODZ.EK[%-\G.'M]W.:]M =F. 0-#U3 <U:J68=WT>@CK
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M'=GX;F4:[=@..8YNQN%@H].S]5<-3.E4M2/@7;25/:H>L<-R\,O=-T*6V0V
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M1_'PD#SG.\9Q,AO4K- T10#7"@(2$;-3SR'@I8R4P*.<D]RDQI3,Y/W7[^N
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M=1NB'VU$0I5-RLR0)X]+6<7]J,1\?%FS"3ξ&N_!_7/@23%P>ARSG5'"N
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M*6EO^!?AYDE->YQ'W)L.3.';)>EU@+A*MY%\N>>;JA!=2+:I9QO)Y\[G&Z[
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M9(7UV3D@R/Y3EC)C*4?$C?KW2C]3,SNOE%9&,)FLU9-:VH.S0>[B)53=3$P
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M=ZOE5S.S'EXIOOULFJBXIX4DB$E: VIF?N",T"92"V7?T%R+8USX!6L=JZ3
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M-M2ML$DK;?*BBV0C\.4 V^?T1V=0+ZB0X>C^HCN !S[AAYOCEP+OKU0OY=R
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MY@< -F /WX_	OW"PV/O&OO5^]TNW[E>7^38,NRKAW]P9/G)_115G(%]?PN
M:COHHSML:;2O[*P"W<_J_ /#?+?W:FMK;E1?I53REQ__OE%F.[B[C]OS@N\^
M."0$(:5D]DB9 BR1 C13",B,%D4.N<[\BO7XBS"UY:C#2K^3U7.O-V <W!S)
MN.A&MA!&^+J43RN^C7IZ835(YLL_G:6OC[*3' YB(,=V@ "C.L'# 3IVF&]H
M:>#NU2S2%:/:_$G]IL3CNFJ\KIR@Y!NCJHUU>JQS.C[H-OSVHUI7(4SOYDOU
M=JL>-C-%S>:W3!4HB4 TQ0!PH0&(A5Y*02DE'O%N(82;&K6LJM7LE<L:35+
M[.>5='2S@0>[ '6C7AW'F'RQ&B:5BIX,(L&&W'$O_PP#&?LT8,PQ]#];" QX
MJ-.)4&*->[X1&,R3$Y+0[0^]^/R_CYMM&\-Q_G9D7VW[L![WWQ[GF_G62+]^
MF@ME))NOY"<E5E^752MUQ<72YD 0;#-I4PUPEFM L%DC)%<ESC.=J=R)\F\L
M@:>V;%09T:!2QI*C[H/BF^A6WTO8R,/M>H\[G4&,O61\?/OR[GS*PCY^O*H
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M_^>FJPNNU\]!;A=K.(-1X443<% E@-W^Y?[!<DAT"#E%6JHTHRE0HBP EEH
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MO^@\6<O1<O2]4O7_S;\7C[*ZVA+?;/R[/3!_K;42VUF6*IQ!KD"J"F/A%<.
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M!U!+ P04 " 8. I7_&FBRQ)H 3V 0 %0 &AO=VPM,C R,S V,S!?
M<')E+GAM;.R]V9:;N8XN>%]/D;W[MK&3\U"KJLYRVLXZ[G;:;MMYZIR^T>(
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M"1AJ&41D*/'(A\E;J^T& -TO YFW<@BKX__9^\^SV=7P3D;#>U169#2*6)
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MNFC1R=(2%;>6W@T7'8<UVS!U9&0\HQWD]2[.PJ>)-<;Z[ JD6J^MZFN.1Z?
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MC6%_ZR $JS,7W$,0"4&9["!*IT$(%B*CV]W*UF'#!PG9"3/-L^:&P,S1;.X
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M*3</_!P4[!ZRX'PXD6_KKZ/X?S" ON!B.J_!UL5JJ=I'&'>A;/3ZJ-,BKJVD>K@0'][5
MNDG?S:8B2ZDD@9"P-H8O=;"!" HPVVB5RBK*UD;83H2-7E(U-OJ.D%._X-L<
MJ9?G7\[FWQ W_2,O%NDSL?C=69@M)RF%0IY2 L[);U*1J5K"P6F;629RBJ4V
M[7O)'T3JZ$GN8P.TJ2S[A>SZ'#ZZRXESCBNA$5AE)WEDZW)L!]'P(+*R(K$3
M7=]/$SIZ@OW8<&THQP[ ^BS_OQ>;\K?EQ_DCX>GU 8UAG9=R7LN:UN)^C\3M
MY72%'W#Q=9IPPYWWF.:?9NM/V<S_BQ@U;9M!+NMI]-F!0Y\AH##1HP\^M5;$
M0^]I].3<DQV!KM#1P6EY\@9;__#MEW7/QY=_XB)-B2<37C $KCUXI5G-F:Y9
M>%J!SM9IYGA1JG6!R_Y4CMMKM0.EWDJ"_6)T?=X>WJ!G09 /$,B@\@*4IUTZ
M'20(;6W1ENGL6U?2[$WDN+/7.D!H(_EU -"[-;!<%V1&^MKEF/Q1GVM#M"1K
M;(0+&>KLPM;!]?UKC#G[*R#K<,9W@)K[SP(\<^/)M@9AN0052@0G$KF%DAG'
M1'"!R]9JZ[!GF;_HN\P^ C@RFOYREH=ZE7':HL'(P8HZ+C/&.E[$%I#96>N$
M\+YYCXP#7V7X7_599A\1- 52-]4J=R9P+D]=N[*U^LB5+$_QXJ1U+2S($-6Z
M.DL84"XI\(B!?%5MA=0BV]3>+CY!7<M.7OV-%5K_K$-CG\^7J^6DB%!$3AIT
M0E+Z"0U$Y3A(.HLY&AMM\\F1Q]#;2>9-,YP=%*%I(<L?M$+P>5A^_O5L_L?
M4T8>6.846O1[NVNO+J]7O$9O=BD*%Q)DH0,H8QV!J$C(60LN8M:&M[>?'J>G
M@7=:/_/=8OYU2IS[Y=OOQ/]7L^N6J,_2:OIU,R#]B@,HR--6HH!SNN8G65$[
M.$G@1?G(@RE2MF[2MS^5W2C"XQ#T@$\[I+@Z<'SO>NVE2.4E<<B&0*Z[)?\]
M2"6@A,!3#%XY/0#6]@V7# 6CH:7]9,!D']9W@)L[ED%]>)FEZ1G>V=+'^;[<
M3)SII)@$K,WJE*HM51D=5?JV\(HIQUSK+)\A]C%R0]/3HGAT('1P&*ZZ=-Q]
MI)QHB2G0_0+.Z-KSTQKPU11.HO+9)Q5];FV[/$C)N&IU?(0\%&L\3EP=@.X%
MTLIINJ'=8\Y%9@DZU"3V0N9.-($L'1U1>LE08>LBI]OKCZOQN@/8P:(9$5;K
MSD-OYK/*IU<S^CQ<7@\34D7+++P!D9*L)K0%IQ4'1XRPVF'@]V:W/MRP[N'/
M'S>%NQOTM)) ![KIFC6O:[S_?>TL];80UYXME[AZ=CY?K*;_N1;P];@JXY-A
MC('-29 %0DSS.A<P*4K::/ H6CL>^](X;JIW-R@]B8@[@/#]1ZL7N)A^7<_#
M>CT-<7JVYN7$&8DVUS=N6V=T,W+>8IU'Z;A$C<$$KEK?O#N2-F[J=W> '4*@
M'>#T]E&[GB8^^[0)P3NK,$@OH*1$>U%:0JRC2;FU6@<N:P^_U@[U$_2,F]W=
M'2*;B:X#&-X_7==<NWPGNNE22>K>6;3 C#*UF1)Y7++FEW%4.L6 GK7.V=Z=
MNI'GB)PV=C.0T+J$X[L%?@G3_.*2GJOY++--.]6UU;*<Q*@*<XC M&>@-,L0
MN%; M5#<9%1>M!Y)<ABEO17LM\'-=^'97(C[0]5OH#K#3_6Y]..0"K3NB>XI
M)",EGI%EDG+4V2L% NN5P ,CHT0;,"%']"%*8UJG)'Z?JMXJ_D^$Q*.$TSWJ
MWI!M=+&H K@\4T460P9)AA0MJTDD#H*UU496OC#.@FX^JVE'TGJK_S\E_HX2
M4\\@?);2_(+L]'?A6SU='Q<AX\1H81,/"-K1,5.9<_#**<@D-B922$D.;S<^
M1%EO30!.!,&CA=2EG4B[6EP0';<B B9RQ6.@LU1;&:A CI[+4H)+TKF8/6K9
MND/N+G3U5MI_.M@=(Z N0?=\/ENSZM^FJ\_/+Y:K^3DNKC;X;2(X;2;F AE9
M[=PI _A4.##+->TUR92'5WQ/DMA;V?Z)H-A.;&,__#W!PG5\_WI7Y&MMQ?HG
MZ(JSC(R.K&.=.I(D!)\L1.Y9PIQJ%&RGU\$CB.BM:+XI $\JH2[UX]K:O=GO
M+=6O2XF2%P=&K,?0<0F>D<<?LTU%&9>M&+X[YZ/D]5;Y?DKGY&AQ=8#$W>.Q
M$T84HA(9K,OUC 4-/M86J*3NA8_>2MGZJ65WZL;U4$Z?5SN$T#H8D?S(SC9#
MYA]FI$[&)\X$;4E:4(DV%Q2Y9TE9;W@1J-B)J@>>H+*3[M@GJAYH):X.]".Y
M_E?%8>D_+J8+I+W2,5M]J\VJ5F2)U%JT+_57)MJEPEA]'N6UZ;B7A32_<<17
MQ8-*I1C=VHG>G;HNZPZ:X61^$J'U$T_<G9\3Y"%96P(D7L@>B5*!M]E"X%&H
M8GB=8SB:>NRRCF H5 XDM'YO[>M\CP<8*716)G,%)1DZ=[D4B,%:$#FZHIS,
M0;:>E+,_E>.^O)SZUFXEKAYN[<4\(>;EK\34JY)MXN+-\*D)SU8ZH4C1\SI]
M.$1.AGBNLZ>2%28G1<>\]67]/:*ZO*.;H6+[CFXJHDXQ]ZKV:@QG[R[BV32]
M+417[?LC@F<Y>X3@R>%3)9-V=T* ]-;DJ%,HNG7+KIV)Z_)&/B4&CQ=9#UB\
M-( OVV;<[5H1)"I.Y@1$QAU='72D@L8ZR@8%CRXZU*V3;)ZBI\M\Q,$0UTHP
M_?@BMP_1IIWSINFXE;JHY(%H-^1810/!%DOV"M?2>J=X:NX-/TA)EY'!4VBT
M X71@_K:WL6]EIU1%.WI7( M==0CMXEX).BO"0.WFCOAS-#H.JC%ZF#9"F,#
M[2@1=8"YW?DW25'7AE,9N/:ZQHP,.%ZS<:7+=6RM$]C:=]B=NG$3%4Z,PH&$
MUD%(I6ZK_K]&*K^&LVHSO$?BV#31Y5U_4!_![WSCUF]N.A[??[5,9Q>U\>C+
M/]/G,/N$[\D0>$D6+@F!6VFT4!%R9'6NJ@KD9M%?E6(>==1*N=:W]6EW.*X5
M,%@HIV.8_.B':,)C)BTA$PA1<TJ4YW6S-?M.9D'J0H72.D1Y%,'CVA]]0GPO
M(78SL?"X+3/+?#%T-&,R')2(-;- T7678I%*$CM"ZP?QX7$[F,72*6[W$6(G
MO<%ONJ=>,?+EV:;1)NWTP\67+YN_W?SXU:S,%^<;25]Q7-$%@Z;4YA^%3JG4
MMN[;@TPV8G$^:=>Z9W +NL?-SAP,PR<7:0>.X&7BX+KRDG9_0;)\M2E"RK]<
MK-[,5_\+5[4]\,30XI%V!M9ZNEJP#L.508"0(;" P1=L#=5=:1N['=JI47-/
M]0X@PK$3V.\'C!_>$RV<0G!QDP6MN!?@C V0DV-)>*.4W:V5U8X+CMT9;22L
M#2:3#E3@56^N2OL;)+=/<44\2!!+H3T(7U^_B%-,!\M-5#*IU@^66R2,W4!M
M9(5VC$"ZT%N;Z/!5</A65?EUQX/+3@?+JU8'S^^4_:(Q$:,C<UAR,H>#MQ""
M9U 8&C*5#2M\>[KK$TKM2&K&[I,VNL8[I33[G)OP)E2K8EY^N5A.9[@\:.+,
MO<]H,/'@:;H:C3-XN_@49I==G6XF*U1XS?*[6X1?=WRJ(S2NABY<0]!+KCER
MN@2=K=.O+$*,WM0AU<A+-DRPUN9S$\*/[AQY#!$OILMT-E^2C#^2,'\YJWE2
MA5NT+-=CK.@T1?00>/# !8]!&V6"Z8J1#^QA7'_E]'B^UVIR3$STJ6$_7)R?
MA\6W>?DP_32;EFFJF?N;?@QUIB=Q*-77S@/T[HZ?W$ ;'[*'1CKZ_C(W#?T,
M2E&D@.BLJLD@M4VI(0O2<,$2_<Q*UEA?/$[-T8WIG^+LK?-@9.&!)4C<VNKH
M1P@V63#2A*1CIF\TGW6Y$V4C1VK:H.1>^_GV0NE32?V?X3__\_G\C' Y7ZP_
M*LSRZVE:MVS[M,"U?CY$1>WTN0T4U/[T-U)/5_;I\_EYI!OM\JK;=%:N)5O+
MZ5UW)6+RW!:PL;[=:5<;33 )6AK/8H@JBM:EQ_M1>'30^48(7_'98E'?W2OS
M'[K;HY V:7*<LJ[.?_8!R&$SD)E$)W@N!/[6<>?=R1M7H0V(JWM!YH%$UJ>F
MN[8[7\V(=Q=KPY.4Q:]ANEA/5O\-0]WR^ON':+R]/K^!YCM\/XTTX/5*-WBY
MN7R9JPEJT8!6!6MXAJYA[P1DNI*YR('9YC.5GZ+G6.WVT&??' Z7+"M:6&"\
MIFA$9. P6,"D$U.9)]2MAP@]2="X&JP9+K;U53LA]*FA[N92T%G>3C,Y0"M]
M]S,;:*+]Z&ZD?2[S3[:6NKD70[96%PVY2 _**82@.8&C:">CE]PW+Q%ZFJ(6
M&57W/_VAJYK+)$1MW5.43N3W:$5'3'%R2D2)7O@40NL^L#L3-ZYF:HB9AW*E
MVHNG3SUUV=WQZH4DW'TAN=U:ZP"%M?N'-]!<!^ZDD0J[;,I:GYC6A(2S&RQ:
MX3-#F<':K.DV\PDB0S*_N9+%H0C9-Z^P?9R<HYY/MYC\[%$F/W1:<DJ%!:/!
MK6/!RA?P+FJPJMCB79'&;"NSAY]-CZ%B7*W5"B9W7D%/)I0^5=A'7)R_GH?9
M(1KJ^M\V4$ /T]%(O[S >,N7OWGF,=[F@ (28W3-*?K*U?YJ$H5.V>N,V-H^
M>)B2XZ=KQ@=C%0J5,K*VH[,U8<GK ('G&I\U23"74XBMPTN/D#*NXF@@__M3
M,X]G>9\:8=.W(ZQ?*S<T;3J:'* @'ONH!OIB)RH;J8]JQZZ^7<,FJAR*(NEJ
M4OZ@#!FO@5L'P0?CM4.)K+7:N$O!T0]ME5.?YV=TZ):;3WXS7^%#:-:&-FL1
MZ4*MG5;I;J-=\@)&D0^@D@U:;N=J'?W6MBMQXZJ4(S!Q[XEM$''TJ5S6>XWW
M1GX?\O3_\">U>.K?@<96ALFUD-?]DJX7>X]GM;/'.@UY/0!\3<Y5QY%KU!5N
M"TKOP=>\.R50TU<107(,R+,Q!5L?S^,H/MK0V77U7VZO?G. O'"*&X;@:H:D
M$H;L]6@EE*+HMJ=C%.-H#'N8Y)$-I]/A\YZ!=4)1]ZDK+W?Z+BP.#2%M?4*3
M"/?C-#72B;>6^/9Q$4CL:=V.Y*9QIU.VYIN DT5OS/8@! =GG0\6<Q&A]8O:
M]V@Z5J\]]OD/&0%8K W")*A#UD$%3L<+"=B6!QN<9T7PUK7L>Y WKKYJBIUM
MC324D/K4/F]P58<,/UNM%M-XL:J!M]7\5D_'2X/U"R[66OB@K/D]EVB15'_,
MKEJYDV$QF\X^U9X=ZT5N8I@YN,BX *DC75E2$#@SEX"Z$)ZX#B*T;D;T&"W'
M*K3MS[WUZE,KFF1!*++6:2J,X$4RP(2)GF6;HFYM@CU*S,@N9 L<;"NI-HSO
M4R7MEH,]?#[YZ?/*Q\HO=Y@(<YI R.@N4S9:<$$R4,DSE7C6S+;N)35<?CDY
M"M/EV[*UP+?-G[?29UR)EI< HI!UH!R=&)^%!F>*5XQ'[D3KGBN[4=9M?OD^
M*-G65P,(I8.JZ]^7Y+6^7*ZFYV0Q+B<F&V;J2+,4R 56.GDR. ,''AWF)+BS
MOC6D[E(P<F'_,- Y@LD=0.0-_G&++XOYC+Y,FR35AX] DLF:'"P(90TQJ'"(
M4C%PA:>8,GH1VX]9V(_&D4O[AX'9H(+J (@?+N(2_^."]O/RZ^.;\JA3;3\$
MS,5:$ID+V:2VFJBVU&')TMW,W&OU$K0+82,7\ \#N?8BZ=.@WZ5FZ>,ZY6>H
MRJO+3S]1_=5#>QFG"BM)H[4F/Y 77=.E<H 0C0-M6)1:*(,L_>!56/>G'6_6
MFEU/X_ZVEL>MYU5TG,NHP,CZQJI+S0>1&30J4YBVVMY+L3N^&FMO,G^HJJQ]
M<':_*FM8$?:I$_>I9CI<-QZPRHDKM0;4E4_6Y1AA""P^@K'>U=QW =$@ 9C<
M"Z8TTE]:F]DGJ=?:].NY=73(6+GD=WX[>X^UUUEMLS[+;^:SQ=5?U^[YUAFS
MP6?DF8-+CBR;1,PADS8!LSX5YSGRU-J;;;^+CBO#]D'@HY5AXXB[ W=FBP,/
M['F]R=]G<[*Q%^M>5Z]F7RY6].,YZ::SZ1H$M[VYZ*4B&:0:@E>J: BESE]6
M1H7"#?&C]7M%XRV,&_PY%=1/*N@^38?OE1\>;B[L^,DG**$<T"SX3E&<$]9I
M+0P9E$&1*5OGO9<003+&7:V(X^''*J3\D#YCOCC#M^5>,_-MIM]T/V"%^2 1
M'$MT&0A1Q^AQ#H6'Z(2QS*;F"<'[D]EU<>4^.+H7&!I89'WJM9V+$P]7</LN
M<<J2RP%5WE,5=4DR'0OWM<\\ X4B@1,E@7"IQ!BX$*QU+X<!"B_OGYQ+OF\S
M^-9;8Y;"!R8 F21#P%HZJA@%N&BC%@ZE:UX6MCMU_59@[H.7Q_5:4^GTJ<ZN
M2AT/UU9;G]"P_') 7?-($5[AKJ@@.&2;"39.>P@N.$ E1> ZJ6Q:/RP-4X1Y
M@^'Z^;<B7+>CDR*2%QV(I")J8I>$H ,'[Z3//F0GFX]F^SY5799F[H.*QY5)
M$T'TJ40>J7\\7*<\_8'#56P.J'&V:O1R9CR[.HX2.1G"C!OP,7BPF2,Y]\Q*
MU;INH''=YC6P[Y<,;MV2=$>F)+T :W(M%V1T?CSA74KAZ'XN):76[WN[4]=5
MY>8^J'A<TS052)\:Y^&RR,,5SI.?-U@9YY &SG'%<EG%S!P/Y*>'3%=>ICNI
M B;7U$?AO37MNU&,6LQY<WI>$E[FWQ _X.+K-.%-6=]MHIZ=K3]RW3J]QG _
MS:;_242MY]ZM*;WE(Y##881UP,GW *6K>V#JXX4T688@7,FM7=?!-O-#%X#N
M@^G'E>N8\.C@1>O-?/85E\3MFYC?6K>M^;"\G(N]?=\4(U*R3$+D:$&E[" *
M;<%Q+DQ$[J1I/MC\ #K'?9L:$=V#"[4#X-XRC[8+M9_]$1;YU@"B97W)V\A]
MN;PXWWQO:_?9HBE<!D ZOG4J1P%G40/Q6O"@1,QYN+>'%CL8-SVZ"U5^<B!T
M>@QN"^#V[A\Y^,;$XG(H("Q7M9F! Q^*!>L5SR'2U^84T-^/ZG%3LSN#^X "
M[]-=W+/2^G _\K"%3E]+/F2@Z[%*8L5BL.@R<%T'1H>:7V/I#\ZQ>.Z"0-MZ
MGMA0%>6WGHAFJVF>GEW480T?:J[/^IGHY9_I[()8^2MI@GK8+J[&;#U>$8TV
MA& 5 RWK*%>O-- YUR!$D,5I)4OSZ4GM=]%I#?L^R'OB-7 ,47>J3[?&0;[
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MA8BT(Q<*Z6?% 9EF1C"G\%ZGVN.][>]1U5. _SAP#22)#K!UETOKD1T?B)9
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M0G"%,Z)/0_#!$$=J5Z;: 8S+$D/.S#K3>GK7[G,G?JB0]][L[ "6QKTLKWW
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M/&Y=Z.]IP<57S&6^N+KPV^=\[KOR<"FA1_%@F(Q15#QJR0(4YTSM6%J=/"9
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M_K@U.=K=S^^E<-++4;:U;3K"U<K'=$F69QG!N,A!D<=!E-Q"9L64X'/*CR9
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M(IR=:;0E6$U^*Z, Q1@GS6L/S%JE(XN*F=8;_UX$6\]!WL2]<7] ZN &$XI
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MSWOR)!O$]Y<7L]E9<EAO "Q(2LY 95,@1F\!>9)6&U^8:3T\; Q#I2+I%^/
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M+[5_XW_^X_\!4$L! A0#% @ &#@*5Z-)P0C(!P SB0 !(
M ( ! &$P-C,P,C R,V5X,S$Q+FAT;5!+ 0(4 Q0 ( !@X"E>=
M1GP"P0< .,D 2 " ?@' !A,#8S,#(P,C-E>#,Q,BYH
M=&U02P$"% ,4 " 8. I74Y.R*3$% M&P $@ @ 'I
M#P 83 V,S R,#(S97@S,C$N:'1M4$L! A0#% @ &#@*5PYR;N^+60(
M#G@4 !$ ( !2A4 &AO=VPM,C R,S V,S N:'1M4$L! A0#
M% @ &#@*5S:$'O (#0 4(4 !$ ( !!&\" &AO=VPM
M,C R,S V,S N>'-D4$L! A0#% @ &#@*5]:GC=W)$P M[, !4
M ( !.WP" &AO=VPM,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0 (
M !@X"E>C)#O(33L $+3 @ 5 " 3>0 @!H;W=L+3(P,C,P
M-C,P7V1E9BYX;6Q02P$"% ,4 " 8. I7RUYHAG"; RL@8 %0
M @ &WRP( :&]W;"TR,#(S,#8S,%]L86(N>&UL4$L! A0#% @
M&#@*5_QIHLL2: $]@$ !4 ( !6F<# &AO=VPM,C R,S V
@,S!?<')E+GAM;%!+!08 "0 ) $H" "?SP, !
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>